{"title": "PDF", "author": "PDF", "url": "https://seq.es/wp-content/uploads/2022/09/full.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Publicaci\u00f3n Oficial\nde la Sociedad Espa\u00f1olade QuimioterapiaREVISTA ESPA\u00d1OLA DEREVISTA ESPA\u00d1OLA DEQuimioterapiaQuimioterapia\nISSN: 0214-3429\nVolumen 35\nN\u00famero 5\nOctubre 2022\nP\u00e1ginas: 421-508SPANISH JOURNAL\nOF CHEMOTHERAPYQuimioterapiaREVISTA ESPA\u00d1OLA DE\nRevista Espa\u00f1ola de \nQuimioterapia tiene un car\u00e1cter multidisciplinar y est\u00e1 dirigida a todos aquellos profesionales involucrados en la epidemiolog\u00eda, diagn\u00f3stico, cl\u00ednica y tratamiento de las enfermedades infecciosas\nFundada en 1988 por la Sociedad \nEspa\u00f1ola de Quimioterapia\nIndexada en\nScience Citation IndexExpanded (SCI),Index Medicus (MEDLINE), Excerpta Medica/EMBASE,\u00cdndice M\u00e9dico Espa\u00f1ol (IME), \u00cdndice Bibliogr\u00e1fico en Ciencias de la Salud (IBECS)\nSecretar\u00eda t\u00e9cnica \nDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madridrevista@seq.esDisponible en Internet:www.seq.esPublicidad y SuscripcionesSociedad Espa\u00f1ola de QuimioterapiaDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madrid\nAtenci\u00f3n al cliente\nTel\u00e9fono 91 394 15 12Correo electr\u00f3nicoinfo@seq.es\nConsulte nuestra p\u00e1gina web\nwww.seq.es\n\u00a9 Copyright 2022Sociedad Espa\u00f1ola deQuimioterapia\nReservados todos los derechos.\nQueda rigurosamente prohibida,sin la autorizaci\u00f3n escrita deleditor, la reproducci\u00f3n parcialo total de esta publicaci\u00f3npor cualquier medio oprocedimiento, comprendidos lareprograf\u00eda y el tratamientoinform\u00e1tico, y la distribuci\u00f3n deejemplares mediante alquiler opr\u00e9stamo p\u00fablicos, bajo lassanciones establecidas por la leySociedad Espa\u00f1ola de Quimioterapia\nPublicaci\u00f3n que cumple los requisitos de\nsoporte v\u00e1lido\nISSN\n0214-3429\ne-ISSN \n1988-9518\nDep\u00f3sito Legal\nM-32320-2012\nMaquetaci\u00f3n\nVic+DreamStudio\nImpresi\u00f3n\nEspa\u00f1a\nEsta publicaci\u00f3n se imprime en papel no \u00e1cido. \nThis publication is printed in acid free paper.\nLOPD\nInformamos a los lectores que, seg\u00fan lo previsto en el Reglamento General de Protecci\u00f3n de Datos (RGPD) 2016/679 del Parlamento Europeo, sus datos personales forman parte de la base de datos de la Sociedad Espa\u00f1ola de Quimioterapia (si es usted socio)\nSi desea realizar cualquier rectificaci\u00f3n o \ncancelaci\u00f3n de los mismos, deber\u00e1 enviar una solicitud por e-mail a la Sociedad Espa\u00f1ola de Quimioterapia (info@seq.es)QuimioterapiaREVISTA ESPA\u00d1OLA DE\nDirector\nJ. Barber\u00e1n L\u00f3pez\nComit\u00e9 Editorial\nF. \u00c1lvarez Lerma (Barcelona)\nF. Baquero Mochales (Madrid)\nE. Bouza Santiago (Madrid)\nJ. A. Garc\u00eda Rodr\u00edguez (Salamanca)\nM. Gobernado Serrano (Valencia)\nConsejo Editorial\nL. Aguilar (Madrid)\nJ. I. Al\u00f3s (Madrid)\nJ. R. Azanza (Pamplona)\nJ. Arag\u00f3n (Las Palmas de Gran Canaria) \nA. Artero (Valencia)V. Asensi (Oviedo)\nG. Barbeito (Santiago de Compostela)\nJ. M. Barbero (Madrid)\nJ. Campos (Madrid)F.J. Candel (Madrid)\nE. Cant\u00f3n (Valencia)\nR. Cant\u00f3n (Madrid)\nJ. A. Capdevila Morell\n(Barcelona)\nM. Casal (C\u00f3rdoba)\nJ. Castillo (Zaragoza) \nF. Cobo (Granada)\nJ. Cobo Reinoso (Madrid)\nN. Cobos (Madrid)\nJ. L. del Pozo (Navarra)R. De la C\u00e1mara (Madrid)\nC. De la Calle (Barcelona)\nM. Dominguez-Gil (Valladolid)\nJ. Eiros (Valladolid)P. Escribano (Madrid)\nA. Estella (C\u00e1diz)\nM. C. Fari\u00f1as \u00c1lvarez (Santander)\nC. Fari\u00f1as (Santander)J. Fort\u00fan (Madrid)J. J. Gamazo (Vizcaya)\nE. Garc\u00eda S\u00e1nchez (Salamanca)\nI. Garc\u00eda Garc\u00eda (Salamanca)\nJ. E. Garc\u00eda S\u00e1nchez (Salamanca)E. Garc\u00eda V\u00e1zquez (Murcia)\nJ. G\u00f3mez G\u00f3mez (Murcia)\nM. L. G\u00f3mez-Lus (Madrid)\nJ. Gonz\u00e1lez del Castillo (Madrid)F. Gonz\u00e1lez Romo (Madrid)\nJ. J. Granizo (Madrid)\nS. Grau (Barcelona)\nJ.M. Guardiola (Barcelona)\nJ. Guinea (Madrid)\nX. Guirao (Barcelona)\nJ. Guti\u00e9rrez (Granada)\nJ. B. Guti\u00e9rrez (C\u00f3rdoba)\nB. Isidoro (Madrid)\nP. Llinares (La Coru\u00f1a)\nJ. E. Losa Garcia (Madrid)J. R. Maestre Vera (Madrid)\nL. Mart\u00ednez Mart\u00ednez (C\u00f3rdoba)\nE. Maseda (Madrid)\nR. Men\u00e9ndez (Valencia)P. Merino (Madrid))\nP. Mu\u00f1oz (Madrid)\nJ. L. Mu\u00f1oz Bellido (Salamanca)\nV. Navarro (Alicante)M. Ortega (Barcelona) \nJ. Oteo (Madrid)\nJ. A. Oteo (Logro\u00f1o)\nE. Palencia Herrej\u00f3n (Madrid) \nA. Pascual Hern\u00e1ndez (Sevilla)\nJ. Pasquau (Sevilla)J. Pem\u00e1n (Valencia)J. L P\u00e9rez-Arellano (Las Palmas)B. P\u00e9rez-Gorricho (Madrid)A. Ramos (Madrid)J. M. Ramos (Alicante)J. Reina (Palma de Mallorca)\nM. A. Ripoll (\u00c1vila)\nI. Rodriguez-Avial (Madrid)M. Ruiz (Alicante)M. Sabri\u00e1 (Barcelona)M. Salavert (Valencia)B. S\u00e1nchez Artola (Madrid)M. Segovia (Murcia)R. Serrano (Madrid)D. Sevillano (Madrid)\nA. Su\u00e1rez (Madrid)\nA. Tenorio (Huelva)A. Torres (Murcia)C. Vallejo (Oviedo)J. Vila (Barcelona)J. Yuste (Madrid)J. Mensa Pueyo (Barcelona)\nJ. J. Picazo de la Garza (Madrid)\nJ. Prieto Prieto (Madrid)\nB. Regueiro Garc\u00eda (Santiago de Compostela)\nA. Torres Mart\u00ed (Barcelona)Secretario de Redacci\u00f3n\nLuis Alou CerveraSumario\nCOVID-19: Algunos asuntos no resueltos  42 1\nJavier G\u00f3mez-Pav\u00f3n, Juan Gonz\u00e1lez Del Castillo, Mari Cruz Mart\u00edn-Delgado, Francisco Javier \nMart\u00edn-S\u00e1nchez, Manuel Mart\u00ednez-Sell\u00e9s, Jos\u00e9 Mar\u00eda Molero Garc\u00eda, Santiago Moreno Guill\u00e9n, \nFernando Rodr\u00edguez-Artalejo, Juli\u00e1n Ruiz-Galiana, Rafael Cant\u00f3n, Pilar De Lucas Ramos, Alejandra Garc\u00eda-Botella, Alberto Garc\u00eda-Lled\u00f3, Teresa Hern\u00e1ndez-Sampelayo, Emilio Bouza\nDocumento de opini\u00f3n de expertos para la mejora de la cobertura vacunal  435 \nfrente a la gripe estacional\nCarmen Velicia Pe\u00f1as, V\u00edctor Miguel Del Campo P\u00e9rez, Irene Rivero Calle, Lorenzo Armenteros \nDel Olmo, Mar\u00eda Teresa P\u00e9rez Rodr\u00edguez, Juan Jes\u00fas Gestal Otero\nLecciones de la COVID-19 para futuras cat\u00e1strofes: un documento de opini\u00f3n  444\nJuan Gonz\u00e1lez Del Castillo, Mari Cruz Mart\u00edn-Delgado, Francisco Javier Mart\u00edn-S\u00e1nchez, Manuel Mart\u00ednez-Sell\u00e9s, Jos\u00e9 Mar\u00eda Molero Garc\u00eda, Santiago Moreno Guill\u00e9n, Fernando \nRodr\u00edguez-Artalejo, Juli\u00e1n Ruiz-Galiana, Rafael Cant\u00f3n, Pilar De Lucas Ramos, Alejandra \nGarc\u00eda-Botella, Alberto Garc\u00eda-Lled\u00f3, Teresa Hern\u00e1ndez-Sampelayo, Javier G\u00f3mez-Pav\u00f3n, \nEmilio Bouza\nRevisi\u00f3n sistem\u00e1tica de la literatura y consenso de expertos sobre los factores  455 \nde riesgo asociados a la progresi\u00f3n de la infecci\u00f3n en pacientes adultos con  \ncolonizaci\u00f3n del tracto respiratorio o rectal por bacterias gramnegativas resistentes a \ncarbapen\u00e9micos\nRicard Ferrer, Alex Soriano, Rafael Cant\u00f3n, Jos\u00e9 Luis Del Pozo, Carolina Garc\u00eda-Vidal, Jos\u00e9 \nGarnacho-Montero, Nieves Larrosa, Pedro Rascado, Miguel Salavert, Vicente Pintado, Ariadna \nGir\u00f3-Perafita, Xavier Badia\nImpacto de la bacteriemia por Staphylococcus aureus  en pacientes con COVID-19  468\nMaria Espinosa Perez, Rosa Garc\u00eda Fenoll, Saray Mormeneo Bayo, Rosa Mar\u00eda Mart\u00ednez \n\u00c1lvarez, Violeta Frutos Mill\u00e1n, Mar\u00eda Cruz Villuendas Us\u00f3n, Mar\u00eda Pilar Palaci\u00e1n Ruiz, Jos\u00e9 \nMiguel Arbon\u00e9s Mainar, Mar\u00eda Carmen Mart\u00ednez Jim\u00e9nez, Carlos Ramos Paesa\nTratamiento con clindamicina, y no con inmunoglobulinas intravenosas, disminuye  475 \nla mortalidad en una cohorte retrospectiva de pacientes cr\u00edticos con bacteriemia por Streptococcus del Grupo A\nAdela Fern\u00e1ndez-Galilea, \u00c1ngel Estella, Jos\u00e9 Luis Garc\u00eda-Garmendia, Ana Loza, Inmaculada \nPalacios-Garc\u00eda, Rafael Sierra-Camerino, Gemma Seller, Marina Rodr\u00edguez-Delgado, Isabel \nRodriguez-Higueras, Jos\u00e9 Garnacho-Montero\nLa infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en  482 \nneonatos expuestos al VIH?\nJorge Bustamante-Amador, Isabel Mellado-Sola, Mar\u00eda Pilar Romero-G\u00f3mez, Marta Cabrera-\nLafuente, Mar\u00eda De La Calle-Fern\u00e1ndez-Miranda, Tal\u00eda Sainz-Costa, Mar\u00eda Jos\u00e9 Mellado-Pe\u00f1a, \nLuis Escosa-Garc\u00eda, En Representaci\u00f3n Del Grupo De Trabajo Sobre Infecci\u00f3n Perinatal-\nNeonatolog\u00eda-Ginecolog\u00eda (Ginper)OriginalesQuimioterapiaREVISTA ESPA\u00d1OLA DE\nRevisi\u00f3n \nsistem\u00e1ticaRevisi\u00f3nVolumen 35N\u00famero 5Octubre 2022Sumario\nEl c\u00f3digo postal como \u201cc\u00f3digo de barras\u201d de las resistencias antimicrobianas  492\nPilar Galicia, Manuel Linares, \u00c1ngel Miguel-Benito, Felipe P\u00e9rez Garc\u00eda, Miguel G\u00f3rgolas, \nJos\u00e9-Manuel Ramos-Rinc\u00f3n, Juan Cuadros\nOsteomielitis polimicrobiana en extremidad de la mano tras mordedura de gato  498\nPablo Camacho Zamora, Mercedes Rom\u00e1n Cabello, Patricia \u00c1lvarez Garc\u00eda,  \nEsther V\u00e1zquez Canal\nDos casos raros de infecci\u00f3n pleural debida a especies de Prevotella  500\nFernando Cobo, Ana Lara-Oya, Ignacio Correa, Enrique Rodr\u00edguez-Guerrero, Virginia P\u00e9rez-\nCarrasco, Jos\u00e9 A. Garc\u00eda-Salcedo, Jos\u00e9 Mar\u00eda Navarro-Mar\u00ed\nOsteomielitis del cuboides por Mycobacterium smegmatis  503\nAna Ruiz-Castillo, Alberto Tenorio-Abreu, Alicia Hidalgo-Jim\u00e9nez, Jos\u00e9 Mar\u00eda Saavedra-\nMart\u00edn\nTuberculosis cong\u00e9nita en una neonata prematura  506\nLaura Solaz Escrig, Manuel Belda \u00c1lvarez, Raquel Soria Martin, Aaron Romualdo Pupl\u00e0 \nBartoll, Ma Dolores Tirado Balaguer\n 508QuimioterapiaREVISTA ESPA\u00d1OLA DE\nFe de erratasCartas al DirectorVolumen 35\nN\u00famero 5Octubre 2022\nOriginal BreveContents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nCOVID-19: Some unresolved issues  421\nJavier G\u00f3mez-Pav\u00f3n, Juan Gonz\u00e1lez del Castillo, Mari Cruz Mart\u00edn-Delgado,  \nFrancisco Javier Mart\u00edn-S\u00e1nchez, Manuel Mart\u00ednez-Sell\u00e9s, Jos\u00e9 Mar\u00eda Molero Garc\u00eda, Santiago \nMoreno Guill\u00e9n, Fernando Rodr\u00edguez-Artalejo, Juli\u00e1n Ruiz-Galiana, Rafael Cant\u00f3n, Pilar De \nLucas Ramos, Alejandra Garc\u00eda-Botella, Alberto Garc\u00eda-Lled\u00f3, Teresa Hern\u00e1ndez-Sampelayo, Emilio Bouza\nExpert opinion on strategies to improve vaccination coverage against  435 \nseasonal influenza\nCarmen Velicia Pe\u00f1as, V\u00edctor Miguel del Campo P\u00e9rez, Irene Rivero Calle, Lorenzo Armenteros \ndel Olmo, Mar\u00eda Teresa P\u00e9rez Rodr\u00edguez, Juan Jes\u00fas Gestal Otero\nLessons from COVID-19 for future disasters: an opinion paper  444\nMari Cruz Mart\u00edn-Delgado, Francisco Javier Mart\u00edn-S\u00e1nchez, Manuel Mart\u00ednez-Sell\u00e9s,  \nJos\u00e9 Mar\u00eda Molero Garc\u00eda, Santiago Moreno Guill\u00e9n, Fernando Rodr\u00edguez-Artalejo, Juli\u00e1n \nRuiz-Galiana, Rafael Cant\u00f3n, Pilar De Lucas Ramos, Alejandra Garc\u00eda-Botella, Alberto Garc\u00eda-\nLled\u00f3, Teresa Hern\u00e1ndez-Sampelayo, Javier G\u00f3mez-Pav\u00f3n, Juan Gonz\u00e1lez del Castillo, Emilio \nBouza\nA systematic literature review and expert consensus on risk factors associated to  455 \ninfection progression in adult patients with respiratory tract or rectal colonisation  by carbapenem-resistant Gram-negative bacteria\nRicard Ferrer, Alex Soriano, Rafael Cant\u00f3n, Jos\u00e9 Luis Del Pozo, Carolina Garc\u00eda-Vidal, Jos\u00e9 \nGarnacho-Montero, Nieves Larrosa, Pedro Rascado, Miguel Salavert, Vicente Pintado, Ariadna \nGir\u00f3-Perafita, Xavier Badia\nImpact of \nStaphylococcus aureus  bacteremia in COVID-19 patients  468\nMaria Espinosa Perez, Rosa Garc\u00eda Fenoll, Saray Mormeneo Bayo, Rosa Mar\u00eda Mart\u00ednez \n\u00c1lvarez, Violeta Frutos Mill\u00e1n, Mar\u00eda Cruz Villuendas Us\u00f3n, Mar\u00eda Pilar Palaci\u00e1n Ruiz, Jos\u00e9 \nMiguel Arbon\u00e9s Mainar, Mar\u00eda Carmen Mart\u00ednez Jim\u00e9nez, Carlos Ramos Paesa\nClindamycin but not Intravenous Immunoglobulins reduces mortality in a  475 \nretrospective cohort of critically ill patients with bacteremic Group A Streptococcal infections\nAdela Fern\u00e1ndez-Galilea, \u00c1ngel Estella, Jos\u00e9 Luis Garc\u00eda-Garmendia, Ana Loza, Inmaculada \nPalacios-Garc\u00eda, Rafael Sierra-Camerino, Gemma Seller, Marina Rodr\u00edguez-Delgado, Isabel \nRodriguez-Higueras, Jos\u00e9 Garnacho-Montero\nCongenital cytomegalovirus infection, is more prevalent in our country in newborns  482 \nexposed to HIV?\nJorge Bustamante-Amador, Isabel Mellado-Sola, Mar\u00eda Pilar Romero-G\u00f3mez, Marta Cabrera-\nLafuente, Mar\u00eda de la Calle-Fern\u00e1ndez-Miranda, Tal\u00eda Sainz-Costa, Mar\u00eda Jos\u00e9 Mellado-Pe\u00f1a, Luis Escosa-Garc\u00eda, En representaci\u00f3n del Grupo de Trabajo sobre Infecci\u00f3n Perinatal-\nNeonatolog\u00eda-Ginecolog\u00eda (GINPER)Review\nSystematic \nreview\nOriginalsVolume 35\nNumber 5October 2022Contents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nThe postal code as a \u201cbar code\u201d of antimicrobial resistance  492\nPilar Galicia, Manuel Linares, \u00c1ngel Miguel-Benito, Felipe P\u00e9rez Garc\u00eda, Miguel G\u00f3rgolas, \nJos\u00e9-Manuel Ramos-Rinc\u00f3n, Juan Cuadros\nPolymicrobial osteomyelitis on the limb of the hand after a cat bite  498\nPablo Camacho Zamora, Mercedes Rom\u00e1n Cabello, Patricia \u00c1lvarez Garc\u00eda, Esther V\u00e1zquez \nCanal\nTwo rare cases of pleural infection due to Prevotella  species  500\nFernando Cobo, Ana Lara-Oya, Ignacio Correa, Enrique Rodr\u00edguez-Guerrero, Virginia P\u00e9rez-\nCarrasco, Jos\u00e9 A. Garc\u00eda-Salcedo, Jos\u00e9 Mar\u00eda Navarro-Mar\u00ed\nOsteomyelitis of the cuboid due to Mycobacterium smegmatis  503\nAna Ruiz-Castillo, Alberto Tenorio-Abreu, Alicia Hidalgo-Jim\u00e9nez, Jos\u00e9 Mar\u00eda Saavedra-\nMart\u00edn\nCongenital tuberculosis in a premature newborn  506\nLaura Solaz Escrig, Manuel Belda \u00c1lvarez, Raquel Soria Martin, Aaron Romualdo Pupl\u00e0 \nBartoll, Ma Dolores Tirado Balaguer\n 508 ErratumVolume 35\nNumber 5October 2022\nBrief Report\nLetters to the \neditorISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/028.2022\nRev Esp Quimioter 2022;35(5): 421-434421COVID-19: Algunos asuntos no resueltos\nRESUMEN\nCuando han transcurrido ya dos a\u00f1os de la pandemia de \nCOVID-19 persisten muchas incertidumbres sobre el agente \ncausal, la enfermedad y su futuro. El presente documento \ncontiene la reflexi\u00f3n del grupo de trabajo sobre COVID-19 del Ilustre Colegio Oficial de M\u00e9dicos de Madrid (ICOMEM) \nen relaci\u00f3n a algunas preguntas que nos parecen sin resol-\nver. El documento incluye reflexiones sobre el origen del vi -\nrus, la indicaci\u00f3n actual de pruebas diagn\u00f3sticas, el valor de los \u201cscores\u201d de gravedad en el comienzo de la enfermedad y \nel riesgo a\u00f1adido que supone la hipertensi\u00f3n o la demencia. Se discute tambi\u00e9n, la posibilidad de deducir del examen de la estructura del genoma viral completo el comportamien -\nto viral, el futuro de algunas asociaciones de f\u00e1rmacos y el \npapel actual de recursos terap\u00e9uticos como los corticoides \no la oxigenaci\u00f3n extracorp\u00f3rea (ECMO). Revisamos la esca -\nsa informaci\u00f3n existente sobre la realidad de la COVID-19 en \u00c1frica, las incertidumbres sobre el futuro de la pandemia y la \nsituaci\u00f3n de las vacunas y los datos e incertidumbres sobre \nlas secuelas pulmonares a largo plazo de los que padecieron neumon\u00eda grave.\nPalabras clave: COVID-19, SARS-CoV2, tratamiento, vacunaci\u00f3n, origen del \nvirus, scores diagn\u00f3sticos, pruebas diagn\u00f3sticas, hipertensi\u00f3n arterial, de -\nmencia, genoma viral, combinaci\u00f3n de f\u00e1rmacos, corticosteroides, ECMO, \u00c1frica, futuro y vacunas, fibrosis pulmonar, secuelas.COVID-19: Some unresolved issuesJavier G\u00f3mez-Pav\u00f3n1\nJuan Gonz\u00e1lez del Castillo2\nMari Cruz Mart\u00edn-Delgado3\nFrancisco Javier Mart\u00edn \nS\u00e1nchez4\nManuel Mart\u00ednez-Sell\u00e9s5\nJos\u00e9 Mar\u00eda Molero Garc\u00eda6\nSantiago Moreno Guill\u00e9n7\nFernando Rodr\u00edguez-\nArtalejo8\nJuli\u00e1n Ruiz-Galiana9\nRafael Cant\u00f3n10\nPilar De Lucas Ramos11\nAlejandra Garc\u00eda-Botella12\nAlberto Garc\u00eda-Lled\u00f313\nTeresa Hern\u00e1ndez-\nSampelayo14\nEmilio Bouza15Review\nArticle history\nReceived: 23 March 2022; Accepted: 1 April 2022; Published: 21 April 2022\nABSTRACT\nTwo years after the COVID-19 pandemic, many uncer -\ntainties persist about the causal agent, the disease and its fu -\nture. This document contains the reflection of the COVID-19 \nworking group of the Official College of Physicians of Madrid \n(ICOMEM) in relation to some questions that remain unre -\nsolved. The document includes considerations on the origin of \nthe virus, the current indication for diagnostic tests, the value \nof severity scores in the onset of the disease and the added \nrisk posed by hypertension or dementia. We also discuss the \npossibility of deducing viral behavior from the examination of the structure of the complete viral genome, the future of some \ndrug associations and the current role of therapeutic resources such as corticosteroids or extracorporeal oxygenation (ECMO). \nWe review the scarce existing information on the reality of \nCOVID 19 in Africa, the uncertainties about the future of the pandemic and the status of vaccines, and the data and un -\ncertainties about the long-term pulmonary sequelae of those who suffered severe pneumonia.\nKeywords: COVID-19, SARS-CoV2, treatment, vaccination, virus origin, \ndiagnostic scores, diagnostic tests, arterial hypertension, dementia, viral \ngenome, drug combination, corticosteroids, ECMO, Africa, future and vac -\ncines, pulmonary fibrosis, sequelae.\nCorrespondence: \nEmilio Bouza Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas del Hospital \nGeneral Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense. CIBERES. Ciber de \nEnfermedades Respiratorias. Madrid \nE-mail: emilio.bouza@gmail.com \nAll authors belong to the Scientific Committee on COVID-19 of the Madrid College of Physicians (ICOMEM).1Geriatrics Service. Central Hospital of the Red-Cross. Alfonso X el Sabio University. Madrid\n2Emergency Service. San Carlos University Clinical Hospital. Complutense University. Madrid.\n3Intensive Medicine Service. Torrej\u00f3n University Hospital. Francisco de Vitoria University. Madrid.\n4Geriatrics Service. San Carlos University Clinical Hospital. Complutense University. Madrid\n5Cardiology Service. Gregorio Mara\u00f1\u00f3n General University Hospital, European University. Madrid.\n6Family Medicine. Infectious diseases. Madrid.\n7Infectious Diseases Service. Ram\u00f3n y Cajal Hospital. University of Alcal\u00e1 de Henares. Madrid.\n8Department of Public Health. Autonomous University. Madrid\n9Internal Medicine Service. Ruber International Hospital. Madrid.\n10Microbiology Service. Ram\u00f3n y Cajal Hospital and Ram\u00f3n y Cajal Institute for Health Research (IRYCIS). Spanish Net -\nwork for Research in Infectious Pathology (REIPI). Madrid.\n11Emeritus. Pneumology Service. Gregorio Mara\u00f1\u00f3n General University Hospital, Complutense University. Madrid\n12General Surgery Service. San Carlos University Clinical Hospital. Complutense University. Madrid.\n13Cardiology Service. Prince of Asturias Hospital. University of Alcal\u00e1. Madrid.\n14Pediatrics and ACES Service. Gregorio Mara\u00f1\u00f3n General University Hospital, Complutense University. Madrid.\n15Clinical Emeritus, Community of Madrid. Clinical Microbiology and Infectious Diseases Service of the Gregorio Mara -\n\u00f1\u00f3n General University Hospital, Complutense University. CIBERES. Cyber of Respiratory Diseases. Madrid.COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434422doubt about the need for very strict security measures in virol-\nogy laboratories, this controversy should make us aware of the \nneed to control wildlife trafficking, to enhance epidemiological \nsurveillance and to demand transparency and early communi -\ncation from the corresponding authorities in all epidemiolog -\nical events.\nWHO SHOULD BE TESTED FOR COVID-19 AT THE \nPRESENT TIME?\nThe performance of diagnostic tests for SARS-CoV-2 has \ntwo main purposes: a health care purpose, individual, in symp-\ntomatic persons diagnosed with COVID-19 who can benefit \nfrom specific health care, and a public health purpose, collec -\ntive, to carry out measures to prevent transmission and help globally to control the pandemic. According to these objec -\ntives, the indications for COVID-19 diagnostic tests should be adapted to the epidemiological reality of each moment of the \npandemic.\nAt the present time (March 2022), the characteristics of \nthe pandemic in Spain are conditioned by two main factors: the high vaccination rate in the Spanish population (>90% in \nthe population over 12 years of age) and the characteristics \nof the disease produced by the SARS-CoV-2 Omicron variant, \nresponsible for practically all infections. These two factors de -\ntermine, on the one hand, a high incidence, but with a high \npercentage of asymptomatic individuals (up to 80%-90%) and \nlow severity in symptomatic individuals, assessed by the rate of \nhospitalizations, ICU admissions and deaths. Mortality due to COVID-19 among vaccinated persons is estimated at 0.003% \nin our country. It should not be forgotten, however, that cer -\ntain groups have a higher risk of serious disease. Among them, \nunvaccinated persons should be considered, especially those of \nadvanced age or with underlying diseases, and immunocom -\npromised vaccinated persons or those of advanced age (>80 \nyears). \nWith these premises in mind, attempts should be made \nto rationalize the indications for COVID-19 diagnostic tests to \navoid overflowing diagnostic laboratories, optimizing resourc-es, avoiding inconvenience to the population and making in -\nappropriate decisions that may ultimately harm patients.\nIn our opinion, diagnostic tests should be considered in \nthe situations listed in Table 1.\nARE THERE EVOLUTIONARY \u201cSCORES\u201d CLEARLY \nSUPERIOR TO THE OTHERS AND OF INDISPUTABLE USE?\nThe stratification of the risk of poor outcomes is one of \nthe most important tasks of the physician during the initial \ncare of any pathology in order to make the first decisions. \nCOVID-19 has been a challenge in this regard, as we are faced \nwith an unknown disease. Numerous research studies have \nbeen published describing variables related to increased mor -\ntality [9] and risk stratification models [10-18]. However, the INTRODUCTION\nAs the sixth wave of the COVID-19 pandemic is heading \ntowards its extinction and after the extraordinary spread of \nthe Omicron variant, it is time to continue thinking on the sit -\nuation in which we find ourselves in the pandemic. The COVID \nCommittee of the Illustrious College of Physicians of Madrid \n(ICOMEM) has discussed some of the issues that remain un -\nclarified two years after the beginning of the pandemic among us and despite the fact that hundreds of thousands of scientif -\nic papers have been published on it.\nIt is not possible to be exhaustive and we have selected \nsome questions whose answer seemed to us inconclusive or \nopen to debate on which we have tried to offer our point of \nview thinking that it may be of interest, first for the members of ICOMEM and also for anyone with concern about this phe -\nnomenon.\nWHAT IS THE ORIGIN OF SARS-COV-2? NATURAL \nSELECTION OR LABORATORY MANIPULATION?\nThere is little doubt that the COVID-19 pandemic origi -\nnated in the Chinese city of Wuhan. The same authors who \nproposed the name of the pathogen (SARS-CoV-2) described \nits close relationship with viruses specific to bats in various re -\ngions of China and considered the existence of an intermedi-ate mammal (as yet unidentified) in the virus jump from bat to man. According to them, this jump most likely occurred in the Wuhan market, where the first human cases were identified, \nand where wild mammalian species are traded [1]. Other Chi -\nnese researchers believe that the jump between species may have occurred at a location other than Wuhan [2], however \nthe origin of the pandemic in that city seems undoubted.\nThe main controversy centers on the way in which the \nvirus developed. The most widely accepted is the passage \nfrom the bat to an intermediate animal host, as yet uniden -\ntified, prior to transmission to humans. It is also considered the possibility that the virus passed from bat to human, and \nevolved in asymptomatic transmission to acquire the charac -\nteristics that caused the pandemic transmission [3-5]. Finally, \nthe presence of a virology laboratory located in Wuhan, with \nlines of work on mammalian viruses, raises the possibility that \nthe virus, modified during passage through cell cultures or by \ndifferent species, could leave the laboratory accidentally. This \nhypothesis is considered unlikely [3-5], since there have been \ncases of accidental virus escapes from laboratories in the past \n[4,6,7], in all of them the outbreak started in workers and rel -\natives of laboratory personnel, something that has not been confirmed in the Wuhan outbreak [8]. The lack of transparency \nof the Chinese authorities has facilitated the doubts that fuel \nthe controversy. Finally, we believe that the theories of those who posit the intentional release of the virus, in the absence of evidence other than various conspiracy theories, do not merit \nfurther attention.\nFrom a practical point of view, and given that there is no COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434423and laboratory values (such as LDH, ferritin, D-dimer or C-re -\nactive protein) that show the patient\u2019s inflammatory status. \nFuture studies should focus on validating, comparing, im -\nproving and updating the available predictive models in order \nto safely discharge patients and avoid unnecessary admissions.\nDO FACTORS SUCH AS HYPERTENSION OR \nDEMENTIA WORSEN THE PROGNOSIS OF THE \nDISEASE?\nAn unquestionable fact is that the burden of morbidity and \nmortality in COVID-19 falls disproportionately on the elderly \nand those with comorbidities [24]. In this context, identifying \nindependent risk factors appears as a critical issue, especially if a putative risk factor is highly prevalent. It is estimated that approximately one third of the population in developed and developing countries is affected by high blood pressure (HBP), \nwith more than 60% of the population over 60 years of age \nbeing hypertensive [25]. In relation to dementia, the number of \npeople with dementia is projected to increase from 57.4 million \ncases worldwide in 2019 to 152.8 million cases in 2050 [26]. \nThese figures justify their importance in COVID-19. The first \nanalyses performed in the pandemic by Wu and McGoogan \n[27], which included 44.672 patients with confirmed COVID-19 \nshowed higher case-fatality rates than the overall rates for car-\ndiovascular disease (10.5%), diabetes (3%), and HT (6%). Subse -\nquently, studies were added that maintained these vascular co -\nmorbidity relationships, with HT as an independent risk factor publications include high or uncertain risks of bias [19] due to \na combination of the use of retrospective data, poor clinical reporting, and inadequate methodological conduct. A descrip -\ntion of the population characteristics included is critical for clinicians to understand whether the proposed model might be appropriate for their population or setting. Unfortunately, published studies often lack this. Moreover, often the available \nsample sizes and number of events for the outcomes of inter -\nest are usually limited, which increases the risk of overfitting \nthe model, so that the performance of these models is likely to be worse than that reported by the investigators. Finally, most \ndo not include external validation of the model.\nThese risk factors and models have been developed in the \nunvaccinated population, so their usefulness in the current scenario may not be adequate, since vaccinated individuals have been shown to be at lower risk for a fatal outcome [20]. \nHowever, the studies that are beginning to be published with vaccinated populations show that the risk factors are similar to those previously published, although the risk of poor evolution \nis lower [21-23].\nIn conclusion, the models published to date raise doubts \nabout their applicability in routine clinical practice. None of \nthem can yet be recommended for widespread use. However, \nthey could be a helpful tool, in conjunction with the clinical \njudgment of the professional. In routine clinical practice, the attending physician\u2019s decision making takes into account the patient\u2019s age, comorbidity, vaccination status or susceptibili -\nty to poor response to vaccination, time since symptom onset, Table 1   Indication of COVID-19 diagnostic tests at present.\nIndication of tests\n1.-Symptomatic persons:\n - Persons with severe symptoms requiring health care. - Persons with mild-moderate symptoms who may benefit from treatment to prevent progression (immunocompromised, unvaccinated or vaccinated elderly (>80 years), unvaccinated persons >65 years with significant underlying disease).\n2. Asymptomatic persons:\n- Persons who are going to undergo immunosuppressive medical procedures, regardless of vaccination status: solid organ or hematopoietic progenitor transplantation, chemotherapy and cancer immunotherapy (individualizable).\n- May be considered in individuals who are to undergo surgical procedures or aerosol-generating procedures. \nContraindication of tests\nWe do not consider COVID-19 diagnostic testing indicated in the following situations:\n1. Symptomatic persons:\n- Persons with mild symptoms who do not benefit from health care. Isolation measures to prevent transmission are of limited \neffectiveness considering that most transmissions can occur by persons without symptoms. Persons with symptoms should avoid \ncontact with vulnerable persons at high risk for severe disease.\n- Repeat testing to make decisions, such as the duration of isolation. No laboratory test is efficient in this regard and the decision \nshould be guided by clinical-epidemiological criteria.\n2. Asymptomatic persons:\n- Routine hospital admissions or medical-surgical procedures in groups other than those mentioned above.\n- Contact studies, in the case of low-risk individuals.COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434424mortality do so depending on their intensity, as in the case of \nthe severity of HT or dementia. More global clinical markers \nsuch as frailty that better reflect the overall pathological sit-\nuation associated with aging may be perhaps of better prog -\nnostic performance than the different comorbidities taken in \nisolation.\nCAN THE CLINICAL AND EPIDEMIOLOGICAL \nBEHAVIOR OF A VARIANT BE DEDUCED IN THE \nLABORATORY FROM THE EXAMINATION OF THE \nSTRUCTURE OF THE COMPLETE VIRAL GENOME?\nThe evolution of the COVID-19 pandemic has been \nmarked by the successive introduction and global expansion \nof the so-called variants of concern (VOC) of SARS-CoV-2, \nwith the alpha, delta and more recently omicron variants be -\ning the most prominent [46]. Their recognition has only been \npossible thanks to the large-scale introduction of the so-called next-generation sequencing (NGS) systems in microbiology laboratories and the enormous effort they have put into both sequencing and subsequent bioinformatics analysis. \nEach of these VOC is characterized, in addition to its easy \ntransmission capacity, by mutations (change of the original \nnucleotides for different ones) or deletions (absence of one \nor several nucleotides) in the RNA sequence and affecting the amino acid sequences in the SARS-CoV-2 proteins [46-48]. The most relevant mutations and deletions are those in the spicule region (protein S). They affect binding to the ACE\n2 receptor, \nthe development of specific antibodies, including neutralizing \nantibodies, and the response to currently used mRNA vaccines \ndesigned against the spicule protein of the original Wuhan \nstrain [49]. The sequence of this strain is collected in the GI -\nSAID page with the access ID EPI_ISL_402124. Figure 1 shows the amino acid changes present in more than 85% of the ana -\nlyzed sequences of different VOC and variants of interest (VOI), \nsome of them accumulating more than 35 mutations (https://\nwww.ecdc.europa.eu/en/covid-19/variants-concern). It is im -\nportant to note that not all amino acid changes in the spicule protein (S) are associated with possible changes in the char -associated with higher mortality, both in meta-analyses [28] as \na survival analysis [29]. Finally, data from some studies using multivariate logistic regression models to identify independ -\nent clinical predictors of mortality or severity would also sup -\nport these results. Rodilla et al, in a study with data from 150 Spanish hospitals and 12,226 patients included, showed that HT was associated with an increased risk of mortality due to \nCOVID,19 independently of the sex and age of the patients [30]. \nBut the association between HT and mortality or severity of COVID-19 could also be partly explained by increasing age and \nhigher prevalence of cardiovascular disease, both well-known \nrisk factors for mortality in critically ill patients. Thus, models \nshould be appropriately adjusted to exclude these potential confounding effects [31]. Thus, Sun\u2019s study [32] with multi -\nvariable model adjusted among 2,304 patients with no other identified comorbidities beyond HT or diabetes, confirmed that HT alone did not increase mortality. In relation to dementia, the mortality rate described for people with dementia, outside \nof pandemic situations, is three times higher than what would \nnormally be expected for the 5-year average [33].  In a study \nconducted in England between March 27, 2020 and January 8, \n2021, the excess mortality in people with dementia was ana -\nlyzed and found to be 31% in people over 65 years of age. This, combined with the fact that only 4% of people over the age of 65 have a formal diagnosis of dementia, suggests that COVID-19 has had a disproportionate impact on death in the \ndementia population [33]. \nYang et al. meta-analysis [34], based on 34 studies with \nadjusted estimated effects, showed that COVID-19 patients with dementia had a significantly higher risk of mortality com -\npared to those without dementia. In multivariate predictive \nmodels, dementia also appeared as an independent risk factor \nfor death in COVID patients [35-39]. \nCurrently, frailty is shown to be a good integrative clini -\ncal marker of pathological aging. Thus, greater frailty is always \nassociated with poorer health outcomes [40-44] and even as a \nmarker of resource use [45].\nIn all the studies discussed, biases in the models are possi -\nble and it is possible that the factors mentioned that influence Figure 1   Sequence changes in different variants of concern (VOC) and variants of interest (VOI) (https://www.\nwho.int/docs/default-source/coronaviruse/spike-omicron-ba-1-ba-2.pdf?sfvrsn=d33f5c42_15).\nCOVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434425ARE DRUG ASSOCIATION STUDIES RELEVANT AND \nNECESSARY IN DIFFERENT POPULATION GROUPS?\nIt seems reasonable that pharmacological treatment \nshould be adapted to the evolution of the disease, using antivi -\nrals and immunotherapy early on and anti-inflammatory drugs \nand immunomodulators later on. There are currently a mul-\ntitude of clinical trials underway trying to identify the most \npotent drug or the best combination of specific treatment for COVID-19, but we have not yet solved this great challenge. \nThe drugs and biologics currently available are antivirals \n(remdesivir, molnupiravir, nirmatrelvir); intravenous immu-noglobulins or convalescent plasma, monoclonal antibodies \n(sotrovimab, bamlanivimab + etesevimab, casirivimab and imdevinab, cignailmab +tixagevimab, BRII-196 and BRII-198), \nimmunomodulators (tocilizumab, sarilizumab, anakinra, canak-inumab, baricitinib and tocitinib) and systemic corticosteroids.\nStudies on all these therapeutic agents have usually been \ncarried out individually and in isolation and therefore, among \nthose with recognized efficacy, it is pertinent to consider com -\nbination studies.\nTrials with combination therapies [56-58] suggest that the \nassociation of several drugs acting at different times of infec -\ntion improves prognosis and survival. \nSome antiviral drugs (molnupiravir and favipiravir) that \nact in association on different targets of the reproductive cycle of the virus have demonstrated their efficacy [59]. They have \na synergistic effect that allows them to be used at low doses, \nwhich reduces side effects and certainly the possibility of gen -\nerating resistance. \nThe association of remdesivir with baricitinib has been \nshown to be better than remdesivir alone in the treatment \nof patients with COVID-19 pneumonia [60,61]. The combina -\ntion shortened recovery time, reducing the likelihood of poor \noutcome and need for invasive ventilation by up to 31%. In addition, the combined treatment was associated with fewer serious adverse events. The largest randomized study conduct -\ned by the RECOVERY collaborative group [62] analyzes the ef -\nfect of tocilizumab in the treatment of 4,116 adult patients hospitalized for COVID-19 disease with hypoxia and systemic \ninflammation (elevated CRP). The results demonstrate that to -\ncilizumab (immunomodulator inhibitor of the IL-6 response) \nsignificantly reduces mortality at 28 days of follow-up, in-\ncreases the probability of being discharged within 28 days, and \nin patients who at randomization did not require mechanical \nventilation, the probability of requiring mechanical ventilation \nand mortality was reduced. These benefits are independent of \nthe respiratory support received and of the additional benefit \nof the systemic corticosteroids administered [62].\nRecently, the casirivimab/imdevimab monoclonal an -\ntibody combinations (ronopreve, REGEN-COV) [63] or bam -\nlanivimab/etesevimab [64] have been licensed (by emergency procedure) in non-hospitalized patients with mild to moderate COVID-19 at high risk of disease progression. Emerging da -\nta on monoclonal antibody combinations are promising, but acteristics of the virus variant and that they can also occur in \nother regions of the SARS-CoV-2 genome (ORF1ab, ORF3a, E, \nM, ORF6, ORF6, ORF8 and N). These mutations may eventual -\nly affect the secondary and tertiary structure of the S protein \nand thus its affinity for ACE\n2 receptors [50,51].\nGiven that the number of mutations and the combina -\ntions between them are very high, it is difficult to say that the mere presence of a single mutation alone can affect the \nvirulence of SARS-CoV-2. In fact, and although the current \nscenario with high vaccination coverage in highly developed \ncountries makes it difficult to determine the real extent of the \nvariants, none of the known VOC has a virulence greater than \nthe original Wuhan strain and only the transmission capacity \nwould be affected [52,53]. This idea is reinforced by the fact \nthat the alpha (B.1.1.7), delta (B.1.617.2) and omicron (BA.1) \nvariants only coincide in amino acid changes at two positions \n(D614G and P681R/P681H). The D614G change arose very ear -\nly in the pandemic and appears to accelerate virus replication, \nbeing present in all the VOC described so far. The mutations at \nposition 861 would be related to the anchoring of the S1 and S2 subunits of the spicule and the better entry of the virus into the cell [52,54]. \nSome reports have coined the term \u201cmutations of con -\ncern\u201d in an attempt to relate their presence to the different \ncharacteristics that define VOCs increased transmissibility, in -\ncreased severity of symptoms and interference with diagnostic \ntechniques, response to treatment or vaccine protection [55]. The most relevant would be those affecting the RBD region of the spicule responsible for binding to ACE\n2 receptors that \ncould escape the action of neutralizing antibodies [52]. One of \nthe latest ECDC reports [56] includes as VOC those occurring \nat spike protein residues 319-541 (receptor binding domain) and 613-705 (the S1 part of the S1/S2 junction and a small stretch on the S2 side) and additional unusual variant-specific changes. \nAmong the \u201cmutations of concern\u201d the role of position \n484 has been highlighted as it is present in both VOC and \nVOI, E484K in the beta, gamma and mu variants and E484A in \nomicron. Although not a key position in binding to the ACE2 receptor, mutations at this position have been shown to great -\nly reduce binding to some of the monoclonal antibodies and result in escape from neutralizing antibodies. Other mutations such as L452R, present in omicron, reduce the affinity for monoclonal antibodies by up to 20-fold [52]. \nToday, it is difficult to predict whether new mutations will \noccur that will have an even greater effect on the transmis -\nsibility of SARS-CoV-2 as well as its potential virulence. The selection factor for variants remains the number of infected patients, so it is necessary to extend vaccination strategies to all countries. It should also be pointed out that, although the natural tendency of the virus is to lose virulence, mutations or combinations of mutations could arise which by chance could break this rule. For this reason, surveillance for possible new \nvariants should continue, although it is uncertain to be able to \npredict their characteristics.COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434426of 37.1% similar to that of non-COVID ARDS patients. Age and \nduration of ECMO were associated with worse prognosis, but \nnot with multi-organ dysfunction as measured by Sequential Organ Failure Assessment (SOFA). Another recent study shows \na 40% mortality in COVID 19 and ECMO patients. Age, multiple \ncomorbidities, lower pre-ECMO pH, renal replacement tech -\nniques, requirement of vasoactive drugs and bleeding were predictors of death in these patients [68-71]. \nThe series with the largest number of patients included \nwith ECMO (ELSO registry) with data from 1,035 patients with \nCOVID 19 shows a cumulative incidence of in-hospital mortal -\nity at 90 days after ECMO initiation of 37% [72]. In France, a \nretrospective multicenter study of 83 patients showed a mor -\ntality of 36.1%, concluding that mortality is similar to that \nof studies published in the last 2 years in patients with ARDS \ntreated with ECMO [73]. \nThere is still much uncertainty regarding the use of ECMO \nin COVID-19 patients ranging from the impact of concomitant use of immunomodulators, the possibility of an increased risk \nof complications such as bleeding, thromboembolic disease or \ninfections in COVID-19 patients, or the long-term sequelae in \nthese patients. \nClinical trials are therefore required to show the effective-\nness of the use of V-V ECMO in patients with severe COVID, as well as the impact of certain practices such as the use of prone \nposition, early extubation, adequate anticoagulation or the use \nof mechanical support of the right ventricle and the impact on long-term morbidity and mortality.\nFinally, it is necessary to establish regional strategies that \nallow equitable access to these techniques [74].\nIS THE ISSUE OF THE INDICATION OF \nCORTICOSTEROIDS AT DIFFERENT TIMES IN THE NATURAL HISTORY OF COVID SETTLED?\nSystemic corticosteroids (CS) have been used since the \nbeginning of the pandemic to treat hyperinflammation asso-\nciated with severe forms of COVID-19, particularly those with pneumonia and ARDS. The role of corticosteroids in the treat-\nment of COVID-19 has generated controversy because of limit-\ned rigorous data on their efficacy, optimal doses and regimens, or their effect on disease progression, delayed viral clearance, or secondary infections and other complications  [75]. Based \non data from large multicenter randomized controlled trials \n(RCTs), the WHO and other scientific institutions recommend \nthe administration of CS to patients with severe or critical \nCOVID-19 requiring oxygen supplementation, both with con -\nventional oxygen therapy and mechanical ventilation (MV) [76]. \nIn contrast, it is not recommended in patients with non-se-\nvere COVID-19, who do not require additional oxygen therapy. \nThese recommendations were made based on the results of the Randomized Evaluation of COVID-19 Therapy (RECOVERY), an \nopen-label, controlled trial that compared a variety of possible \ntreatments in hospitalized patients with COVID-19 [77]. The study showed that administration of 6 mg of dexamethasone more data are needed. The biggest problem at present is their \nlimited availability, which is insufficient to meet the enormous \ndemand that may arise if they prove their prophylactic and \ntherapeutic efficacy. \nDespite all the recent progress, there are still many un -\nanswered questions including the clear identification of which agents are most effective for mild, moderate and severe dis -\nease, the optimal timing for initiation of therapy, the ideal dose, the duration of therapy and which combination therapy would be most appropriate and beneficial.\nWHAT IS THE ROLE OF EXTRACORPOREAL \nMEMBRANE OXYGENATION (ECMO) IN PATIENTS WITH COVID? \nTreatment of adult respiratory distress syndrome (ARDS) \nin severe cases of COVID-19 is based on invasive mechani -\ncal ventilation, muscle relaxation and pronation. When these \nmeasures fail, the Extracorporeal Life Support Organization (ELSO) guidelines [65] suggest the use of an extracorporeal \nmembrane oxygenator (ECMO). Prior to the pandemic, there \nwere only two controlled studies for the use of ECMO in ARDS, \nthe CESAR [65] with reduced mortality compared to conven -\ntional treatment and the ELOLIA study [66] which showed no \nimpact on 60-day mortality. The 2019 guidelines for the treat-ment of ARDS recommended its use based on the opinion of an expert center in cases of severe hypoxemia (PaO2/FiO2 < 80 \nmmHg) and impossibility of protective ventilation despite high \nPEEP, neuromuscular block and prone decubitus.\nThe use of ECMO during the SARS-CoV-2 pandemic in \ncritically ill patients admitted to the ICU was between 3 and \n11.1%. In the case of ARDS due to COVID-19 we do not have any randomized study evaluating the use of ECMO. The So -\nciedad Espa\u00f1ola de Medicina Intensiva, Cr\u00edtica, y Unidades Coronarias (SEMICYUC) recommends the use of venovenous ECMO (ECMO V-V) in COVID-19 patients in experienced or reference centers, in selected patients with severe ARDS with \nrefractory hypoxemic and/or hypercapnic respiratory failure, in \nthe absence of contraindications, in the absence of response to conventional therapies, especially prone decubitus [66]. The Surviving Sepsis Campaign guidelines for the management of adult patients with COVID-19 disease in the ICU establish a \nweak recommendation regarding the use of ECMO as rescue \ntherapy, always taking into account the availability of resourc -\nes and the safety of professionals [67].\nDifferent meta-analyses have been performed on the use \nof ECMO in patients with COVID 19 with a very high mortality, \nup to 82%, considering that the high pressure of care during \nthe first wave of the pandemic could have contributed to the \npoor results. A systematic review published in 2021, which in -\ncluded 1,545 patients with V-V ECMO shows a hospital survival \nof 49%, with 17.7% of patients still dependent on ECMO at the \ntime of publication. Another systematic review and meta-anal -\nysis in 1,986 patients showed that in 98% of cases V-V ECMO \nwas used for respiratory support with an in-hospital mortality COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434427There is a need for good quality evidence on the magni -\ntude of effect in specific COVID-19 severity subgroups in which \nthere is greater benefit. Benefit with early administration of CS \n(<7 days of ARDS onset) on reduction of in-hospital mortality \nand duration of MV in ARDS cases is demonstrated [75]. The \nevidence for its use in the context of septic shock associat -\ned with COVID-19 remains to be elucidated. Benefit has also \nbeen proven in severe cases with hypoxemia with or without \nthe need for MV [77,78]. As for patients with mild to moderate \nCOVID, no reduction in mortality was observed in the RECOV -\nERY study [77]. There is a need to confirm whether CS admin -\nistration in patients with COVID-19 who do not require oxygen \nsupplementation or respiratory support (first week of the dis -\nease course), may be harmful and is associated with delayed \nviral clearance and increased risk of mortality.\nThe optimal time to initiate CS therapy in COVID-19 is not \nwell understood. In the RECOVERY study, the mortality benefit was only evident in patients with a symptom duration of 7 days \nor more [77]. On the other hand, low doses of corticosteroids \nmay not have a significant impact on the duration of SARS-\nCoV-2 viral shedding [84]. It is necessary to clarify whether \nthere is any subpopulation of infected patients in which the \nearly use of corticosteroids may be justified to prevent progres -\nsion to more severe forms of COVID-19. \nThere are doubts as to whether the benefit of CS on mor -\ntality is a class effect or there are differences between them. According to the RECOVERY study, such a class effect could exist [77]. However, some published studies establishing direct comparisons between IQs show some discrepancy in relation to \nthis class effect [85-87].\n Another aspect that remains unclear is the correct dose. \nMost published studies, as well as clinical recommendations, \nuse low doses of corticosteroids (dexamethasone 6 mg/day \nor equivalent doses), which do not seem to have a significant \nimpact on viral clearance. In published studies comparing dif -\nferent doses of corticosteroids, no clinical benefit seems to be \nshown with high doses of corticosteroids [88-90]. However, \nthere are studies that obtain better results at higher doses [91]. There are also questions about whether higher doses may be beneficial in patients who develop ARDS [92].\nIn relation to the regimen, some studies have shown an \nadvantage in treatment with corticosteroid pulses versus fixed \ndaily doses, probably due to the activation of the non-genomic \ncorticosteroid pathway [93].\n Few studies have reported adverse effects of glucocorti -\ncoids in patients with COVID-19. Although adverse event rates \nappear relatively low, potential side effects should be evaluat -\ned to improve patient outcomes. \nWHAT IS THE REALITY OF COVID-19 IN AFRICAN \nCOUNTRIES?\nLittle is known about the extent of SARS-CoV-2 transmis -\nsion or its impact in Africa. In the absence of data, there is a \nwidespread view that, in Africa, COVID-19 has had little im -for up to 10 days in patients with COVID 19 with pulmonary \ninvolvement reduced 28-day mortality (22.9% vs. 25.7%) in hypoxemic patients, compared to standard practice [77]. The benefit was obtained in patients who were receiving MV at the time of randomization (29.3% vs. 41.4%) or oxygen ther -\napy (23.3% vs. 26.2%), but not in patients without hypoxemia (17.8% vs. 14.0%) [77]. To support the results of the RECOV -\nERY study, the WHO, through the Rapid Evidence Assessment for COVID-19 Therapies (REACT) Working Group, conducted a \nprospective meta-analysis of 7 RCTs that contained RECOVERY \nand included 1,703 critically ill patients with COVID-19. The \nresults showed that administration of CS (dexamethasone, hy-\ndrocortisone, or methylprednisolone) to hospitalized critically \nill patients with suspected or confirmed COVID-19, compared \nwith usual care or placebo, was associated with lower all-cause \nmortality at 28 days, with no increased risk of serious adverse events [78]. This meta-analysis did not find a greater effect in \nhypoxemic patients who underwent MV versus those who did \nnot require MV, nor did the effect depend on the duration of symptoms [78]. \nThese findings contrast with the results reported in a series \nof systematic reviews (SR) and meta-analyses of studies pub -\nlished in the first months of the pandemic, in which treatment with CS did not reduce mortality in cases of severe COVID-19, and in some of them was even associated with higher mortali -\nty, longer hospital stay, and a higher rate of bacterial infection and hypokalemia [79-82]. A limitation of these meta-analyses was the absence of RCTs with optimized design and the inclu -\nsion of observational studies and case series, which had various confounding factors or biases.\nSubsequently, other systematic reviews have been pub -\nlished with a greater representation of RCTs, confirming the beneficial effect of corticosteroids, including a reduction in the mortality rate of patients with severe or critical COVID-19 and the need for mechanical ventilation [83-89]. The Cochrane collaboration updates through an ongoing systematic review approach the evidence on the efficacy and safety of CS in the treatment of people with COVID-19. In the latest update (August 2021), 11 randomized clinical trials with 8,075 par-ticipants, completed by April 16, 2021, were included [83]. The results showed moderate certainty evidence for the likelihood of CS slightly reducing all-cause mortality in persons hospi -\ntalized for symptomatic COVID-19. In addition, there was low certainty evidence for a reduction in ventilator-free days. No meta-analyses on quality of life and adverse effects were per -\nformed, due to high risk of bias, heterogeneous definitions, and \nlack of information. Nor was it possible to identify published \nRCTs on non-hospitalized patients with mild or asymptomatic \ndisease treated with CS, so that, at present, there is no evidence \nin this regard [83]. We identified 42 ongoing and 16 completed \nbut unpublished RCTs in trial registries that point to possible \nchanges in effect estimates and certainty of evidence in the \nfuture. \nCS have become first-line treatment for hospitalized pa -\ntients with COVID-19. However there are still unresolved ques -\ntions regarding the treatment of COVID-19 infection with CS:COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434428WHAT ARE THE MAIN UNCERTAINTIES IN THE \nVACCINE ISSUE?\nThe uncertainties have to do with the evolution of the \npandemic itself, the characteristics of the vaccines and the re-\nsulting immunity. The well-documented historical experience of how and when respiratory virus pandemics ended is very \nlimited and corresponds mainly to influenza pandemics. The \ntwo major pandemics, the \u201cRussian\u201d influenza pandemic at the \nend of the nineteenth century [103] and that of the 1918 influ -\nenza, ended in the absence of vaccines, and the return to nor -\nmal life occurred very quickly. However, it is not known what \nexactly was the virus causing the \u201cRussian\u201d pandemic and why \nboth pandemics were relatively short-lived: the \u201cRussian\u201d one \nhad only a few waves in about four years, and the 1918 one had three waves in three years. It seems that the H1N1 virus responsible for the 1918 pandemic continued to circulate until \n1957, and then disappeared and re-emerged in 1977. The rea -\nsons for this behavior of the virus are also not well known. For \nall these reasons, we do not know when or how the coronavi -\nrus pandemic will end. We do not know when, partly because \nwe do not know whether a new variant will be selected that, in addition to being highly transmissible (in order to replace omicron), has some escape from the immunity generated by \nnatural infection or vaccination. And we do not know how, i.e. \nwhether the virus will disappear or whether, as seems more \nlikely, it will remain with us endemically, and perhaps mani -\nfest itself mainly in winter when people concentrate their lives indoors.\nIf SARS-CoV-2 infection remains endemic (most likely be -\ncause there is beginning to be evidence of animal reservoirs, such as deer), it seems reasonable to maintain a medium- to long-term vaccination strategy. The question is who to vac -\ncinate, how often to vaccinate, and with what type of vac -\ncines. If the severity of infection in the population as a whole is similar or less than that of omicron, it seems reasonable to revaccinate (or give booster doses) only to those who are vulnerable to the most severe forms of the disease, because: \na) they have a certain degree of immunosuppression accom -\npanied by a poor response to vaccination, or b) even if they \nhave a good response to previous vaccination, they are very \nold and have high comorbidity that causes them to lose immu -\nnity fairly quickly. In the rest of the population it would not be essential to revaccinate or administer a booster, because there \nis accumulating evidence that cellular immunity (the most im-\nportant to avoid severe disease) is reasonably well maintained \nfor a long time against all known variants of SARS-CoV-2, and \nis improved with repeated contact with the virus or vaccine \nboosters [104-106]. \nThe frequency of vaccination or booster will depend on \nthe duration of immunity in vulnerable persons, on the ap-\npearance of new variants with certain vaccine escape, and on \nthe interaction between these last two variables. It is too early \nto tell, but from recent experience on the loss of vaccine effec -\ntiveness with the usual vaccines so far and especially the high efficacy of boosters reducing symptomatic and severe infec -pact. But this idea is generated in the absence of evidence and \ntherefore in the absence of scientific evidence.\nThere has been much speculation, with the term \n\u201cAfrican paradox\u201d being used because of the low prevalence \nof COVID-19. There are different theories that have tried to explain this fact: a high exposure to other coronaviruses that would make them cross-immune, that the population is younger and therefore less vulnerable, or that the experience during the Ebola crisis would have allowed public health agencies throughout Africa to better contain COVID-19 [94] and that certain live attenuated vaccines (BCG vaccine, oral polio vaccine and measles vaccine) would have created non-specific innate immunity that would also protect against COVID-19 [95-97]. But the reality seems very different from these theories and most likely there is an under-diagnosis, with little data available, mainly due to lack of resources. Most of the data on the impact of the pandemic come from South \nAfrica, documenting more than 750,000 cases, more than \n20,000 deaths and a case fatality rate of 2.7% [98-100].\nIn a cross-sectional study, conducted in November 2020 \nin Nairobi, Kenya [101], including 1,164 individuals, the adjust -\ned seroprevalence was 34.7%. Half of the enrolled households had at least one positive participant. COVID-19 in that study was 2 times more frequent in persons aged 20-59 years than \nin those aged 0-9 years. Infection case fatality rates were 40 per 100,000 infections, being higher in persons older than 60 \nyears. According to this work, more than one-third of Nairobi \nresidents had been exposed to SARS-CoV-2 in November 2020, \nbut with a case fatality rate 10 times lower than that reported \nin Europe and the U.S. The national surveillance system detect -\ned 2.4% of all SARS-CoV-2 infections in Nairobi, reflecting an underestimation ratio of 42:1.\nA paper providing routine surveillance data in Zambia has \nbeen published in February 2022 [102]. Since 2017 this group \nhas been conducting systematic postmortem surveillance for \nrespiratory pathogens among deceased infants in Lusaka, Zam -\nbia. When the pandemic breaks out, they employ such systems \nfor SARS-CoV-2 detection. The study was conducted from June to September 2020 (3 months). A total of 372 deceased patients were included, with PCR available in 364 (97.8%). SARS-CoV-2 was detected in 58/364 (15.9%) at the recommended cycle threshold value of <40 and in 70/364 (19.2%) when amplified at any PCR detection level. None of the patients were tested before death. The prevalence of mortality in Zambia, based on the data reported in this paper, is surprisingly high. Deaths from COVID occurred across a broader age spectrum than reported elsewhere and were concentrated in persons younger than 65 \nyears, aged 20 to 59 years. Ten percent (7/70) of deaths occurred \nin children, including three infants. No differences by sex were found. The most common conditions were identified in at least 10% of the cohort: tuberculosis (31%), hypertension (27%), HIV/AIDS (23%), alcohol consumption (17%) and diabetes (13%). This study, with limitations but well conducted, puts the spotlight on \nthe need to establish prevalence in this continent, because if the \ndata obtained were generalizable, the impact of COVID-19 in Af -\nrica would have been considerably underestimated.COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434429logical alterations in the CT, with 10% of totally established \nfibrosis and around 15% with persistent interstitial infiltrate [116]. A substudy published by one of the participating hospi -\ntals shows even higher figures of pulmonary fibrosis, reaching \n21% and ground glass pattern in 30% [117]. Also from the CI -\nBERESRESUCOVID cohort, there are recent data from a sub-\ngroup of 67 subjects showing fibrosis data at 6 months in CT, with figures above 30% and already without any modification \nin relation to the previous data at 3 months [118]. Another \nseries, with data at 6 months, confirms a high incidence, be -\ntween 30 and 50%, of pulmonary fibrosis with functional im -\npairment in very severe patients, with lower figures of 20% in \npatients with moderate disease [119].\nThe figures are confirmed in studies that are primarily \nradiological based but which relate imaging changes to func-\ntional impairment and find established fibrosis patterns in 35% of patients, most of whom also have impaired diffusion \ncapacity. when the studies are exclusively radiological [120]. \nFinally, we have at least one series of patients with follow-up \nat 3, 6, 9 and 12 months. These patients, severe but not requir -\ning invasive mechanical ventilation, at 12 months presented a ground glass interstitial pattern in 24% of the cases, with al -\ntered diffusion capacity, but not severe fibrosis. Of greatest in -\nterest is that the changes did not change after the 9th month \nof life [121]. \nAs for the treatment of post-COVID-19 pulmonary fibro -\nsis, the drugs used in the treatment of idiopathic pulmonary fibrosis are being used in practice, but there is no evidence of their efficacy. A population-based study conducted in Ko -\nrea has shown that idiopathic pulmonary fibrosis is associat -\ned with an increased incidence of COVID-19 [122] and very recently a bioinformatics analysis study has hypothesized that post-COVID fibrosis may share gene networks with id -\niopathic pulmonary fibrosis [123]. Studies are underway to evaluate the efficacy of pirfenidone (IL-6 inhibitor) and \nnintedanib (IL-1 inhibitor) [124] and other molecules with \nantifibrotic capacity [125]. In patients with terminal disease, the therapeutic option is transplantation, although so far the number of reported cases of this procedure in patients with \npost-COVID lung lesions is not high. Only one case has been reported in Spain, which has not been published in scientific \njournals. We have a multicenter and multinational series of 12 cases, with good results [126] and very recently a large American series has been published with 214 cases of COV-ID-19 patients transplanted between October 2020 and Sep -\ntember 2021, which corresponds to 7% of the total number of transplants performed in the United States in that period \nof time. Of these, 140 cases were performed in unresolved \nacute situation and 74 in already chronic fibrosis. It should be noted that 118 patients were on ECMO and 97 on me -\nchanical ventilation. Survival at 3 months was 95%, which should be considered a good result [127]. There is no doubt that transplantation has to be considered in end-stage lung disease secondary to COVID-19 and some clear protocols for \nits performance have already been published [128].tion, it is possible that the frequency should be at least annual. \nFinally, the ideal is to use sterilizing vaccines, because they re -\nduce the risk of infection (and therefore community transmis -\nsion) more than the current ones, which are only neutralizing; \nbut sterilizing vaccines have not yet been fully developed, nor \ntheir efficacy tested, nor their costs evaluated. In the medium term, emphasis should be placed on vaccines that are easy to \nstore, that generate longer-lasting protection than the cur -\nrent ones derived from mRNA technology, that are simple to manufacture and less costly, such as some based on tradition -\nal technologies that are being approved very recently. Finally, \nthey should protect against any new variant of SARS-CoV-2. We will see if all this comes to fruition.\nWHAT DO WE KNOW ABOUT THE LONG-TERM \nIMPACT OF COVID-19 ON LUNG FUNCTION?\nOne of the major medium and long-term complications in \npatients who have suffered SARS-CoV-2 infection is the devel -\nopment of interstitial disease with pulmonary fibrosis, whose \npathogenesis is linked to the existence of acute respiratory \ndistress syndrome, but in which capillary thrombosis, drug tox -\nicity and, where appropriate, the use of ECMO could also be in -\nvolved. This had already been reported in relation to outbreaks \nof SARS-CoV-1 and MERS, in which series of patients followed over the long term have shown the presence of radiological alterations or functional deterioration in up to 30% of patients \nwith a history of hospitalization with or without admission to \nthe ICU [107,108].\nThe radiological pattern of interstitial disease with ground \nglass image and fibrosis appears already at the time of dis -\ncharge, mainly, but not exclusively, in patients who have sur-vived severe and critical illness. Studies published at the be -\nginning of the pandemic show that between 50 and 75% of patients who suffered severe or critical illness have alterations in pulmonary function in the first month after discharge [109, 110] and that this alteration is related to the degree of radi -\nological involvement. Already in studies at 3-4 months after discharge, the radiological alteration figures are higher than \n45% with pulmonary function alteration ranging between 20 \nand 70%, but this depends on the severity of the acute disease [111]. Thus, in a study carried out in patients with mild disease and previous normal lung function, no functional alterations were observed at 3 months after the disease [112]. In studies \nstratifying by severity, the occurrence of interstitial disease is \nclearly related to the severity of the disease, such that in se -\nvere and very severe patients, severe fibrosis is observed above \n35%, while in moderate disease, interstitial changes are mild [113,114]. In very severe and critical patients discharged from the ICU, the number of radiological and functional alterations in some series reaches up to 50% of the cases [115]. \nOne of the most important series available is that of the \nSpanish CIBERESUCICOVID study, with 1,255 patients dis -\ncharged from the ICU, for whom 3-month follow-up data have \nbeen published. In 65% of the cases, diffusion capacity alter -\nation persists and more than 93% of the cases present radio-COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434430DOI: \n14. Juli\u00e1n-Jim\u00e9nez A, Eduardo Garc\u00eda D, Gonz\u00e1lez Del Castillo J, Penna \nGuimar\u00e3es H, Garc\u00eda-Lamberechts EJ, Men\u00e9ndez E, et al. Key is -\nsues in emergency department management of COVID-19: propos-\nals for improving care for patients in Latin America. Emergencias. \n2021;33(1):42-58. DOI: \n15. Gonz\u00e1lez Del Castillo J. Keys to interpreting predictive models for \nthe patient with COVID-19. Emergencias. 2021;33(4):251-3. DOI: \n16. Mart\u00edn-Rodr\u00edguez F, Sanz-Garc\u00eda A, Alberdi Iglesias A, Ortega Rab -\nbione G, Del Pozo Vegas C, de la Torre-D\u00edez I, et al. Mortality risk model for patients with suspected COVID-19 based on informa -\ntion available from an emergency dispatch center. Emergencias. 2021;33(4):265-72. DOI: \n17. Garc\u00eda-Mart\u00ednez A, L\u00f3pez-Barbeito B, Coll-Vinent B, Placer A, Font \nC, Rosa Vargas C, et al. Mortality in patients treated for COVID-19 in the emergency department of a tertiary care hospital during the first phase of the pandemic: Derivation of a risk model for emer -\ngency departments. Emergencias. 2021;33(4):273-81. DOI: \n18. L\u00f3pez-Izquierdo R, Ruiz Albi T, Bermejo-Mart\u00edn JF, Almansa R, Vil -\nlafa\u00f1e Sanz FV, Arroyo Olmedo L, et al. Risk models for predicting \nin-hospital mortality from COVID-19 pneumonia in the elderly. \nEmergencias. 2021;33(4):282-91. DOI: \n19. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et \nal. Prediction models for diagnosis and prognosis of covid-19: sys -\ntematic review and critical appraisal. Bmj. 2020;369:m1328. DOI: 10.1136/bmj.m1328\n20. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et \nal. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospec -\ntive, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55. DOI: 10.1016/s1473-3099(21)00460-6\n21. Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz \nK, Khunti K, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. Bmj. 2021;374:n2244. DOI: 10.1136/bmj.\nn2244\n22. Yek C, Warner S, Wiltz JL, Sun J, Adjei S, Mancera A, et al. Risk \nFactors for Severe COVID-19 Outcomes Among Persons Aged \u226518 \nYears Who Completed a Primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. \nMMWR Morb Mortal Wkly Rep. 2022;71(1):19-25. DOI: 10.15585/\nmmwr.mm7101a4\n23. Bierle DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, Arndt LL, \nWilker CG, et al. Monoclonal Antibody Treatment of Breakthrough \nCOVID-19 in Fully Vaccinated Individuals with High-Risk Comor-bidities. J Infect Dis. 2022;225(4):598-602. DOI: 10.1093/infdis/\njiab570\n24. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, \net al. Factors associated with COVID-19-related death using Open -\nSAFELY. Nature. 2020;584(7821):430-6. DOI: 10.1038/s41586-020-2521-4\n25. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Bad -\ndour LM, et al. Global Burden of Cardiovascular Diseases and Risk FUNDING\nNone to declare \nCONFLICTS OF INTEREST \nThe authors declare no conflicts of interest\nREFERENCES\n1. Zhang L, Shen FM, Chen F, Lin Z. Origin and evolution of the 2019 \nnovel coronavirus. Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa112\n2. Wu Z, Jin Q, Wu G, Lu J, Li M, Guo D, et al. SARS-CoV-2\u2019s origin \nshould be investigated worldwide for pandemic prevention. Lancet. \n2021. DOI: 10.1016/s0140-6736(21)02020-1\n3. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The \nproximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-2. DOI: 10.1038/s41591-020-0820-9\n4. Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Chris -\ntoph A, Wertheim JO, et al. The origins of SARS-CoV-2: A critical re -\nview. Cell. 2021;184(19):4848-56. DOI: 10.1016/j.cell.2021.08.017\n5. Senior K. Recent Singapore SARS case a laboratory accident. Lancet \nInfect Dis. 2003;3(11):679. DOI: 10.1016/s1473-3099(03)00815-6\n6. Lim PL, Kurup A, Gopalakrishna G, Chan KP, Wong CW, Ng LC, et al. \nLaboratory-acquired severe acute respiratory syndrome. N Engl J Med. 2004;350(17):1740-5. DOI: 10.1056/NEJMoa032565\n7. Est\u00e9vez Reboredo RM. [Origin of SARS-CoV-2 theories, keys and \nunknowns of an emerged disease.]. Rev Esp Salud Publica. 2020;94. \nDOI: \n8. WHO . WHO-convened Global Study of Origins of SARS-CoV-2: \nChina Part Joint WHO-China Study 14 January-10 Febru -\nary 2021. Available at: https://appswhoint/gb/COVID-19/pdf_\nfiles/2021/28_03/20210328-%20Full%20reportpdf. \n9. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe dis -\nease and death. Bmj. 2020;368:m1198. DOI: 10.1136/bmj.m1198\n10. Berenguer J, Borobia AM, Ryan P, Rodr\u00edguez-Ba\u00f1o J, Bell\u00f3n JM, \nJarr\u00edn I, et al. Development and validation of a prediction mod -\nel for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021. DOI: 10.1136/thorax-\njnl-2020-216001\n11. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk \nstratification of patients admitted to hospital with covid-19 using \nthe ISARIC WHO Clinical Characterisation Protocol: development \nand validation of the 4C Mortality Score. Bmj. 2020;370:m3339. DOI: 10.1136/bmj.m3339\n12. Sol\u00e0 S, Jacob J, Azeli Y, Trenado J, Morales-\u00c1lvarez J, Jim\u00e9n -\nez-F\u00e0brega FX. Priority in interhospital transfers of patients with severe COVID-19: development and prospective validation of a tri -\nage tool. Emergencias. 2022;34(1):29-37. DOI: \n13. Albert A, Jacob J, Malchair P, Llopis F, Fuentes L, Mart\u00edn C, et al. Pre -\ndictors of revisits within 1 year by patients after acute COVID-19: the HUBCOVID365 cohort study. Emergencias. 2022;34(1):38-46. COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434431risk factors for mortality among long-term care facility residents \nhospitalized due to COVID-19 in Spain. J Gerontol A Biol Sci Med Sci. 2021. DOI: 10.1093/gerona/glab305\n39. Pranata R, Huang I, Lim MA, Yonas E, Vania R, Kuswardhani RAT. \nDelirium and Mortality in Coronavirus Disease 2019 (COVID-19) \n- A Systematic Review and Meta-analysis. Arch Gerontol Geriatr. 2021;95:104388. DOI: 10.1016/j.archger.2021.104388\n40. Cunha AIL, Veronese N, de Melo Borges S, Ricci NA. Frailty as a pre -\ndictor of adverse outcomes in hospitalized older adults: A system -\natic review and meta-analysis. Ageing Res Rev. 2019;56:100960. DOI: 10.1016/j.arr.2019.100960\n41. Dumitrascu F, Branje KE, Hladkowicz ES, Lalu M, McIsaac DI. Associ -\nation of frailty with outcomes in individuals with COVID-19: A liv -\ning review and meta-analysis. J Am Geriatr Soc. 2021;69(9):2419-\n29. DOI: 10.1111/jgs.17299\n42. Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri \nA, et al. The effect of frailty on survival in patients with COVID-19 \n(COPE): a multicentre, European, observational cohort study. \nLancet Public Health. 2020;5(8):e444-e51. DOI: 10.1016/s2468-\n2667(20)30146-8\n43. Welch C. Age and frailty are independently associated with in -\ncreased COVID-19 mortality and increased care needs in survi -\nvors: results of an international multi-centre study. Age Ageing. \n2021;50(3):617-30. DOI: 10.1093/ageing/afab026\n44. H\u00e4gg S, Jylh\u00e4v\u00e4 J, Wang Y, Xu H, Metzner C, Annetorp M, et al. \nAge, Frailty, and Comorbidity as Prognostic Factors for Short-Term \nOutcomes in Patients With Coronavirus Disease 2019 in Geriatric \nCare. J Am Med Dir Assoc. 2020;21(11):1555-9.e2. DOI: 10.1016/j.\njamda.2020.08.014\n45. Subramaniam A, Shekar K, Afroz A, Ashwin S, Billah B, Brown H, \net al. Frailty and mortality associations in patients with COVID-19: A Systematic Review and Meta-analysis. Intern Med J. 2022. DOI: 10.1111/imj.15698\n46. Cant\u00f3n R, De Lucas Ramos P, Garc\u00eda-Botella A, Garc\u00eda-Lled\u00f3 \nA, G\u00f3mez-Pav\u00f3n J, Gonz\u00e1lez Del Castillo J, et al. New variants of SARS-CoV-2. Rev Esp Quimioter. 2021;34(5):419-28. DOI: \n10.37201/req/071.2021\n47. Centers for Disease Control and Prevention. 2021. SARS-CoV-2 \nVariant Classifications and Definitions. Available at: ( https://ww-\nwcdcgov/coronavirus/2019-ncov/variants/variant-classification -\nshtml. \n48. Hirabara SM, Serdan TDA, Gorjao R, Masi LN, Pithon-Curi TC, Co -\nvas DT, et al. SARS-COV-2 Variants: Differences and Potential of \nImmune Evasion. Front Cell Infect Microbiol. 2021;11:781429. DOI: \n10.3389/fcimb.2021.781429\n49. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew \nM, Jin T. Mutations of SARS-CoV-2 spike protein: Implications on \nimmune evasion and vaccine-induced immunity. Semin Immunol. 2021;55:101533. DOI: 10.1016/j.smim.2021.101533\n50. Kim S, Nguyen TT, Taitt AS, Jhun H, Park HY, Kim SH, et al. SARS-\nCoV-2 Omicron Mutation Is Faster than the Chase: Multiple \nMutations on Spike/ACE2 Interaction Residues. Immune Netw. \n2021;21(6):e38. DOI: 10.4110/in.2021.21.e38Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll \nCardiol. 2020;76(25):2982-3021. DOI: 10.1016/j.jacc.2020.11.010\n26. Anonymous . Estimation of the global prevalence of demen -\ntia in 2019 and forecasted prevalence in 2050: an analysis for \nthe Global Burden of Disease Study 2019. Lancet Public Health. \n2022;7(2):e105-e25. DOI: 10.1016/s2468-2667(21)00249-8\n27. Wu Z, McGoogan JM. Characteristics of and Important Lessons \nFrom the Coronavirus Disease 2019 (COVID-19) Outbreak in China: \nSummary of a Report of 72  314 Cases From the Chinese Center for \nDisease Control and Prevention. Jama. 2020;323(13):1239-42. DOI: \n10.1001/jama.2020.2648\n28. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of \ncomorbidities and its effects in patients infected with SARS-CoV-2: \na systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-\n5. DOI: 10.1016/j.ijid.2020.03.017\n29. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Asso -\nciations of type 1 and type 2 diabetes with COVID-19-related mor -\ntality in England: a whole-population study. Lancet Diabetes Endo -\ncrinol. 2020;8(10):813-22. DOI: 10.1016/s2213-8587(20)30272-2\n30. Rodilla E, Saura A, Jim\u00e9nez I, Mendiz\u00e1bal A, Pineda-Cantero A, \nLorenzo-Hern\u00e1ndez E, et al. Association of Hypertension with All-\nCause Mortality among Hospitalized Patients with COVID-19. J Clin Med. 2020;9(10). DOI: 10.3390/jcm9103136\n31. Salazar MR. Is hypertension without any other comorbidities an \nindependent predictor for COVID-19 severity and mortality? J Clin Hypertens (Greenwich). 2021;23(2):232-4. DOI: 10.1111/jch.14144\n32. Sun Y, Guan X, Jia L, Xing N, Cheng L, Liu B, et al. Independent \nand combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. J Clin Hypertens (Greenwich). 2021;23(2):218-31. DOI: \n10.1111/jch.14146\n33. Burns A, Howard R. COVID-19 and dementia: A deadly combina -\ntion. Int J Geriatr Psychiatry. 2021;36(7):1120-1. DOI: 10.1002/\ngps.5551\n34. Yang H, Liang X, Hou H, Xu J, Shi L, Wang Y. The association of \ndementia with COVID-19 mortality: Evidence based on adjust -\ned effect estimates. J Infect. 2021;82(5):e6-e10. DOI: 10.1016/j.jinf.2021.02.013\n35. Damayanthi H, Prabani KIP, Weerasekara I. Factors Associated for \nMortality of Older People With COVID 19: A Systematic Review and \nMeta-analysis. Gerontol Geriatr Med. 2021;7:23337214211057392. DOI: 10.1177/23337214211057392\n36. Hariyanto TI, Putri C, Arisa J, Situmeang RFV, Kurniawan A. De -\nmentia and outcomes from coronavirus disease 2019 (COVID-19) \npneumonia: A systematic review and meta-analysis. Arch Gerontol \nGeriatr. 2021;93:104299. DOI: 10.1016/j.archger.2020.104299\n37. Liu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The Impact of De -\nmentia on the Clinical Outcome of COVID-19: A Systematic Review \nand Meta-Analysis. J Alzheimers Dis. 2020;78(4):1775-82. DOI: \n10.3233/jad-201016\n38. Ramos-Rinc\u00f3n JM, Bernabeu-Whittel M, Fiteni-Mera I, L\u00f3pez-Sam -\npalo A, L\u00f3pez-R\u00edos C, Garc\u00eda-Andreu MD, et al. Clinical features and COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-4344322021:8971900211048139. DOI: 10.1177/08971900211048139\n65. Peek GJ, Clemens F, Elbourne D, Firmin R, Hardy P, Hibbert C, et al. \nCESAR: conventional ventilatory support vs extracorporeal mem -\nbrane oxygenation for severe adult respiratory failure. BMC Health \nServ Res. 2006;6:163. DOI: 10.1186/1472-6963-6-163\n66. Vidal-Cort\u00e9s P, D\u00edaz Santos E, Aguilar Alonso E, Amezaga Men\u00e9ndez \nR, Ballesteros M, Bod\u00ed MA, et al. Recommendations for the man -\nagement of critically ill patients with COVID-19 in Intensive Care \nUnits. Med Intensiva (Engl Ed). 2022;46(2):81-9. DOI: 10.1016/j.\nmedine.2021.11.019\n67. Alhazzani W, Evans L, Alshamsi F, M\u00f8ller MH, Ostermann M, Pres -\ncott HC, et al. Surviving Sepsis Campaign Guidelines on the Man -\nagement of Adults With Coronavirus Disease 2019 (COVID-19) in \nthe ICU: First Update. Crit Care Med. 2021;49(3):e219-e34. DOI: 10.1097/ccm.0000000000004899\n68. Ramanathan K, Shekar K, Ling RR, Barbaro RP, Wong SN, Tan CS, \net al. Extracorporeal membrane oxygenation for COVID-19: a sys -\ntematic review and meta-analysis. Crit Care. 2021;25(1):211. DOI: \n10.1186/s13054-021-03634-1\n69. Nagraj S, Karia R, Hassanain S, Ghosh P, Shah VR, Thomas A. Role \nof Invasive Mechanical Ventilation and ECMO in the Manage -\nment of COVID-19: A Systematic Review. Indian J Crit Care Med. \n2021;25(6):691-8. DOI: 10.5005/jp-journals-10071-23870\n70. Chong WH, Saha BK, Medarov BI. A systematic review and me -\nta-analysis comparing the clinical characteristics and outcomes of COVID-19 and influenza patients on ECMO. Respir Investig. \n2021;59(6):748-56. DOI: 10.1016/j.resinv.2021.07.006\n71. Chong WH, Saha BK, Medarov BI. Clinical Characteristics Between \nSurvivors and Nonsurvivors of COVID-19 Patients Requiring Extra -\ncorporeal Membrane Oxygenation (ECMO) Support: A Systematic Review and Meta-Analysis. J Intensive Care Med. 2022;37(3):304-\n18. DOI: 10.1177/08850666211045632\n72. Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan \nE, et al. Extracorporeal membrane oxygenation support in COV -\nID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020. DOI: 10.1016/s0140-\n6736(20)32008-0\n73. Schmidt M, Hajage D, Lebreton G, Monsel A, Voiriot G, Levy D, et al. \nExtracorporeal membrane oxygenation for severe acute respiratory \ndistress syndrome associated with COVID-19: a retrospective co-hort study. Lancet Respir Med. 2020;8(11):1121-31. DOI: 10.1016/\ns2213-2600(20)30328-3\n74. MacLaren G, Combes A, Brodie D. What\u2019s new in ECMO for COV -\nID-19? Intensive Care Med. 2021;47(1):107-9. DOI: 10.1007/\ns00134-020-06284-z\n75. FakhriRavari A, Jin S, Kachouei FH, Le D, Lopez M. Systemic corticos -\nteroids for management of COVID-19: Saving lives or causing harm? \nInt J Immunopathol Pharmacol. 2021;35:20587384211063976. \nDOI: 10.1177/20587384211063976\n76. World Health Organisation. Living guidance for clinical manage -\nment of COVID-19. WHO; 2021 [updated november 29. 2021; \nassessed february 10th 2022 ]. Available at: https://wwwwhoint/\npublications/i/item/WHO-2019-nCoV-clinical-2021-2. 51. Park G, Hwang BH. SARS-CoV-2 Variants: Mutations and Effec -\ntive Changes. Biotechnol Bioprocess Eng. 2021;26(6):859-70. DOI: \n10.1007/s12257-021-0327-3\n52. Liu H, Wei P, Kappler JW, Marrack P, Zhang G. SARS-CoV-2 Variants \nof Concern and Variants of Interest Receptor Binding Domain Mu -\ntations and Virus Infectivity. Front Immunol. 2022;13:825256. DOI: \n10.3389/fimmu.2022.825256\n53. Yang WT, Huang WH, Liao TL, Hsiao TH, Chuang HN, Liu PY. SARS-\nCoV-2 E484K Mutation Narrative Review: Epidemiology, Immune \nEscape, Clinical Implications, and Future Considerations. Infect \nDrug Resist. 2022;15:373-85. DOI: 10.2147/idr.S344099\n54. Ghosh N, Nandi S, Saha I. A review on evolution of emerging SARS-\nCoV-2 variants based on spike glycoprotein. Int Immunopharmacol. \n2022;105:108565. DOI: 10.1016/j.intimp.2022.108565\n55. Salehi-Vaziri M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh \nK, Pouriayevali MH, Jalali T, et al. The ins and outs of SARS-CoV-2 \nvariants of concern (VOCs). Arch Virol. 2022;167(2):327-44. DOI: \n10.1007/s00705-022-05365-2\n56. Yin J, Li C, Ye C, Ruan Z, Liang Y, Li Y, et al. Advances in the de -\nvelopment of therapeutic strategies against COVID-19 and per -\nspectives in the drug design for emerging SARS-CoV-2 variants. \nComput Struct Biotechnol J. 2022;20:824-37. DOI: 10.1016/j.\ncsbj.2022.01.026\n57. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou \nD, Migkou M, Tzanninis IG, et al. Emerging treatment strategies \nfor COVID-19 infection. Clin Exp Med. 2021;21(2):167-79. DOI: 10.1007/s10238-020-00671-y\n58. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. \nAn update on COVID-19 pandemic: the epidemiology, pathogen -\nesis, prevention and treatment strategies. Expert Rev Anti Infect \nTher. 2021;19(7):877-88. DOI: 10.1080/14787210.2021.1863146\n59. Eloy P, Le Grand R, Malvy D, Guedj J. Combined treatment of mol -\nnupiravir and favipiravir against SARS-CoV-2 infection: One  + zero \nequals two? EBioMedicine. 2021;74:103663. DOI: 10.1016/j.ebi -\nom.2021.103663\n60. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghaz -\naryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults \nwith Covid-19. N Engl J Med. 2021;384(9):795-807. DOI: 10.1056/\nNEJMoa2031994\n61. Thoms BL, Gosselin J, Libman B, Littenberg B, Budd RC. Efficacy \nof Combination Therapy with the JAK Inhibitor Baricitinib in the \nTreatment of COVID-19. SN Compr Clin Med. 2022;4(1):42. DOI: 10.1007/s42399-022-01121-4\n62. RECOVERY Collaborative Group. Tocilizumab in patients admitted \nto hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-45. DOI: 10.1016/s0140-6736(21)00676-0\n63. Deeks ED. Casirivimab/Imdevimab: First Approval. Drugs. \n2021;81(17):2047-55. DOI: 10.1007/s40265-021-01620-z\n64. Nhean S, Varela ME, Nguyen YN, Juarez A, Huynh T, Udeh D, et al. \nCOVID-19: A Review of Potential Treatments (Corticosteroids, Rem -\ndesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/\nImdevimab) and Pharmacological Considerations. J Pharm Pract. COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-434433of Hospitalized COVID-19 Patients. Antibiotics (Basel). 2021;10(12). \nDOI: 10.3390/antibiotics10121510\n89. Ji J, Wu M, Zhong L, Liu Z, Wang C, Shao Z, et al. Early, low-dose, \nshort-term methylprednisolone decreased the mortality in critical COVID-19 patients: A multicenter retrospective cohort study. J In-fect. 2021;82(4):84-123. DOI: 10.1016/j.jinf.2020.11.001\n90. Munch MW, Myatra SN, Vijayaraghavan BKT, Saseedharan S, Ben -\nfield T, Wahlin RR, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With \nCOVID-19 and Severe Hypoxemia: The COVID STEROID 2 Rand -\nomized Trial. Jama. 2021. DOI: 10.1001/jama.2021.18295\n91. Pinz\u00f3n MA, Ortiz S, Holgu\u00edn H, Betancur JF, Cardona Arango D, \nLaniado H, et al. Dexamethasone vs methylprednisolone high dose \nfor Covid-19 pneumonia. PLoS One. 2021;16(5):e0252057. DOI: 10.1371/journal.pone.0252057\n92. Jamaati H, Hashemian SM, Farzanegan B, Malekmohammad M, \nTabarsi P, Marjani M, et al. No clinical benefit of high dose cor -\nticosteroid administration in patients with COVID-19: A pre-liminary report of a randomized clinical trial. Eur J Pharmacol. \n2021;897:173947. DOI: 10.1016/j.ejphar.2021.173947\n93. Fern\u00e1ndez-Cruz A, Ruiz-Antor\u00e1n B, Mu\u00f1oz-G\u00f3mez A, Sancho-L\u00f3pez \nA, Mills-S\u00e1nchez P, Centeno-Soto GA, et al. A Retrospective Con -\ntrolled Cohort Study of the Impact of Glucocorticoid Treatment in \nSARS-CoV-2 Infection Mortality. Antimicrob Agents Chemother. \n2020;64(9). DOI: 10.1128/aac.01168-20\n94. Ditekemena J. COVID-19 amidst Ebola\u2019s retreat. Science. \n2020;368(6490):445. DOI: 10.1126/science.abc4859\n95. Thompson KM, Kalkowska DA, Badizadegan K. A Health Econom -\nic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in \nthe United States. Risk Anal. 2021;41(2):376-86. DOI: 10.1111/\nrisa.13614\n96. Ogimi C, Qu P, Boeckh M, Bender Ignacio RA, Zangeneh SZ. Asso -\nciation between live childhood vaccines and COVID-19 outcomes: \na national-level analysis. Epidemiol Infect. 2021;149:e75. DOI: \n10.1017/s0950268821000571\n97. \u00d6zdemir \u00d6. Measles-Mumps-Rubella Vaccine and COVID-19 Rela -\ntionship. mBio. 2020;11(5). DOI: 10.1128/mBio.01832-20\n98. Abdool Karim SS. The South African Response to the Pandemic. N \nEngl J Med. 2020;382(24):e95. DOI: 10.1056/NEJMc2014960\n99. Nordling L. \u2018Our epidemic could exceed a million cases\u2019 - South \nAfrica\u2019s top coronavirus adviser. Nature. 2020;583(7818):672. DOI: \n10.1038/d41586-020-02216-5\n100. National Institutes for Communicable Diseases (NICD). COVID-19 \nweekly epidemiology brief. National Institutes of Communica-ble Diseases. Week 46. 2020. Available at: https://wwwnicdacza/wp-content/uploads/2020/11/COVID-19-Weekly-Epidemiolo-\ngy-Brief-week-46-Provinces-breakdownpdf. \n101. Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, et al. \nHigh seroprevalence of SARS-CoV-2 but low infection fatality ratio \neight months after introduction in Nairobi, Kenya. Int J Infect Dis. 2021;112:25-34. DOI: 10.1016/j.ijid.2021.08.062\n102. Mwananyanda L, Gill CJ, MacLeod W, Kwenda G, Pieciak R, Mupila \nZ, et al. Covid-19 deaths in Africa: prospective systematic post -77. RECOVERY Collaborative Group HP, Lim WS, Emberson JR, Mafham \nM, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, \nPrudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, \nBaillie JK, Haynes R, Landray MJ,. Dexamethasone in Hospitalized \nPatients with Covid-19. . N Engl J Med 2021;384:693-704. DOI: 10.1056/NEJMoa2021436. \n78. Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et \nal. Association Between Administration of Systemic Corticosteroids \nand Mortality Among Critically Ill Patients With COVID-19: A Me -\nta-analysis. Jama. 2020. DOI: 10.1001/jama.2020.17023\n79. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticos -\nteroid treatment on patients with coronavirus infection: a system -\natic review and meta-analysis. J Infect. 2020;81(1):e13-e20. DOI: 10.1016/j.jinf.2020.03.062\n80. Pei L, Zhang S, Huang L, Geng X, Ma L, Jiang W, et al. Antiviral \nagents, glucocorticoids, antibiotics, and intravenous immunoglob -\nulin in 1142 patients with coronavirus disease 2019: a systematic \nreview and meta-analysis. Pol Arch Intern Med. 2020;130(9):726-\n33. DOI: 10.20452/pamw.15543\n81. Cheng W, Li Y, Cui L, Chen Y, Shan S, Xiao D, et al. Efficacy and Safety \nof Corticosteroid Treatment in Patients With COVID-19: A System -\natic Review and Meta-Analysis. Front Pharmacol. 2020;11:571156. DOI: 10.3389/fphar.2020.571156\n82. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, \nMelo GC, et al. Methylprednisolone as Adjunctive Therapy for \nPatients Hospitalized With Coronavirus Disease 2019 (COVID-19; \nMetcovid): A Randomized, Double-blind, Phase IIb, Placebo-con -\ntrolled Trial. Clin Infect Dis. 2021;72(9):e373-e81. DOI: 10.1093/cid/\nciaa1177\n83. Wagner C, Griesel M, Mikolajewska A, Mueller A, Nothacker M, \nKley K, et al. Systemic corticosteroids for the treatment of COV -\nID-19. Cochrane Database Syst Rev. 2021;8(8):Cd014963. DOI: 10.1002/14651858.Cd014963\n84. Cano EJ, Fuentes XF, Campioli CC, O\u2019Horo JC, Saleh OA, Odeyemi \nY, et al. \u201cImpact of Corticosteroids in COVID-19 Outcomes: Sys -\ntematic Review and Meta-Analysis\u201d. Chest. 2020. DOI: 10.1016/j.chest.2020.10.054\n85. Buso R, Cinetto F, Dell\u2019Edera A, Veneran N, Facchini C, Biscaro V, \net al. Comparison between Dexamethasone and Methylpredni -\nsolone Therapy in Patients with COVID-19 Pneumonia Admitted \nto Non-Intensive Medical Units. J Clin Med. 2021;10(24). DOI: \n10.3390/jcm10245812\n86. Mohanty RR, Das S, Padhy BM, Meher BR. Comparison of Clini -\ncal Outcome between Dexamethasone and Methyl Prednisolone in \nTreatment of Moderate to Severe COVID-19: A Systematic Review \nand Meta-Analysis. J Assoc Physicians India. 2022;70(1):11-2. DOI: \n87. Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. A Compar -\nison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19. J Intensive Care Med. 2021;36(6):673-80. \nDOI: 10.1177/0885066621994057\n88. Jamil Z, Almajhdi FN, Khalid S, Asghar M, Ahmed J, Waheed Y. Com -\nparison of Low-Versus High-Dose Steroids in the Clinical Outcome COVID-19: Some unresolved issues J. G\u00f3mez-Pav\u00f3n, et al.\nRev Esp Quimioter 2022;35(5): 421-43443410.1111/aas.13996\n116. Martin-Loeches I, Motos A, Men\u00e9ndez R, Gabarr\u00fas A, Gonz\u00e1lez J, \nFern\u00e1ndez-Barat L, et al. ICU-Acquired Pneumonia Is Associated \nwith Poor Health Post-COVID-19 Syndrome. J Clin Med. 2021;11(1). DOI: 10.3390/jcm11010224\n117. Gonz\u00e1lez J, Ben\u00edtez ID, Carmona P, Santisteve S, Monge A, Mon -\ncus\u00ed-Moix A, et al. Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. \nChest. 2021;160(1):187-98. DOI: 10.1016/j.chest.2021.02.062\n118. Cabo-Gambin R, Ben\u00edtez ID, Carmona P, Santiesteve S, Minguez O, \nVaca R, et al. Three to Six Months Evolution of Pulmonary Function \nand Radiological Features in Critical COVID-19 Patients: A Prospec -\ntive Cohort. Arch Bronconeumol (Engl Ed). 2021. DOI: 10.1016/j.arbres.2021.07.005\n119. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month con -\nsequences of COVID-19 in patients discharged from hospital: a co -\nhort study. Lancet. 2021;397(10270):220-32. DOI: 10.1016/s0140-\n6736(20)32656-8\n120. Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M, et al. Six-month Fol -\nlow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radi -\nology. 2021;299(1):E177-e86. DOI: 10.1148/radiol.2021203153\n121. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, \n9-month, and 12-month respiratory outcomes in patients fol -\nlowing COVID-19-related hospitalisation: a prospective study. \nLancet Respir Med. 2021;9(7):747-54. DOI: 10.1016/s2213-2600(21)00174-0\n122. Lee H, Choi H, Yang B, Lee SK, Park TS, Park DW, et al. Interstitial \nlung disease increases susceptibility to and severity of COVID-19. Eur Respir J. 2021;58(6). DOI: 10.1183/13993003.04125-2020\n123. Chen Q, Xia S, Sui H, Shi X, Huang B, Wang T. Identification of \nhub genes associated with COVID-19 and idiopathic pulmo -\nnary fibrosis by integrated bioinformatics analysis. PLoS One. 2022;17(1):e0262737. DOI: 10.1371/journal.pone.0262737\n124. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COV -\nID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-15. DOI: 10.1016/s2213-2600(20)30225-3\n125. Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before \nand after COVID-19: a double threat? Eur Respir J. 2021;58(6). DOI: 10.1183/13993003.01956-2021\n126. Bharat A, Machuca TN, Querrey M, Kurihara C, Garza-Castillon R, Jr., \nKim S, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four coun -\ntries. Lancet Respir Med. 2021;9(5):487-97. DOI: 10.1016/s2213-\n2600(21)00077-1\n127. Roach A, Chikwe J, Catarino P, Rampolla R, Noble PW, Megna D, \net al. Lung Transplantation for Covid-19-Related Respiratory Fail -\nure in the United States. N Engl J Med. 2022. DOI: 10.1056/NE -\nJMc2117024\n128. King CS, Mannem H, Kukreja J, Aryal S, Tang D, Singer JP, et \nal. Lung Transplantation for Patients With COVID-19. Chest. \n2022;161(1):169-78. DOI: 10.1016/j.chest.2021.08.041mortem surveillance study. Bmj. 2021;372:n334. DOI: 10.1136/bmj.\nn334\n103. Valleron AJ, Cori A, Valtat S, Meurisse S, Carrat F, Bo\u00eblle PY. Trans -\nmissibility and geographic spread of the 1889 influenza pandemic. \nProc Natl Acad Sci U S A. 2010;107(19):8778-81. DOI: 10.1073/pnas.1000886107\n104. Muecksch F, Wang Z, Cho A, Gaebler C, Tanfous TB, DaSilva J, et \nal. Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. . bioRxiv 2022 Feb 15:20220214480394 doi: 101101/20220214480394 Preprint. 2022. DOI: \n105. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et \nal. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022. DOI: 10.1038/s41586-022-04460-3\n106. Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, \net al. Vaccines Elicit Highly Conserved Cellular Immunity to SARS-\nCoV-2 Omicron. Nature. 2022. DOI: 10.1038/s41586-022-04465-y\n107. Das KM, Lee EY, Singh R, Enani MA, Al Dossari K, Van Gorkom K, et \nal. Follow-up chest radiographic findings in patients with MERS-\nCoV after recovery. Indian J Radiol Imaging. 2017;27(3):342-9. DOI: 10.4103/ijri.IJRI_469_16\n108. Chan KS, Zheng JP, Mok YW, Li YM, Liu YN, Chu CM, et al. SARS: \nprognosis, outcome and sequelae. Respirology. 2003;8 Suppl(Suppl 1):S36-40. DOI: 10.1046/j.1440-1843.2003.00522.x\n109. Frija-Masson J, Debray MP, Gilbert M, Lescure FX, Travert F, Borie \nR, et al. Functional characteristics of patients with SARS-CoV-2 \npneumonia at 30  days post-infection. Eur Respir J. 2020;56(2). DOI: \n10.1183/13993003.01754-2020\n110. Truffaut L, Demey L, Bruyneel AV, Roman A, Alard S, De Vos N, et \nal. Post-discharge critical COVID-19 lung function related to se -\nverity of radiologic lung involvement at admission. Respir Res. 2021;22(1):29. DOI: 10.1186/s12931-021-01625-y\n111. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, So -\nlis-Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27(4):328-37. DOI: 10.1016/j.pulmoe.2020.10.013\n112. Lewis KL, Helgeson SA, Tatari MM, Mallea JM, Baig HZ, Patel NM. \nCOVID-19 and the effects on pulmonary function following infec -\ntion: A retrospective analysis. EClinicalMedicine. 2021;39:101079. DOI: 10.1016/j.eclinm.2021.101079\n113. Guler SA, Ebner L, Aubry-Beigelman C, Bridevaux PO, Brutsche M, \nClarenbach C, et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective \nobservational Swiss COVID-19 lung study. Eur Respir J. 2021;57(4). \nDOI: 10.1183/13993003.03690-2020\n114. Zou JN, Sun L, Wang BR, Zou Y, Xu S, Ding YJ, et al. The characteris -\ntics and evolution of pulmonary fibrosis in COVID-19 patients as as -\nsessed by AI-assisted chest HRCT. PLoS One. 2021;16(3):e0248957. DOI: 10.1371/journal.pone.0248957\n115. Compagnone N, Palumbo D, Cremona G, Vitali G, De Lorenzo R, \nCalvi MR, et al. Residual lung damage following ARDS in COVID-19 ICU survivors. Acta Anaesthesiol Scand. 2022;66(2):223-31. DOI: ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/031.2022\nRev Esp Quimioter 2022;35(5): 435-443435targets; however, these figures improved significantly after \nthe COVID-19 pandemic. Given the importance of achieving \nand maintaining high vaccination rates in order to avoid the \nclinical and economic impact of influenza, our multidiscipli -\nnary group of experts on vaccines analyzed the impact of low vaccination rates in Spain and drafted a series of measures to \nboost influenza vaccination coverage, particularly among pri -\nority groups. \nKeywords: Influenza, influenza vaccine, vaccine hesitancy, cardiovascular \nevents, respiratory disease, elderly, health care professionals\nINTRODUCCI\u00d3N\nLa gripe estacional es todav\u00eda a d\u00eda de hoy un problema \nde salud mundial debido a su elevada morbimortalidad, con \nhasta 650  000 muertes anuales reportadas en el mundo [1]. \nSe trata de una enfermedad respiratoria aguda que produ -\nce una afectaci\u00f3n sist\u00e9mica causada principalmente por los virus de la gripe tipo A y B [1]. Su elevada variabilidad anti -\ng\u00e9nica y su capacidad de evoluci\u00f3n permiten que sigan man -\nteniendo su virulencia. Aunque en la mayor\u00eda de los casos se presenta de forma leve y autolimitada, puede evolucionar a formas graves o complicadas e incluso llegar a ser letal.\nEn Espa\u00f1a, durante la temporada 2019-2020 se estima-\nron 619  000 casos confirmados de gripe que acudieron a las \nconsultas de atenci\u00f3n primaria, 27  700 hospitalizaciones con \ngripe confirmada por el laboratorio, 1  800 ingresos en la uni-\ndad de cuidados intensivos (UCI) con confirmaci\u00f3n por labo -\nratorio y 3  900 muertes atribuibles a esta enfermedad [2]. Los \nmayores de 65 a\u00f1os fueron los m\u00e1s afectados y supusieron el 47  % de los casos graves hospitalizados confirmados de \ngripe [2]. \nLa vacuna frente a la gripe es la medida m\u00e1s efectiva pa -\nra prevenir la enfermedad y sus complicaciones. Su efectivi-dad global se sit\u00faa en torno al 65  %, pero var\u00eda en funci\u00f3n de Documento de opini\u00f3n de expertos para la \nmejora de la cobertura vacunal frente a la gripe \nestacional\n1Pediatr\u00eda de Atenci\u00f3n Primaria del Centro de Salud S\u00e1rdoma de Vigo. Espa\u00f1a\n2Servicio de Medicina Preventiva. Complexo Hospitalario Universitario de Vigo. Espa\u00f1a.\n3Secci\u00f3n de Pediatr\u00eda Cl\u00ednica, Infectol\u00f3gica y Translacional. Hospital Cl\u00ednico Universitario de Santiago de \nCompostela. Espa\u00f1a.\n4Centro de Salud Islas Canarias. Lugo. Espa\u00f1a.\n5Unidad de Infecciosas. Servicio de Medicina Interna. Hospital \u00c1lvaro Cunqueiro. Instituto de Investigaci\u00f3n \nBiom\u00e9dica Galicia Sur. Vigo. Espa\u00f1a.\n6Medicina Preventiva y Salud P\u00fablica de la Universidad de Santiago de Compostela. Acad\u00e9mico numerario de \nlas Reales Academias de Medicina y de Farmacia de Galicia. Miembro del nodo del CIBERESP de Santiago de Compostela. Espa\u00f1a.Carmen Velicia Pe\u00f1as1\nV\u00edctor Miguel del Campo P\u00e9rez2\nIrene Rivero Calle3\nLorenzo Armenteros del Olmo4\nMar\u00eda Teresa P\u00e9rez Rodr\u00edguez5\nJuan Jes\u00fas Gestal Otero6Revisi\u00f3n\nArticle history\nReceived: 21 March 2022; Revision Requested: 5 April 2022; Revision Received: 10 May 2022; Accepted:  18 May 2022; \nPublished: 21 June 2022\nRESUMEN\nLa gripe estacional sigue siendo un importante proble -\nma de salud p\u00fablica, y la vacuna antigripal es la medida m\u00e1s \nefectiva para su prevenci\u00f3n. En nuestro pa\u00eds, los datos de co -\nberturas vacunales de las \u00faltimas temporadas muestran unas \ntasas de vacunaci\u00f3n muy por debajo de los objetivos marcados \npor los organismos oficiales. Tras la pandemia de la COVID19, \nlas coberturas vacunales para la gripe han experimentado una \nnotable mejor\u00eda. Dado que resulta imperativo alcanzar y man -\ntener unas elevadas tasas de vacunaci\u00f3n con el fin de evitar el impacto cl\u00ednico y econ\u00f3mico de la gripe, un grupo multidisci -\nplinar de expertos en el \u00e1rea de las vacunas hemos analizado \nc\u00f3mo afectan las bajas coberturas en nuestro pa\u00eds y hemos \ndise\u00f1ado una serie de medidas para incrementar la cobertura \nvacunal de la gripe, especialmente en los colectivos definidos \ncomo prioritarios. \nPalabras clave: Gripe, vacuna antigripal, reticencia a la vacunaci\u00f3n, even-\ntos cardiovasculares, enfermedades respiratorias, ancianos, profesionales \nsanitarios.\nExpert opinion on strategies to improve \nvaccination coverage against seasonal influenza\nABSTRACT\nSeasonal flu continues to be a major public health con -\ncern, and the influenza vaccine remains the most effective \npreventive measure. In Spain, vaccination coverage data from \nprevious seasons show vaccination rates well below official \nCorrespondencia:\nProf. Dr. Juan Jes\u00fas Gestal Otero. \nProfesor em\u00e9rito de Medicina Preventiva y Salud P\u00fablica de la USC\nFacultad de Medicina. c/ San Francisco s/n. 15701. Santiago de Compostela\nE-mail: jjgestalo@gmail.comDocumento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-443436nales en Espa\u00f1a es la falsa percepci\u00f3n que tiene la poblaci\u00f3n \ngeneral sobre la gripe como una enfermedad leve [9]. Por un lado, se trata de un virus que se puede confundir con otros virus estacionales que producen una sintomatolog\u00eda m\u00e1s leve y menos complicaciones asociadas, como los del catarro co -\nm\u00fan (rinovirus) [10]. Adem\u00e1s, dado que la mayor parte de la poblaci\u00f3n clasificada como sana no desarrolla una infecci\u00f3n grave como consecuencia de la gripe, ni presenta complica -\nciones asociadas, esto promueve de nuevo la sensaci\u00f3n de \nque se trata de una enfermedad poco grave. Sin embargo, \nla vacuna antigripal impacta positivamente sobre la super -\nvivencia en la poblaci\u00f3n de riesgo (definida como mayores \nde 65 a\u00f1os y pacientes con enfermedades cr\u00f3nicas previas) \ny reduce las infecciones graves y complicaciones asociadas \na la infecci\u00f3n por la gripe [11]. Esta puede ser la raz\u00f3n por \nla que esta poblaci\u00f3n presente un mayor porcentaje de tasas de vacunaci\u00f3n y de que dichas complicaciones se hayan visto reducidas. \nEn este grupo de trabajo consideramos que la falta o au -\nsencia de confirmaci\u00f3n diagn\u00f3stica de la infecci\u00f3n por gripe \nmediante una prueba r\u00e1pida o un an\u00e1lisis microbiol\u00f3gico en \natenci\u00f3n primaria (AP) es otra posible causa que puede estar \ncontribuyendo a que la tasa de vacunaci\u00f3n se est\u00e9 viendo re -\nducida ya que implica un infra diagn\u00f3stico que no visibiliza la \ncarga real de la enfermedad. Adem\u00e1s, el hecho de que la gri -\npe no aparezca como motivo de defunci\u00f3n en pacientes con patolog\u00edas previas agravadas por esta patolog\u00eda, contribuye a no valorar la gravedad de la enfermedad. En atenci\u00f3n prima -\nria es donde m\u00e1s casos se tratan de gripe y, al no realizarse dicha prueba, se desconoce la tasa real de incidencia.\nPor otra parte, existe una desconfianza creciente sobre \nla efectividad de la vacuna antigripal. A pesar de las m\u00falti -\nples evidencias cient\u00edficas que han demostrado su eficacia/efectividad y que respaldan el uso de las vacunas, la tasa de \nvacunaci\u00f3n en muchos pa\u00edses sigue siendo insatisfactoria [5]. \nDe hecho, y de forma preocupante, en los \u00faltimos a\u00f1os ha crecido una actitud antivacunaci\u00f3n y la reticencia o rechazo al uso de vacunas es cada vez m\u00e1s prevalente [12]. Esto se atribuye a la existencia de creencias y mitos que est\u00e1n arrai -\ngados en la sociedad y fomentan la vacilaci\u00f3n ante el uso de las vacunas. De hecho, seg\u00fan se\u00f1ala la Organizaci\u00f3n Mundial de la Salud (OMS), se trata de una de las principales amena -\nzas para la salud p\u00fablica [13]. \nTambi\u00e9n existen datos que indican que los profesionales \nsanitarios perciben la vacuna antigripal como poco efectiva [14]. A pesar de que los ensayos cl\u00ednicos han demostrado una elevada eficacia para la vacunaci\u00f3n frente a la gripe, los re-sultados de efectividad en los estudios en vida real presentan una elevada variabilidad debida principalmente a las diferen -\ncias de dise\u00f1o entre los diferentes estudios; a factores rela -\ncionados con el virus (transmisibilidad, virulencia, comporta -\nmiento epidemiol\u00f3gico); de la vacuna (grado de concordancia entre las cepas de la vacuna y las circulantes esa temporada \n[15,16], tipo de vacuna -atenuada o inactivada-, presencia de \nadyuvantes y v\u00eda de administraci\u00f3n), as\u00ed como factores del \nhu\u00e9sped (edad, comorbilidad, riesgo de exposici\u00f3n). Esta he -las caracter\u00edsticas de la vacuna, del virus (variaci\u00f3n antig\u00e9 -\nnica/cepa circulante), de la poblaci\u00f3n (edad, comorbilidades, \ninfecciones previas, vacunaci\u00f3n anterior) y del objetivo que se persigue alcanzar (diagn\u00f3stico confirmado, enfermedad \ncl\u00ednica, complicaciones o fallecimientos) [3]. Asimismo, las \nvacunas antigripales tienen buenos perfiles de seguridad y se \nhan reportado pocos efectos adversos [4]. A pesar de esto, las \ntasas de vacunaci\u00f3n se han reducido en los \u00faltimos a\u00f1os y las \ncoberturas vacunales para la gripe estacional var\u00edan en fun-\nci\u00f3n de los pa\u00edses entre menos del 1  % hasta m\u00e1s del 75  % en \nlas personas de 65 y m\u00e1s a\u00f1os, mientras que para las perso-nas con enfermedades cr\u00f3nicas y el personal sanitario la co-\nbertura es inferior al 40  % en la mayor\u00eda de los pa\u00edses [5]. En \nnuestro pa\u00eds, solo un 22,5  % de las personas de entre 60 y 64 \na\u00f1os se vacun\u00f3 en la temporada 2018-19 [6]. Con respecto al \npersonal sanitario, esa misma temporada se report\u00f3 \u00fanica-mente un 35  % de cobertura vacunal [6]. Las bajas coberturas \nno solo reducen el n\u00famero de personas vulnerables que esta -\nr\u00edan protegidas durante las epidemias anuales de gripe, sino \nque adem\u00e1s pueden afectar negativamente la capacidad de producir vacunas en caso de una pandemia.\nLa temporada pasada, 2020-2021, la gripe convivi\u00f3 con \nla pandemia mundial de la COVID-19. En este escenario, las tasas de vacunaci\u00f3n aumentaron significativamente y se al -\ncanzaron valores de cobertura vacunal de m\u00e1s del 65 % en los mayores de 65 a\u00f1os, del 40  % en las personas de entre 60 \ny 64 a\u00f1os y del 62 % entre el personal sanitario [7].\nTeniendo en cuenta este contexto, un grupo multidisci -\nplinar de expertos relacionados con la vacunaci\u00f3n, en el que \nse incluyen profesionales m\u00e9dicos de medicina preventiva, \npediatr\u00eda, medicina interna y atenci\u00f3n primaria, y de enfer -\nmer\u00eda de atenci\u00f3n primaria, hemos analizado el impacto a \nnivel sanitario que pueden tener unas bajas coberturas va -\ncunales en nuestro pa\u00eds y, por otra parte, c\u00f3mo ha influido la pandemia de la COVID-19 en el aumento de estas cobertu-\nras. Finalmente, hemos propuesto una serie de medidas para \ntratar de mantener elevadas las tasas de vacunaci\u00f3n en las \npr\u00f3ximas temporadas.\nAN\u00c1LISIS DEL GRUPO DE EXPERTOS \nCoberturas vacunales prepandemia. Desde el a\u00f1o \n2011-hasta la pandemia de la COVID-19 en el a\u00f1o 2019, la \nmedia de cobertura vacunal de gripe a nivel nacional s\u00f3lo fue \nsuperior al 50  % en el colectivo de mayores de 65 a\u00f1os, con \nun m\u00ednimo del 54,3 % y un m\u00e1ximo del 57,7 % en este pe -\nriodo. A partir del a\u00f1o 2017 se registraron tambi\u00e9n los datos \nde cobertura vacunal de otros colectivos como las personas \nde 60 a 64 a\u00f1os, las mujeres embarazadas y los profesionales \nsanitarios. La cobertura vacunal de las personas entre 60 y 64 \na\u00f1os en este periodo (2017-2019) fue del 22,1 % y 22,3 % respectivamente [6,8]. En estas dos temporadas \u00fanicamente se vacunaron el 31,1 % y el 35 % de los profesionales sani-tarios [6,8].\nUna de las posibles causas de las bajas coberturas vacu -Documento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-443437Efecto de la pandemia de la COVID-19 en la cober -\ntura vacunal. Siguiendo las recomendaciones de la OMS, el \nMinisterio de Sanidad propuso unos objetivos de vacunaci\u00f3n \nmuy exigentes para la campa\u00f1a 2020-21, con un 75 % en la \npoblaci\u00f3n de m\u00e1s de 64 a\u00f1os, en los sanitarios de primera \nl\u00ednea de atenci\u00f3n a personas infectadas y en los profesionales \nde centros sociosanitarios, y un 60 % en mujeres embara -\nzadas y personas con factores de riesgo entre 6 meses y 64 a\u00f1os [46]. Aunque solo se ha conseguido alcanzar el objeti-vo en el grupo de mujeres embarazadas, las coberturas han \naumentado significativamente esta temporada [6,7]. Resulta \nespecialmente llamativo el aumento de la cobertura vacunal \nen el grupo de personas con edades comprendidas entre 60 \ny 64 a\u00f1os, que se ha incrementado hasta un 40 %, as\u00ed como \nlas coberturas del 62 % alcanzadas en el grupo de personal sanitario [7]. \nEl aumento de las coberturas vacunales que se observ\u00f3 \nla pasada temporada se puede atribuir, entre otras causas, \na una mayor concienciaci\u00f3n de la importancia de las vacu -\nnas entre la poblaci\u00f3n [47]. Debido a la pandemia por la CO-VID-19, la poblaci\u00f3n general ha tenido m\u00e1s acceso a la infor -\nmaci\u00f3n sobre vacunas a trav\u00e9s de diferentes escenarios como \nlos medios de comunicaci\u00f3n o desde las administraciones sanitarias [48]. Adem\u00e1s, la COVID-19 plantea en la poblaci\u00f3n la percepci\u00f3n de vulnerabilidad frente a las enfermedades \ntransmisibles, sobre todo en los pa\u00edses desarrollados en los \nque la incidencia y la mortalidad por estas enfermedades en la poblaci\u00f3n general son menores [49,50]. Por otro lado, el mensaje enviado por las autoridades sanitarias en el que se informaba del riesgo cl\u00ednico que podr\u00eda implicar el sufrir a un \ntiempo ambas patolog\u00edas y como consecuencia la sobrecarga \nde los recursos asistenciales puede haber ayudado tambi\u00e9n al incremento de la cobertura vacunal, especialmente en los grupos de riesgo y en los profesionales sanitarios [48]. \nOtro punto que considerar es el cambio que ha supuesto \nla pandemia de COVID-19 en los sistemas de vigilancia de la gripe y de otros virus respiratorios en nuestro pa\u00eds. La llegada de la COVID-19 en el a\u00f1o 2020 produjo una importante dis -\ntorsi\u00f3n en el funcionamiento de estos sistemas. Como conse -\ncuencia, y siguiendo las indicaciones del Centro Europeo para \nla Prevenci\u00f3n y el Control de las Enfermedades (ECDC) y la OMS, se han creado sistemas de vigilancia de infecci\u00f3n res -\npiratoria aguda que incluyen de forma conjunta la vigilancia para la gripe, la COVID-19 y otros virus respiratorios como \nel virus respiratorio sincitial (VRS) [51]. Sin embargo, seg\u00fan \nestablecen instituciones relevantes como el ECDC, en el caso \nconcreto del VRS la infecci\u00f3n por este virus no es de notifica -\nci\u00f3n obligatoria en la mayor\u00eda de los pa\u00edses de Europa [52]. De hecho, los datos se recogen de manera voluntaria por los dis -\ntintos pa\u00edses en el sistema TESSy ( The European Surveillance \nSystem), un sistema muy flexible basado en metadatos para \nla recogida, validaci\u00f3n, limpieza, an\u00e1lisis y difusi\u00f3n de datos \n[53]. Adicionalmente la mayor\u00eda de los pa\u00edses del espacio eco -\nn\u00f3mico europeo ya disponen de vigilancia activa y la sufi -\nciente capacidad para analizar muestras de laboratorio que \npodr\u00eda utilizarse para identificar VRS, pero las definiciones y terogeneidad en los resultados de efectividad vacunal podr\u00eda \ncondicionar negativamente la opini\u00f3n de colectivos como el \nde los sanitarios [3,17].\nImpacto cl\u00ednico de las bajas coberturas vacunales. \nLa gripe estacional est\u00e1 asociada a una elevada morbimor -\ntalidad, con 290  000 a 650  000 de muertes debidas a la \ngripe cada a\u00f1o a nivel mundial [1]. En nuestro pa\u00eds, duran -\nte las temporadas de 2015 a 2020, la tasa media acumula -\nda de hospitalizaci\u00f3n de casos graves de gripe (CGHCG) fue \ndel 20,04 %, report\u00e1ndose la tasa m\u00e1xima en la temporada \n2017-2018 con un 28,1 % [2,18-21]. Del total de CGHCG en estas cinco temporadas el porcentaje de pacientes que in -\ngres\u00f3 en UCI fue similar, con una media global de 25,3 %, llegando a alcanzar el 35,1 % en la temporada 2016-2017 \n[2,18-21], con una letalidad media, estimada en t\u00e9rminos de \ndefunciones, del 15,36 % [2,18-21].\nEl impacto de la infecci\u00f3n por el virus de la gripe es es -\npecialmente importante en la poblaci\u00f3n con patolog\u00edas pre -\nvias como enfermedad cardiovascular, respiratoria, metab\u00f3 -\nlica y renal [22-26]. Se trata de enfermedades cr\u00f3nicas muy \nprevalentes con una elevada tasa de mortalidad [27-30]. La infecci\u00f3n por gripe se asocia a un peor pron\u00f3stico de estas enfermedades y los pacientes que experimentan complica -\nciones tienen una mayor morbimortalidad asociada [22-26]. Con respecto a las enfermedades cardiovasculares y respira -\ntorias cr\u00f3nicas, se ha descrito que la infecci\u00f3n por el virus de \nla gripe incrementa el riesgo de sufrir un infarto y acciden -\ntes cerebrovasculares [31]. Espec\u00edficamente, la gripe aumenta \nentre 6 y 10 veces el riesgo de sufrir un infarto de miocardio, y entre 3 y 8 veces el riesgo de accidentes cerebrovascula -\nres [31-33]. Adem\u00e1s, tambi\u00e9n exacerba la sintomatolog\u00eda y la progresi\u00f3n de la enfermedad pulmonar obstructiva cr\u00f3nica y el asma [34]. Consecuentemente, la gripe provoca un au -\nmento de la morbilidad y mortalidad hospitalaria en estos \npacientes, as\u00ed como un incremento de los costes y recursos \nsanitarios, debido a un mayor n\u00famero de hospitalizaciones e \ningresos en unidades de cuidados intensivos (UCI) [22,35,36]. \nEn esta l\u00ednea, en el \u00faltimo informe del Sistema de Vigilancia de la gripe en la temporada 2019-2020, los factores de riesgo m\u00e1s frecuentes asociados a la aparici\u00f3n de complicaciones hospitalarias en pacientes hospitalizados por gripe fueron la enfermedad cardiovascular previa (34 %), la enfermedad res -\npiratoria previa (28 %) y la diabetes (28 %) [2].\nLa vacunaci\u00f3n frente a la gripe es la mejor forma de \nasegurar la protecci\u00f3n frente a la infecci\u00f3n y de prevenir las complicaciones asociadas. Se estima que la vacuna antigripal \ndisminuye el riesgo relativo de infarto de miocardio entre un \n15 % y un 45 % [37]. Varios ensayos cl\u00ednicos y metaan\u00e1li -\nsis han demostrado tambi\u00e9n que la vacuna es eficaz en la prevenci\u00f3n secundaria de aparici\u00f3n, hospitalizaci\u00f3n y mor-talidad por eventos cardiovasculares [38-42]. Asimismo, con respecto a las enfermedades cr\u00f3nicas respiratorias, la vacu -\nnaci\u00f3n reduce el n\u00famero de sobreinfecciones bacterianas y contribuye a la reducci\u00f3n del n\u00famero de hospitalizaciones y a la disminuci\u00f3n del riesgo de muerte [43-45]. Documento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-443438edad avanzada con respecto a las vacunas de dosis est\u00e1ndar \n[57-59] Existe pues una amplia evidencia cient\u00edfica que co -\nrrobora la idoneidad de estas vacunas en este colectivo, ba -\nsada en la consistencia y robustez de los datos obtenidos en \nlos m\u00faltiples estudios a lo largo de diferentes temporadas de \ngripe [56,58]. \nLas mujeres embarazadas tienen tambi\u00e9n m\u00e1s riesgo de \nsufrir complicaciones tras la infecci\u00f3n por gripe [60]. En Es -\npa\u00f1a, se ha estimado que el embarazo incrementa ocho veces el riesgo de hospitalizaci\u00f3n por gripe. La vacuna de la gripe \nha demostrado un m\u00faltiple beneficio en este colectivo. En la \nmadre, es beneficiosa en cualquier trimestre de la gestaci\u00f3n, pero especialmente en el tercer trimestre, cuando existe una leve inmunosupresi\u00f3n junto a una limitaci\u00f3n f\u00edsica evidente como es la reducci\u00f3n de la capacidad pulmonar [61]. Tambi\u00e9n presenta ventajas sobre el feto, dado que la infecci\u00f3n por el \nvirus de la gripe durante el primer trimestre se ha asociada \na un aumento de malformaciones cardiacas, labio leporino \ny defectos del tubo neural, y durante el segundo y tercer tri -\nmestre a un mayor n\u00famero de abortos y partos prematuros. \nAs\u00ed, la vacunaci\u00f3n frente a la gripe reduce en un 40 % la po-sibilidad de un aborto y en un 45 % la de muerte fetal provo-cada por esta enfermedad [61,62]. En el neonato (durante los  \nprimeros 6 meses de vida) la vacunaci\u00f3n de la embarazada consigue evitar el 75 % de los casos graves hospitalizados por gripe [63]. Adem\u00e1s, la vacunaci\u00f3n de las embarazadas \ntambi\u00e9n protege a los posibles  convivientes vulnerables dis -\nminuyendo las posibilidades de transmisi\u00f3n. A pesar de todos \nestos datos, la cobertura vacunal de las mujeres embarazadas en las temporadas preCOVID-19 ha estado por debajo de los objetivos, con un 29,4 % en la temporada 2017-2018 y un 40,6 % en la temporada 2018-2019 [6-8].\nEntre los profesionales sanitarios, otro de los grupos \nprioritarios a vacunar, las tasas de vacunaci\u00f3n han sido es -\npecialmente bajas en los \u00faltimos a\u00f1os, si bien se han incre -\nmentado a consecuencia de la pandemia de la COVID-19 [7]. Los motivos por los que este colectivo muestra reticencia a la vacunaci\u00f3n han sido objeto de estudio durante los \u00faltimos a\u00f1os, tanto internacionalmente como en nuestro pa\u00eds. Las m\u00faltiples investigaciones, que incluyen desde metaan\u00e1lisis hasta estudios unic\u00e9ntricos regionales, coinciden en que la actitud ante la vacunaci\u00f3n en las temporadas previas es un factor predictor de una mayor vacunaci\u00f3n, as\u00ed como convivir con personas de riesgo, y el miedo a enfermar o a contagiar a los pacientes [64]. Adem\u00e1s, un estudio descriptivo realizado \nen la Comunidad Valenciana que comprende tres temporadas \n(2011-2014) concluy\u00f3 que existen diferencias significativas \nentre los profesionales que se vacunan siendo los facultati -\nvos los menos vacunados y el personal de enfermer\u00eda el que presenta una mayor cobertura vacunal [65]. Por tanto, resul -\nta imperativo en este colectivo mejorar la cobertura vacunal \ny concienciar del papel que representa el personal sanitario como potenciales transmisores de la infecci\u00f3n por virus de la \ngripe a pacientes y familiares.los m\u00e9todos de laboratorio deber\u00edan estandarizarse para po -\nder ser consolidados [52]. En general, el sistema de vigilancia \nde VRS de preferencia ser\u00e1 la vigilancia centinela activa, con pacientes de atenci\u00f3n primaria y hospitalarios a los que se les \ntoma muestras y se analizan de manera sistem\u00e1tica [54]. \nEn el caso concreto de Espa\u00f1a la vigilancia virol\u00f3gica de \nla gripe se complementa con la vigilancia no centinela del VRS desde 2006-2007 y de un sistema de vigilancia centinela \ny no centinela para el SARS-CoV-2. Esto ha permitido dispo -\nner de informaci\u00f3n de la estacionalidad y de la epidemiologia \nde estos virus respiratorios a nivel nacional [51]. Con respec -\nto al VRS, el desarrollo de nuevas vacunas y anticuerpos mo -\nnoclonales enfatizan la necesidad de un sistema de vigilancia fiable para este virus. Disponer de un sistema de vigilancia \nespecifico de VRS es una prioridad, tanto como para estimar \nla carga del sistema sanitario como para medir el impacto \nde las futuras estrategias de inmunizaci\u00f3n frente al VRS [54]. \nEn resumen, como resultado de la pandemia, se han im -\nplementado mecanismos de prevenci\u00f3n para estas enferme -\ndades, como puede ser la vacunaci\u00f3n frente a la COVID- 19 y una mayor concienciaci\u00f3n sobre el VRS debido a la mayor disponibilidad de datos epidemiol\u00f3gicos. Estas medidas ten -\ndr\u00e1n, especialmente en el caso de la COVID-19, un efecto po -\nsitivo sobre las coberturas antigripales al permitir una posible \ncoadministraci\u00f3n y tambi\u00e9n a un incremento de conciencia -\nci\u00f3n con la vacunaci\u00f3n, especialmente en los grupos de ries -\ngo. En el caso concreto del VRS es m\u00e1s complejo anticipar la \nposible influencia en las coberturas vacunales de gripe al no \ndisponer actualmente de estrategias preventivas que permi -\ntan una vacunaci\u00f3n universal en lactantes o adultos.\nGrupos objetivos para mejorar las coberturas va -\ncunales. A pesar de ser el que mayor porcentaje de cober -\ntura presenta [7], el grupo de personas mayores de 65 a\u00f1os continua siendo uno de los grupos prioritarios a vacunar. Se \ntrata del colectivo con mayor riesgo de presentar complica -\nciones a causa de la gripe, y, consecuentemente, una mayor \nmorbimortalidad asociada. Adem\u00e1s, se debe tener en cuen -\nta que muchas de las personas ancianas sufren un deterioro funcional durante los ingresos hospitalarios de los que no se \nrecuperar\u00e1n a pesar de haber resuelto la enfermedad, de ma -\nnera que la gripe puede acelerar el declive de la situaci\u00f3n funcional [55]. Eso, juntamente con la fragilidad y las m\u00falti -\nples comorbilidades presentes en este grupo de poblaci\u00f3n se \nrelacionan con una p\u00e9rdida importante de la calidad de vida.\nPor otra parte, la inmunosenescencia que acontece a \npartir de los 65 a\u00f1os provoca que la inmunogenicidad de la vacuna de la gripe sea menor en este grupo de poblaci\u00f3n \n[56]. El empleo de vacunas m\u00e1s inmun\u00f3genas y efectivas que \ngeneren una mayor protecci\u00f3n frente a las cepas circulan -\ntes, y con un perfil de seguridad adecuado, garantizar\u00edan una \nmejor cobertura vacunal en esta poblaci\u00f3n. De hecho, diver -\nsos estudios han demostrado que la vacuna inactivada de \nvirus fraccionados de alta dosis es una alternativa m\u00e1s inmu -\nnog\u00e9nica y eficaz en la prevenci\u00f3n de la infecci\u00f3n por el virus \nde la gripe y sus complicaciones asociadas en la poblaci\u00f3n de Documento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-443439Medidas centradas en las personas con patolog\u00eda \ncardiorrespiratoria previa \n\u2022 Investigar y profundizar en el conocimiento sobre el im -\npacto de la infecci\u00f3n del virus de la gripe en estas pato -\nlog\u00edas, realizando en este pa\u00eds estudios sobre mortalidad y \nmorbilidad (hospitalizaciones, ingresos en UCI) asociadas a la infecci\u00f3n por gripe en esta poblaci\u00f3n con enfermedades \ncr\u00f3nicas. Por otro lado, se debe difundir la informaci\u00f3n de \nlos resultados y de los efectos conocidos de la infecci\u00f3n \ndel virus de la gripe en este grupo poblacional a trav\u00e9s \nde los medios de comunicaci\u00f3n, asociaciones de pacien -\ntes y profesionales sanitarios, especialmente por parte de \nlos m\u00e9dicos y profesionales en enfermer\u00eda de los centros \nde AP, as\u00ed como los facultativos especialistas en las \u00e1reas de cardiolog\u00eda, neumolog\u00eda, endocrinolog\u00eda y nefrolog\u00eda, \nentre otros.\n\u2022 Promover una mayor implicaci\u00f3n y un mayor fomento \nen la indicaci\u00f3n de la vacuna a los pacientes por parte de \nlos m\u00e9dicos. Cuando los pacientes acudan a sus consulta \no revisiones, se debe indicar la vacunaci\u00f3n antigripal en el informe al alta o tras un episodio de hospitalizaci\u00f3n, \ncomo una recomendaci\u00f3n m\u00e1s de cuidados y medida de \npromoci\u00f3n de la salud. La evidencia cl\u00ednica se\u00f1ala que la \nrecomendaci\u00f3n del sanitario es la medida m\u00e1s eficaz para PROPUESTAS DE MEDIDAS PARA MEJORAR LAS \nCOBERTURAS VACUNALES (TABLA 1)\nMedidas centradas en la poblaci\u00f3n general\n\u2022 Estudiar los colectivos que han aumentado su tasa de va -\ncunaci\u00f3n en la \u00faltima temporada y sus motivaciones para \nvacunarse con la intenci\u00f3n de fidelizarles.\n\u2022 Aplicar en las campa\u00f1as de vacunaci\u00f3n de gripe estrategias \nm\u00e1s impactantes c\u00f3mo las usadas por la Direcci\u00f3n General \nde Tr\u00e1fico (DGT) en la prevenci\u00f3n de lesiones externas por \naccidentes de tr\u00e1fico, con el objetivo de concienciar de la importancia de la vacunaci\u00f3n.\n\u2022 Ahondar en las causas y en los motivos por los que la po -\nblaci\u00f3n decide no vacunarse, para plantear posteriores in-\ntervenciones, incidiendo en esos motivos para conocer el \nimpacto en la vacunaci\u00f3n. En esta l\u00ednea, y de acuerdo con \nlas propuestas de la OMS [66], ser\u00eda importante realizar es-tudios coste-beneficio de la vacunaci\u00f3n y dar a conocer a la poblaci\u00f3n general los costes asociados a la morbimorta -\nlidad asociada a la gripe y el ahorro estimado de los casos evitados gracias a la vacuna.\n\u2022 Fomentar el uso en todos los niveles asistenciales de test serol\u00f3gicos de diagn\u00f3stico r\u00e1pidos y de f\u00e1cil manejo de gripe, VRS y otros virus que causen enfermedades con una sintomatolog\u00eda similar, con el objetivo de concienciar a la poblaci\u00f3n de la elevada incidencia real de gripe.\n\u2022 Generar y difundir actividades y experiencias previas de vacunaci\u00f3n proactiva (visitas con la posibilidad de vacu -\nnaci\u00f3n \u201cin situ\u201d) para acercar y facilitar la vacunaci\u00f3n a la poblaci\u00f3n general, as\u00ed como el dise\u00f1o de campa\u00f1as que involucren de forma proactiva a la poblaci\u00f3n a la que va destinada la vacunaci\u00f3n y a los responsables de llevarla a t\u00e9rmino (Modelo PRECEDE) [67].\n\u2022 Aumentar la formaci\u00f3n sobre vacunas a todos los nive -\nles. Se propone impartir conocimientos acerca de las va -\ncunas desde la etapa educativa (en educaci\u00f3n primaria y secundaria), y formar en vacunas, de manera rigurosa y exhaustiva, en aquellos estudios de formaci\u00f3n profesional y universitaria que conduzcan a las diferentes profesio-nes sanitarias. Adem\u00e1s, se debe acercar el conocimiento y aumentar la formaci\u00f3n en vacunas a la poblaci\u00f3n general para reducir los mitos y creencias err\u00f3neas preexistentes.\n\u2022 Mejorar la transmisi\u00f3n del valor de la vacunaci\u00f3n. Ge -\nnerar una cultura de la vacunaci\u00f3n como elemento de \nprotecci\u00f3n individual y colectiva, para tener mejores co -\nberturas.\n\u2022 Planificar las campa\u00f1as de vacunaci\u00f3n, mediante la ad-\nquisici\u00f3n de dosis disponibles en funci\u00f3n de los datos de campa\u00f1as anteriores. Tener en cuenta a los representantes \nde los centros de salud dado que conocen la estructura, \nlos medios y la organizaci\u00f3n de cada centro. Dar flexibili -\ndad en la distribuci\u00f3n de vacunas seg\u00fan el momento de la campa\u00f1a. Habilitar una plataforma din\u00e1mica y operativa. Tabla 1   Resumen de las medidas para aumentar \nlas coberturas vacunales.\nInvestigar \n\u2022 Estudiar los colectivos que han aumentado su tasa de vacunaci\u00f3n y conocer sus \nmotivaciones para vacunarse.\n\u2022 Explorar el impacto de la infecci\u00f3n del virus de la gripe en personas con enfermedades cardiorrespiratorias en nuestro pa\u00eds en t\u00e9rminos de morbimortalidad y de consumo de recursos sanitarios.\n\u2022 Profundizar en el conocimiento y en la b\u00fasqueda de vacunas m\u00e1s seguras y efectivas\nInformar\n\u2022 Acercar y difundir los resultados para que resulten m\u00e1s comprensibles y \neliminar mitos y creencias acerca de las vacunas.\nFormar\n\u2022 Reforzar el conocimiento sobre vacunas en la poblaci\u00f3n general y en concreto \nen los colectivos m\u00e1s susceptibles.\n\u2022 Incluir formaci\u00f3n rigurosa sobre vacunas en las profesiones sociosanitarias\nConcienciar \n\u2022 Aplicar estrategias en las campa\u00f1as de prevenci\u00f3n de gripe como las usadas por la DGT, para que la poblaci\u00f3n general sea consciente del riesgo y el impacto que provoca la infecci\u00f3n por virus de la gripe.\nImplementar\n\u2022 Fomentar la buena pr\u00e1ctica profesional sanitaria, protegiendo a los pacientes y liderando con el ejemplo.Documento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-443440do las reuniones del panel de expertos. Los autores han desa -\nrrollado y consensuado el contenido con independencia de la \nfuente de financiaci\u00f3n.\nCONFLICTOS DE INTERESES\nCVP ha participado como ponente o asistente en activida -\ndes formativas patrocinadas por Sanofi-Pasteur, GSK, Pfizer y Roche. VDC ha participado como ponente en actividades rela-\ncionadas con vacunas de Sanofi-Pasteur, GSK, Pfizer o Seqirus. \nIRC ha colaborado en actividades docentes subvencionadas por GSK, MSD, Pfizer y Sanofi Pasteur; como investigadora \nen ensayos cl\u00ednicos de vacunas de Ablynx, Abbot, Cubist, GSK, \nJanssen, Medimmune, Merck, MSD, Novavax, Novartis, Pfizer, \nRoche, Regeneron, Sanofi Pasteur, Seqirus y Wyeth, y como \nconsultora en Advisory Board de MSD, Pfizer y Sanofi Pasteur. \nLAO ha colaborado en actividades docentes subvencionadas \npor laboratorios Lundbeck, Almirall, Servier, Esteve, Astra Zene-\nca, GSK, MSD, Pfizer, Sanofi Pasteur, Lilly, Mylan, Grunenthal y como consultor en Advisory Board de Lundbeck y Pfizer. JJGO \ncodirige un curso Universitario de especializaci\u00f3n en Vacunas que cuenta con financiaci\u00f3n de Sanofi Pasteur y ha participa -\ndo como ponente y asistido a reuniones cient\u00edficas sobre vacu -\nnas apoyadas por laboratorios Sanofi Pasteur, GSK, y Seqirus.  \nMTPR declara no tener conflictos de intereses. \nBIBLIOGRAF\u00cdA\n1. World Health Organization (WHO). Influenza (seasonal). 2018. 11 \nde noviembre de 2021. Available from: https://www.who.int/news-\nroom/fact-sheets/detail/influenza-(seasonal). \n2. Sistema de Vigilancia de la gripe en Espa\u00f1a. Informe de Vigilancia \nde la Gripe en Espa\u00f1a Temporada 2019-2020. 2020. 8 de noviembre \nde 2021. Available from: https://www.isciii.es/QueHacemos/Servi-\ncios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/\nDocuments/GRIPE/INFORMES%20ANUALES/Vigilancia%20de%20\nla%20Gripe%20en%20Espa%C3%B1a.%20Informe%20Tempora -\nda%202019-2020.pdf#search=gripe. \n3. Ortiz de Lejarazu R, Tamames S. [Influenza vaccination. Effective -\nness of current vaccines and future challenges]. Enferm Infecc Mi -\ncrobiol Clin. 2015;33(7):480-90. DOI: 10.1016/j.eimc.2015.06.011\n4. World Health Organization (WHO). Vaccines against influen -\nza WHO position paper - November 2012. Wkly Epidemiol Rec. \n2012;87(47):461-76. \n5. World Health Organization (WHO). Influenza vaccination covera -\nge and effectiveness. 2021. 10 de noviembre de 2021. Available \nfrom: https://www.euro.who.int/en/health-topics/communicable-\ndiseases/influenza/vaccination/influenza-vaccination-coverage-\nand-effectiveness. \n6. Ministerio de Sanidad Consumo y Bienestar Social. Coberturas de \nvacunaci\u00f3n frente a gripe en \u226565 a\u00f1os, personas de 60-64 a\u00f1os, \nembarazadas y personal sanitario. Campa\u00f1a 2018-2019. 2020. 2 noviembre de 2021. Available from: https://www.mscbs.gob.es/\nprofesionales/saludPublica/prevPromocion/vacunaciones/docs/Co -el incremento de la cobertura vacunal en las personas con \npatolog\u00edas previas [68]. \nMedidas centradas en los grupos prioritarios\n\u2022 Seguir profundizando en el conocimiento de la inmuno -\nsenescencia para la b\u00fasqueda de vacunas m\u00e1s seguras y \nefectivas en los mayores de 65 a\u00f1os. Difundir la informa -\nci\u00f3n sobre la vacuna de alta dosis y sobre su utilizaci\u00f3n \npodr\u00eda ayudar a mejorar las coberturas. Pueden ser las va-cunas de futuro para esta poblaci\u00f3n, ya que buscan una eficacia superior a la de las vacunas conocidas hasta ahora \ny presentan un perfil de seguridad adecuado.\n\u2022 Acercar a los destinatarios el mensaje acerca de las vacu -\nnas disponibles, explicar y difundir el conocimiento sobre \nlos mecanismos de la inmunidad asociados al envejeci -\nmiento adecuando el mensaje a los receptores, e indican -\ndo el uso de una vacuna de alta dosis con un perfil de seguridad adecuado.\n\u2022 En el colectivo de los profesionales sanitarios, ahondar en \nlas causas de las reticencias ante la vacunaci\u00f3n o los mo -\ntivos de vacunarse mediante la realizaci\u00f3n de encuestas, con el fin de encontrar qu\u00e9 alicientes podr\u00edan estimular a \npoblaci\u00f3n para incrementar su cobertura vacunal.\n\u2022 \u201cLiderar con el ejemplo\u201d, visibilizando la vacunaci\u00f3n por par -\nte de este colectivo a trav\u00e9s de fotos y mostrando resultados \nmediante la elaboraci\u00f3n de materiales informativos.\n\u2022 Emplear o realizar formaci\u00f3n para rebatir los falsos mitos y creencias, teniendo en cuenta que son profesiones ligadas estrechamente a la ciencia\n\u2022 Plantear por parte de la Administraci\u00f3n Sanitaria la obli-gatoriedad de vacunaci\u00f3n en especialidades y colectivos que por su estrecho contacto con los pacientes puedan ser vectores de transmisi\u00f3n.\n\u2022 Realizar una vacunaci\u00f3n activa por parte de los servicios de Medicina Preventiva/Salud Laboral y enfermer\u00eda para vacunar al personal sanitario de los diferentes centros. Adem\u00e1s, ser\u00eda interesante incentivar la vacunaci\u00f3n me -\ndiante beneficios.\n\u2022 Fomentar la buena pr\u00e1ctica profesional sanitaria, prote-giendo a los pacientes de desarrollar la infecci\u00f3n por gripe y sus complicaciones asociadas para evitar el mayor da\u00f1o posible.\nAGRADECIMIENTOS\nLos autores agradecen la ayuda de Laura Vilorio Marqu\u00e9s, \nPhD y Vanessa Marfil, PhD (Medical Statistics Consulting, Va -\nlencia, Espa\u00f1a) en la redacci\u00f3n y edici\u00f3n de este manuscrito.\nFINANCIACI\u00d3N\nSanofi Pasteur Espa\u00f1a ha promovido el desarrollo de este \ntrabajo financiando los servicios de medical writing y facilitan-Documento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-443441Guti\u00e9rrez S, et al. Factors associated with acceptance of pandemic \nflu vaccine by healthcare professionals in Spain, 2009-2010. Res Nurs Health. 2017;40(5):435-43. DOI: 10.1002/nur.21815\n18. Sistema de Vigilancia de la gripe en Espa\u00f1a. Informe de Vigilan -\ncia de la Gripe en Espa\u00f1a. Temporada 2015-2016. 2016. 12 de \nnoviembre de 2021. Available from: https://vgripe.isciii.es/docu-\nmentos/20152016/InformesAnuales/Informe_Vigilancia_GRI -\nPE_2015-2016_v16082016.pdf. 12 de noviembre de 2021\n19. Sistema de Vigilancia de la gripe en Espa\u00f1a. Informe de Vigilancia \nde la Gripe en Espa\u00f1a. Temporada 2016-2017. 2017. 12 de no-viembre de 2021. Available from: https://vgripe.isciii.es/documen-\ntos/20162017/InformesAnuales/Informe_Vigilancia_GRIPE_2016-2017_v.28septiembre2017.pdf. \n20. Sistema de Vigilancia de la gripe en Espa\u00f1a. Informe de Vigilancia \nde la Gripe en Espa\u00f1a. Temporada 2017-2018. 2018. 12 de no-\nviembre de 2021. Available from: https://vgripe.isciii.es/documen-\ntos/20172018/InformesAnuales/Informe_Vigilancia_GRIPE_2017-2018_27julio2018.pdf. \n21. Sistema de Vigilancia de la gripe en Espa\u00f1a. Informe de Vigilancia \nde la Gripe en Espa\u00f1a. Temporada 2018-2019. 2019. 12 de no-viembre de 2021. Available from: https://vgripe.isciii.es/documen-\ntos/20182019/InformesAnuales/Informe_Vigilancia_GRIPE_2018-2019_22julio2019.pdf. \n22. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal \nInfluenza Infections and Cardiovascular Disease Mortality. JAMA \nCardiol. 2016;1(3):274. DOI: 10.1001/jamacardio.2016.0433\n23. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. \nAssociation of influenza vaccination and reduced risk of recurrent \nmyocardial infarction. Circulation. 2000;102(25):3039-45. DOI: \n10.1161/01.cir.102.25.3039\n24. Musher DM, Abers MS, Corrales-Medina VF. Acute Infection and \nMyocardial Infarction. N Engl J Med. 2019;380(2):171-6. DOI: \n10.1056/NEJMra1808137\n25. Mallia P, Johnston SL. Influenza infection and COPD. Int J Chron Obs -\ntruct Pulmon Dis. 2007;2(1):55-64. DOI: 10.2147/copd.2007.2.1.55\n26. Centers for Disease Control and Prevention (CDC). People at Higher \nRisk of Flu Complications 2021 [Available from: https://www.cdc.\ngov/flu/highrisk/index.htm.\n27. Rojo-Mart\u00ednez G, Vald\u00e9s S, Soriguer F, Vendrell J, Urrutia I, P\u00e9rez \nV, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. 2020;10(1):2765. \nDOI: 10.1038/s41598-020-59643-7\n28. Gorostidi M, S\u00e1nchez-Mart\u00ednez M, Ruilope LM, Graciani A, de la \nCruz JJ, Santamar\u00eda R, et al. Chronic kidney disease in Spain: Pre -\nvalence and impact of accumulation of cardiovascular risk fac-tors. Nefrologia (Engl Ed). 2018;38(6):606-15. DOI: 10.1016/j.ne -\nfro.2018.04.004\n29. World Health Organization (WHO). Fact Sheet Cardiovascular di -\nseases (CVDs) [Available from: https://www.who.int/en/news-room/\nfact-sheets/detail/cardiovascular-diseases-(cvds).\n30. Soriano JB, Alfageme I, Miravitlles M, de Lucas P, Soler-Catalu\u00f1a JJ, \nGarc\u00eda-R\u00edo F, et al. Prevalence and Determinants of COPD in Spain: \nEPISCAN II. Arch Bronconeumol (Engl Ed). 2021;57(1):61-9. DOI: berturasVacunacion/Tabla13.pdf. \n7. Ministerio de Sanidad Consumo y Bienestar Social. Coberturas de \nvacunaci\u00f3n frente a gripe en \u226565 a\u00f1os, en \u226575 a\u00f1os, personas de \npersonas de 65-74 a\u00f1os, personas de personas de 60-64 a\u00f1os, em-barazadas y personal sanitario. Comunidades aut\u00f3nomas. Campa\u00f1a \n2020-2021 (actualizaci\u00f3n octubre 2021). 2021. 2 de noviembre de \n2021. Available from: https://www.mscbs.gob.es/profesionales/sa-\nludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/coberturas/docs/Tabla13.pdf. \n8. Ministerio de Sanidad Consumo y Bienestar Social. Coberturas de \nvacunaci\u00f3n frente a gripe en \u226565 a\u00f1os, personas de 60-64 a\u00f1os, \nembarazadas y personal sanitario. Comunidades aut\u00f3nomas. Cam -\npa\u00f1a 2017-2018 (Tabla 13). 2018. 5 de noviembre de 2021. Avai -\nlable from: https://www.mscbs.gob.es/profesionales/saludPublica/\nprevPromocion/vacunaciones/calendario-y-coberturas/coberturas/\ndocs/Todas_las_tablas2017.pdf. 8 de noviembre de 2021\n9. Api\u00f1aniz A, L\u00f3pez-Picado A, Miranda-Serrano E, Latorre A, Cobos \nR, Parraza-D\u00edez N, et al. Estudio transversal basado en la poblaci\u00f3n \nsobre la aceptabilidad de la vacuna y la percepci\u00f3n de la gravedad \nde la gripe A/H1N1: opini\u00f3n de la poblaci\u00f3n general y de los profe -\nsionales sanitarios. Gaceta Sanitaria. 2010;24:314-20. \n10. To KKW, Yip CCY, Yuen KY. Rhinovirus - From bench to bedsi -\nde. J Formos Med Assoc. 2017;116(7):496-504. DOI: 10.1016/j.\njfma.2017.04.009\n11. Godoy P, Romero A, Soldevila N, Torner N, Jan\u00e9 M, Mart\u00ednez A, et \nal. Influenza vaccine effectiveness in reducing severe outcomes \nover six influenza seasons, a case-case analysis, Spain, 2010/11 \nto 2015/16. Euro Surveill. 2018;23(43). DOI: 10.2807/1560-7917.\nes.2018.23.43.1700732\n12. Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Unders -\ntanding vaccine hesitancy around vaccines and vaccination from \na global perspective: a systematic review of published literature, \n2007-2012. Vaccine. 2014;32(19):2150-9. DOI: 10.1016/j.vacci -\nne.2014.01.081\n13. Xiao X, Wong RM. Vaccine hesitancy and perceived behavioral con -\ntrol: A meta-analysis. Vaccine. 2020;38(33):5131-8. DOI: 10.1016/j.\nvaccine.2020.04.076\n14. Galicia-Garc\u00eda MD, Gonz\u00e1lez-Torga A, Garc\u00eda-Gonz\u00e1lez C, Fuster-\nP\u00e9rez M, Garrig\u00f3s-Gordo I, L\u00f3pez-Fresne\u00f1a N, et al. [Influenza vac -\ncination in healthcare workers. Why are some vaccinated whereas \nothers are not]. Enferm Infecc Microbiol Clin. 2006;24(7):413-7. \nDOI: 10.1157/13091777\n15. Kalligeros M, Shehadeh F, Mylona EK, Dapaah-Afriyie C, van Aalst \nR, Chit A, et al. Influenza vaccine effectiveness against influenza-\nassociated hospitalization in children: A systematic review and meta-analysis. Vaccine. 2020;38(14):2893-903. DOI: 10.1016/j.va -\nccine.2020.02.049\n16. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Oster -\nholm MT, et al. Variable influenza vaccine effectiveness by subty -\npe: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51. DOI: 10.1016/s1473-\n3099(16)00129-8\n17. Fern\u00e1ndez-Villa T, Molina AJ, Torner N, Castilla J, Astray J, Garc\u00eda-Documento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-44344245. Song JY, Lee JS, Wie SH, Kim HY, Lee J, Seo YB, et al. Prospective \ncohort study on the effectiveness of influenza and pneumococ -\ncal vaccines in preventing pneumonia development and hospita-\nlization. Clin Vaccine Immunol. 2015;22(2):229-34. DOI: 10.1128/\nCVI.00673-14\n46. Consejo Interterritorial. Sistema Nacional de Salud. Recomendacio -\nnes de vacunaci\u00f3n frente a la gripe. Temporada 2020-2021. 2020. \n12 de noviembre de 2021. Available from: https://www.mscbs.gob.\nes/profesionales/saludPublica/prevPromocion/vacunaciones/docs/\nRecomendaciones_vacunacion_gripe.pdf. 12 de noviembre de \n2021\n47. Bonet-Esteve A, Mu\u00f1oz-Miralles R, Gonzalez-Claramunt C, Rufas \nAM, Cruz XP, Vidal-Alaball J. Influenza vaccination during the co -\nronavirus pandemic: intention to vaccinate among the at-risk po -\npulation in the Central Catalonia Health Region (VAGCOVID). BMC \nFam Pract. 2021;22(1):84. DOI: 10.1186/s12875-021-01434-8\n48. Ministerio de Sanidad Consumo y Bienestar Social. Campa\u00f1a #Yo \nme vacuno. 2021. 3 de noviembre de 2021; (3 de noviembre de \n2021). Available from: https://www.mscbs.gob.es/campannas/cam-\npanas21/GripeYoMeVacuno/Carteles/Anciano_50x70_2021.pdf. \n49. World Health Organization (WHO). Enfermedades no transmisibles. \n2021. 2 de noviembre de 2021. Available from: https://www.who.\nint/es/news-room/fact-sheets/detail/noncommunicable-diseases . \n50. Global(Barcelona) IIdS. La transici\u00f3n epidemiol\u00f3gica (o de qu\u00e9 \nmor\u00edamos, morimos y moriremos) 2017 [Available from: https://\nwww.isglobal.org/healthisglobal/-/custom-blog-portlet/la-tran -\nsicion-epidemiologica-o-de-que-moriamos-morimos-y-morire -\nmos-/3098670/0.\n51. Sistema de Vigilancia de la gripe en Espa\u00f1a. Vigilancia de Gripe y \notros virus respiratorios en Espa\u00f1a. Sistemas y fuentes de informa-\nci\u00f3n. 2020. 13 de abril de 2021. Available from: https://vgripe.isciii.\nes/documentos/20202021/home/Sistemas%20y%20fuentes%20\nde%20informacion%20del%20SVGE_2020-21_vf.pdf. \n52. European Centre for Disease Prevention and Control (ECDC). ECDC \nstrategic framework for the integration of molecular and geno -\nmic typing into European surveillance and multi-country outbreak \ninvestigations \u2013 2019\u20132021. 2019. 2 de mayo de 2022. Available \nfrom: https://www.ecdc.europa.eu/en/publications-data/ecdc-\nstrategic-framework-integration-molecular-and-genomic-typing-european. \n53. European center for disease prevention and control (ECDC). The \nEuropean Surveillance System (TESSy). 2021. 2 de mayo de 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy. \n54. Teirlinck AC, Broberg EK, Stuwitz Berg A, Campbell H, Reeves RM, \nCarnahan A, et al. Recommendations for respiratory syncytial vi -\nrus surveillance at the national level. Eur Respir J. 2021;58(3). DOI: 10.1183/13993003.03766-2020\n55. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. Recomendaciones \nde vacunaci\u00f3n para adultos y mayores- 2019-2020. 2020. 17 de noviembre de 2011. Available from: https://www.segg.es/media/\ndescargas/VACUNAS-SEGG-2019-2020.pdf. \n56. Gil de Miguel A, Redondo Marguello E, D\u00edez Domingo J, Ortiz de Le -10.1016/j.arbres.2020.07.024\n31. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, \nKarnauchow T, et al. Acute Myocardial Infarction after Laboratory-\nConfirmed Influenza Infection. N Engl J Med. 2018;378(4):345-53. DOI: 10.1056/NEJMoa1702090\n32. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for \nacute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9(10):601-10. DOI: 10.1016/s1473-3099(09)70233-6\n33. Boehme AK, Luna J, Kulick ER, Kamel H, Elkind MSV. Influenza-\nlike illness as a trigger for ischemic stroke. Ann Clin Transl Neurol 2018;5(4):456-63. DOI: 10.1002/acn3.545\n34. Schwarze J, Openshaw P, Jha A, Del Giacco SR, Firinu D, Tsilochris -\ntou O, et al. Influenza burden, prevention, and treatment in asth -\nma-A scoping review by the EAACI Influenza in asthma task force. \nAllergy. 2018;73(6):1151-81. DOI: 10.1111/all.13333\n35. Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward \nAC. Laboratory-confirmed respiratory infections as triggers for \nacute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Clin Respir J. \n2018;51(3):1701794. DOI: 10.1183/13993003.01794-2017\n36. Panhwar MS, Kalra A, Gupta T, Kolte D, Khera S, Bhatt DL, et al. \nEffect of Influenza on Outcomes in Patients With Heart Failure. \nJACC: Heart Fail. 2019;7(2):112-7. DOI: 10.1016/j.jchf.2018.10.011\n37. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine \nas a coronary intervention for prevention of myocardial infarction. \nHeart. 2016;102(24):1953-6. DOI: 10.1136/heartjnl-2016-309983\n38. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, \nChaiwarith R, Sukonthasarn A. Influenza vaccination reduces car-\ndiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32(14):1730-5. DOI: 10.1093/eurheartj/ehr004\n39. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza \nvaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015. DOI: 10.1002/14651858.CD005050.pub3\n40. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, \nPhrommintikul A, et al. Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients: A Meta-analy -\nsis. JAMA. 2013;310(16):1711. DOI: 10.1001/jama.2013.279206\n41. Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, et \nal. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail. 2016;4(2):152-8. DOI: 10.1016/j.jchf.2015.10.012\n42. Tsivgoulis G, Katsanos AH, Zand R, Ishfaq MF, Malik MT, Karapana -\nyiotides T, et al. The association of adult vaccination with the risk of cerebrovascular ischemia: A systematic review and meta-analysis. J \nNeurol Sci. 2018;386:12-8. DOI: 10.1016/j.jns.2018.01.007\n43. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness \nof influenza vaccine in the community-dwelling elderly. N Engl J \nMed. 2007;357(14):1373-81. DOI: 10.1056/NEJMoa070844\n44. Mulpuru S, Li L, Ye L, Hatchette T, Andrew MK, Ambrose A, et al. \nEffectiveness of Influenza Vaccination on Hospitalizations and Risk \nFactors for Severe Outcomes in Hospitalized Patients With COPD. \nChest. 2019;155(1):69-78. DOI: 10.1016/j.chest.2018.10.044Documento de opini\u00f3n de expertos para la mejora de la cobertura vacunal frente a la gripe estacional C. Velicia Pe\u00f1as, et al.\nRev Esp Quimioter 2022;35(5): 435-443443courses and attitudes in general population and healthcare wor -\nkers.]. Rev Esp Salud Publica. 2021;95. jarazu R, Martin\u00f3n Torres F. [High-dose trivalent influenza vaccine. \nEfficacy and effectiveness]. Rev Esp Quimioter. 2020;33(4):226-39. DOI: 10.37201/req/043.2020\n57. Young-Xu Y, Snider JT, van Aalst R, Mahmud SM, Thommes EW, \nLee JKH, et al. Analysis of relative effectiveness of high-dose versus \nstandard-dose influenza vaccines using an instrumental variable method. Vaccine. 2019;37(11):1484-90. DOI: 10.1016/j.vacci -\nne.2019.01.063\n58. Ortiz de Lejarazu R, Martinon Torres F, Gil de Miguel A, Diez Domin -\ngo J, Redondo Marguello E. [High-dose trivalent influenza vaccine: \nsafety and immunogenicity]. Rev Esp Quimioter. 2021;34(1):1-11. \nDOI: 10.37201/req/110.2020\n59. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins \nA, et al. Efficacy of high-dose versus standard-dose influenza vacci -\nne in older adults. N Engl J Med. 2014;371(7):635-45. DOI: 10.1056/NEJMoa1315727\n60. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et \nal. Populations at risk for severe or complicated influenza illness: \nsystematic review and meta-analysis. BMJ. 2013;347:f5061. DOI: 10.1136/bmj.f5061\n61. Mazagatos C, Delgado-Sanz C, Oliva J, Gherasim A, Larrauri A, Spa -\nnish Influenza Surveillance S. Exploring the risk of severe outco -\nmes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-\n2015/16. PLoS One. 2018;13(8):e0200934. DOI: 10.1371/journal.\npone.0200934\n62. Asociaci\u00f3n Espa\u00f1ola de Vacunolog\u00eda CG. Vacunaci\u00f3n frente a la \ngripe en las embarazadas. 2019. 17 de noviembre de 2021. Availa -\nble from: https://www.vacunas.org/wp-content/uploads/2019/12/\nEmbarazadas_Gripe_Embarazo_Def.pdf. \n63. Mazagatos C GP, Mu\u00f1oz Almagro CM, et al. Efectividad de la va -\ncuna antigripal en embarazadas para prevenir la infecci\u00f3n de gripe \ngrave en ni\u00f1os menores de 6 meses. Espa\u00f1a 2017-2019. XXXVII \nReuni\u00f3n Cient\u00edfica de la Sociedad Espa\u00f1ola de Epidemiolog\u00eda y XIV \nCongresso da Associa\u00e7\u00e3o Portuguesa de Epidemiologia. 2019. p. \n1-307. .\n64. Mart\u00ednez-Baz I, D\u00edaz-Gonz\u00e1lez J, Guevara M, Toledo D, Zabala A, \nDom\u00ednguez A, et al. Actitudes, percepciones y factores asociados a \nla vacunaci\u00f3n antigripal en los profesionales de atenci\u00f3n primaria de Navarra, 2011-2012. An Sist Sanit Navar. 2013;36:263-73. \n65. Tuells J, Garc\u00eda-Rom\u00e1n V, Duro-Torrijos JL. Cobertura de vacu -\nnaci\u00f3n antigripal (2011-2014) en profesionales sanitarios de dos \ndepartamentos de salud de la Comunidad Valenciana y servicios \nhospitalarios m\u00e1s vulnerables a la gripe. Rev Esp Salud Publica. \n2018;92. \n66. World Health Organization (WHO). Global influenza strategy 2019-\n2030. 2019. 3 de noviembre de 2021. Available from: https://apps.\nwho.int/iris/handle/10665/311184. \n67. Cristia Civit E, Mendoza Barbero A, Estape Maduell M, Esteve Sero \nE. Aplicaci\u00f3n del modelo PRECEDE en la farmacia. Farmac\u00e9uticos \nComunitarios.4(Suplemento 1). \n68. Olmedo Lucer\u00f3n C, Limia S\u00e1nchez A, Santamarina C. [Vaccination \nconfidence against influenza in Spain: reasons of hesitancy dis -ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/058.2022\nRev Esp Quimioter 2022;35(5): 444-454444Juan Gonz\u00e1lez del Castillo1\nMari Cruz Mart\u00edn-Delgado2\nFrancisco Javier Mart\u00edn S\u00e1nchez3\nManuel Mart\u00ednez-Sell\u00e9s4\nJos\u00e9 Mar\u00eda Molero Garc\u00eda5\nSantiago Moreno Guill\u00e9n6\nFernando Rodr\u00edguez-Artalejo7\nJuli\u00e1n Ruiz-Galiana8\nRafael Cant\u00f3n9\nPilar De Lucas Ramos10\nAlejandra Garc\u00eda-Botella11\nAlberto Garc\u00eda-Lled\u00f312\nTeresa Hern\u00e1ndez-Sampelayo13\nJavier G\u00f3mez-Pav\u00f3n14\nEmilio Bouza15\nfor this sector in critic circumstances. Finally, we believe that \nthe creation of National Coordination Centers for major disas -\nters and Public Health can contribute to better face the crises \nof the future.\nKeywords: COVID-19, SARS-CoV2, catastrophes, pandemics, primary care, \nhospital care, socio-health centers, health organization, teaching in me -\ndicine, medical education, specialist training, research, communication, health industry, media, bioethics \nLecciones de la COVID-19 para futuras \ncat\u00e1strofes: un documento de opini\u00f3n\nRESUMEN\nEs necesaria una \u201cLey de Pandemias/cat\u00e1strofes\u201d que con -\ndense y ordene la dispersa y m\u00faltiple legislaci\u00f3n actual. El Es -\ntado tiene que ejercer un poder y mando \u00fanico adecuado a \ncada situaci\u00f3n, con vigencia nacional. Se recomienda la con -\nfecci\u00f3n de planes de utilizaci\u00f3n de suelo e inmuebles como centros potenciales de asistencia sanitaria, refugio o albergue. \nDeber\u00e1n existir planes de cat\u00e1strofes espec\u00edficos al menos para la Atenci\u00f3n Primaria, Atenci\u00f3n Hospitalaria y Centros Socio-sanitarios. La garant\u00eda del mantenimiento de las v\u00edas de co -\nmunicaci\u00f3n y abastecimiento es esencial, as\u00ed como la garant\u00eda de producci\u00f3n aut\u00f3ctona de materias de primera necesidad. La pandemia ha puesto de manifiesto la necesidad de redefinir los planes de formaci\u00f3n de los m\u00e9dicos que en sus distintas \nespecialidades tienen que asumir reformas que permitan un entrenamiento m\u00e1s vers\u00e1til y transversal. La investigaci\u00f3n na-\ncional debe tener planes para poder responder con rapidez a preguntas que planteen las distintas crisis, utilizando para ello, Lessons from COVID-19 for future disasters: an \nopinion paper \n1Emergency Service. San Carlos University Clinical Hospital. Complutense University. Madrid.\n2Intensive Medicine Service. Torrej\u00f3n University Hospital. Francisco de Vitoria University. Madrid.\n3Geriatrics Service. San Carlos University Clinical Hospital. Complutense University. Madrid\n4Cardiology Service. Gregorio Mara\u00f1\u00f3n General University Hospital, European University. Madrid.\n5Family Medicine. Infectious diseases. Madrid.\n6Infectious Diseases Service. Ram\u00f3n y Cajal Hospital. University of Alcal\u00e1 de Henares. Madrid.\n7Department of Public Health. Autonomous University. Madrid\n8Internal Medicine Service. Ruber International Hospital. Madrid.\n9Microbiology Service. Ram\u00f3n y Cajal Hospital and Ram\u00f3n y Cajal Institute for Health Research (IRYCIS). Spanish \nNetwork for Research in Infectious Pathology (REIPI). Madrid.\n10Emeritus. Pneumology Service. Gregorio Mara\u00f1\u00f3n General University Hospital, Complutense University. Madrid\n11General Surgery Service. San Carlos University Clinical Hospital. Complutense University. Madrid.\n12Cardiology Service. Prince of Asturias Hospital. University of Alcal\u00e1. Madrid.\n13Pediatrics and ACES Service. Gregorio Mara\u00f1\u00f3n General University Hospital, Complutense University. Madrid.\n14Geriatrics Service. Central Hospital of the Red-Cross. Alfonso X el Sabio University. Madrid\n15Clinical Emeritus, Community of Madrid. Clinical Microbiology and Infectious Diseases Service of the Gregorio \nMara\u00f1\u00f3n General University Hospital, Complutense University. CIBERES. Cyber of Respiratory Diseases. Madrid.Review\nArticle history\nReceived: 16 June 2022; Accepted: 21 June 2022; Published: 27 June 2022\nABSTRACT\nA \u201cPandemic/Disaster Law\u201d is needed to condense and or -\nganize the current dispersed and multiple legislation. The State \nmust exercise a single power and command appropriate to \neach situation, with national validity. The production of plans for the use of land and real estate as potential centers for \nhealth care, shelter or refuge is recommended. There should \nbe specific disaster plans at least for Primary Health Care, Hos-\npitals and Socio-sanitary Centers. The guarantee of the main -\ntenance of communication and supply routes is essential, as well as the guarantee of the autochthonous production of ba -\nsic goods. The pandemic has highlighted the need to redefine the training plans for physicians who, in their different spe -\ncialties, have to undertake reforms that allow a more versatile \nand transversal training. National research must have plans to \nbe able to respond quickly to questions posed by the various \ncrises, using all the nation\u2019s resources and in particular, all the data and capabilities of the health sector. Contingency plans must consider ethical aspects, and meet the needs of patients \nand families with a humanized approach. In circumstances \nof catastrophe, conflicts increase and require a bioethical re -\nsponse that allows the best decisions to be made, with the ut -\nmost respect for people\u2019s values. Rapid, efficient and truthful \ncommunication systems must be contained in a special project \nCorrespondence: \nEmilio Bouza Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas del Hospital \nGeneral Universitario Gregorio Mara\u00f1\u00f3n, Universidad Complutense. CIBERES. Ciber de \nEnfermedades Respiratorias. Madrid \nE-mail: emilio.bouza@gmail.com\nAll authors belong to the Scientific Committee on COVID-19 of the Madrid College of \nPhysicians (ICOMEM).Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-454445national and constitutional legal tangle and the most elemen -\ntary natural law [2]. In the early stages of the current pandemic, \neven with accredited health systems, as fortunately ours is, the \nresponse to basic demands (an oxygen supply, a medical visit...), \nwere not always met, or arrived late. The delay, if it could be \nshortened, was due to the voluntarism, intuition and profession -\nalism of healthcare workers and other social agents, rather than to the established institutional response. \nThis first line of action of security forces and social and \nhealth care, whose raison d\u2019\u00eatre is immediate intervention, \nshould be strengthened by the State with human and tech -\nnical resources. An example of what is needed should be plans \nfor the use of land and real estate, which can be made avail -\nable within hours, to be used as shelters or as areas for assis -\ntance or isolation.\nPrevention, information and education for the health of \nthe population are essential aspects. Educational programs should be established to promote compliance with hygiene \nstandards and to raise awareness of the usefulness of vacci -\nnation and other preventive measures. It is also important to \npromote self-care and individual responsibility in health. \nIn major disaster situations, it is essential to secure com -\nmunication routes, the transport network and the production \nof essential materials. \nThe use of social networks and other means of communi -\ncation allows immediate interconnectivity, which can facilitate \nrapid and effective organization. Their good use can be deci -\nsive in the development of events [3-8]. \nThe transport network is essential for the management of \na major disaster and ensuring it will depend on the coordina -\ntion of a single command, with the involvement, when neces-\nsary, of the so-called essential bodies. All available resources \nmust be used, whether by land, sea or air, in order to supply \nfood, equipment, transport of people, etc. \nAnother line of work that COVID-19 has reminded us \nof is the necessary and permanent connection of assistance \nwith basic research and with the industrial and productive re -\nsources. The initial regulations during the pandemic, far from strengthening them, annulled them. The laboratories of uni -\nversities and large research centers, which would have had \ngreat potential for diagnostic assistance and technological treatment, were preventively closed. International markets \nwith high international demand were resorted to in a situation of low competitiveness, instead of activating and facilitating national production [9, 10]. In addition, in Spain, a national co -\nordination center should be established to facilitate a single \nmanagement in these circumstances. This has been hindered \nby the decentralization of healthcare competencies to the au-\ntonomous communities.\nThe national pharmaceutical industry, although with ex-\nemplary examples, should ensure sufficient production capac -\nity for essential drugs, especially antimicrobials and vaccines. \nA more centralized collaboration and organization in \nwhich equity is ensured is necessary. Our nation must not for -todos los recursos de la naci\u00f3n y en particular todos los datos \ny capacidades del sector sanitario.   Los planes de contingen -\ncia deben considerar los aspectos \u00e9ticos, y cubrir las necesida -\ndes de pacientes y familias con un enfoque humanizado. En \ncircunstancias de cat\u00e1strofe aumentan los conflictos que re -\nquieren una respuesta bio\u00e9tica que permita tomar las mejores \ndecisiones, con el m\u00e1ximo respeto a los valores de las personas. \nLa comunicaci\u00f3n, r\u00e1pida, eficiente y veraz debe estar contenida \nen un proyecto especial para este sector en circunstancias de crisis. Pensamos finalmente que la creaci\u00f3n de un Centro coor-\ndinador nacional de grandes cat\u00e1strofes y Salud P\u00fablica puede \ncontribuir a enfrentarnos mejor a las crisis del futuro.\nPalabras clave: COVID-19, SARS-CoV2, cat\u00e1strofes, pandemias, atenci\u00f3n \nprimaria, atenci\u00f3n hospitalaria, centros socio-sanitarios, organizaci\u00f3n sa -\nnitaria, docencia en medicina, educaci\u00f3n m\u00e9dica, formaci\u00f3n de especialis -\ntas, investigaci\u00f3n, comunicaci\u00f3n, industria sanitaria, medios de comunica -\nci\u00f3n, bio\u00e9tica.\nINTRODUCTION\nThe major concern of the society in general, and of the \nscientific society in particular, is to predict the future of the \nCOVID-19 pandemic. It is necessary to try to anticipate wheth -\ner there will be new waves of the disease, whether particularly \nvirulent variants may appear, whether vaccines will evolve at \na sufficient rate to cope with the situation and whether the \npharmaceutical industry will be able to continue producing ef -\nfective drugs against present and future coronaviruses.\nIn addition to the above, lessons need to be drawn from \nthe situation suffered to deal with other potential catastro -\nphes, not only of a viral or microbial nature, but of any other cause.\nThe COVID Committee of the Illustrious College of Phy -\nsicians of Madrid, whose mission is to deliberate on this and other aspects related to the pandemic and emerging patho -\ngens, has formulated a series of questions that do not pretend \nneither to cover the universe of the problem nor to issue any \ndogma. We have simply intended to offer some reflections to our members, and to whom they may be useful, on lessons for \nthe future learned from COVID-19. The questions have been formulated and discussed by the members of the Committee and the deliberations are set out below.\nWHAT LINKS AND PLANS SHOULD BE \nIMPLEMENTED IN THE EVENT OF MAJOR \nDISASTERS? \nIn addition to natural biological threats, which are always \nlatent [1], there are other types of threats, which are current \nand highly probable. \nSpain and the rest of the states, have a response capacity, \nhealth and social, that translated into written rules, overwhelms in thousands of pages. But if they are to become real practices, \nit will be necessary to generate a more synthetic document with \nfreer and more executive decisions, which will allow legally con -\nstituted institutions to act effectively among the autonomous, Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-454446semination among professionals of the clinical information \ngenerated by healthcare organizations.\nHOW SHOULD MAJOR DISASTER PLANS BE \nORGANIZED IN HOSPITALS? \nIt is essential that hospital disaster preparedness is well \norganized and incorporated into the routine operation of hos -\npitals [15-21].\nIn the preparation and management of catastrophes, the \nconcept of the maximum benefit of the greatest number of \nvictims takes precedence over that of the individual, and the \norder of priority in intervention is not determined solely by the \nseverity of the injuries, but by the possibility of survival [17, \n18]. Some documents serve as examples of hospital organiza -\ntion in recent catastrophes such as the COVID-19 pandemic \nand the 11M terrorist attack in Madrid [19,20].\nAll hospitals should have organized a Commission re -\nsponsible for preparing a Disaster Plan in advance, specific to \neach center and to the situations to which it may be exposed \n(natural disasters, pandemics, terrorism, chemical or biological \nweapons, accidents due to radioactive contamination, etc). The Commission will report directly to the hospital manager and may be subdivided into groups, with specific composition and \nresponsibilities, mainly the Permanent Disaster Committee and \nthe Disaster Commission. \nThe Standing Committee should be made up of the hos -\npital\u2019s most responsible operational and organizational bodies: Manager, Medical Director, Director of Nursing, Director of Management (or whoever they delegate), Emergency Coordi -\nnator, Head of the IT Service, Communication Service or Office, \nand the President or Coordinator of the General Committee. It \nis essential to have permanent internal and external communi -\ncation and coordination within and outside the hospital, with other hospitals, health care facilities that attend to patients (primary care, rescue services, out-of-hospital emergencies, \netc.) and the relevant authorities. \nThe Disaster Plan is made up of those protocols, proce -\ndures and pre-established actions to be applied in the man -\nagement of disasters, seeking the greatest efficiency of the \navailable resources and the least impact on the hospital. The following areas will be represented: direct assistance areas, \nassistance support areas, General Services, Admission Service, \nSecurity Service, Communication Service and Press Office, In -\nformation Technology Service, Human Resources Services and \nFamily Care Area.\nWith regard to organization and operation, it is important \nto work in advance on: \n1.-  Defining, forecasting and availability of additional resourc -\nes needed in the first moments (care spaces, mobilization of \nhuman and material resources to the emergency and criti -\ncal areas that receive the maximum influx of patients).\n2.-  Defining the essential active activity of the hospital dur -\ning the disaster, as well as the temporarily delayable one.get past experiences and must legislate a law on catastrophes \nand pandemics that will provide a legal framework for action and collaboration between the public and private sectors. If \nthis is not done, a new opportunity will have been lost and the \nimprovements that can be derived from past experience will \nnot become evident.\nIn the following points of the document, more specific \naspects of the healthcare response are raised that may be of great use in putting an end to this threat or facing the next \none, which, as we well know, awaits us.\nWHAT ESSENTIAL ELEMENTS SHOULD A MAJOR \nDISASTER PLAN ADDRESS IN PRIMARY CARE?\nIn order to face future health emergencies with greater \nguarantees, it is essential to strengthen Primary Care (PC). The \nproper functioning of PC guarantees a higher quality, safer, \nmore equitable and efficient healthcare system. The strength-ening of PC requires a substantial increase in its financing. In -\nvestment in PC should increase from 11% of the current health budget to the 25% recommended by the World Health Organ -\nization (WHO) [11]. Investment should cover both human and technological resources and the adequacy of infrastructures.\nIt is necessary to design in advance a specific contingency \nplan in PC for major disasters, with the active participation of PC physicians in its elaboration. \nIn addition to care for the victims of the catastrophic ep-\nisode, it is essential to ensure access to PC for the rest of the \npopulation, particularly the most vulnerable (elderly, chronic, \ndependent, etc.) [12]. To this end, new alternative care models to the conventional ones should be promoted and consolidat -\ned, encompassed in the concept of telemedicine [13] with pos -\nsibilities of active follow-up of patients with remote monitor -\ning that can guarantee efficient care, control and prevention of chronic processes and multi-pathological patients. \nThe plan we suggest should promote home care from PC, \nespecially by nurses, providing them with the capacity to pro -\nvide resources related to the care and attention of complex \nchronic patients. \nIt would also increase efficiency and accessibility in PC, \nthe elimination of all those activities that provide little care value and increase bureaucratization, such as the manage -\nment of sick leave, favoring the digitization of administrative \nprocesses [14].\nNew care models should be implemented with multidisci -\nplinary teams, less dependent on the figure of the family phy -\nsician, and it is necessary to reorganize the responsibilities of all \nthe professionals that make up PC based on different profiles \nthat allow a more efficient response to demand. It is also neces -\nsary to promote the creation and adaptation of new profession -\nal profiles (psychologists, occupational therapists, community \nagents or managers, health promoters, clinical assistants).\nFinally, we believe it is important to design and develop \ninternal and external communication plans to ensure the dis-Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-4544472.- The creation of Residential Care Units by means of \nmultidisciplinary teams of doctors, nurses and pharmacists, \ndepending on primary care, directly coordinated with Hospital \nGeriatrics and Public Health.\nThe need for a new regulatory and financing system for \nthe creation of a new model of comprehensive care centered \non the person, reducing the fragmentation between social and \nhealth care, equalizing the qualifications required as well as \nthe economic compensation [26] (Table 1).3.-  To prioritize the safety and support of the workers in -\nvolved in the attention to the catastrophe.\n4.-  To ensure updated and truthful information on the evolu -\ntion of the disaster.\n5.-  To anticipate and guarantee the management of new \nneeds (protection measures, food, medicines, furniture, \netc.).\n6.-  To establish the means of social and health support for \npatients and families.\n7.-  To develop training and support plans in the resolution \nand decision making of ethical problems [19, 21]. \n8.-  To prepare psychological support groups for patients and \nworkers, dependent on mental health services.\n9.-  To design stabilization and evacuation plans for pediatric \npatients in hospitals without a pediatric service.\n10.- To have a plan for the reorganization and recovery of the \nhospital\u2019s previous activity, to be applied once the ca-\ntastrophe is over. \nWHAT REFORMS ARE NEEDED IN HEALTH CARE \nINSTITUTIONS?\nIn Spain there are more than 400,000 residential places in \nthese socio-health centers for all population groups, with the \nelderly being the most notable [22]. Residents have pluripa -\nthology, need for polypharmacy and have high levels of phys -\nical and mental dependence that determine important family \nand psychosocial conditioning [23]. \nThis situation is reflected in the figures produced by the \npandemic with an 80% mortality rate due to COVID-19 in the over-70 age group, reaching up to 47% of deaths in nursing \nhomes [24], figures that could be even higher [25]. \nThe Pandemic has revealed, among others, the following \ndeficits in the socio-health environment, which a future disas -\nter plan should try to solve:\n- Significant lack of health personnel assigned from pri -\nmary care or hospital referral. Doctors and nurses in these \ncenters do not always have the necessary training in family \nand community medicine or geriatric medicine. In addition, \nthey tend to have a very rapid turnover.\nThere are usually no plans for catastrophes or pandemics \nin the social and health centers, nor a plan of audits to guar -\nantee their implementation.\n- There are usually no coordinated information systems \nthat facilitate access to residents\u2019 medical records for health -\ncare professionals in order to provide coordinated and speed \ncare.\nIn view of the above, there is a need to redesign and con -\nsolidate a social and health care structure that responds to the needs of these people and these centers, which should include \nthe following:\n1- The figure of a liaison Geriatrician in each hospital.HOW SHOULD THE KNOWLEDGE AND TRAINING \nOF HEALTHCARE WORKERS BE IMPLEMENTED IN DISASTER PLANS?\nThe SARS-CoV-2 pandemic has highlighted the main val -\nue of the healthcare system, which is its professionals. Espe-\ncially in the first wave of the pandemic, the need to provide care to an unusual number of COVID 19 patients, which sat -\nurated healthcare resources, and the drastic reduction in care \nfor other pathologies, led to substantial changes in the organ -\nization of work and healthcare teams [27]. \nMany healthcare professionals with specialized training \nhad to support teams with high care loads such as the emer -\ngency department, hospital wards and critical care areas [28]. \nTeamwork, motivation and professionalism managed to pro -\nvide an exceptional response to care, teaching and research needs, even innovating and incorporating technology and dig -\nitization in healthcare systems. But it has also had negative consequences not only physically but also emotionally on pro -\nfessionals and sometimes even on care outcomes, by reducing \nthe quality of care in highly specialized environments.Table 1   Measures to be contemplated in \ncontingency plans for residential \nhealth and social care centers [26]\n1. In relation to the Organization of the residential center itself:\n- Location of all residential centers in the area.\n- Adjustment of visits according to the incidence of the pandemic.\n- Continuous training of all personnel in the different teams.- Adequate hygiene measures\n- Necessary protective equipment\n- Isolation capacity in: red zone (infected patients), orange zone (suspected \npatients) and green zone (not infected and infection overtaken).\n2. In relation to the Sociosanitary Coordination:\n- Well-established consultation circuits with hospital referents.\n- Health and social resources (both human and material) according to the needs of \neach center and type of patient (degree of dependence).\n- Adequate communication with Hospital-PHC-Public Health-SUMMA teams.\n- Capacity for diagnostic tests according to indications.Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-454448to these needs and ensure the maintenance of competencies \nthrough continuing education [34]. Knowing the institutional \ncontingency plans, and their periodic training through drills, \nis one of the basic pillars to act effectively and safely in these \ncontexts [35].\nOther competencies, such as digital competencies and \ncompetencies in the use of technology should be considered in \nthe training programs of healthcare professions [36,37]. \nThe best prepared organizations will be the ones that have \nthose professionals with excellence in the specialized technical part but also have the flexibility to adapt to a changing con -\ntext such as the one we have faced during this pandemic.\nWHAT CHANGES IN THE ORGANIZATION OF \nHEALTHCARE MANAGEMENT ARE MOST NEEDED \nTO DEVELOP AND ACTIVATE SUCH PLANS?\nThe COVID-19 pandemic has led to multiple changes and \nadaptations in health system care and management. Some of \nthese changes could be maintained in the future to improve health care and improve response to emerging situations and are as follows: \n1.- There is a need to redesign hospitals to allow for the \nexpansion of critical areas in an agile manner and the isola -\ntion of infectious-contagious patients. Hospital contingency \nplans should foresee where these critical areas should grow, \nthe material needed to equip them and the human resources that should be employed.\n2.- Work in coordination between the three levels of care \n(primary care, out-of-hospital emergencies and specialized hospital medicine) to be able to carry out common preven -\ntive medicine. The management of at least the most frequent processes between the different levels of care should be pro -\nmoted by means of agreed and common protocols and clinical \npathways. The use of information systems as tools to help the \nprofessional and not only as a way of recording and storing \nclinical and administrative information on the patient is fun -\ndamental to their success. \n3.- To increase the coordination of the different national \nterritories, so that solutions to common problems are shared, patients\u2019 healthcare information is available when they are \ntreated outside their Autonomous Community and to ensure \nthe greatest possible equity in healthcare, regardless of where it is provided. \n4.- The crisis situation led to the need to urgently hire \nmultiple health care workers and even to incorporate medical personnel who were not yet specialized or who had already re -\ntired. The organizational staffs of health centers should be ad-equately equipped to respond to crisis emergencies and would make it possible to avoid or mitigate the suspension of surgi -\ncal, diagnostic or chronic patient care activity in the event of \nany emergency, as has occurred in the current crisis. \n5.- The multidisciplinary work carried out in the COVID-19 \ncare has highlighted the value of this type of strategy, which One of the lessons learned from this pandemic leads us to \nreflect on how the new training models for these healthcare \nprofessions should be approached. \nThe first consideration would be related to the need for \ncompetency-based training. Specialized medical training has followed the classic model of programs based on experience acquired in programmed rotations in different care areas with the participation of expert clinical professionals act -\ning as teachers. The evaluation of the results is carried out through the certification of these stays by means of subjec-tive observation and supervised practice, generally without a final exam, which presupposes the benefits of this training model. This model does not ensure homogeneity of results and does not always meet the expectations of profession -\nals. Competency-based training is currently an alternative to \nthese classical training models. They are based on the defini -\ntion of a series of observable and measurable competencies (knowledge, skills, behaviors and attitudes) that a profession -\nal must have in order to meet the needs of patients and solve \nthe problems they pose. The training is based on reflective \nlearning, places the physician in training at the center of the \nsystem, incorporates innovative teaching tools such as clin -\nical simulation for the acquisition of competencies, requires \nthe training of teachers as facilitators of this learning, em -\nphasizes periodic and structured formative evaluation with objective and validated instruments through the recording of achievements and sometimes incorporates or facilitates a summative evaluation through certifications that reliably ensure the effectiveness of the training process [29]. All this favors an objective, structured, transparent and effective training process that, promotes autonomous professional de -\nvelopment and reduces learning variability [30].\nThe second, is the need to define what should be the ba -\nsic competencies for any healthcare professional, regardless of the function he or she performs on a regular basis outside cri -\nsis situations. A common and transversal training, beyond the specialization of each program, favors the response in this con -\ntext. The management of life-threatening emergency situations, the initial response to disasters and especially the acquisition of basic skills such as teamwork and effective communication are essential. Disaster medicine is not incorporated in practically any body of doctrine or in the curricula of the different specialties, although there are clearly defined competencies. During the pandemic, initiatives have been developed that have allowed basic training in critical patient care for many professionals from \nother areas [31]. This requires innovative teaching methodolo -\ngies such as clinical simulation to increase the learning curve. \nThere are training programs such as TeamSTEPPS\u00ae [32] or crisis \nmanagement training (CRM) [33] aimed at training leadership, \neffective communication, supportive behavior, emotional intelli-\ngence and other competencies that favor teamwork and flexibil -\nity of professionals in situations of uncertainty.\nInterdisciplinary training favors collaborative practice, \ntraining teams to work together, and has been shown to im -\nprove care outcomes. All this requires profound changes in \nundergraduate and specialized training programs that respond Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-454449Without falling into the ridicule of the declarations of the \npresidents of some nations, examples include those relating to \nthe use of masks at the beginning of the pandemic, the ap -\npropriate meters to maintain social distance or the number of \npeople who could gather in each territory or period [41]. The \ndispersion of measures of the European Union states and the Spanish autonomous communities has multiplied the dissem -\nination of heterogeneous information, which has overloaded \nthe population and undermined their confidence. It seems es -\nsential that, for the future, there should be real leadership by \nthe World Health Organization (WHO) and adequate coordi -\nnation of the health and information policies of the European Union and Spain, using single, homogeneous channels.\nBeyond the excess, there has been an enormous amount \nof biased or false information that the WHO has called \u201cinfo-demic\u201d [42]. The United Nations (UN) has described it as some -\nthing as worrying as the pandemic itself, as it can generate \ndangerous health behaviors, distrust towards the media and \nhealth authorities, social or racial discrimination and even vi -\nolence.\nGiven the fundamental role of social networks in the dis-\npersion of false and biased news [43], solutions have been pro -\nposed such as public health organizations taking a leading role in the networks, both disseminating truthful information and \ncombating hoaxes [44]. The social networks themselves have \ntaken measures to reduce disinformation [45], and the activ -\nity of many groups of journalists to safeguard the veracity of \ninformation should be highlighted. An example of this is Web Newsguard (https://www.newsguardtech.com). It has even \nproposed the use of artificial intelligence systems to detect \nand stop hoaxes and rumors at an early stage [46]. \nAlthough the right to freedom of expression and infor -\nmation must always be taken into account, the right to health \nand the obligation to provide truthful and verifiable informa-tion must also be considered. In addition to internal control \nmeasures by social networks and control by information pro -\nfessionals, a large part of the solution to this problem involves training society in the critical use of information technologies \n[41,43,44] and paying attention to the doubts and fears of the population, in order to provide them with appropriate answers \n[42].\nIS THERE A NEED FOR NATIONAL RESEARCH \nCOORDINATION TO ADDRESS THE QUESTIONS \nTHAT NEW DISEASES OR NEW SITUATIONS MAY \nPRESENT?\nAlthough the impact experienced during the first wave \nhas given rise to pessimistic reflections on the real potential of \nour national health system research, the fact is that it has also highlighted the organizational capacity and care efforts of the \nprofessionals and their research efforts. Spain occupies the 7th \nplace in the ranking of research publications related to COVID, \nwhich is undoubtedly a good ranking [47]. \nIn Spain, public research in biomedicine is mainly car -provides the knowledge of various specialists in the care of the \nsame care process. Previous experience in this regard already \nexisted, but the organization of the system according to pro -\ncesses with multidisciplinary groups should be encouraged, es -\npecially in prevalent processes affecting the elderly population \nwith comorbidities, where optimal clinical management should \nbe integrated and not patched according to the specialist who \nis evaluating the patient at a given moment.\n6.- Teleconsultation has been greatly enhanced during \nthe pandemic. The key to its success, however, does not lie in \ngeneralizing it, but in choosing appropriately the patients who \ncan benefit from it, avoiding unnecessary trips to the health \ncenter if it is not going to add value to the care provided. The \nfirst contact with the health system when faced with a health \nproblem should always be face-to-face, so that the physician \ncan carry out an adequate anamnesis and physical examina -\ntion, which is imperative at the first moment. \n7.- A double care circuit should be maintained in emer -\ngency departments for the location of patients with commu -\nnicable respiratory diseases to avoid secondary contagion with \nother patients and ensure adequate protection of healthcare \npersonnel. This measure can be useful in other common res -\npiratory viruses such as influenza or RSV pandemics, in addi -\ntion to the coronavirus pandemic. \n8.- Health education and patient empowerment from the \ninitial stages of education is essential to prevent the general population from consulting for minor problems that distort \nthe care of patients who do require such care.\nWHAT ERRORS IN THE COMMUNICATION POLICY \nSHOULD BE CHANGED IN THE FUTURE?\nThe analysis of the information received by the population \nduring the SARS-CoV-2 pandemic reflects three fundamental \nproblems: the excess of information in general, the confusion \ncaused by the diversity of official sources, and the enormous \namount of biased or false information that has been dissem-\ninated. At the very least, these three problems should be cor -\nrected in future disaster plans.\nInformation overload, without going into its quality, has \nled to the coining of the term infoxication [38], and can have negative consequences on prevention behaviors [39]. It can al -\nso be the cause of neuropsychiatric disorders (gathered in the information overload syndrome) with diverse presentations, almost all related to anxiety pictures, loss of concentration and even social isolation responses [40]. In an environment of press \nfreedom, with multiple sources of information and the added \nparticipation of social networks, it is difficult to propose meas -\nures to correct this overload. Health education of the popula-\ntion and the leadership of the health authorities could allow \nsufficient and contrasted information, avoiding the need to resort to multiple sources.\nThe diversity of official national and international sourc -\nes has generated information that is not only excessive, but sometimes confusing, contradictory or openly erroneous. Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-454450WHAT ASPECTS OF HUMANIZATION AND ETHICS \nNEED TO BE IMPROVED IN THE FACE OF A POTENTIAL CATASTROPHE IN THE FUTURE?\nMany and varied are the ethical conflicts that have arisen \nduring the pandemic and have been addressed according to \nits evolution. Suffice it to mention the different reports of the \nSpanish Bioethics Committee [54-56], etc. that have helped to deal with the complex situations experienced in the different waves. Learning from this pandemic must be used to safely \nface new scenarios. \nIn the future, it will be necessary to bring bioethics closer \nto daily clinical practice, relying on bioethicists and the differ -\nent bioethics advisory bodies at all levels (institutional, hospi-\ntal care, etc.). During the pandemic, many scientific societies, \nfaced with the new challenges, drew up recommendations on \nethical aspects that were of great help in decision-making. Lo -\ncal initiatives should be avoided, trying to unify ethical princi -\nples and their implementation in an agile and continuous way in order \u201c...not to leave ethics aside, but rather, in a crisis situ-ation, it is even more important to articulate ethical guidelines for extraordinary circumstances that help decision-makers un -\nder pressure...\u201d. [57]. \nIt is necessary to establish consensual criteria for prior -\nitizing the allocation of resources in situations where there is an imbalance between the demand for care and the available resources. In these cases, decision-making is highly complex \nand requires appropriate management of resources without \nundermining the rights and dignity of citizens. \nThe different ethical reports [54-59] establish that triage \n(admission to ICU, transfer to hospital from residential centers, \netc.) requires the maximum expansion of resources, and must \nbe guided by clinical criteria that, objectively, although in the context of uncertainty, help in decision making. [60]. Protocols should include flexible criteria and be adapted to each particu -\nlar situation. To this end, the best recommended strategy is the \ncreation of care teams that update these protocols and that, \nin crisis situations, are responsible for the daily assessment of \nincoming and outgoing patient flows. In this regard, a basic \nelement is to encourage society to plan care in advance on \nthe basis of its values and preferences, especially in the most \nvulnerable population. \nOnce the above is well defined, it will be possible to de -\ntermine the criteria for resource allocation in a critical disas -\nter situation, recommending mixed model criteria that include \nutility, equity, and protection from vulnerability. However, it will not always be possible to fully achieve both utility and eq -\nuity and there will be no single right way to solve the prob -\nlems. But what is important is that the decisions that are made \nare made in a transparent process that takes into account local \ncircumstances along with those of the rest of the autonomous \ncommunities and the country [60]. \nIt is also necessary to consider the needs of humaniza -\ntion in the assistance and aspects related to the families. The \ncompulsory isolation of infected persons adds to the seri -ried out in hospitals and universities, on numerous occasions \nthrough research institutes that enable collaboration between \nthe two. The Instituto de Salud Carlos III (ISCIII), is the ultimate \nresponsible for public biomedical research in Spain, with a dual \nfunctional dependence on the Ministry of Science and Inno -\nvation and the Ministry of Health [48,49]. The structure of the ISCII for the promotion and development of Research is well \nestablished through its own or linked national research centers (CNI), in addition to other networks and consortium centers \n(CIBERs, RETICs, Platforms). \nIn March 2020, at the beginning of the pandemic, and im -\nmediately after the declaration of the state of alarm, the ISCI -\nII opened a research fund of 24 million euros and, in fact, in \nthat year 129 projects were approved, of which only 17 corre-\nsponded to initiatives of CIBERs or national Centers and Plat-\nforms. These projects have already been the subject of some \npublications [50,51], as have been published the results of the \nENE study, directly developed by the ISCIII, [52] or the COM -\nBIVAC study, also directly funded by the ISCIII and with the participation of its researchers [53]. \nApplied research is crucial in pandemic situations. With \nthe very high number of cases available, the informatic tools and the current research structures, an adequate national re -\nsearch strategy would allow, without adding new organisms, to have viral biology data or, where appropriate, the pathogen \ninvolved in the pandemic that, together with the epidemio-\nlogical data, could be applied to prevention policies, generate knowledge quickly applicable to the detection of vulnerable \npopulations and to research in therapeutic responses sup -\nporting care recommendations. This without forgetting basic research for the development of vaccines and new pharmaco -\nlogical molecules. \nWithout detriment to the research initiatives of the dif -\nferent groups, in an eventual National Pandemic Plan, bio -\nmedical research should be included and centralized under the direction of the ISCIII with an action plan that could very well \nfollow these lines.\n-  Appoint an independent Scientific Advisory Board, made \nup of professionals with recognized knowledge and expe -\nrience in the areas related to the problem generating the \ncrisis. \n-  Establish the National Centers, Networks and Platforms \nthat should work in a coordinated manner in the planning \nof research projects.\n-  Identify priority research areas according to needs and \nfeasibility.\n-  Allocate available resources on a preferential basis for the \ndevelopment of national projects that have been estab -\nlished. \n-  Establish alliances with \u201cbigdata\u201d technology companies \nthat can streamline the processing of clinical records. \n-  Establish research alliances with the pharmaceutical and \nmedical technology industry. Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-454451on the need to strengthen public health structures. [62] and \nmajor public health societies [63], that this can be achieved \nthrough the creation of a State Center for Public Health, al -\nready contemplated in the General Public Health Law 33/2011. \nFor this reason, the Ministry of Health has budgeted for the \ndevelopment of this center, which would become operational \nduring the current legislature. The creation of this State Public \nHealth Institution is described in component 18 of the Govern -\nment of Spain\u2019s 2021 Recovery, Transformation and Resilience \nPlan. [64], which indicates that it should be configured as a center of excellence that performs functions in two main ar -\neas: public health surveillance, risk assessments and analysis of the health situation of the Spanish population; and, prepa -\nration and coordination of the health system in the face of public health threats, mainly of an epidemic nature, but also other health crises resulting from, for example, climate change (increased temperatures, floods, etc.). It should also monitor \nand evaluate the Public Health Strategy, and contribute tech -\nnical and scientific capabilities to the design and evaluation of \nhealth policies and to the improvement of public health servic-\nes and their actions [63,64].\nProbably, the best legal form for the new institution, in \naccordance with the legal context and the functions envis-aged, is that of an \u201cagency\u201d, since it can exercise adminis -\ntrative powers and is characterized by autonomy, agility and flexibility in management, transparency, accountability and \nevaluation by results. In particular, a State Agency for Public \nHealth (AESP) attached to the Ministry of Health, through the \nSecretariat of State for Health, can assume direct management powers [63].\nWe are awaiting the regulatory development of this insti-\ntution and its creation and development. The adequate provi -\nsion of material and human resources, the use of appropriate \nworking procedures, and its relative independence from politi -\ncal power are necessary conditions for it to be an effective in -\nstrument for improving Spain\u2019s response to new public health \nchallenges in the coming years. Experience will tell if all this is \npossible. \nFUNDING\nNone to declare \nCONFLICTS OF INTEREST \nThe authors declare no conflicts of interest\nREFERENCES\n1. Ministerio de Sanidad y Consumo. Actualizaci\u00f3n del Plan Nacional \nde Preparaci\u00f3n y Respuesta ante una Pandemia de Gripe. Diciem -\nbre de 2006. Available at: https://wwwsanidadgobes/ciudadanos/\nenfLesiones/enfTransmisibles/docs/PlanGripeEspanolpdf. \n2. Ortiz ML. Replanteando la gesti\u00f3n de emergencias sanitarias. . Re -\nvista Espa\u00f1ola de Derecho Constitucional. 2021; 122:153-82. DOI: ousness of the disease, an affective deprivation, both in the \nfamily and in health, never experienced before. The need for a \u201cmore compassionate environment\u201d has been learned. [60, \n61], with a fundamental rule: no person should die alone with -\nout having his or her physical, psychological, emotional, and \nspiritual needs effectively met. Therefore, in the face of any \ncatastrophe, in the 21st century, it will always be necessary \nto articulate and guarantee the necessary measures so that all \npatients have the opportunity to live their end of life accom -\npanied and cared for by the healthcare team in their palliative \nneeds. Along these lines, particularly fragile patients such as children, the disabled, the mentally ill, the elderly in need of help with activities of daily living, etc. must always be able to \nbe accompanied. With today\u2019s means (video-calls, telematic connections, etc.), situations of isolation such as those that \nhave been experienced are no longer understandable, and all \nhospital units should provide the means for face-to-face con -\ntact (limited in time) and telematic contact (the time required by the patient). All these measures, as well as triage, should be \ntaken by multidisciplinary teams at middle management level that can guarantee these measures of \u201ccompassionate envi -\nronment as a superior act of hospital humanization\u201d to the \ndifferent ward teams on a daily basis [61]. Finally, communica -\ntion with families at this point should be considered a priority \nand should be as frequent as possible, communicating in an \nempathetic and sensitive way to the adequacy of care accord -\ning to the changing clinical situation.\nA legal framework according to the clinical-ethical situa -\ntions in disaster situations will be necessary. Usually after the pandemic subsides, claims and lawsuits begin. In a pandemic, professionals face a different praxis scenario than usual, act -\ning in a way that is conditioned by limited resources. In this pandemic, initiatives have been taken by legal associations \nexpressing the possibility of expressly excluding healthcare \nprofessionals from their claims, without excluding the viability \nof claims against those responsible for the hypothetical dam -\nage caused in their case. Therefore, as demanded by numerous national and international scientific societies, with what has \nbeen learned in the COVID, it is necessary the existence of legal \nsystems that protect professionals from legal liability taking \ninto account the context in which the care activity is devel -\noped in a disaster situation.\nIS THERE A NEED FOR A NEW NATIONAL COORDI-\nNATION CENTER FOR MAJOR DISASTERS?\nThe response to large-scale disasters is usually coordi -\nnated from the Office of the President of the Government, \nto facilitate the participation of the different Ministerial De -\npartments. This has been the case in the current COVID-19 pandemic. However, for the preparation and response to new pandemics, there is a certain social agreement on the need to \nstrengthen public health structures. Without prejudice to the fact that this includes especially the public health services of \nthe Autonomous Communities, since they have the main com-petences in this field, there is a broad parliamentary consensus Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-45445215. Severe Outcomes Among Patients with Coronavirus Disease 2019 \n(COVID-19) - United States, February 12-March 16, 2020. MMWR \nMorb Mortal Wkly Rep. 2020;69(12):343-6. DOI: 10.15585/mmwr.mm6912e2\n16. World Health Organization, Europe. ROf. Hospital emergency re -\nsponse checklist. An all-hazards tool for hospitals administrators \nand emergency managers. 2011. Available at: ( http://wwweurow-\nhoint/pubrequest \n17. Peleg K, Aharonson-Daniel L, Stein M, Michaelson M, Kluger Y, Simon \nD, et al. Gunshot and explosion injuries: characteristics, outcomes, \nand implications for care of terror-related injuries in Israel. Ann \nSurg. 2004;239(3):311-8. DOI: 10.1097/01.sla.0000114012.84732.\nbe\n18. Einav S, Feigenberg Z, Weissman C, Zaichik D, Caspi G, Kotler D, \net al. Evacuation priorities in mass casualty terror-related events: \nimplications for contingency planning. Ann Surg. 2004;239(3):304-10. DOI: 10.1097/01.sla.0000114013.19114.57\n19. Orsini E, Mireles-Cabodevila E, Ashton R, Khouli H, Chaisson N. Les -\nsons on Outbreak Preparedness From the Cleveland Clinic. Chest. 2020;158(5):2090-6. DOI: 10.1016/j.chest.2020.06.009\n20. Serra Rexach JA, Rodriguez P\u00e9rez P. Actuaci\u00f3n del Hospital General \nUniversitario Gregorio Mara\u00f1\u00f3n en los atentados del 11 de marzo. Medicina Clinica (Barc). 2005;124 (supl1):1-53. DOI: \n21. Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, \nand Therapeutics on the Epidemic\u2019s Front Line. N Engl J Med. 2020;382(20):1873-5. DOI: 10.1056/NEJMp2005492\n22. Levin AT, Jylh\u00e4v\u00e4 J, Religa D, Shallcross L. COVID-19 prevalence and \nmortality in longer-term care facilities. Eur J Epidemiol. 2022:1-8. DOI: 10.1007/s10654-022-00861-w\n23. Levin AT, Jylh\u00e4v\u00e4 J, Religa D, L. S. Prevalencia y mortalidad de COV -\nID-19 en centros de atenci\u00f3n a largo plazo. Eur J Epidemiol 2022. DOI: 10.1007/s10654-022-00861-w. \n24. Imserso. Enfermedad por Coronavirus (COVID-19) en Centros Resi -\ndenciales. Actualizaci\u00f3n No.14 [accessed 11/06/2021]. Available at: https://wwwimsersoes/InterPresent2/groups/imserso/documents/\nbinario/in \n25. COVID-19 Excess Mortality Collaborators. Estimating excess mor -\ntality due to the COVID-19 pandemic: a systematic analysis of \nCOVID-19-related mortality, 2020-21. Lancet. 2022. DOI: 10.1016/\ns0140-6736(21)02796-3\n26. Martinez-Peromingo J, JA. S-R. Long-Term Care Facilities and the \nCOVID-19 Pandemic: Lessons Learned in Madrid. . J Am Geriatr Soc \n2020;68:1920-2. DOI: 10.1111/jgs.16665\n27. Ferrer R. COVID-19 Pandemic: the greatest challenge in the histo -\nry of critical care. Med Intensiva (Engl Ed). 2020;44(6):323-4. DOI: \n10.1016/j.medin.2020.04.002\n28. Balaguer-Castro M, Baduell A, Torner P. Can we help? Our expe -\nrience as orthopedic surgeons during the COVID-19 pandemic. \nEmergencias. 2020;32(4):284-5. DOI: \n29. Castellanos-Ortega A, Rothen HU, Franco N, Rayo LA, Mart\u00edn-Loech -\nes I, Ram\u00edrez P, et al. Training in intensive care medicine. A challenge \nwithin reach. Med Intensiva. 2014;38(5):305-10. DOI: 10.1016/j.\nmedin.2013.12.01110.18042/cepc/redc.122.05 \n3. Garcia-Haro M, Bischofberger Vald\u00e9s C, Vicente-Guijarro J, \nD\u00edaz-Agero P\u00e9rez C, Fabregate-Fuente M, Moreno-Nunez P, et \nal. Decontamination of filtering facepiece respirators using a low-temperature-steam-2%-formaldehyde sterilization process \nduring a pandemic: a safe alternative for re-use. J Hosp Infect. 2021;108:113-9. DOI: 10.1016/j.jhin.2020.10.024\n4. Fillat-Gom\u00e0 F, Coderch-Navarro S, Mart\u00ednez-Carreres L, Monill-\nRaya N, Nadal-Mir T, Lalmolda C, et al. Integrated 3D printing \nsolution to mitigate shortages of airway consumables and personal protective equipment during the COVID-19 pandemic. BMC Health \nServ Res. 2020;20(1):1035. DOI: 10.1186/s12913-020-05891-2\n5. Bibiano-Guillen C, Arias-Arcos B, Collado-Escudero C, Mir-Mon -\ntero M, Corella-Montoya F, Torres-Macho J, et al. Adapted Diving Mask (ADM) device as respiratory support with oxygen output \nduring COVID-19 pandemic. Am J Emerg Med. 2021;39:42-7. DOI: \n10.1016/j.ajem.2020.10.043\n6. Pedraja J, Maestre JM, Rabanal JM, Morales C, Aparicio J, Del Moral \nI. Role of 3D printing for the protection of surgical and critical care professionals in the COVID-19 pandemic. Rev Esp Anestesiol Rean -\nim (Engl Ed). 2020;67(8):417-24. DOI: 10.1016/j.redar.2020.07.011\n7. Seresirikachorn K, Phoophiboon V, Chobarporn T, Tiankanon K, Ae -\numjaturapat S, Chusakul S, et al. Decontamination and reuse of surgical masks and N95 filtering facepiece respirators during the \nCOVID-19 pandemic: A systematic review. Infect Control Hosp Epi -\ndemiol. 2021;42(1):25-30. DOI: 10.1017/ice.2020.379\n8. Armijo PR, Markin NW, Nguyen S, Ho DH, Horseman TS, Lisco SJ, \net al. 3D printing of face shields to meet the immediate need for \nPPE in an anesthesiology department during the COVID-19 pan -\ndemic. Am J Infect Control. 2021;49(3):302-8. DOI: 10.1016/j.\najic.2020.07.037\n9. Viscasillas J, Alonso-I\u00f1igo JM, Gutierrez-Bautista A, Casa\u00f1 Pallard\u00f3 \nM, Redondo JI. Description of ovine model for testing ventilator \nprototypes in the COVID-19 pandemic. Rev Esp Anestesiol Reanim (Engl Ed). 2021;68(10):592-6. DOI: 10.1016/j.redare.2020.10.008\n10. Garmendia O, Rodr\u00edguez-Lazaro MA, Otero J, Phan P, Stoyanova A, \nDinh-Xuan AT, et al. Low-cost, easy-to-build noninvasive pressure support ventilator for under-resourced regions: open source hard-ware description, performance and feasibility testing. Eur Respir J. \n2020;55(6). DOI: 10.1183/13993003.00846-2020\n11. Rodr\u00edguez Blas MC, Ministerio de Sanidad SGdCdSdSyFdC. Estad\u00edsti -\nca de Gasto Sanitario P\u00fablico. Principales resultados [Internet]. \n(Accessed 15/04/2022). Available at: https://wwwsanidadgobes/\nestadEstudios/estadisticas/docs/EGSP2008/egspPrincipalesResulta -\ndospdf. \n12. Lesende IM. [Lessons learned during the COVID-19 pandem -\nic on the follow-up of chronically ill patients]. Aten Primaria. \n2021;53(8):102180. DOI: 10.1016/j.aprim.2021.102180\n13. Greenhalgh T, Wherton J, Shaw S, Morrison C. Video consultations \nfor covid-19. Bmj. 2020;368:m998. DOI: 10.1136/bmj.m998\n14. Tranche S, Carbajo L, Galindo G, Mart\u00edn R, Fern\u00e1ndez M, Arroyo \nA, et al. La necesidad de cambiar la estrategia en la gesti\u00f3n de la \nenfermedad COVID-19. . Clin Med Fam 2022; 15 6-9 DOI: Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-45445345. Centro de ayuda de Whatsapp. C\u00f3mo evitar la propagaci\u00f3n de \ndesinformaci\u00f3n. Available at: https://faqwhatsappcom/general/\nsecurity-and-privacy/how-to-prevent-the-spread-of-misinforma -\ntion/?lang=es (accessed Apr 20, 2022)\n46. Ye A, Lina W, Run W, Wenqi W, Jianpeng K, W. D. An end-to-end \nrumor detection model based on feature aggregation. Complexity \n2021;2021:e6659430. 10.1155/2021/665943. \n47. FECYT. Informe . Producci\u00f3n cientifica Espa\u00f1ola. . Available at: ht -\npps: //wwwcienciagobes. 2021. DOI: \n48. B.O.E. Real Decreto 2/2020, de 12 de Enero por el que se reestructur -\nan los departamentos ministeriales. . BOE num 11 de 13/01/2020. \n2020. DOI: \n49. B.O.E. Real Decreto 1589/2012, de 23 de noviembre, por el que \nse crea la Comisi\u00f3n Mixta de Coordinaci\u00f3n entre el Ministerio de \nEconom\u00eda y Competitividad y el Ministerio de Sanidad, Servicios Sociales e Igualdad, en relaci\u00f3n con el Instituto de Salud Carlos III. . \nBOE-A-2012-14818. 2012. DOI: \n50. Poll\u00e1n M, P\u00e9rez-G\u00f3mez B, Pastor-Barriuso R, Oteo J, Hern\u00e1n \nMA, P\u00e9rez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain \n(ENE-COVID): a nationwide, population-based seroepidemiological \nstudy. Lancet. 2020. DOI: 10.1016/s0140-6736(20)31483-5\n51. P\u00e9rez-Olmeda M, Saugar JM, Fern\u00e1ndez-Garc\u00eda A, P\u00e9rez-G\u00f3mez B, \nPoll\u00e1n M, Avell\u00f3n A, et al. Evolution of antibodies against SARS-\nCoV-2 over seven months: Experience of the nationwide seroprev -\nalence ENE-COVID study in Spain. J Clin Virol. 2022;149:105130. \nDOI: 10.1016/j.jcv.2022.105130\n52. Gonz\u00e1lez J, Ben\u00edtez ID, Carmona P, Santisteve S, Monge A, Mon -\ncus\u00ed-Moix A, et al. Pulmonary Function and Radiologic Features \nin Survivors of Critical COVID-19: A 3-Month Prospective Cohort. \nChest. 2021;160(1):187-98. DOI: 10.1016/j.chest.2021.02.062\n53. Borobia AM, Carcas AJ, P\u00e9rez-Olmeda M, Casta\u00f1o L, Bertran MJ, \nGarc\u00eda-P\u00e9rez J, et al. Immunogenicity and reactogenicity of \nBNT162b2 booster in ChAdOx1-S-primed participants (Combi-VacS): a multicentre, open-label, randomised, controlled, phase \n2 trial. Lancet. 2021;398(10295):121-30. DOI: 10.1016/s0140-\n6736(21)01420-3\n54. Comit\u00e9 de Bio\u00e9tica de Espa\u00f1a. Informe sobre los aspectos bio\u00e9ticos \nde la priorizaci\u00f3n de recursos sanitarios en el contexto de la crisis del coronavirus. [Accessed 5/5/2022]. Available at: http://assets-comitedebioeticaes/files/documentacion/Informe%20CBE-%20\nPriorizacion%20de%20recursos%20sanitarios-coronavirus%20\nCBEpdf. \n55. Coronarias. SEdMICydU. Recomendaciones \u00e9ticas para la toma de \ndecisiones en la situaci\u00f3n excepcional de crisis por pandemia COV -\nID-19 en las Unidades de Cuidados Intensivos. (SEMICYUC). [Ac -\ncessed 5/5/2022]. Available at: https://semicyucorg/wp-content/uploads/2020/03/%C3%89tica_SEMICYUC-COVID-19pdf. \n56. Comunicado. Recomendaciones sobre decisiones \u00e9ticas e ingreso \nen UCI en situaci\u00f3n de crisis Covid-10. 2022. Available at: https://\nwwwsegges/media/descargas/Comunicado-conjunto-10-SSCCpdf. \n57. Ministerio de Sanidad de Espa\u00f1a. Informe sobre los aspectos \u00e9ticos \nen situaciones de pandemia: El SARS-CoV-2. [Accessed 5/5/2022]. \n.Available at: https://wwwsanidadgobes/profesionales/saludPubli-30. Martinez J, Phillips E, Harris C. Where do we go from here? Moving \nfrom systems-based practice process measures to true competency \nvia developmental milestones. Med Educ Online. 2014;19:24441. DOI: 10.3402/meo.v19.24441\n31. European Commission, ESICM. Provision of Training on Intensive \nCare Medicine Skills for Health Professionals Not Regularly Work -\ning on Intensive Care Units. 2021. Available at: https://c19-spacea-\ncademyesicmorg/local/staticpage/viewphp?page=c19space-about. \n32. Buljac-Samardzic M, Doekhie KD, van Wijngaarden JDH. Interven -\ntions to improve team effectiveness within health care: a system-\natic review of the past decade. Hum Resour Health. 2020;18(1):2. \nDOI: 10.1186/s12960-019-0411-3\n33. Lei C, Palm K. Crisis Resource Management Training in Medical \nSimulation. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright \u00a9 2022, StatPearls Publishing LLC.; 2022.\n34. Barnsteiner JH, Disch JM, Hall L, Mayer D, Moore SM. Promoting \ninterprofessional education. Nurs Outlook. 2007;55(3):144-50. DOI: 10.1016/j.outlook.2007.03.003\n35. Parra Cotanda C, Luaces Cubells C. [Disaster situations. What must \nwe know and do?]. An Pediatr (Barc). 2011;74(4):270.e1-6. DOI: \n10.1016/j.anpedi.2010.10.008\n36. Konttila J, Siira H, Kyng\u00e4s H, Lahtinen M, Elo S, K\u00e4\u00e4ri\u00e4inen M, et \nal. Healthcare professionals\u2019 competence in digitalisation: A sys -\ntematic review. J Clin Nurs. 2019;28(5-6):745-61. DOI: 10.1111/\njocn.14710\n37. Murillo-Cabezas F, Vigil-Mart\u00edn E, Raimondi N, P\u00e9rez-Fern\u00e1ndez \nJ. [Covid-19 pandemic and digital transformation in critical care \nunits]. Med Intensiva (Engl Ed). 2020;44(7):457-8. DOI: 10.1016/j.\nmedin.2020.04.004\n38. M DA, Mej\u00eda FM, Mart\u00ed M, Novillo-Ortiz D, Hazrum F, de Cos\u00edo FG. \n[Infoxication in health. Health information overload on the Inter -\nnet and the risk of important information becoming invisible]. Rev Panam Salud Publica. 2018;41:e115. DOI: 10.26633/rpsp.2017.115\n39. Hong H, Kim HJ. Antecedents and Consequences of Information \nOverload in the COVID-19 Pandemic. Int J Environ Res Public \nHealth. 2020;17(24). DOI: 10.3390/ijerph17249305\n40. Parra-Medina LE, \u00c1lvarez-Cervera FJ. [Information overload syn -\ndrome: a bibliographic review]. Rev Neurol. 2021;73(12):421-8. \nDOI: 10.33588/rn.7312.2021113\n41. Larson HJ. A call to arms: helping family, friends and commu -\nnities navigate the COVID-19 infodemic. Nat Rev Immunol. 2020;20(8):449-50. DOI: 10.1038/s41577-020-0380-8\n42. World Health Organization. Infodemic. WHO (2020). . Available \nat: https://wwwwhoint/health-topics/infodemic#tab=tab_1 (Ac-\ncessed 20/04/2022) . \n43. Schillinger D, Chittamuru D, Ram\u00edrez AS. From \u201cInfodemics\u201d to \nHealth Promotion: A Novel Framework for the Role of Social Me -\ndia in Public Health. Am J Public Health. 2020;110(9):1393-6. DOI: \n10.2105/ajph.2020.305746\n44. Ying W, Cheng C. Public Emotional and Coping Responses to the \nCOVID-19 Infodemic: A Review and Recommendations. Front Psy -\nchiatry. 2021;12:755938. DOI: 10.3389/fpsyt.2021.755938Lessons from COVID-19 for future disasters: an opinion paper J. Gonz\u00e1lez del Castillo, et al.\nRev Esp Quimioter 2022;35(5): 444-454454ca/ccayes/alertasActual/nCov/documentos/AspectosEticos_en_sit -\nuaciones_de_pandemiapdf. \n58. Raus K, Mortier E, Eeckloo K. Ethical issues in managing the COV -\nID-19 pandemic. Bioethics. 2021;35(6):581-8. DOI: 10.1111/\nbioe.12877\n59. Jeffrey DI. Relational ethical approaches to the COVID-19 pandem -\nic. J Med Ethics. 2020. DOI: 10.1136/medethics-2020-106264\n60. Yepes-Temi\u00f1o MJ, Callejas Gonz\u00e1lez R, \u00c1lvarez Avello JM. A mo -\nment for reflection. Ethical aspects in the pandemic SARS-CoV-2/COVID-19 in our clinical practice. Rev Esp Anestesiol Reanim (Engl Ed). 2021;68(1):28-36. DOI: 10.1016/j.redar.2020.09.004\n61. Espa\u00f1a. CdBd. Declaraci\u00f3n del Comit\u00e9 de Bio\u00e9tica de Espa\u00f1a so -\nbre el derecho y deber de facilitar el acompa\u00f1amiento y la asist-encia espiritual a los pacientes con Covid-19 al final de sus vidas y en situaciones de especial vulnerabilidad. [Accessed 5/5/2022]. \nAvailable at: http://assetscomitedebioeticaes/files/documentacion/\nCBE_Declaracion_sobre_acompanamiento_COVID19pdf. \n62. Congreso de los Diputados. Dictamen de la Comisi\u00f3n para la Recon -\nstrucci\u00f3n Social y Econ\u00f3mica. Madrid, 2020. [Accessed 10/6/2022]. \nAvailable at https://wwwfdagov/media/137566/download \n63. SESPAS y Escuela de Salud P\u00fablica de Menorca. Informe sobre la \nAgencia Estatal De Salud P\u00fablica. Propuestas de la Sociedad Es -\npa\u00f1ola De Salud P\u00fablica Y Administraci\u00f3n Sanitaria (SESPAS) para su Dise\u00f1o y Funcionamiento. Mah\u00f3n, 2021. Available at: https://\nsespases/wp-content/uploads/2022/02/Informe-SESPAS-sobre-la-futura-Agencia-Estatal-de-Salud-Publica-07_10_2021pdf. \n64. Gobierno de Espa\u00f1a. Plan de Recuperaci\u00f3n, Transformaci\u00f3n y Re -\nsiliencia. Componente 18. Renovaci\u00f3n y ampliaci\u00f3n de las capaci -\ndades del Sistema Nacional de Salud. Madrid, 2021. Available at: https://wwwlamoncloagobes/temas/fondos-recuperacion/Docu -\nments/05052021-Componente18pdf. ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/062.2022\nRev Esp Quimioter 2022;35(5): 455-467455the ICU and longer stay in the ICU were classified as relevant \nRF independently of the pathogen and site of colonisation. \nPrevious exposure to antibiotic therapy or previous \ncarbapenem use were also common relevant RF for patients \nwith CRGNB respiratory tract and rectal colonisation. \nConclusion. The results of this study may contribute to \nthe early identification of CRGNB colonized patients at higher \nrisk of infection development, favouring time-to-effective \ntherapy and improving health outcomes.\nKeywords: Risk factor; Multi-drug resistance; Carbapenem-resistant \ngram-negative bacteria; colonization; expert consensus.\nRevisi\u00f3n sistem\u00e1tica de la literatura y consenso \nde expertos sobre los factores de riesgo asociados a la progresi\u00f3n de la infecci\u00f3n en pacientes adultos con colonizaci\u00f3n del \ntracto respiratorio o rectal por bacterias \ngramnegativas resistentes a carbapen\u00e9micos\nObjetivo. Los factores de riesgo (FR) asociados a la \nprogresi\u00f3n de la infecci\u00f3n en pacientes ya colonizados \npor bacterias gramnegativas resistentes a carbapen\u00e9micos \n(BGNRC) han sido abordados en pocos y dispersos trabajos. \nEl objetivo de este estudio es identificar los factores de \nriesgo relevantes asociados a la progresi\u00f3n de la infecci\u00f3n en \npacientes con colonizaci\u00f3n del tracto respiratorio o rectal.\nMaterial y m\u00e9todos.  Se realiz\u00f3 una revisi\u00f3n sistem\u00e1tica \nde la literatura para identificar los FR asociados a la progresi\u00f3n A systematic literature review and expert \nconsensus on risk factors associated to infection \nprogression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria\n1Servicio de Medicina Intensiva, Hospital Universitario Vall d\u00b4Hebr\u00f3n, Barcelona, Spain\n2Servicio de Enfermedades Infecciosas, Hospital Cl\u00ednic de Barcelona, IDIBAPS, Universidad de Barcelona, Spain \n3Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal e Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria \n(IRYCIS), Madrid, Spain. CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain\n4Servicio de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, Universidad de Navarra, Spain\n5Unidad Cl\u00ednica Cuidados Intensivos, Hospital Universitario Virgen de la Macarena, Seville, Spain\n6Servicio de Microbiolog\u00eda, Hospital Universitario Vall d\u00b4Hebr\u00f3n, Vall d\u2019Hebron Institut de Recerca,\nUniversitat Aut\u00f2noma de Barcelona, Spain\n7Servicio de Medicina Intensiva, Complejo Hospitalario Universitario De Santiago de Compostela, Spain\n8Servicio de Enfermedades Infecciosas, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain\n9Servicio Enfermedades Infecciosas, Hospital Universitario Ram\u00f3n y Cajal, e Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n \nSanitaria (IRYCIS), Madrid, Spain\n10Omakase Consulting S.L., Barcelona, SpainRicard Ferrer1\nAlex Soriano2\nRafael Cant\u00f3n3\nJos\u00e9 Luis Del Pozo4\nCarolina Garc\u00eda-Vidal2\nJos\u00e9 Garnacho-Montero5\nNieves Larrosa6\nPedro Rascado7\nMiguel Salavert8\nVicente Pintado9\nAriadna Gir\u00f3-Perafita10\nXavier Badia10Systematic review\nArticle history\nReceived: 27 June 2022; Revision Requested: 30 June 2022; Revision Received: 5 July 2022; Accepted: 13 July 2022; \nPublished: 21 July 2022\nABSTRACT\nObjective. Risk factors (RFs) associated with infection \nprogression in patients already colonised by carbapenem-\nresistant Gram-negative bacteria (CRGNB) have been \naddressed in few and disperse works. The aim of this study is to \nidentify the relevant RFs associated to infection progression in \npatients with respiratory tract or rectal colonisation.\nMaterial and methods. A systematic literature review \nwas developed to identify RFs associated with infection progression in patients with CRGNB respiratory tract or rectal \ncolonisation. Identified RFs were then evaluated and discussed \nby the expert panel to identify those that are relevant according to the evidence and expert\u2019s experience.\nResults. A total of 8 articles were included for the \nCRGNB respiratory tract colonisation and 21 for CRGNB rectal \ncolonisation, identifying 19 RFs associated with pneumonia \ndevelopment and 44 RFs associated with infection progression, \nrespectively. After discussion, the experts agreed on 13 RFs to \nbe associated with pneumonia development after respiratory tract CRGNB colonisation and 33 RFs to be associated with \ninfection progression after rectal CRGNB colonisation. \nRespiratory tract and rectal colonisation, previous stay in \nCorrespondence:\nXavier Badia\nOmakase Consulting S.L., Barcelona, Spain\nE-mail: xbadia@omakaseconsulting.comA systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467456populations (e.g., patients undergoing organ transplants, \ngeneral population, ICU patients) and is estimated to occur \nin 4% to 57% of the patients [9\u201312]. CRGNB may settle in \ndifferent sites such as urinary tract, skin, or abdominal cavity. Among them, rectal and respiratory tract colonisation are of especial attention due to their high prevalence and the \nmost common sites of screening with microbiological tests \n[13\u201315]. CRGNB, concretely P. aeruginosa, A. baumannii and \nEnterobacterales, have been identified as common rectal and \nrespiratory tract colonizers [11,12]. \nIn the last years, it has been suggested that colonisation \nis associated with clinical infection development and its potential consequences (e.g., septic shock) [7]. Risk factors \n(RFs) associated with CRGNB infection or colonisation have been widely studied [16\u201319]. Recently, an expert\u2019s consensus \nstudy performed in Spain has been published to help to \nclarify the RFs associated with CRGNB P. aeruginosa and A. \nbaumannii infection development [20]. Factors associated with \na risk for infection progression in already CRGNB colonised patients have been addressed in few and disperse works. Due \nto the lack of information and uncertainty regarding the RFs associated with infection progression from CRGNB rectal or \nrespiratory tract colonisation, the main objective of this study \nis to provide clinical recommendations from an experts\u2019s consensus based on the current available evidence.\nMATERIAL AND METHODS\nStudy design. The study was designed in four different \nphases: 1) Systematic literature review (SLR) to identify RFs \nassociated to infection development after rectal or respiratory \ntract colonisation; 2) Creation of the expert panel; 3) \nDevelopment of a questionnaire to evaluate identified RFs in \nSLR and 4) Results analysis and consensus session.\nPHASE I: Systematic Literature Review\nA SLR was conducted in October 2021 to identify the \nevidence available on RFs associated to clinical infection after \nrespiratory tract (Site 1) and rectal (Site 2) CRGNB colonisation. \nThe pathogens included for each site were P. aeruginosa, A. \nbaumannii, and Enterobacterales, more specifically Klebsiella pneumoniae and Escherichia coli. The sources of information \nwere biomedical databases such as MEDLINE, Cochrane \nLibrary and MEDES. The search strategy is depicted in Figure \n1. Inclusion and exclusion criteria for each of the sites are described in Table 1 and Table 2. The population of study \nwere adults for rectal colonisation, while for respiratory tract \ncolonisation it was limited to adults in the ICU with mechanical ventilation. MeSH terms used for each site and pathogen are described in Supplementary Table 1. \nPHASE 2: Expert panel\nA multidisciplinary panel consisting of 2 coordinators (an \ninfectiologist and an intensivist) and 8 experts (2 intensivists, \n3 infectiologists and 3 microbiologists) was created to \nreview the RFs identified in the SLR and evaluate them for de la infecci\u00f3n en pacientes con colonizaci\u00f3n del tracto \nrespiratorio o rectal por BGNRC. Los FR identificados fueron \nluego evaluados y discutidos por el panel de expertos para identificar aquellos que son relevantes seg\u00fan la evidencia \ndisponible y la experiencia de los expertos.\nResultados. Un total de 8 art\u00edculos fueron incluidos en \nel an\u00e1lisis de los FR en la colonizaci\u00f3n del tracto respiratorio y 21 para la colonizaci\u00f3n rectal, identific\u00e1ndose 19 FR \nasociados al desarrollo de neumon\u00eda y 44 FR asociados a la progresi\u00f3n de la infecci\u00f3n respectivamente. Tras la sesi\u00f3n \nde discusi\u00f3n, los expertos acordaron que 13 FR se asociaban \nal desarrollo de neumon\u00eda tras la colonizaci\u00f3n del tracto respiratorio por BGNRC y 33 FR a la progresi\u00f3n de la infecci\u00f3n \ntras la colonizaci\u00f3n rectal por BGNRC. La colonizaci\u00f3n del \ntracto respiratorio y rectal, la estancia previa en la UCI y una estancia prolongada en la UCI se clasificaron como FR relevantes independientemente del pat\u00f3geno y del lugar de \ncolonizaci\u00f3n. La exposici\u00f3n previa a antibi\u00f3ticos o el uso previo \nde carbapen\u00e9micos se clasificaron como FR relevantes para \nvarios de los pat\u00f3genos tanto en pacientes con colonizaci\u00f3n \ndel tracto respiratorio como rectal.\nConclusi\u00f3n. Los resultados de este estudio pueden \ncontribuir a la identificaci\u00f3n precoz de los pacientes \ncolonizados por BGNRC con mayor riesgo de desarrollo de \ninfecci\u00f3n, favoreciendo el uso temprano de terapias efectivas y mejorar los resultados en salud de estos pacientes.\nPalabras clave: factor de riesgo, multirresistencia, bacterias gramnegativas \nresistentes a carbapen\u00e9micos; colonizaci\u00f3n; documento de consenso.\nINTRODUCTION\nMultidrug-resistant (MDR) bacteria have become a \nrelevant and urgent public health threat because few effective \nantibiotics are available for the treatment of infections \ncaused by these bacteria. Among MDR pathogens, Gram-negative bacteria require special attention because of their \nresistance to carbapenems, the most active and potent \nagents available against MDR Gram-negative pathogens [1,2]. In 2017, the World Health Organisation published the \nlist of priority pathogens for which innovative treatments are urgently needed. Carbapenem-resistant Acinetobacter \nbaumannii, Pseudomonas aeruginosa and Enterobacterales \nare listed as the most critical pathogens [3]. In Spain, recently \npublished studies show that carbapenem-resistant Gram-\nnegative bacteria (CRGNB) are the cause of a high number of \ninfections [4\u20136]. More specifically, Pseudomonas aeruginosa, \nAcinetobacter baumannii and Enterobacterales (including \nEscherichia coli, Klebsiella pneumoniae and Enterobacter \ncloacae) were the most common bacteria [4\u20136].\nIn most cases, these pathogens may colonize one or \nmore patients\u2019 sites, constituting a silent and dangerous \nreservoir that can lead to the spread of these bacteria and a \nrisk of development of associated clinical infections that may lead to clinical complications, including patient\u2019s death [7,8]. \nCRGNB colonisation prevalence has been studied on different A systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467457Site 1: Respiratory colonisation\nInclusion criteria Exclusion criteria\nArticles including patients with respiratory colonisation caused by carbapenem-\nresistant Gram-negative bacteria, especially P. aeruginosa, A. baumannii, Enterobacterales (E. coli, K. pneumoniae).\nWorks published in the last 5 years (2016-2021)\nPublications in English or Spanish\nPopulation: Adults (\u2265 18 years), ICU inpatients with artificial airwayOne-arm or pre-post studies.Studies from low- and middle-income countries.Articles related with genetics Articles including \u201cCOVID\u201d, \u201cCOVID-19\u201d, \u201ccoronavirus\u201d or \u201cSARS-CoV-2\u201d infections\nArticles focused on base pathologies other than CRGNB infection (e.g., cystic fibrosis, \nbronchiectasis, chronic obstructive pulmonary disease)\nPaediatric population studiesTable 1   Inclusion and exclusion criteria for respiratory tract colonisation SLR studies\nSite 2: Rectal colonisation\nInclusion criteria Exclusion criteria\nArticles including patients with rectal colonisation caused by carbapenem-resistant \nGram-negative bacteria focused on P. aeruginosa, A. baumannii, Enterobacterales (E. \ncoli, K. pneumoniae).\nWorks published in the last 5 years (2016-2021)Publications in English or Spanish\nPopulation: Adults (\u226518 years).One-arm or pre-post studies\nStudies from low- and middle-income countries.\nArticles related with genetics\nArticles including \u201cCOVID\u201d, \u201cCOVID-19\u201d, \u201ccoronavirus\u201d or \u201cSARS-CoV-2\u201d infections\nPaediatric population studiesTable 2   Inclusion and exclusion criteria for rectal colonisation SLR studiesFigure 1  Systematic Literature Review search strategy\nA systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467458in the SLR for a specific pathogen. Each RF was presented \nas a statement to assess its relevance, and a 3-point scale \nwas used to evaluate it \u201c1-I agree with the statement\u201d; \u201c2- I moderately agree with the statement\u201d and \u201c3- I disagree with the statement\u201d. Experts were asked to provide their rational to \ntheir answer. \nPHASE 4 Results analysis and consensus session\nThe questionnaire and article files were sent to the experts. \nExperts were asked to evaluate the relevance of each RF related \nto infection progression after CRGNB colonisation based on the evidence available and their own clinical experience. In \ncase there was no evidence, or they had no clinical experience, \nexperts were asked to provide their expert opinion. \nResults of the RF assessment were included in an excel \ndatabase and were presented as a percentage of experts \nthat answered each of the options. An arbitrary cut-off of 80% (8 out of 10) was set to determine agreement among the experts for each of the answers. The criteria agreed to \ninclude RF as relevant were: 1) Acceptance of RFs with a \nscore \u226580% with score \u201c1- I agree\u201d or \u201c2 - I moderately \nagree\u201d. In case of a score \u226580% on the item \u201c3- I disagree\u201d, \nthe RF was excluded from the study. 2) For those RF \nwith <80% on any of the 3 scale items, those with \u226580% \nagreement when pooling \u201c1- I agree \u201c and \u201c2- I moderately agree\u201d were included as relevant. 3) Those RF with <80% \nagreement after pooling \u201c1- I agree \u201c and \u201c2- I moderately \nagree\u201d were discussed during the consensus session. 4) If its relevance based on available information and their own \nclinical experience. The Spanish experts were chosen based \non their clinical experience in the study area, as well on their participation in similar studies published in indexed journals.\nPHASE 3: Development of materials to evaluate each \nof the RF identified in the SLR\nFor each article included in the SLR, a file was created \nto collect information in a systematic way. Information included for each article was: site of colonisation, pathogen, reference, year of publication, country, study design, setting, ward, inclusion criteria and exclusion criteria, total number \nof patients in the study and for each study group, type of \nstatistical analysis and a summary of results of the univariate \nand multivariate analysis. \nTogether with the articles file, a questionnaire for each \nof the sites (respiratory tract and rectal colonisation) was \ndeveloped to evaluate each of the RF by the expert panel. The questionnaire included all RF associated with infection \ndevelopment after CRGNB colonisation identified in the SLR. \nThe questionnaire was then divided in two parts. 1) Evidence \nbased, which included RFs by pathogen associated with infection progression in colonised patients found in the SLR \nand presented for each pathogen. For each pathogen, two \ndifferentiated sections were assessed; RF commonly associated \nto infection progression and pathogen-specific RF. 2) Expert\u2019s \nopinion, which included RF commonly associated to infection \nprogression after CRGNB colonisation but were not found Figure 2   PRISM diagram of literature review results for A. Respiratory tract CRGNB colonization and B. rectal \nCRGNB colonization.\nA systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467459An online consensus session was performed in January 2022 to \npresent the results and discuss the RF that did not reach consensus. \nFor each RF to be discussed, a bar chart with the percentage of \nresponses and a summary of statistical analysis of the studies where \nthose RF were identified were presented. Finally, the RFs were accepted or excluded based on the previously described criteria.additional information or clarification was provided during the discussion session that changed the interpretation of the RF, the scoring could be reassessed and classified \naccording to the above criteria. 5) The experts were able \nto exclude from the study those RFs that they considered \nambiguous and difficult to interpret.\nFigure 3   Scoring and results of the assessment of risk factors associated with pneumonia progression after \nCRGNB respiratory tract colonization in ICU adult inpatients with mechanical ventilation. Scores are \nrepresented according to the percentage of responses on the 1- I agree, 2-moderately agree and 3- do \nnot agree. Result column shows if the risk factor was included as relevant, not relevant, or needed to be \ndiscussed in the consensus session.A systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467460Figure 4A   Scoring and results of the assessment of risk factors identified in the literature associated with infection \nprogression after CRGNB rectal colonization in adult population. Scores are represented according to the \npercentage of responses on the 1- I agree, 2-moderately agree and 3- do not agree. Result column shows \nif the risk factor was included as relevant, excluded, or discussed in the consensus session.\nA systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467461stablished criteria, RFs that did not reach consensus in the \nprevious exercise were presented for discussion. \nResults after discussion and re-evaluation of RF \nassociated with pneumonia development after respiratory tract colonisation in adult ICU inpatients with mechanical ventilation are described in Figure 5. \nIn the respiratory tract RF discussion , the panel agreed \nto include \u201cESBL- Enterobacterales respiratory colonisation\u201d \nas a relevant RF for pneumonia development. On the other hand, experts reached consensus on excluding as relevant \nthe following RFs for pneumonia development: \u201cintake of \nvasopressors\u201d and the \u201cpresence of solid cancer\u201d in patients colonised with P. aeruginosa; \u201cDiabetes\u201d in patients colonised with A. baumannii; \u201cadministration of amoxicillin/clavulanic \nacid\u201d in patients colonised with carbapenemase-producing  \nK pneumoniae; \u201cprevious exposure to antibiotic therapy\u201d in patients colonised with Enterobacterales. \nThe \u201cintake of vasopressors\u201d or \u201cpresence of solid \ncancer\u201d were discarded by the experts due to study design of the evidence provided, which proved association but not causality [21,22]. In addition, the presence of solid cancer is a broad concept that should be nuanced (e.g. site, stage, \nimmunocompromised status of the patient), as well the confusion factors associated, such us the treatment the patient \nreceives [22]. Similar rational was concluded when discussing \u201cdiabetes\u201d as a RF. The study analysed the risk of infection \nrecurrence and not infection progression, besides the fact that \nuncontrolled diabetes or patients\u2019 general condition would be more relevant factors than the presence of diabetes itself [23]. The RF \u201cadministration of amoxicillin/clavulanic acid\u201d was \nexcluded because even though there is a strong association \naccording to the literature, it is not associated to an increased risk [24]. \u201cPrevious exposure to antibiotic therapy\u201d in patients RESULTS\nSystematic Literature Review (SLR). A total of 80 \narticles were identified in the SLR for the respiratory tract \nCRGNB colonisation site, and 8 articles were finally included. \nFor rectal CRGNB colonisation site, a total of 101 were \nidentified and 21 included in the review. PRISM diagrams of SLR results are included in Figure 2. \nResults analysis. A total of 19 RF associated with \npneumonia progression after respiratory tract CRGNB colonisation were identified and evaluated for its relevance by the expert panel. Out of 19 RF identified, 13 of them were \nincluded as relevant RF according to the agreed criteria, and 6 \nof them were discussed in the consensus session (Figure 3). Out of the 13 included as relevant, \u201crespiratory tract colonisation\u201d \nby P. aeruginosa, and \u201cuse of mechanical ventilation\u201d in \npatients colonised by A. baumannii reached \u226580% in the score \n\u201c1- I agree with the statement\u201d. \nRegarding the rectal colonisation site, a total of 44 RF \nwere identified to be associated with infection progression and evaluated for its relevance by the expert panel. Out of 44 RF \nidentified, 27 of them were included as relevant RF according \nto the agreed criteria and 17 of them were discussed in the \nconsensus session (Figure 4A and B). Out of the 27 included as \nrelevant, \u201crectal colonisation\u201d by A. baumannii and \u201clonger stay \nin ICU\u201d in patients colonised by K. pneumoniae reached \u226580% \nin the score \u201c1- I agree with the statement\u201d. \u201cPeptic ulcer\u201d in patients with Enterobacterales colonisation also reach \u226580% \nin the score \u201c2- I moderately agree with the statement\u201d. \nConsensus session. The results from the questionnaire \nwere presented to the expert panel for each of the sites (respiratory tract and rectal colonisation). According to the Figure 4B   Scoring and results of the assessment of risk factors associated with infection progression after CRGNB \nrectal colonization in adult population according to expert\u2018s opinion. Scores are represented according to \nthe percentage of responses on the 1- I agree, 2-moderately agree and 3- do not agree. Result column \nshows if the risk factor was included as relevant, excluded, or discussed in the consensus session.\nA systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467462\nFigure 5   Results after consensus of risk factors classified according to its relevance \nby pathogen in pneumonia progression after CRGNB respiratory tract \ncolonisation in ICU adult inpatients with mechanical ventilation.\ncolonised with Enterobacterales was excluded being this RF \nassociated to pathogen resistance development rather than \npneumonia development.\nResults after discussion and re-evaluation of RF associated \nwith infection after rectal colonisation in adult patients are \ndescribed in Figure 6.\nDuring the rectal RF discussion, out of 17 RF included \nin the discussion , the expert panel agreed to include 5 of \nthe 17 discussed RF as relevant for infection development in \nrectal colonised patients: \u201c P. aeruginosa rectal colonisation\u201d; \n\u201cESBL E. coli rectal colonisation\u201d; \u201cPresenting a high-level \nresistance to carbapenems\u201d, \u201cprevious stay in ICU\u201d and \u201cuse of \nmechanical ventilation\u201d in patients with MDR Enterobacterales \nrectal colonisation. Consensus was not reached for the RF \n\u201cLiver dysfunction\u201d in patients colonised with A. baumannii, as \napproximately half of the experts considered it relevant due to the significant association proved in literature, while the other half considered that the disease description was too broad, lacking important information about the disease such as the \ngrade or patient status.\nOn the other hand, the expert panel agreed on considering \nnot relevant for infection development the following RFs: \u201cActive \nexposure to antibiotic therapy\u201d in P. aeruginosa rectal colonised \npatients; \u201cprevious cephamycin use\u201d and \u201cprevious cephalosporin use\u201d in A. baumannii colonised patients; \u201cadministration of \namoxicillin/clavulanic acid\u201d and \u201cTransfer between hospital \nunits\u201d in patients with MDR K. pneumoniae rectal colonisation; \n\u201cCongestive heart failure\u201d, \u201cChronic obstructive pulmonary \ndisease (COPD)\u201d, \u201cImmunological disorder\u201d, \u201cDiabetes\u201d, \u201curological disorder\u201d and \u201cpsychiatric disorder\u201d in patients with MDR \nEnterobacterales rectal colonisation. \nThe rationale behind excluding \u201cActive exposure to \nantibiotic therapy\u201d in patients colonised by P. aeruginosa \nwas the same as in the respiratory tract site, being this \nRF associated to pathogen resistance development rather \nthan pneumonia development [25]. \u201cPrevious cephamycin \nuse\u201d, \u201cprevious cephalosporin use\u201d and \u201cadministration of amoxicillin/clavulanic acid\u201d were excluded because even though there is a strong association according to the literature, \nit is not associated to an increased risk [24,26]. \u201cTransfer \nbetween hospital units\u201d was excluded as that would depend on the units implicated (e.g., chronic vs. acute) [27]. \u201cCongestive heart failure\u201d, \u201cChronic obstructive pulmonary disease (COPD)\u201d, \n\u201cImmunological disorder\u201d, \u201cDiabetes\u201d, \u201cUrological disorder\u201d \nand \u201cPsychiatric disorder\u201d were excluded as relevant RFs by the expert panel due to lack of significant association [10,28]. Furthermore, associated factors to these comorbidities such us disease stage, treatment received, or patient status could be \nrelevant factors to be considered.A systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467463\nFigure 6   Results after consensus of risk factors classified according to its relevance by pathogen \nin infection progression after CRGNB rectal colonisation in adult patients.\nThe evidence supporting each of the RFs identified in the \nSLR after consensus session are described in the Supplementary \nTable 2 and Supplementary Table 3.\nDISCUSSION \nCRGNB colonisation constitute a silent and dangerous \nreservoir that can lead to the spread of these bacteria, in addition to the associated risk of developing clinical \ninfections [7,8]. Identification of RFs associated with infection \ndevelopment in CRGNB colonised patients is important to assist physicians in identifying those patients at high risk that would require close monitoring or/and administration of early treatment. Nevertheless, few studies have been published \nanalysing RFs associated with infection progression in CRGNB \ncolonised patients.\nIn this study, a total of 181 articles were identified in the SLR, 80 for the respiratory tract site and 101 for rectal site. Of \nthese, 8 articles were finally included in the CRGNB respiratory \ntract colonisation and 21 for CRGNB rectal colonisation, \nidentifying 19 RFs associated with pneumonia development \nand 44 RFs associated with infection progression, respectively. \nMost of RFs identified were supported by literature (74% of RF from the respiratory tract site and 86% of RF from rectal \ntract), and few were considered based on expert\u2019s experience \nand opinion (Supplementary Table 2 and Supplementary Table \n3). \nAfter discussion, the experts agreed on 13 RFs to be \nassociated with pneumonia development after respiratory \ntract CRGNB colonisation and 33 RFs to be associated with \ninfection progression after rectal CRGNB colonisation (Table \n3). Consensus was not reached for the RF \u201cLiver dysfunction\u201d in patients colonised with A. baumannii in the rectal tract. \nNoteworthy, respiratory tract and rectal colonisation, A systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467464Risk factor associated with pneumonia development \nin patients with CRGNB respiratory tract colonisation \nadmitted in the ICU and receiving artificial airwayRisk factor associated with the development of \ninfections in patients with CRGNB rectal colonisation\nP. aeruginosa P. aeruginosa respiratory tract colonisation [22]\nPrevious exposure to antibiotic therapy [21,22]Mechanical ventilation at ICU admission [29] Previous stay in ICULong stay in the ICUP. aeruginosa rectal tract colonisation [30]Use of mechanical ventilation [29] Previous stay in ICULong stay in the ICU\nA. baumannii A. baumannii respiratory tract colonisationPrevious exposure to antibiotic therapy [31]Higher age [31]Use of mechanical ventilation [31] Previous stay in ICULong stay in the ICU [31]A. baumannii rectal tract colonisation [26]Previous carbapenem use [26]Previous stay in ICULong stay in the ICU\nE. coli N/A E. coli rectal tract colonisationPrevious carbapenem use [32]Previous cephalosporin use [32]Previous penicillin use [32]Previous stay in ICU [32]Long stay in the ICU\nK. pneumoniae K. pneumoniae respiratory tract colonisationPrevious exposure to antibiotic therapy [24]Previous infection episodes [24]Previous stay in ICULong stay in the ICUK. pneumoniae rectal tract colonisation [10]Previous exposure to antibiotic therapy [24]Previous stay in ICU [33,34]Previous infection episodes [24,34]Longer stay in ICU [27]Use of central venous catheter [27,33]Being in a coma condition [33]\nEnterobacterales Enterobacterales respiratory tract colonisation [35]Previous stay in ICULong stay in the ICUEnterobacterales rectal tract colonisation [28,35\u201337]Use of Mechanical ventilation [38] Previous stay in ICU [39]Long stay in the ICUHigher density of MDR colonies [35]Presenting a high-level resistance to carbapenems [36]Higher age [10]Presence of malign solid tumour [10,28]Haematological malignancy [10]Severe liver disease [28]Peptic ulcer [28]Table 3   Risk factors associated to infection development in adult patients with \nCRGNB colonisation by site and pathogen.\nprevious stay in the ICU and longer stay in the ICU were \nclassified as relevant RFs independently of the pathogen and site of colonisation. Previous exposure to antibiotic therapy or previous carbapenem use was also a common relevant RF for \npatients with CRGNB respiratory tract and rectal colonisation, supported by the literature and experts\u2019 opinion, showing \naltogether their relevance when identifying patients at high \nrisk of infection development after CRGNB colonisation in \nthose sites. \nOther RFs identified are also consistent across the sites, for instance \u201cuse of mechanical ventilation\u201d, \n\u201cprevious infection episodes\u201d, \u201chigher age\u201d, or \u201cpre-existing \ncomorbidities\u201d, nevertheless the association is pathogen \nspecific for each of the sites. The experts agreed that pre-\nexisting comorbidities could be a relevant RF to identify \npatients at high-risk of infection development, nevertheless, \nthose should be refined based on disease severity and patient status. Interestingly, some of the relevant RF associated to infection progression in this study have been associated with CRGNB infections in hospitalized patients in several studies, such as prior use of antibiotics, prior hospital or ICU stay and A systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467465length of stay [16\u201318].\nThe RFs that were excluded by the expert panel were \ngenerally due to the lack of significant association with \nincreased risk in the literature, or because the study design \nwas inadequate to answer the study question. In some cases, RF were excluded due to the existence of confounding factors that might be more relevant that the identified RFs themselves.\nThe limitations of this study are first, the low number of \nstudies identified, due to the scarce evidence available, with most of the RFs identified being supported by only one study. \nSecondly, the design of the studies identified in the SLR, with \ndifferent inclusion and exclusion criteria among them. Further \nprospective studies with less variability between patient \npopulations would be needed, which would also make meta-\nanalysis studies possible. For those reasons, the involvement of an expert panel with extensive experience in the field \nstrengthens the study results.\nTo our knowledge, this study provides the best evidence \navailable based on SLR and experts\u2019 opinion of the RFs associated with infection development in CRGNB colonised \npatients. The results of the study may contribute to the early \nidentification of colonized patients at higher risk of infection development, favouring time-to-effective therapy and improving health outcomes.\nACKNOWLEDGEMENTS\nThe authors would like to thank Jessica Sard\u00e0 (Medical \ndepartment, Shionogi) for her support and contributions to the study and manuscript, and In\u00e9s del Cerro for her contribution to the systematic literature review.\nFUNDING\nThis study was funded by Shionogi S.L.U. \nCONFLICTS OF INTEREST\nRF has participated as a speaker or consultant for \nMSD, Pfizer, Shionogi, Gilead, Grifols and Menarini. AS has \nparticipated in advisory meetings or as a speaker in educational \nactivities for Pfizer, MSD, Angelini, Gilead Sciences and Shionogi. RC has participated in education activities organised \nby MSD, Pfizer and Shionogi and worked on research projects funded by MSD, Shionogi and Venatrox. JLP has participated \nin education activities and advisory meetings organised by Novartis, MSD, Pfizer and Gilead, Angelini and Shionogi and \nworked on research projects funded by Novartis.  CG-V has \nreceived honoraria for talks on behalf of Gilead Science, MSD, Novartis, Pfizer, Janssen, Lilly, Shionogi as well as a grant from \nGilead Science, Pfizer and MSD. JG-M has participated as a \nspeaker in educational activities for MSD, Pfizer and Shionogi. NL has participated in advisory meetings or as a speaker in \neducational activities funded by Pfizer, MSD, Menarini and Shionogi. PR has participated as consultant and speaker in educational activities organized by Pizer, MSD, Menarini \nand Shionogi. MS has collaborated in training or research \nprojects and taken part in symposia, meetings or consultancies \norganised or funded by Gilead, MSD, Janssen, Pfizer and Shionogi. VP has participated in accredit ed educational \nactivities sponsored by MSD, Pfizer and Shionogi and has been a consultant for Pfizer, Shionogi and Correvio. AG-P and \nXB are employees of Omakase Consulting S.L. that received \nfunding from Shionogi Inc. to develop and conduct this study.  \nREFERENCES\n1 Doi Y. Treatment Options for Carbapenem-resistant Gram-negative \nBacterial Infections. Clin Infect Dis. 2019;69(Suppl 7):S565-S575. \ndoi: 10.1093/cid/ciz830.\n2 Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, \nGiske CG, et al. Multidrug-resistant, extensively drug-resistant and \npandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol \nInfect. 2012;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.\n3 Tacconelli E, Carrara E, Savoldi A, Kattula D, Burkert F. Global \npriority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Lancet Infect Dis. 2018;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. \n4 Sociedad Espa\u00f1ola de Medicina Preventiva Salud P\u00fablica e Higiene. \nEstudio EPINE - Prevalencia de infecciones (relacionadas con la \nasistencia sanitaria y comunitarias) y uso de antimicrobianos en \nhospitales de agudos. 2021 [cited May 2022]. Available at: https://\nepine.es/api/documento-publico/2019%20EPINE%20Informe%20\nEspa%C3%B1a%2027112019.pdf/reports-esp.\n5 Cassini A, H\u00f6gberg LD, Plachouras D, Quattrocchi A, Hoxha A, \nSimonsen GS, et al. Attributable deaths and disability-adjusted \nlife-years caused by infections with antibiotic-resistant bacteria in \nthe EU and the European Economic Area in 2015: a population-\nlevel modelling analysis. Lancet Infect Dis. 2019;19(1):56-66. doi: \n10.1016/S1473-3099(18)30605-4.\n6 Garnacho-Montero J, Amaya-Villar R. The problem of multi-\nresistance in gram-negative bacilli in intensive care units: Treatment and prevention strategies. Med Intensiva (Engl Ed). \n2022; 46(6):326-335. doi: 10.1016/j.medine.2022.04.006.\n7 Garnacho-Montero J, \u00c1lvarez Lerma F, Ram\u00edrez Galleymore P, \nPalomar Mart\u00ednez M, \u00c1lvarez Rocha L, Barcenilla Gaite F, et al. \nCombatting resistance in intensive care: the multimodal approach \nof the Spanish ICU \u201cZero Resistance\u201d program. Crit Care. 2015; \n19(1):114. doi: 10.1186/s13054-015-0800-5.\n8 Tischendorf J, De Avila RA, Safdar N. Risk of infection following \ncolonization with carbapenem-resistant Enterobactericeae: A \nsystematic review. Am J Infect Control. 2016; 44(5):539-43. doi: \n10.1016/j.ajic.2015.12.005.\n9 Alhmidi H, Cadnum JL, Koganti S, Jencson AL, Bonomo RA, Wilson \nBM, et al. Shedding of multidrug-resistant gram-negative bacilli by \ncolonized patients during procedures and patient care activities. \nAm J Infect Control. 2020; 48:1336\u201340. https://doi.org/10.1016/J.\nAJIC.2020.06.004.A systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-46746610 Isendahl J, Giske CG, Hammar U, Sparen P, Tegmark Wisell \nK, Ternhag A, et al. Temporal Dynamics and Risk Factors for \nBloodstream Infection With Extended-spectrum \u03b2-Lactamase-producing Bacteria in Previously-colonized Individuals: National \nPopulation-based Cohort Study. Clin Infect Dis. 2019;68(4):641-649. doi: 10.1093/cid/ciy539.\n11 Demiraslan H, Cevahir F, Berk E, Metan G, Cetin M, Alp E. Is \nsurveillance for colonization of carbapenem-resistant gram-negative bacteria important in adult bone marrow transplantation \nunits? Am J Infect Control. 2017; 45(7):735-739. doi: 10.1016/j.\najic.2017.01.006.\n12 Kiddee A, Assawatheptawee K, Na-Udom A, Treebupachatsakul \nP, Wangteeraprasert A, Walsh TR, et al. Risk factors for gastrointestinal colonization and acquisition of carbapenem-resistant Gram-negative bacteria among patients in Intensive \nCare Units in Thailand. Antimicrob Agents Chemother. 2018; \n62(8):e00341-18. doi: 10.1128/AAC.00341-18..\n13 Frencken JF, Wittekamp BHJ, Plantinga NL, Spitoni C, Van De Groep \nK, Cremer OL, et al. Clinical infectious diseases associations between enteral colonization with gram-negative bacteria and intensive care unit-acquired infections and colonization of the respiratory \ntract. Clin Infect Dis. 2018; 66(4):497-503. doi: 10.1093/cid/cix824.\n14 Niederman M. Gram-negative colonization of the respiratory tract: \npathogenesis and clinical consequences. Semin Respir Infect. 1990; \n5(3):173-84. PMID: 2255803.\n15 Tang S, Chee E, Teo J, Chlebicki M, Kwa A. Incidence of a subsequent \ncarbapenem-resistant Enterobacteriaceae infection after previous \ncolonisation or infection: a prospective cohort study. Int J Antimicrob Agents. 2021; 57(6):106340. doi: 10.1016/j.ijantimicag.\n16 Zhu WM, Yuan Z, Zhou HY. Risk factors for carbapenem-resistant \nKlebsiella pneumoniae  infection relative to two types of control \npatients: A systematic review and meta-analysis. Antimicrob Resist \nInfect Control. 2020; 9(1):23. doi: 10.1186/s13756-020-0686-0.\n17 Li J, Li Y, Song N, Chen Y. Risk factors for carbapenem-resistant  \nKlebsiella pneumoniae  infection  : A meta-analysis. J Glob Antimicrob  \nResist. 2020; 21:306-313. doi: 10.1016/j.jgar.2019.09.006.\n18 Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors \nfor hospitalized patients with resistant or multidrug-resistant \nPseudomonas aeruginosa infections: A systematic review and meta-analysis. Antimicrob Resist Infect Control 2018;7:1\u201314. \nhttps://doi.org/10.1186/s13756-018-0370-9.\n19 Logan LK, Weinstein RA. The Epidemiology of Carbapenem-\nResistant Enterobacteriaceae: The Impact and Evolution of a \nGlobal Menace. J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36. doi: 10.1093/infdis/jiw282.\n20 Ferrer R, Soriano A, Cant\u00f3n R, Del Pozo JL, Garc\u00eda-Vidal C, \nGarnacho-Montero J, et al. A systematic review and expert\u2019s \nanalysis of risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii \nin Spain. Rev Esp Quimioter. 2021; 34(4):298-307. doi: 10.37201/\nreq/034.2021.\n21 Borgatta B, Gattarello S, Mazo CA, Imbiscuso AT, Larrosa MN, \nLuj\u00e0n M, et al. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant \nPseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs. Eur J Clin Microbiol Infect Dis. \n2017; 36(11):2155-2163. doi: 10.1007/s10096-017-3039-z.\n22 Fern\u00e1ndez-Barat L, Ferrer M, De Rosa F, Gabarr\u00fas A, Esperatti M, \nTerraneo S, et al. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance. J Infect. 2017; 74(2):142-152. doi: 10.1016/j.jinf.2016.11.008.\n23 Lin CY, Chen YM, Lin MC, Chang YP, Chao TY, Wang CC, et al. Risk \nfactors of multidrug-resistant Acinetobacter baumannii recurrence \nafter successful eradication in ventilated patients. Biomed J. 2016 \nApr;39(2):130-8. doi: 10.1016/j.bj.2015.07.001.\n24 Sbrana F, Malacarne P, Bassetti M, Tascini C, Vegnuti L, Siega P \nDella, et al. Risk factors for ventilator associated pneumonia due to \ncarbapenemase-producing Klebsiella pneumoniae in mechanically \nventilated patients with tracheal and rectal colonization. Minerva \nAnestesiol. 2016; 82(6):635-40. PMID: 26745619.\n25 Hoang S, Georget A, Asselineau J, Venier AG, Leroyer C, Rogues AM, \net al. Risk factors for colonization and infection by Pseudomonas \naeruginosa in patients hospitalized in intensive care units in \nFrance. PLoS One. 2018 Mar 9; 13(3):e0193300. doi: 10.1371/\njournal.pone.0193300.\n26 Qiao F, Huang W, Gao S, Cai L, Zhu S, Wei L, et al. Risk factor \nfor intestinal carriage of carbapenem-resistant Acinetobacter \nbaumannii and the impact on subsequent infection among patients in an intensive care unit: An observational study. BMJ \nOpen. 2020;10(9):e035893. doi: 10.1136/bmjopen-2019-035893.\n27 Madue\u00f1o A, Gonzalez Garcia J, Aguirre-Jaime A, Lecuona \nM. A hospital-based matched case-control study to identify risk factors for clinical infection with OXA-48-producing Klebsiella pneumoniae in rectal carriers. Epidemiol Infect. \n2017;145(12):2626-2630. doi: 10.1017/S095026881700142X.\n28 Denkel LA, Maechler F, Schwab F, Kola A, Weber A, Gastmeier P, et \nal. Infections caused by extended-spectrum \u03b2-lactamase-producing Enterobacterales after rectal colonization with ESBL-producing \nEscherichia coli or Klebsiella pneumoniae. Clin Microbiol Infect. \n2020;26(8):1046-1051. doi: 10.1016/j.cmi.2019.11.025.\n29 Paling FP, Wolkewitz M, Depuydt P, de Bus L, Sifakis F, Bonten \nMJM, et al. P. aeruginosa colonization at ICU admission as a risk \nfactor for developing P. aeruginosa ICU pneumonia. Antimicrob \nResist Infect Control. 2017;6:38. doi: 10.1186/s13756-017-0197-9.\n30 G\u00f3mez-Zorrilla S, Camoez M, Tubau F, Ca\u00f1izares R, Periche \nE, Dominguez MA, et al. Prospective observational study of prior rectal colonization status as a predictor for subsequent development of Pseudomonas aeruginosa  clinical infections. \nAntimicrob Agents Chemother. 2015;59(9):5213-9. doi: 10.1128/AAC.04636-14.\n31 Chen L, Yuan J, Xu Y, Zhang F, Chen Z. Comparison of clinical \nmanifestations and antibiotic resistances among three genospecies of the Acinetobacter calcoaceticus-Acinetobacter baumannii \ncomplex. PLoS One. 2018 Feb 1;13(2):e0191748. doi: 10.1371/\njournal.pone.0191748.\n32 Liu M, Li M, Wu L, Song Q, Zhao D, Chen Z, et al. Extended-A systematic literature review and expert consensus on risk factors associated to infection progression in \nadult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteriaR. Ferrer, et al.\nRev Esp Quimioter 2022;35(5): 455-467467spectrum \u03b2-lactamase-producing E. coli septicemia among rectal \ncarriers in the ICU. Medicine (Baltimore). 2018;97(38):e12445. doi: \n10.1097/MD.0000000000012445.\n33 Chen X, Liu Q, Liu WE, Yan Q. Risk factors for subsequential \ncarbapenem-resistant Klebsiella pneumoniae  clinical infection \namong rectal carriers with carbapenem-resistant Klebsiella \npneumoniae. Infect Drug Resist. 2020 May 5;13:1299-1305. doi: 10.2147/IDR.S247101.\n34 Giacobbe DR, Del Bono V, Bruzzi P, Corcione S, Giannella M, \nMarchese A, et al. Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella \npneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study. Eur J Clin Microbiol Infect Dis. 2017;36(4):663-669. doi: 10.1007/s10096-016-2843-1.\n35 Andremont O, Armand-Lefevre L, Dupuis C, de Montmollin E, \nRuckly S, Lucet JC, et al. Semi-quantitative cultures of throat and rectal swabs are efficient tests to predict ESBL- Enterobacterales \nventilator-associated pneumonia in mechanically ventilated ESBL \ncarriers. Intensive Care Med. 2020;46(6):1232-1242. doi: 10.1007/\ns00134-020-06029-y.\n36 Lin Q, Wang Y, Yu J, Li S, Zhang Y, Wang H, et al. Bacterial \ncharacteristics of carbapenem-resistant Enterobacteriaceae (CRE) \ncolonized strains and their correlation with subsequent infection. \nBMC Infect Dis. 2021;21(1):638. doi: 10.1186/s12879-021-06315-\n0.\n37 McConville TH, Sullivan SB, Gomez-Simmonds A, Whittier \nS, Uhlemann AC. Carbapenem-resistant Enterobacteriaceae \ncolonization (CRE) and subsequent risk of infection and 90-day \nmortality in critically ill patients, an observational study. PLoS One. 2017;12(10):e0186195. doi: 10.1371/journal.pone.0186195.\n38 Freedberg DE, Zhou MJ, Cohen ME, Annavajhala MK, Khan S, \nMoscoso D, et al. Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. Intensive Care Med. 2018;44(8):1203-1211. doi: 10.1007/s00134-018-5268-8.\n39 Pintos-Pascual I, Cantero-Caballero M, Rubio EM, S\u00e1nchez-Romero \nI, Asensio-Vegas \u00c1, Ramos-Mart\u00ednez A. Epidemiology and clinical of infections and colonizations caused by Enterobacterales producing \ncarbapenemases in a tertiary hospital. Rev Esp Quimioter. 2020;33(2):122-129. Spanish. doi: 10.37201/req/086.2019.ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/022.2022\nRev Esp Quimioter 2022;35(5): 468-474468Impact of Staphylococcus aureus  bacteremia in \nCOVID-19 patients\nIntroduction. The disease caused by SARS-CoV-2 (COV -\nID-19) has been a challenge for healthcare professionals since \nits appearance. Staphylococcus aureus has been described as \none of the main pathogens causing bacterial infections in viral \npandemics. However, co- infection with  S. aureus causing bac-\nteremia in patients with COVID-19 has yet to be well studied. \nMethods: We performed a e study of S. aureus bacter -\nemia (SAB) at Hospital Miguel Servet (Zaragoza) from March \n2020 to February 2021. The clinical characteristics, mortality and risk factors of adults hospitalized patients with BSA asso -\nciated COVID-19 compared to patients without COVID-19.\nResults. A total of 95 patients with SAB were identified. \n27.3% were positive for SARS-CoV-2. SAB represented 9.9% of \nbacteremia, being the second agent in frequency after E. co-\nli. Nosocomial bacteremia was more frequent in the group of \nCOVID-19 patients. The most frequent source of BSA in these \npatients was the respiratory source (26.9% vs 0%; P<0.001) \nfollowed by the skin (15.5% vs 15.9%; P=1). The development of sepsis was more frequent in COVID-19 patients (61,5% vs 7,8%; P=0,336) and among them, who received dexametha -\nsone at doses > 6 mg/day (62.5% vs. 37.5%, P<0.05).\nConclusions. Our data suggest that BSA has a negative \nimpact on the evolution of patients with COVID-19. However, further and preferably prospective studies are required to ob -\ntain solid data on the impact of BSA on coronavirus patients.\nKeywords: bacteremia; Staphylococcus aureus ; COVID-19; mortality \nINTRODUCCI\u00d3N\nLa enfermedad causada por el SARS-CoV-2 (COVID-19) es \nuna enfermedad infecciosa que se identific \u00f3 por primera vez \nen diciembre de 2019 en Wuhan, China, y actualmente es pan-\nd\u00e9mica [1,2]. Esta infecci\u00f3n ha supuesto un formidable desaf\u00edo Impacto de la bacteriemia por Staphylococcus \naureus en pacientes con COVID-19\n1Hospital Universitario Miguel Servet, Servicio de Medicina Interna. Zaragoza (Zaragoza), Espa\u00f1a.\n2Hospital Universitario Miguel Servet, Servicio de Microbiolog\u00eda. Zaragoza (Zaragoza), Espa\u00f1a. \n3Hospital Universitario Miguel Servet, Unidad de Enfermedades Infecciosas. Zaragoza (Zaragoza), Espa\u00f1a. \n4Unidad de Investigaci\u00f3n Traslacional, Hospital Universitario Miguel Servet, Instituto Aragon\u00e9s de Ciencias de la \nSalud, Instituto de Investigaci\u00f3n Sanitaria de Arag\u00f3n. Zaragoza (Zaragoza), Espa\u00f1a.Maria Espinosa Perez1\nRosa Garc\u00eda Fenoll1\nSaray Mormeneo Bayo2\nRosa Mar\u00eda Mart\u00ednez \u00c1lvarez3\nVioleta Frutos Mill\u00e1n2\nMar\u00eda Cruz Villuendas Us\u00f3n2\nMar\u00eda Pilar Palaci\u00e1n Ruiz2\nJos\u00e9 Miguel Arbon\u00e9s Mainar4\nMar\u00eda Carmen Mart\u00ednez Jim\u00e9nez2 \nCarlos Ramos Paesa3Original\nArticle history\nReceived: 6 March 2022; Revision Requested: 25 March 2022; Revision Received: 24 June 2022; Accepted: 4 July 2022; \nPublished: 22 July 2022\nRESUMEN\nIntroducci\u00f3n. La enfermedad causada por SARS-CoV-2  \n(COVID-19) ha supuesto un desaf\u00edo para los profesionales sanita -\nrios desde su aparici\u00f3n. Staphylococcus aureus es uno de los prin-\ncipales pat\u00f3genos causantes de infecciones bacterianas en pan -\ndemias virales. Sin embargo, se debe estudiar bien la co-infecci\u00f3n \npor S. aureus causante de bacteriemia en pacientes con COVID-19.\nM\u00e9todos. Se analizaron los casos de bacteriemia por S. aureus \n(BSA) atendidos en el Hospital Miguel Servet (Zaragoza) desde mar -\nzo de 2020 hasta febrero de 2021. Se compararon las caracter\u00edsticas cl\u00ednicas, los factores de riesgo y mortalidad de los pacientes con BSA \nasociada a COVID-19 respecto los pacientes no-COVID-19. \nResultados. Se identificaron 95 pacientes con BSA. El \n27,3% fueron COVID-19 positivos. La BSA represent\u00f3 el 9,9% de las bacteriemias, siendo el segundo microorganismo en \nfrecuencia tras E. coli. La bacteriemia nosocomial fue m\u00e1s \nfrecuente en el grupo de pacientes con COVID-19. La fuen -\nte de BSA fue desconocida en el 46,2% de los pacientes con  \nCOVID-19. La fuente de BSA m\u00e1s frecuente en estos pacien-tes fue la respiratoria (26,9% vs 0%; P<0,001) seguida de la \ncut\u00e1nea (15,5% vs 15,9%; P=1). El desarrollo de sepsis fue m\u00e1s frecuente en los pacientes con COVID-19 (61,5% vs 7,8%; \nP=0,336) y de ellos, los que recibieron dosis de dexametasona \n>6 mg/d\u00eda (62,5% vs 37,5%; P< 0,05).\nConclusiones. Nuestros datos sugieren que la BSA influye \nnegativamente en la evoluci\u00f3n de los pacientes con COVID-19. \nSin embargo, se requieren m\u00e1s estudios y preferiblemente \nprospectivos para obtener datos s\u00f3lidos sobre el impacto de la \nBSA en los pacientes con coronavirus. \nPalabras clave: bacteriemia; Staphylococcus aureus ; COVID-19; mortalidad; \nCorrespondencia: \nMar\u00eda Espinosa P\u00e9rez. \nHospital Universitario Miguel Servet, Servicio de Medicina Interna. \nP.\u00ba Isabel la Cat\u00f3lica, 1-3, 50009 Zaragoza, Espa\u00f1a. \nE-mail: mariespiperez@gmail.com. Impacto de la bacteriemia por Staphylococcus aureus en pacientes con COVID-19 M. Espinosa P\u00e9rez, et al.\nRev Esp Quimioter 2022;35(5): 468-474469ter) siguiendo los criterios vigentes del European Committee \non Antimicrobial Susceptibility Testing (EUCAST).\nLa detecci\u00f3n de RNA viral se realiz\u00f3 por RT-PCR, principal -\nmente con Allplex \u2122 (Seegen, Corea), COBAS 6800tm (Roche, \nSuiza) Panther (Hologic, San Diego), Cobas Liat (Roche, EE. UUy \nXpert Xpress (Cepheid, Sunnyvale). Los casos se clasificaron en \npacientes con COVID-19, aquellos positivos para SARS- CoV-2 \npor PCR a trav\u00e9s de frotis nasofar\u00edngeo, y en pacientes no- CO -\nVID-19. Se consider\u00f3 BSA asociada a COVID-19 en los pacien -\ntes que desarrollaron la bacteriemia hasta un mes despu\u00e9s de \nla positividad de la PCR para SARS-CoV-2. \nSe analiz\u00f3 la fuente de infecci\u00f3n consider\u00e1ndose bacterie-\nmia relacionada con el cat\u00e9ter (BRC) el aislamiento de S. au-\nreus, en el hemocultivo extra\u00eddo tanto de vena perif\u00e9rica como en el cultivo semicuantitativo de la punta del cat\u00e9ter en un paciente, con cuadro cl\u00ednico de sepsis y sin otro foco aparente de infecci\u00f3n. En las situaciones en las que no se enviaron la punta del cat\u00e9ter a cultivar, se consider\u00f3 BRC cuando se ais -\nl\u00f3 S. aureus tiempo diferencial mayor a 120 minutos entre el \nhemocultivo extra\u00eddo por el cat\u00e9ter y por venopunci\u00f3n [10]. Para la interpretaci\u00f3n de los cultivos de esputo, se comprob\u00f3 \nque cumpl\u00edan los criterios de calidad de Murray y Washington \ny se consider\u00f3 S. aureus cuando el crecimiento era en cantidad \nsignificativa y predominante en el cultivo. En las muestras ob-\ntenidas por fibrobroncoscpia los puntos de corte se fijaron en \n1.000 ufc/ml para el cultivo del cepillado bronquial y 10.000 \nufc/ml para el cultivo bacteriano del lavado broncoalveolar. El \nfoco cut\u00e1neo se diagnostic\u00f3 a partir del aislamiento de S. au-\nreus en la muestra obtenida de la lesi\u00f3n (herida). \nA partir del Servicio de Admisi\u00f3n y Documentaci\u00f3n Cl\u00ednica \ny de la historia cl\u00ednica electr\u00f3nica de nuestro centro, se obtu -\nvieron datos demogr\u00e1ficos (edad y sexo) y cl\u00ednicos (obesidad, \nenfermedad renal cr\u00f3nica, HTA, diabetes, dislipemia, neoplasia, \nbroncopat\u00eda cr\u00f3nica, trasplante previo, enfermedad hep\u00e1tica y \nreum\u00e1tica) de los pacientes. Los antimicrobianos recibidos se \nclasificaron como emp\u00edricos (antibi\u00f3tico pautado antes del ais -\nlamiento microbiol\u00f3gico) o dirigido (pautado una vez conocida \nla identificaci\u00f3n bacteriana). \nEn el grupo de los pacientes con BSA asociada a COVID-19 \nse recogieron las terapias recibidas, clasificando a los pacientes \nen aquellos que recibieron dexametasona (DXT) a dosis bajas \n(d1), 6 mg al d\u00eda durante 14 d\u00edas administrada por v\u00eda oral o por v\u00eda intravenosa, pacientes que recibieron DXT a dosis altas (d2), siendo superiores a 6 mg al d\u00eda y pacientes que recibieron tratamiento con tocilizumab. Tambi\u00e9n se recogi\u00f3 la necesidad \nde ingreso en UCI y de ventilaci\u00f3n mec\u00e1nica invasiva (VMI). \nLas variables principales empleadas para valorar el im-\npacto de la bacteriemia fueron la mortalidad hospitalaria a los \n14 y 30 d\u00edas del primer hemocultivo positivo, el desarrollo de \ncomplicaciones (aortitis, endocarditis, espondilodiscitis, artritis \ny abscesos), sepsis y bacteriemia persistente, definida por la \npresencia de hemocultivos positivos a las 72 horas del trata -\nmiento antibi\u00f3tico adecuado.\nAn\u00e1lisis estad\u00edstico. Se analizaron las caracter\u00edsticas cl\u00ed -m\u00e9dico para los sistemas de salud y los profesionales sanitarios.\nLas infecciones bacterianas secundarias asociadas a infec-\nciones virales respiratorias est\u00e1n bien descritas en la literatura \ny se conoce que son causa de una mayor morbilidad y mortali-dad. En concreto, entre los pacientes infectados con el virus de \nla gripe las bacteriemias se han asociado a una mortalidad cer -\ncana al 50% en comparaci\u00f3n con el 1,4% en pacientes con gri -\npe sin bacteriemia [3]. Las especies bacterianas principalmente \nasociadas a infecciones virales son Mycoplasma pneumoniae, \nStaphylococcus aureus, Legionella pneumophila, Streptococ-\ncus pneumoniae, Haemophilus y Klebsiella spp [4]. \nActualmente se est\u00e1n llevando a cabo estudios epidemio-\nl\u00f3gicos sobre las sobreinfecciones bacterianas en los pacientes \ncon COVID-19, especialmente las bacteriemias [5]. Adem\u00e1s, se \nest\u00e1 observando una creciente incidencia de estas co- infec -\nciones en los pacientes con COVID-19 que han ingresado en \nlas unidades de cuidados intensivos (UCI), as\u00ed \u0301 como mayores \ntasas infecci\u00f3n por bacterias nosocomiales multirresistentes, \nponiendo en relieve la necesidad de prestar especial atenci\u00f3n al uso de tratamientos emp\u00edricos de amplio espectro en pacientes \ncon COVID-19 [1,6,7]. \nNo obstante, los datos sobre las infecciones bacterianas \nsecundarias en pacientes COVID- 19 son limitados debido a la \npropagaci\u00f3n todav\u00eda en curso de esta enfermedad en todo el mundo. \nEn nuestro medio, la incidencia poblacional de bacteriemia \npor S. aureus (BSA) var\u00eda de 10 a 30/100.000 personas -a\u00f1o y \ncontin\u00faa siendo un reto diario para los cl\u00ednicos dada su elevada \nmortalidad y morbilidad [8,9]. A pesar de los esfuerzos en me -\njorar el manejo de esta infecci\u00f3n, no se ha conseguido observar \nuna mejor\u00eda significativa de su pron\u00f3stico en los \u00faltimos a\u00f1os ya que la poblaci\u00f3n en riesgo contin\u00faa aumentando [9]. \nS. aureus se ha descrito como uno de los principales pa -\nt\u00f3genos causantes de infecciones bacterianas en pandemias virales previas [3]. Sin embargo, todav\u00eda se debe estudiar bien \nla asociaci\u00f3n de las co-infecciones por S. aureus y los pacientes \ninfectados con SARS-CoV-2, as\u00ed como su impacto en cuanto a \nmorbilidad y mortalidad para buscar medidas preventivas. \nMATERIAL Y M\u00c9TODOS\nTemas de estudio y recopilaci\u00f3n de datos. Se trata de \nun estudio observacional y retrospectivo realizado a partir de la revisi\u00f3n de los casos de BSA documentados por hemocultivo \ny atendidos en el Hospital Miguel Servet de Zaragoza. Se in -\ncluyeron pacientes adultos que ingresaron en el hospital entre \nel 4 de marzo de 2020 (fecha del primer positivo para SARS- \nCoV-2 en Arag\u00f3n) hasta el 15 de febrero de 2021. \nDatos microbiol\u00f3gicos y cl\u00ednicos. Para la detecci\u00f3n mi -\ncrobiol\u00f3gica, los hemocultivos se incubaron en BD BACTEC \u2122 FX durante 5 d\u00edas. La identificaci\u00f3n de los hemocultivos posi-\ntivos se realiz\u00f3 por espectrometr\u00eda de masas (MALDI-TOF MS) (MaldiBiotyper\u00ae Bruker Daltonics). La sensibilidad antibi\u00f3tica se determin\u00f3 mediante MicroScan WalkAway (Beckman Coul -Impacto de la bacteriemia por Staphylococcus aureus en pacientes con COVID-19 M. Espinosa P\u00e9rez, et al.\nRev Esp Quimioter 2022;35(5): 468-474470debido a las condiciones de confidencialidad en la recogida de \ndatos y la naturaleza retrospectiva del estudio.\nRESULTADOS\nDatos microbiol\u00f3gicos, cl\u00ednicos y tratamiento anti-\nbi\u00f3tico. Se identificaron 95 pacientes en nuestro hospital con \ndiagn\u00f3stico de BSA en el periodo establecido. Del total de la \nmuestra, 26 pacientes (27,3%) fueron positivos para SARS-CoV-2 por RT-PCR. \nEl n\u00famero de extracciones de hemocultivos realizadas \nfue de 15930, diagnostic\u00e1ndose bacteriemia en 958 pacientes, \nsiendo la tasa de positividad de los hemocultivos del 12,1%. La \nBSA represent\u00f3 un 9,9 % de las bacteriemias totales, siendo el \nsegundo agente etiol\u00f3gico de bacteriemia en frecuencia tras \nEscherichia coli que fue el responsable de 297 bacteriemias \n(31%). La tasa de contaminaci\u00f3n de los hemocultivos fue del \n5,4% (852 hemocultivos). \nEl tiempo medio que transcurri\u00f3 desde que el hemocul-\ntivo se incub\u00f3 hasta que result\u00f3 positivo fue de 12 horas, sin \ndiferencia entre los pacientes con COVID-19 y no COVID -19 \n(p= 0,613). La mayor\u00eda de las bacteriemias fueron monomicro -\nbianas (90,6%) y en el caso de las polimicrobianas (9,4%) se asociaron a bacilos Gram negativos el 66,7% de las veces.\nLas caracter\u00edsticas cl\u00ednicas de los pacientes por grupos se \nmuestran en la tabla 1. Las comorbilidades m\u00e1s prevalentes en \nlos casos COVID-19 de nuestra muestra fueron la hipertensi\u00f3n, \ndislipemia, ECV, diabetes mellitus y la obesidad, sin ser diferen -\ntes a las comorbilidades de los pacientes no- COVID-19 con \nBSA. No se encontraron diferencias estad\u00edsticamente significa -\ntivas entre grupos. \nEl tratamiento antibi\u00f3tico emp\u00edrico fue adecuado en el \n61,5% (16/26) de pacientes con infecci\u00f3n por coronavirus sin \nencontrar diferencias estad\u00edsticamente significativas respecto \na los pacientes no co-infectados (61,5% vs 47,8%; P =0,557). \nEl antibi\u00f3tico dirigido m\u00e1s empleado en el grupo de pa -\ncientes con COVID-19 fue daptomicina (34,6%) seguido de \ncloxacilina (26,9%). Se emple\u00f3 biterapia en un 23,1% (6/26) de nicas de los pacientes con BSA asociada a COVID-19 as\u00ed como \nlos factores que influyen en el aumento de la mortalidad en este grupo, compar\u00e1ndolo con los pacientes con BSA no aso -\nciada a COVID-19 con el objetivo de observar diferencias entre \nlos grupos. \nSe realiz\u00f3 un an\u00e1lisis descriptivo de las variables recogi-\ndas mediante medidas de tendencia central (media o media -\nna) (edad, tiempo transcurrido desde el ingreso hasta el primer \nhemocultivo positivo), y medidas de dispersi\u00f3n (desviaci\u00f3n es -\nt\u00e1ndar o rango intercuart\u00edlico). La comparativa entre grupos se realiz\u00f3 mediante las pruebas de la t de Student o la U de Mann-Whitney para comparar variables continuas de distri -\nbuci\u00f3n normal y no normal respectivamente. Para comparar proporciones de las variables categ\u00f3ricas, se emple\u00f3 la prueba \nde la chi cuadrado con correcci\u00f3n de continuidad o correcci\u00f3n \nde Yates. Los Odds Ratio (OR) de sufrir un evento de inter\u00e9s se calcul\u00f3 a partir de modelos de regresi\u00f3n log\u00edstica uni- o multi-variantes, siendo la variable dependiente la ocurrencia/ausencia del evento y la/s variables independientes aquellas \nque se consideraron de inter\u00e9s. Para calcular la significaci\u00f3n \nde cada coeficiente del modelo se utilizaron el estad\u00edstico de Wald. Todos los c\u00e1lculos estad\u00edsticos se realizaron utilizando el software estad\u00edstico R versi\u00f3n 4.3.1 y los paquetes apropiados.\nAprobaci\u00f3n \u00e9tica. El Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n \nde Arag\u00f3n (CEICA) aprob\u00f3 el estudio y consider\u00f3 la no necesi -\ndad de solicitar consentimiento informado para su realizaci\u00f3n No COVID-19 \nn=69 \n(72,6%)COVID-19 \nn=26 \n(27,3%)p\nMediana de d\u00edas desde el \ningreso hasta el primer hemocultivo positivo1,00 \n[0,00;6,00]6,50 \n[1,25;13,8]0,012\nUnidad de cuidados intensivos 14 (20,3%) 9 (34,6%) 0,236\nVentilaci\u00f3n mec\u00e1nica invasiva 7 (10,1%) 9 (34,6 %) 0,011\nBacteriemia nosocomial 29 (42%) 23 (88,5 %) < 0,001Tabla 2   Variables asociadas a COVID-19\nNo COVID-19 \nn=69 \n(72,6%)COVID-19 \nn=26 \n(27,3%)p\nSexo (var\u00f3n); N (%) 54 (78,3%) 18 (69,2%) 0,517\nEdad; Media a\u00f1os, [DE] 70,0 \n[57,0;81,0]68,5 \n[63,2;77,2]0,858\nObesidad (IMC > 30);N (%) 25 (36,2%) 7 (26,9%) 0,540\nECV; N (%) 35 (50,7%) 11 (42,3%) 0,616\nHipertensi\u00f3n arterial; N (%) 46 (66,7%) 15 (57,7%) 0,566\nDiabetes mellitus; N (%) 27 (39,1%) 8 (30,8%) 0,607\nDislipemia; N (%) 26 (37,7%) 15 (57,7%) 0,128\nEnfermedad renal cr\u00f3nica; N (%) 19 (27,5%) 8 (30,8%) 0,955\nNeoplasia; N (%) 25 (36,2%) 5 (19,2%) 0,180\nBroncopat\u00eda cr\u00f3nica; N (%) 11 (15,9%) 6 (23,1%) 0,549\nTrasplante; N (%) 4 (5,8%) 1 (3,8%) 1,000\nEnfermedad hep\u00e1tica; N (%) 9 (13%) 0 (0%) 0,060\nEnfermedad reum\u00e1tica; N (%) 5 (7,2%) 2 (7,6%) 1,00Tabla 1   Caracter\u00edsticas demogr\u00e1ficas y cl\u00ednicas\nIMC: \u00edndice de masa corporal. ECV: enfermedad cardio- vascular (cardiopat\u00eda isqu\u00e9mica, insuficiencia cardiaca, accidente cerebro- vascular, accidente isqu\u00e9mico transitorio, etc.). Impacto de la bacteriemia por Staphylococcus aureus en pacientes con COVID-19 M. Espinosa P\u00e9rez, et al.\nRev Esp Quimioter 2022;35(5): 468-474471Complicaciones y mortalidad. No se observaron dife -\nrencias estad\u00edsticamente significativas entre pacientes con \nCOVID-19 y no COVID-19 en el desarrollo de: endocarditis \n(0% vs 7,2%), espondilodiscitis (3,8% vs 10,1%), embolismos perif\u00e9ricos (0% vs 7,2%), aortitis (11,5% vs 1,4%), abscesos en \u00f3rganos solidos (0% vs 2,9%), abscesos en piel y partes blandas \n(3,8% vs 7,2%) ni artritis (3,8% vs 7,2%). \nLa bacteriemia fue considerada persistente en el 30,7% \n(8/26) de los pacientes con COVID-19, no encontr\u00e1ndose di -\nferencias estad\u00edsticamente significativas respecto a los pacien -\ntes no COVID-19 (30,7% vs 27,5%, P= 0,783). El desarrollo de \nsepsis secundaria a la bacteriemia fue mayor en el grupo de \npacientes co-infectados por coronavirus (61,5% vs 47,8%, P= \n0.336).\nDe manera global, no hubo diferencias estad\u00edsticamente \nsignificativas entre la mortalidad de los pacientes con BSA y COVID-19 respecto a los pacientes no co- infectados por coro -\nnavirus (Tabla 4 y Figura 1). \nNo hubo diferencias en cuanto al desarrollo de complica -\nciones derivadas de la bacteriemia en funci\u00f3n del tratamiento \nCOVID-19 recibido. \nLa mortalidad de los pacientes que desarrollaron sepsis \nfue significativamente mayor (91,6% vs 8,3%, P < 0,01). \nDISCUSI\u00d3N\nDurante el periodo de estudio, en nuestro centro se notifi -\nc\u00f3 una tasa global de 0,27% (95/35.174) BSA. \nLa incidencia de la BSA en nuestro medio var\u00eda de 10 a \n30/100.000 personas -a\u00f1o [8,9]. En nuestro estudio, el 27,3% los pacientes de este grupo. No se encontraron diferencias es -\ntad\u00edsticamente significativas en el tratamiento antimicrobiano \nempleado entre ambos grupos. \nLa mediana de duraci\u00f3n del tratamiento antimicrobiano \nfue significativamente mayor en el grupo de los pacientes no COVID-19, 19 d\u00edas [13;30] vs 14 d\u00edas [4;24] en pacientes con \nCOVID-19 positivos (P= 0,038). \nDatos asociados a COVID-19 y tratamiento inmuno -\nsupresor. El 34,6% (9/26) de los pacientes con COVID-19 con \nBSA requirieron ingreso en UCI y VMI, resultando esto \u00faltimo \nestad\u00edsticamente significativo (34,6% vs 10,1%; P < 0,05). La \nmediana de d\u00edas desde la fecha de ingreso hasta el primer he -\nmocultivo positivo para S. aureus fue mayor en el grupo de los \npacientes infectados por coronavirus con una diferencia esta -\nd\u00edsticamente significativa (6,5 vs 1; P< 0,05). La bacteriemia \nnosocomial fue significativamente m\u00e1s frecuente en el grupo \nde pacientes con COVID-19 (Tabla 2).\nEl 26,9% del grupo COVID-19, recibi\u00f3 pauta d1, el 46,1% \nrecibi\u00f3 pauta d2 y el 23% de los pacientes recibieron trata -\nmiento con tocilizumab. Los que recibieron tratamiento d2 desarrollaron un cuadro de sepsis secundario a la bacteriemia en mayor proporci\u00f3n que los pacientes que no recibieron este tratamiento, resultando estad\u00edsticamente significativo (62,5% vs 37,5%, P < 0,05). \nFuente de bacteriemia. La fuente de bacteriemia fue \ndesconocida en el 46,2% de los pacientes con COVID-19. La fuente de infecci\u00f3n conocida m\u00e1s frecuente de nuestra mues -\ntra fue la piel y las partes blandas (15,8%) sin encontrar di -\nferencias estad\u00edsticamente significativas entre pacientes con COVID-19 y no COVID-19. Siete pacientes del total presentaron \ncomo fuente de infecci\u00f3n la respiratoria, siendo todos ellos pa-\ncientes con COVID-19 positivos e ingresados en UCI, resultan -\ndo estad\u00edsticamente significativo (P< 0.001) (Tabla 3). \nEl 15,4% de los pacientes con COVID-19 presentaron BSA \nresistente a meticilina (SARM), sin encontrar diferencias es -\ntad\u00edsticamente significativas respecto a los pacientes no CO -\nVID-19 (15,4% vs 15,9%, P=1). No COVID-19 \nn=69 \n(72,6%)COVID-19 \nn=26 \n(27,3%)p\nSepsis 33 (47,8%) 16 (61,5%) 0,336\nBacteriemia persistente 19 (27,5%) 8 (30,7%) 0,783\nEspondilodiscitis 7 (10,1%) 1 (3,8%) 0,439\nEmbolismos perif\u00e9ricos 5 (7,2%) 0 (0%) 0,318\nEndocarditis 5 (7,2%) 0 (0%) 0,318\nAortitis 1 (1,4%) 3 (11,5%) 0,061\nAbscesos \u00f3rganos s\u00f3lidos 2 (2,9%) 0 (0%) 1\nAbscesos piel y partes blandas 2 (2,9%) 1 (3,8%) 1\nArtritis 5 (7,2%) 1 (3,8%) 1\nMortalidad global 26 (37,6%) 12 (46,1%) 0,222\nMortalidad a los 14 d\u00edas 15 (21,7%) 8 (30,8%) 0,517\nMortalidad a los 30 d\u00edas 11 (15,9%) 4 (15,4%) 1Tabla 4   Mortalidad y complicaciones asociadas a \nla bacteriemia por S. aureusTabla 3   Fuente de bacteriemia por S. aureus\nNo COVID-19 \nn=69 \n(72,6%)COVID-19 \nn=26 \n(27,3%)p\nFuente desconocida 45 (65,2%) 12 (46,2%) 0,145\nFoco cat\u00e9ter venoso central 6 (8,7%) 1 (3,8%) 0,669\nFoco urol\u00f3gico 7 (10,1%) 2 (7,6%) 1\nFoco respiratorio 0 (0%) 7 (26,9%) < 0,001\nFoco piel y partes blandas 11 (15,9%) 4 (15,4%) 1Impacto de la bacteriemia por Staphylococcus aureus en pacientes con COVID-19 M. Espinosa P\u00e9rez, et al.\nRev Esp Quimioter 2022;35(5): 468-474472nuestra muestra difieren de las caracter\u00edsticas cl\u00ednicas de los \npacientes con COVID-19 que ingresaron en nuestro pa\u00eds, don -\nde la dislipemia y la diabetes mellitus fueron menores, 39,7% y 19,4% respectivamente [13], lo que sugerir\u00eda que estas comor -\nbilidades pudieran predisponer a la BSA [3,9]. \nEl hecho de que transcurriera un periodo de tiempo su -\nperior en los pacientes con COVID-19 desde el ingreso hasta \nque el hemocultivo fuese positivo estar\u00eda relacionado con un \norigen nosocomial de la bacteriemia (88,5%), como ya ha sido observado por otros autores [3,11], y que podr\u00eda deberse al tipo \nde manejo de estos pacientes, con una mayor utilizaci\u00f3n de \ncat\u00e9teres venosos perif\u00e9ricos o maniobras invasivas. En los pa -\ncientes con BSA sin co-infecci\u00f3n por coronavirus, sin embargo, \nel origen es con m\u00e1s frecuencia comunitario y relacionado con \notros focos.\nEl foco de la infecci\u00f3n fue en la mayor\u00eda de los casos des -\nconocido en ambos grupos de pacientes, siendo la infecci\u00f3n de piel y partes blandas la principal fuente conocida. A diferencia \nde lo que ocurri\u00f3 en los pacientes con COVID-19, en los que el \nfoco respiratorio tuvo un papel importante, en los pacientes sin COVID-19 el foco respiratorio no fue el causante de ningu -\nna bacteriemia (p<0.001). Esto podr\u00eda explicarse debido a que un gran n\u00famero de pacientes con COVID-19 precisaron VMI, a diferencia de los pacientes no- COVID-19. Sin embargo, se \nsabe que S. aureus act\u00faa sin\u00e9rgicamente en todas las tempo -\nradas de influenza, aumentando la mortalidad y la gravedad de \nla enfermedad, pudiendo ocurrir lo mismo con esta infecci\u00f3n \nviral [18]. de los pacientes con BSA estaban co-infectados por COVID-19, \nlo que corresponde al 0,9% de los ingresados por COVID-19, \nsiendo un porcentaje muy similar al obtenido por Cusumano \nJA et al (1,6%) [3].  Estos datos sugieren que esta infecci\u00f3n \npodr\u00eda ser en estos pacientes ligeramente m\u00e1s prevalente, un \n2,8% m\u00e1s que en los pacientes no infectados (11,4% vs 8,8%) [11], ya sea por una predisposici\u00f3n relacionada con el propio virus a este tipo de infecci\u00f3n o con el tipo especial de manejo que estos pacientes requieren. \nS. aureus fue el segundo agente etiol\u00f3gico m\u00e1s frecuente \nde bacteriemia en nuestro estudio, s\u00f3lo por detr\u00e1s de E. co-\nli. A diferencia de otros estudios que muestran un aumento de las bacteriemias por Gram negativos y disminuci\u00f3n de las bacteriemias por grampositivos, especialmente S. aureus y Sta-\nphylococcus coagulasa negativos [12,13].\nLa tasa de contaminaci\u00f3n de los hemocultivos se conside -\nra un indicador de la calidad asistencial y no deber\u00eda sobrepa-sar el 3% de los hemocultivos totales recibidos [14]. En nuestro estudio se super\u00f3 esta cifra, este hecho podr\u00eda explicarse por la no familiaridad del personal sanitario con los equipos de protecci\u00f3n individual (EPIs) as\u00ed como por la alta rotaci\u00f3n del \npersonal que se produjo durante la pandemia. \nLa BSA en los pacientes con COVID-19 se produjo prin -\ncipalmente en mayores de 65 a\u00f1os y mayoritariamente en \nvarones, hechos que se corresponden con el global de casos COVID-19 que ingresan en nuestro pa\u00eds, sin que esto marque alguna diferencia con el resto de BSA [11,15,16].\nLas comorbilidades de los pacientes con COVID-19 de \nFigura 1  Supervivencia en paciente con bacteriemia por S. aureus  por grupos.Probabilidad de supervivencia\nTiempo (semanas)\nTiempo (semanas)Aumento de riesgoImpacto de la bacteriemia por Staphylococcus aureus en pacientes con COVID-19 M. Espinosa P\u00e9rez, et al.\nRev Esp Quimioter 2022;35(5): 468-474473de las bacteriemias en pacientes con COVID-19. La bacteriemia \nnosocomial fue m\u00e1s frecuente en los pacientes co-infectados \npor coronavirus del mismo modo que el foco respiratorio. El \ndesarrollo de sepsis fue mayor en el grupo de pacientes con \nCOVID-19, especialmente en aquellos que se utiliz\u00f3 una pauta \ncon dosis altas de corticoides. En este estudio no se han en -\ncontrado diferencias estad\u00edsticamente significativas en cuanto a la mortalidad, sin embargo, se observa una tendencia hacia la mayor supervivencia de los pacientes no- COVID-19. \nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n \npara la realizaci\u00f3n de este estudio. \nCONFLICTOS DE INTER\u00c9S\nLos autores declaran los siguientes intereses financieros/\nrelaciones personales que pueden considerarse como posibles \nintereses en competencia: Espinosa P\u00e9rez, Mar\u00eda informa que \nla Fundaci\u00f3n Biom\u00e9dica Miguel Servet brind\u00f3 asistencia para el an\u00e1lisis estad\u00edstico.\nBIBLIOGRAF\u00cdA\n1. Fattorini L, Creti R, Palma C, Pantosti A; Unit of Antibiotic Resis -\ntance and Special Pathogens; Unit of Antibiotic Resistance and \nSpecial Pathogens of the Department of Infectious Diseases, Isti -\ntuto Superiore di Sanit\u00e0, Rome. Bacterial coinfections in COVID-19: \nan underestimated adversary. Ann Ist Super Sanita. 2020 Jul-\nSep;56(3):359-364. doi: 10.4415/ANN_20_03_14.\n2. Garcia-Vidal C, Sanjuan G, Moreno-Garc\u00eda E, Puerta-Alcalde P, et al; COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retros -\npective cohort study. Clin Microbiol Infect. 2021 Jan;27(1):83-88. doi: 10.1016/j.cmi.2020.07.041. 2020 Jul 31. \n3. Cusumano JA, Dupper AC, Malik Y, Gavioli EM, et al.  Staphylococ-\ncus aureus  Bacteremia in Patients Infected With COVID-19: A Case \nSeries. Open Forum Infect Dis. 2020 Nov 12;7(11):ofaa518. doi: 10.1093/ofid/ofaa518. \n4. Mirzaei R, Goodarzi P, Asadi M, Soltani A, et al. Bacterial co-infec -\ntions with SARS-CoV-2. IUBMB Life. 2020 Oct;72(10):2097-2111. doi: 10.1002/iub.2356. \n5. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals \nWith Coronavirus: A Rapid Review To Support COVID-19 Antimi-\ncrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. \ndoi: 10.1093/cid/ciaa530. \n6. Segala FV, Bavaro DF, Di Gennaro F, Salvati F, Marotta C, et al. Im -\npact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Li -\nterature Review. Viruses. 2021 Oct 20;13(11):2110. doi: 10.3390/v13112110.\n7. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christen -\nsen L, Safdar N. Prevalence and outcomes of co-infection and su -El 15,4% de las BSA en COVID-19 eran debidas a SARM, de \nforma similar a lo ocurrido en los pacientes no co-infectados, \nhasta un 20,1% seg\u00fan las series [9], pero que implica un cier -\nto riesgo de fracaso en el tratamiento inicial si no se tiene en cuenta esta contingencia. As\u00ed, el tratamiento antibi\u00f3tico emp\u00ed -\nrico fue inadecuado en un elevado n\u00famero de casos y los m\u00e1s utilizados como dirigidos, una vez conocido el antibiograma, \nfueron daptomicina y cefazolina, utilizando biterapia en un n\u00famero elevado de casos, sin que esta estrategia haya demos -\ntrado un mejor pron\u00f3stico y sin que se realizara de forma pre -\nferente en uno u otro grupo. Sin embargo, la duraci\u00f3n del tra -\ntamiento en no-COVID-19 fue 5 d\u00edas superior, quiz\u00e1s explicado porque el tipo de foco de origen en los COVID-19 se control\u00f3 \ncon terapias m\u00e1s cortas (bacteriemia asociada a cat\u00e9ter en la \nmayor\u00eda de las ocasiones). \nEl 26,9% y 46,1% de los COVID-19 recibieron tratamien-\nto con dexametasona con pauta d1 y d2 respectivamente, y el \n23% con tocilizumab, lo que implica un n\u00famero importante de casos sometidos a inmunosupresi\u00f3n durante el ingreso y lo que explicar\u00eda que estos pacientes tuvieran con m\u00e1s frecuencia \nun cuadro de sepsis, sobre todo aquellos en los que utiliz\u00f3 una \npauta d2 (62,5% vs 37,5%) [19,20]. \nEn cuanto a la evoluci\u00f3n, el 34,6% de los pacientes con \nCOVID-19 requirieron ingreso en UCI y VMI, datos muy simila -\nres a los registrados a nivel nacional (33,1% desarroll\u00f3 distr\u00e9s \nrespiratorio) [15]. \nLa mortalidad global (46%) y la mortalidad antes de los \n14 d\u00edas (30%) result\u00f3 mayor en los pacientes con COVID-19, sin ser estad\u00edsticamente significativo, siendo superior tambi\u00e9n \na los registros globalmente de estos pacientes a nivel nacional (21%), por lo que parece claro que la contingencia de una BSA \npodr\u00eda empeorar el pron\u00f3stico de estos pacientes. Parece que \nla mortalidad es superior en los que presentan un cuadro de \nsepsis (91,6% vs 8,3%), y va aumentando con la edad, como \nocurre en los casos COVID-19 en nuestro medio (50-59 a\u00f1os: \n4,7%; 60-69 a\u00f1os: 10,5%; 70-79 a\u00f1os: 26,9%; \u2265 80 a\u00f1os: \n46%) [15], por lo que estos factores quiz\u00e1s puedan ayudar a seleccionar aquellos que pudieran tener una peor evoluci\u00f3n. \nLa principal limitaci\u00f3n que se aprecia en este estudio es la \nfalta del c\u00e1lculo del tama\u00f1o muestral para poder detectar dife -\nrencias entre los grupos. Esto se refleja en los resultados, don-\nde en varias variables, existen diferencias entre grupos, pero \nsin alcanzarse la significaci\u00f3n estad\u00edstica, no pudiendo obtener \nconclusiones firmes. Otra de las limitaciones de este estudio es \nel elevado n\u00famero de episodios de BSA de origen desconocido. \nLa mayor\u00eda de estos episodios probablemente se tratasen de \nbacteriemias asociadas al cat\u00e9ter perif\u00e9rico (donde S. aureus \nes el agente causal m\u00e1s frecuente) sin poder documentarlo por no enviarse al laboratorio de microbiolog\u00eda cuando se extraen \nlos cat\u00e9teres perif\u00e9ricos, infradiagnosticando los casos de BRC. \nEste dato pone en alerta la necesidad de vigilancia m\u00e1s estre -\nchad el manejo de estos accesos venosos en los pacientes con COVID-19.\nHasta un 0,9% de los ingresados por COVID-19 presenta -\nron BSA. S. aureus fue el segundo agente causal en frecuencia Impacto de la bacteriemia por Staphylococcus aureus en pacientes con COVID-19 M. Espinosa P\u00e9rez, et al.\nRev Esp Quimioter 2022;35(5): 468-474474perinfection with SARS-CoV-2 and other pathogens: A systematic \nreview and meta-analysis. PLoS One. 2021 May 6;16(5):e0251170. \ndoi: 10.1371/journal.pone.0251170. \n8. Laupland KB, Lyytik\u00e4inen O, S\u00f8gaard M, Kennedy KJ, Knudsen JD, \nOstergaard C, et al; International Bacteremia Surveillance Colla -\nborative. The changing epidemiology of Staphylococcus aureus \nbloodstream infection: a multinational population-based survei -\nllance study. Clin Microbiol Infect. 2013 May;19(5):465-71. doi: \n10.1111/j.1469-0691.2012.03903.x. \n9. L\u00f3pez-Cort\u00e9s LE, G\u00e1lvez-Acebal J, Rodr\u00edguez-Ba\u00f1o J. Therapy of Staphylococcus aureus bacteremia: Evidences and challenges. En -\nferm Infecc Microbiol Clin (Engl Ed). 2020 Dec;38(10):489-497. doi: 10.1016/j.eimc.2020.01.018. \n10. Aldea Mansilla C, Mart\u00ednez-Alarc\u00f3n J, Gracia Ahufinger I, Guem -\nbe Ram\u00edrez M. Diagn\u00f3stico microbiol\u00f3gico de las infecciones aso -\nciadas a cat\u00e9teres intravasculares. 2018. 15a. Guembe Ram\u00edrez M (coordinador). Procedimientos en Microbiolog\u00eda Cl\u00ednica. Cercenado Mansilla E, Cant\u00f3n Moreno R (editores). Sociedad Espa\u00f1ola de En-\nfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC). 2018.\n11. Mormeneo Bayo S, Palaci\u00e1n Ru\u00edz MP, Moreno Hijazo M, Villuen-das Us\u00f3n MC. Bacteremia during COVID-19 pandemic in a tertiary hospital in Spain. Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb \n11:S0213-005X(21)00037-9. doi: 10.1016/j.eimc.2021.01.015\n12. Mart\u00ednez P\u00e9rez-Crespo PM, L\u00f3pez-Cort\u00e9s LE, Retamar-Gentil P, Garc\u00eda JFL, Vinuesa Garc\u00eda D, Le\u00f3n E, et al. Epidemiologic changes in bloodstream infections in Andaluc\u00eda (Spain) during the last decade. \nClin Microbiol Infect. 2021;27(2):283.e9-283.e16. doi:10.1016/j.cmi.2020.05.015\n13. Nielsen SL, Pedersen C, Jensen TG, Gradel KO, Kolmos HJ, Lassen AT. Decreasing incidence rates of bacteremia: a 9-year popula -\ntion-based study. J Infect. 2014 Jul;69(1):51-9. doi: 10.1016/j.\njinf.2014.01.014. \n14. Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan \nPH, et al..  A Guide to Utilization of the Microbiology Laboratory for \nDiagnosis of Infectious Diseases: 2018 Update by the Infectious Di -\nseases Society of America and the American Society for Micro-bio-\nlogy. Clin Infect Dis. 2018:31;67(6):e1-e94. doi: 10.1093/cid/ciy381\n15. Casas-Rojo JM, Ant\u00f3n-Santos JM, Mill\u00e1n-N\u00fa\u00f1ez-Cort\u00e9s J, et al , \nen nombre del Grupo SEMI-COVID-19 Network. Caracter\u00edsticas cl\u00ednicas de los pacientes hospitalizados con COVID-19 en Espa\u00f1a: \nresultados del Registro SEMI-COVID-19. Rev Clin Esp (Barc). 2020 Nov;220(8):480-494. doi: 10.1016/j.rce.2020.07.003\n16. Thorlacius-Ussing L, Sandholdt H, Larsen A, Petersen A, Ben -\nfield T. Age-Dependent Increase in Incidence of Staphylococ-cus aureus Bacteremia, Denmark, 2008\u20132015. Emerg Infect Dis. \n2019;25(5):875-882. doi: 10.3201/eid2505.181733\n17. L\u00f3pez-Cort\u00e9s LE, Del Toro MD, G\u00e1lvez-Acebal J, Bereciartua-Basta -\nrrica E, Fari\u00f1as MC, et al; REIPI/SAB group. Impact of an evidence-\nbased bundle intervention in the quality-of-care management and \noutcome of Staphylococcus aureus bacteremia. Clin Infect Dis. 2013 Nov;57(9):1225-33. doi: 10.1093/cid/cit499\n18. Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. Front Microbiol. 2017 Jun 23;8:1041. doi: 10.3389/fmicb.2017.01041. \n19. Estella \u00c1, Vidal-Cort\u00e9s P, Rodr\u00edguez A, Andaluz Ojeda D, Mart\u00edn-\nLoeches I, D\u00edaz E, et al. Management of infectious complications as -\nsociated with coronavirus infection in severe patients admitted to ICU. Med Intensiva (Engl Ed). 2021 Apr 30:S0210-5691(21)00081-4. English, Spanish. doi: 10.1016/j.medin.2021.04.007. \n20. Hoertel N, S\u00e1nchez-Rico M, Vernet R, Beeker N, Neuraz A, et al. Paris N, Et al.; AP-HP/Universit\u00e9 de Paris/INSERM Covid-19 re -\nsearch collaboration and AP-HP Covid CDR Initiative. Dexametha-sone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study. Br J Clin Pharmacol. 2021 Feb 19:10.1111/bcp.14784. doi: 10.1111/bcp.14784. ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/030.2022\nRev Esp Quimioter 2022;35(5): 475-481475Conclusion. In this cohort of critically ill patients the use \nof intravenous immunoglobulin was not identified as a protec -\ntive factor for ICU or hospital mortality treatment with clin -\ndamycin significantly reduced mortality after controlling for \nconfounders.\nKeywords: Clindamycin; Intravenous Immunoglobulins; Bacteriemia; \nCritically ill patients; Group A Streptococcal infections.\nTratamiento con clindamicina, y no con \ninmunoglobulinas intravenosas, disminuye la mortalidad en una cohorte retrospectiva de pacientes cr\u00edticos con bacteriemia por \nStreptococcus  del Grupo A\nRESUMEN\nObjetivo. La mortalidad de los pacientes que requieren \ningreso en la Unidad de Cuidados Intensivos (UCI) por una in -\nfecci\u00f3n invasiva por estreptococos del grupo A (GAS) contin\u00faa \nsiendo inaceptablemente alta. El objetivo del estudio fue deter -\nminar los factores de riesgo de mortalidad en pacientes cr\u00edticos \ncon infecci\u00f3n estreptoc\u00f3cica bacter\u00e9mica del grupo A.\nPacientes y m\u00e9todos. Estudio retrospectivo multic\u00e9ntrico \nrealizado en nueve UCI del sur de Espa\u00f1a. Se incluyeron pa -\ncientes consecutivos ingresados en las UCI participantes desde \nenero de 2014 hasta junio de 2019 con un hemocultivo positi -\nvo para S. pyogenes. Se registraron las caracter\u00edsticas de los pa -\ncientes, las variables relacionadas con la infecci\u00f3n, las interven -\nciones terap\u00e9uticas, el fracaso de los \u00f3rganos y el pron\u00f3stico. \nSe determinaron mediante an\u00e1lisis de regresi\u00f3n multivariante \nlos factores de riesgo asociados de forma independiente con la \nmortalidad en UCI y hospitalaria.Clindamycin but not Intravenous \nImmunoglobulins reduces mortality in a \nretrospective cohort of critically ill patients with bacteremic Group A Streptococcal infections\n1Hospital Universitario Virgen Macarena. Sevilla, Spain\n2Hospital Universitario de Jerez. Departamento de Medicina Universidad de C\u00e1diz, INiBICA, Jerez de la Frontera \n(C\u00e1diz), Spain\n3Hospital San Juan de Dios del Aljarafe, Sevilla, Spain\n4Hospital Universitario Virgen de Valme. Sevilla, Spain\n5Hospital Universitario Virgen del Roc\u00edo. Sevilla, Spain\n6Hospital Universitario Puerta del Mar, C\u00e1diz, Spain\n7Hospital Universitario Regional de M\u00e1laga. M\u00e1laga, Spain\n8Hospital Universitario Reina Sof\u00eda; C\u00f3rdoba, Spain\n9Hospital Universitario Torrec\u00e1rdenas. Almer\u00eda, SpainAdela Fern\u00e1ndez-Galilea1\n\u00c1ngel Estella2 \nJos\u00e9 Luis Garc\u00eda-Garmendia3\nAna Loza4 \nInmaculada Palacios-Garc\u00eda5\nRafael Sierra-Camerino6\nGemma Seller7\nMarina Rodr\u00edguez-Delgado8\nIsabel Rodriguez-Higueras9\nJos\u00e9 Garnacho-Montero1Original\nArticle history\nReceived: 20 March 2022; Revision Requested: 18 May 2022; Revision Received: 25 May 2022; Accepted:  31 May 2022; \nPublished: 7 July 2022\nABSTRACT\nObjectives. Mortality of patients requiring Intensive Care \nUnit (ICU) admission for an invasive group A streptococcal \n(GAS) infection continues being high. In critically ill patients with bacteremic GAS infection we aimed at determining risk \nfactors for mortality. \nPatients and methods. Retrospective multicentre study \ncarried out in nine ICU in Southern Spain. All adult patients ad -\nmitted to the participant ICUs from January 2014 to June 2019 \nwith one positive blood culture for S. pyogenes were included \nin this study. Patient characteristics, infection-related varia -\nbles, therapeutic interventions, failure of organs, and outcomes were registered. Risk factors independently associated with ICU \nand in-hospital mortalities were determined by multivariate re -\ngression analyses.\nResults. Fifty-seven patients were included: median age \nwas 63 (45-73) years, median SOFA score at admission was 11 (7-13). The most frequent source was skin and soft tissue \ninfection (n=32) followed by unknown origin of bacteremia (n=12). In the multivariate analysis, age (OR 1.079; 95% CI 1.016-1.145), SOFA score (OR 2.129; 95% CI 1.339-3.383) were \nthe risk factors for ICU mortality and the use of clindamycin \nwas identified as a protective factor (OR 0.049; 95% CI 0.003-\n0.737). Age and SOFA were the independent factors associated \nwith hospital mortality however the use of clindamycin showed \na strong trend but without reaching statistical significance (OR 0.085; 95% CI 0.007-1.095).\nCorrespondence:\n\u00c1ngel Estella\nHospital Universitario de Jerez.  Departamento de Medicina Universidad de C\u00e1diz, INiBICA,  \nCarretera Nacional IV s/n. Jerez de la Frontera. 11407, Jerez de la Frontera  (C\u00e1diz)\nE-mail: litoestella@hotmail.comClindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically \nill patients with bacteremic Group A Streptococcal infectionsA. Fern\u00e1ndez-Galilea, et al.\nRev Esp Quimioter 2022;35(5): 475-481476patient consent was not required because of the retrospective \nnature of this study.\nAll adult patients (\u226518 years) admitted to the participant \nICUs from January 2014 to June 2019 with one positive blood culture for S. pyogenes were included in this study. Patient \nbaseline characteristics, infection-related variables and subse -\nquent evolution were obtained from the automated hospital \nmedical record and microbiology database of the participating \ncenters. All patients were followed up for 90 days after the \nadmission to the ICU for invasive GAS.\nThe following data were collected: age, gender, source of \ninfection (skin and soft tissue, lung, unknow origin, and oth -\ners) and underlying diseases: diabetes mellitus, liver cirrhosis, chronic renal disease, chronic heart failure, chronic obstructive \npulmonary disease, and cancer. Severity of illness at ICU ad -\nmission was evaluated by the Acute Physiology and Chronic \nHealth Evaluation (APACHE) II score and by the Sequential Or-\ngan Failure Assessment (SOFA) scale considering the worst data point of the first 24 h in the ICU [7,8]. Clinical presentation was \nclassified as sepsis or septic shock following Sepsis-3 defini-\ntions. The presence of a SOFA score of each organ >3 points at admission or during the ICU stay was considered as failure of \nthis organ [9].\nData regarding management of these patients were also \ngathered: empirical antimicrobial regimen, use of clindamycin \nor linezolid, use of penicillin G as the \u03b2-lactam in directed ther-\napy, administration of intravenous immunoglobulins (IVIG), \nmechanical ventilation and need of renal replacement therapy. \nIn patients with skin and soft tissue infection (SSTI), date of \nthe first surgical debridement and the total number of surgical \ninterventions were also noted.\nStandard microbiological methods were used by all the \nparticipating centers. This included the use of an automated continuous monitoring blood culture system, the performance \nof standard identification biochemical test, Lancenfield anti-gen immunoassay detection or, automated rapid test such as \nmatrix-assisted laser desorption ionization-time of flight mass \nspectrometry (Maldi-tof). Susceptibility testing was performed using accepted methods at each hospital and results were in -\nterpreted according to the Clinical Laboratory Standard Insti -\ntute (CLSI) or the European Committee on Antimicrobial Sus -\nceptibility Testing (EUCAST) recommendations.\nStatistical analysis. Qualitative variables are presented as \nthe absolute numbers and frequency, quantitative variables as mean (\u00b1 SD) if their distribution was normally distributed or as median (percentile 25 \u2013 percentile 75) if the distributions \nwere skewed. Student\u2019s t test was used to compare continu -\nous variables with normal distribution, U Mann-Whitney tests \nfor skewed distributed variables. Chi-2 and Fisher\u2019s exact tests \nwere used for comparisons of categorical variables. Logistic regression models using variables with a p value <0.2 in the \nunivariate analysis and those considered potentially relevant were used to determine the factors independently associated with ICU and in-hospital mortalities. All comparisons were \ntwo-tailed and signification was set at p<0.05.Resultados. Se incluyeron cincuenta y siete pacientes: la \nmediana de edad fue de 63 (45-73) a\u00f1os, la mediana de la pun -\ntuaci\u00f3n SOFA al ingreso fue de 11 (7-13). El foco m\u00e1s frecuente \nfue la infecci\u00f3n de la piel y los tejidos blandos (n=32) seguida \nde la bacteriemia de origen desconocido (n=12). En el an\u00e1lisis \nmultivariante, la edad (OR 1,079; IC del 95%: 1,016-1,145), y la \npuntuaci\u00f3n SOFA (OR 2,129; IC del 95%: 1,339-3,383) se iden -\ntificaron como factores de riesgo para la mortalidad en UCI. El \nuso de clindamicina se identific\u00f3 como un factor protector (OR \n0,049; IC del 95%: 0,003-0,737). La edad y la SOFA se asociaron \nde forma independiente con la mortalidad hospitalaria, mien -\ntras que el tratamiento con clindamicina mostr\u00f3 una tendencia \nfuerte pero sin alcanzar significaci\u00f3n estad\u00edstica (OR 0,085; IC del 95%: 0,007-1,095).\nConclusi\u00f3n. En esta cohorte de pacientes cr\u00edticos, el uso \nde inmunoglobulina intravenosa no se identific\u00f3 como un fac -\ntor protector para la mortalidad en UCI u hospitalaria, el trata -\nmiento con clindamicina redujo significativamente la mortali -\ndad despu\u00e9s de controlar los factores de confusi\u00f3n\nPalabras clave: Clindamicina; inmunoglobulinas intravenosas; Bacteriemia; \npacientes cr\u00edticos; infecciones estreptococos grupo A\nINTRODUCTION\nIn spite of the advances in modern medicine, invasive \ngroup A streptococcal (GAS) infections cause a significant \nmorbidity and mortality. Even though the resistance rates of \nGAS (Streptococcus pyogenes) to several antibiotics vary con-\nsiderably worldwide, GAS remains universally susceptible to \n\u03b2-lactams antibiotics including penicillin [1], the lethality of severe invasive GAS infections requiring ICU admission remains \nhigh, about 50% in different series [2]. In these severe forms, S. \npyogenes exotoxins act as superantigens to trigger polyclonal T-cell activation, cytokine cascade, shock, and death [3].\nThe low incidence of the invasive GAS disease explains the \ndifficulties of randomized controlled trials evaluating manage -\nment strategies. Likewise, observational cohort studies have been \ncarried out using the majority of them administrative databases [4-6]. Moreover, conflicting results have been reported about the \nimpact on mortality of different therapeutical strategies, specifi-cally with the use of clindamycin or immunoglobulins [5,6].\nIn order to contribute to our knowledge about risk factors \nassociated with mortality of severe invasive GAS infections, we \nperformed this multicenter study including only patients ad\n-\nmitted to the ICU. Our purposes were to stablish predictors of \ndeath carefully examining the clinical impact of antimicrobial strategies and the use of immunoglobulins on mortality after controlling for confounding variables.\nMETHODS\nThis is a retrospective multicenter study carried out in nine \nSpanish Intensive Care Units in Andalusia. The study was ap-proved by the Spanish Agency of Medicinal Products and Medi -\ncal Devices and by the local institutional review boards; written Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically \nill patients with bacteremic Group A Streptococcal infectionsA. Fern\u00e1ndez-Galilea, et al.\nRev Esp Quimioter 2022;35(5): 475-481477demonstrate a beneficial effect of IVIG and survival was similar \nin patients who did or did not receive IVIG.\nTo the best of our knowledge, there is a paucity of studies \ncarried out in patients with GAS requiring ICU admission. In \nour series, mortality rate is very high dying in the hospital 50% of the patients admitted to the ICU with this infection. These \nhigh figures have been reported previously by other authors. As \nan exception, an observational study reported an ICU mortality \nrate as low as 5.7% and even lower than the mortality of a \nheterogeneous group of septic patients. Importantly, only 60% \nof these 53 patients with invasive GAS presented septic shock \nand the rate of bloodstream infection is not reported by the \nauthors [11].\nBecause the mortality rate with invasive GAS remains \nhigh, the therapeutical approach must be prompt and aggres-\nsive. In the present study, clinical and demographic character -\nistics were similar between patients treated and not treated with clindamycin, with the exception that severity of illness \nassessed by APACHE II score was significantly higher in the \nnon-clindamycin group. Nevertheless, although severity of \nillness at admission to the ICU is a strong predictor of death \nin critically ill septic patients [12], treatment with clindamy-\ncin was a protective factor after controlling for confounding \nvariables. Two observational studies have concluded that clin-\ndamycin improves survival in patients with invasive GAS [5,6]. \nA large observational study of patients with GAS infection has \nrecently confirmed the reduction of mortality with the admin -\nistration of clindamycin and this beneficial effect was present also present if the patient was not in septic shock or in another \nsource of infection different to SSTI [13]. Conversely, a retro -\nspective study evaluating patients with invasive GAS admitted \nto the ICU, the use of clindamycin was not associated with a \nbetter survival [14]. Linezolid is another theoretical alternative \nwith a mechanism of action similar to that of clindamycin [15]. \nThe experience with this oxazolidinone in invasive GAS is scarce \nbut our findings do not support its use in invasive GAS for toxin \nsynthesis inhibition. \nThe current surviving sepsis guidelines for adults recom -\nmends against the use of IVIg in patients with sepsis and septic \nshock [16]. However, the role of IVIG in patients with strepto -\ncoccal septic shock has been a moot point during the last years. \nThe largest observational study using propensity score match -\ning and involving 4,127 patients with necrotizing fasciitis and \nstreptococcal toxic shock concluded that IVIG had no effect on \nmortality or length of hospital stay [17]. The aforementioned studies about the beneficial effect of clindamycin also con -\ncluded that the use of IVIG was associated with higher survival [5,6]. A multicenter, randomized, double-blinded, placebo-con-trolled trial of IVIG in SSTI was prematurely stopped due to the \nlack of recruitment after enrolling only 21 patients [18].\nSSTI and pneumonia were the most common sites of in-\nfection at presentation. In our series, source of infection does \nnot have a prognostic value. Nevertheless, bacteremia with -\nout an identified focus was independently associated with an \nincreased risk of a fatal outcome in a heterogenous group of SPSS 15.0 software (IBM SPSS, Chicago, IL, USA) was used \nfor statistical analysis.\nThis analysis is reported following the STROBE recommen -\ndations [10].\nRESULTS\nDuring the study period, 57 patients were diagnosed of \ninvasive GAS in the participant ICUs. The median age was 63 \n(45-73) years and 70.2 % were male. Median SOFA score at \nadmission was 11 (7-13). The median time from hospital ad-\nmission to positive blood culture was 0 (0, 1) days and the time elapsed from positive blood culture to ICU admission was 0 days (-1, 0). Twenty-eight patients (49.1%) died in the ICU, 30 patients (52.6%) during hospitalization, and mortality rate at 90 days was 64.9% (37 patients).\nAll patients had received empirical antibiotic treatment \nwith a \u03b2-lactam antibiotic active against S. pyogenes . Bivariate \nanalyses for ICU and hospital mortality are shown in Table 1. At baseline, there were no significant differences in sex, comor -\nbid illnesses (except liver cirrhosis), or site of infection between \nsurvivors and non-survivors. All isolates were susceptible to \npenicillin although only 23 patients received penicillin G in the directed therapy. Eleven patients received IVIG and all of them were treated with clindamycin as well. All patients treated with \nclindamycin received this antibiotic during the first 48 hours \nafter blood culture collection. In the multivariate analysis, two \nvariables were identified as risk factors for ICU death mean -\nwhile treatment of clindamycin was a protective factor (Table \n2). Results of the multivariate analysis for hospital mortality \nis also depicted in the Table 2. Notably, use of IVIG was not identified as a protective factor for ICU or hospital mortality.\nThe comparison of clindamycin-treated patients and those \nwho did not receive clindamycin is shown in table 3. Medi -\nan duration of therapy with clindamycin was 7 days. Of note, clindamycin was more frequently used in patients with SSTI as source of bacteremia.\nIn the present study, the most frequent organ failure was \ncardiovascular, followed by respiratory (n=29) and renal failure (n=29). The incidence of other failure of organs was lower: co-\nagulation (23.2%), central nervous system (22.8%), and hepatic \nfailure (12.3%). The median number of organs failing in a pa -\ntient was 2 (1-4). In our series, 41/57 (71.9%) required invasive \nmechanical ventilation and 28/57 (49.1%) needed continous \nrenal replacement therapy (CRRT). Table 4 depicts the associa -\ntion between failure of the different organs and mortality.\nDISCUSSION\nOur multicenter study including severely ill patients with \nhigh-grade of organ dysfunction secondary to bacteremic in -\nvasive GAS confirms that this infection has a significant mor -\nbidity and a high mortality rate. Importantly, clindamycin as part of the antimicrobial therapy significantly reduced mor -\ntality after controlling for confounders while we could not Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically \nill patients with bacteremic Group A Streptococcal infectionsA. Fern\u00e1ndez-Galilea, et al.\nRev Esp Quimioter 2022;35(5): 475-481478ICU mortality In-hospital mortality\nVariables Non-survivors (n=28) Survivors (n=29) p value Non-survivors (n=30) Survivors (n=27) p value\nAge (years) 68 (61-75) 52 (44-70) 0.006 69 (61-75) 52 (43-67) 0.002\nSex (man) 16 (57.1%) 24 (82.8%) 0.035 18 (60%) 22 (81.5%) 0.077\nUnderlying diseases\n    Diabetes    Cirrhosis    Immunosuppression\n    Chronic Heart Failure    Chronic Kidney Disease\n    Cancer\n    COPD10 (35.7%)\n4 (14.3%)\n4 (14.3)\n3 (10.7%)\n5 (17.9%)\n7 (25%)\n6 (21.4%)9 (31%)\n0 (0%)\n5 (17.2%)6 (20.7%)\n3 (10.3%)\n5 (17.2%)4 (13.8%)0.708\n0.035\n0.760\n0.302\n0.414\n0.473\n0.44911 (36.7%)\n4 (13.3%)\n5 (16.7%)\n4 (13.3%)5 (16.7%)\n8 (26.7)\n5 (16.7%)8 (29,6%)\n0 (0%)\n4 (14,8%)5 (18,5%)\n3 (11,1%)\n4 (14,8%)5 (18,5%)0.574\n0.0490.484\n0.5920.547\n0.273\n0.854\nSource of iGAS\n    Skin and soft tissue\n    Unknown\n    Lung\n    Other14 (50.0%)\n8 (28.6%)\n4 (14.3%)\n2 (7.2%)18 (62.1%)\n4 (13.8%)5 (17.2%)\n0 (0%)0.515 16 (53.3%)\n8 (26.7%)4 (13.3%)\n4 (13.3%)16 (59.3%)\n4 (14.8%)\n5 (18.5%)\n2 (7.4%)0.622\nAPACHE II score at ICU admission 29 (22-32) 21 (16-25) 0.000 29 (22-32) 21 (16-25) 0.001\nSOFA score at ICU admission\n     Respiratory     Cardiovascular\n     Renal\n     Coagulation\n     Liver     Central Nervous System13 (11-15)\n3 (2-3)\n4 (3-4)\n3 (2-4)\n1 (0-2)\n1 (0-2)1 (1-3)8 (6-10)\n1 (1-2)\n3 (1-4)\n2 (1-2)\n1 (0-2)\n1 (0-2)0 (0-0)0.000\n0.006\n0.020\n0.0090.565\n0.3280.00013 (11-15)\n3 (2-3)\n4 (3-4)\n2 (2-4)1 (0-2)\n1 (0-2)\n2 (1-2)8 (6-10)\n2 (1-2)\n3 (1-4)2 (1-3)\n1 (0-2)\n1 (0-2)\n0 (0-0)0.0000.094\n0.0390.039\n0.126\n0.151\n0.000\nWorst SOFA score in the ICU\n     Respiratory\n     Cardiovascular     Renal\n     Coagulation\n     Liver\n     Central Nervous System15 (12-17)\n4 (3-4)\n4 (4-4)4 (2-4)\n2 (0-3)\n2 (0-2)\n2 (1-4)10 (6-11)\n2 (1-2)\n4 (3-4)2 (1-4)\n2 (0-2)\n1 (0-2)\n0 (0-1)0.000\n0.000\n0.016\n0.0030.667\n0.362\n0.00015 (12-16)\n3 (2-4)\n4 (4-4)4 (2-4)\n2 (0-3)\n2 (0-2)\n2 (1-4)10 (6-12)\n2 (1-3)\n4 (3-4)2 (1-4)\n2 (0-2)\n1 (0-2)\n0 (0-1)0.000\n0.053\n0.0580.039\n0.346\n0.224\n0.000\nTherapeutic approach\n    Clindamycin\n    Linezolid    Penicillin G in directed therapy    Immunoglobulin14 (50%)\n7 (25%)\n9 (32.1%)\n6 (21.4%)25 (86.2%)\n8 (27.6%)\n14 (48.3%)\n5 (17.2%)0.003\n1\n0.215\n0.68916 (53.3%)\n8 (26.7%)\n10 (33.3%)\n6 (20%)23 (85.2%)\n7 (25.9%)\n13 (48.1%)\n5 (18.5%)0.010\n1\n0.2550.887\nMechanical ventilation 28 (100%) 13 (44.8%) 0.000 28 (93.3%) 13 (48.1%) 0.000\nRenal Replacement Therapy 18 (64.3%) 10 (34.5%) 0.024 17 (56.7%) 11 (40.7%) 0.230Table 1   Bivariate Analysis for ICU Mortality and Hospital Mortality.\nCOPD: Chronic obstructive pulmonary disease; ICU: Intensive care unit; iGAS: invasive group A Streptococcus .Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically \nill patients with bacteremic Group A Streptococcal infectionsA. Fern\u00e1ndez-Galilea, et al.\nRev Esp Quimioter 2022;35(5): 475-481479non-critically ill patients with a mortality rate much lower than \nours (14%) [19].\nOur data also highlight that the high incidence and the se-\nverity of organ failures in patients with invasive GAS requiring \nICU admission explaining the high mortality and the burden of care associated with this disease. In our series, degree of \norgan disfunction assessed by SOFA score is an independent predictor of ICU and hospital mortality. Similarly, the number of dysfunctional organs correlated with mortality being co -\nagulopathy and liver failure factors independently associated with mortality [14]. Invasive mechanical ventilation was used \nin two-thirds of our patients and 50% of them fulfilled criteria \nof severe respiratory failure. Likewise, half of the patients de -\nveloped acute renal failure requiring CRRT. Information regard -\ning failure of organs is lacking in previous studies that have observed the beneficial effect of clindamycin in invasive GAS \n[5,6,13]. The SOFA score as a mortality estimation tool presents \na high discriminatory capacity to predict ICU mortality [20].\nWe acknowledge several limitations of this study. First, \nthis is a retrospective study and as our sample size was rela -\ntively small for some comparisons, a type II error is possible. \nSecond, the gold standard for demonstrating that a therapeu -\ntic intervention impacts on the outcome is a randomized, con -\ntrolled, blinded trial. Nevertheless, observational studies can \nprovide valuable information about treatment effectiveness \nespecially in infections with low frequency of presentation. \nThird, although we could not demonstrate a beneficial impact of immunoglobulins on survival both the quantity and quality \nof neutralizing antitoxin antibodies vary from batch to batch \nof IVIG what may have influence our negative findings [21]. Fourth, sequencing of the variable M serotype\u2013specific region \nof the emm gene has not been carried out in our study. This is \nimportant since certain GAS emm sequence types have been \nassociated with mortality [22,23].\nTo sum up, our findings are of the utmost importance \nsince, in this cohort of critically ill patients with multiple organ \ndysfunction secondary to bacteremic GAS, we have demon -\nstrated the beneficial effect in terms of mortality of adding \nclindamycin as part of the antimicrobial management. In these ICU MORTALITY OR CI 95% p\nAge 1.079 1.016-1.145 0.013\nUse of clindamycin 0.049 0.003-0.737 0.029\nSOFA 2.129 1.339-3.383 0.001\nHOSPITAL MORTALITY\nAge 1.092 1.026-1.162 0.005\nUse of clindamycin 0. 085 0.007-1.095 0.085\nSOFA 2.089 1.345-3.246 0. 001Table 2   Factor independently associated with \nICU and Hospital Mortality in the \nmultivariate analysis\nVariables Clindamycin \n(n=39)No clindamycin \n(n=18)p value\nAge (years) 61 (44-73) 68 (61-75) 0.091\nSex (man) 28 (71.8%) 12 (66.7%) 0.694\nUnderlying diseases\n    Diabetes\n    Cirrhosis\n    Immunosuppression    Chronic Heart Failure    Chronic Kidney Disease\n    Cancer\n    COPD12 (30.8%)\n0\n6 (15.4%)5 (12.8%)6 (15.4%)\n8 (20.5%)\n4 (10.3%)7 (38.9%)4 (22.2%)\n3 (16.7%)4 (22.2%)\n2 (11.1%)\n4 (22.2%)6 (33.3%)0.546\n0.0020.902\n0.3660.666\n0.883\n0.033\nSource of iGAS    Skin and soft tissue    Unknown    Lung\n    Others   26 (66,7%)\n7 (17.9%)\n5 (12,8%)\n1 (2.6%)6 (33.3%)5 (27,8%)4 (22.2%)\n3 (16,7%)0.031\nAPACHE II score at ICU admission 29 (22-32) 21 (16-25) 0.000\nSOFA score at ICU admission\n     Respiratory     Cardiovascular\n     Renal\n     Coagulation\n     Liver\n     Central Nervous System13 (11-15)\n3 (2-3)4 (3-4)\n3 (2-4)\n1 (0-2)\n1 (0-2)\n1 (1-3)8 (6-10)\n1 (1-2)3 (1-4)\n2 (1-2)\n1 (0-2)\n1 (0-2)\n0 (0-0)0.0000.006\n0.020\n0.009\n0.565\n0.328\n0.000\nWorst SOFA score in the ICU\n     Respiratory\n     Cardiovascular     Renal     Coagulation\n     Liver\n     Central Nervous System10 (7-12)\n2 (1-3)\n4 (3-4)2 (1-3)1 (0-2)\n1 (0-2)\n0 (0-1)13 (7-15)\n2 (1-3)\n3 (1-4)2 (2-3)1 (0-2)\n1 (0-2)\n1 (0-3)0.130\n0.180\n0.3600.785\n0.413\n0.221\n0.026\nTherapeutic approach    Linezolid\n    Penicillin G in directed therapy\n    Immunoglobulin15 (38.5%)\n21 (53.8%)\n11 (28.2%)8 (44.4%)\n2 (11.1%)\n00.669\n0.002\n0.012\nMechanical ventilation 26 (66.7%) 15 (83.3%) 0.193\nRenal Replacement Therapy 19 (48.7%) 9 (50%) 0.928\nICU mortality 14 (35.9%) 14 (77.8%) 0.003\nHospital mortality 16 (41%) 14 (77.8%) 0.010\n90-day mortality 23 (60.5%) 14 (77.8%) 0.203Table 3   Comparison of clindamycin-treated \npatients and those who did not receive \nthis antibiotic\nCOPD: Chronic obstructive pulmonary disease; ICU: Intensive care unit; iGAS: in-\nvasive group A Streptococcus .Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically \nill patients with bacteremic Group A Streptococcal infectionsA. Fern\u00e1ndez-Galilea, et al.\nRev Esp Quimioter 2022;35(5): 475-481480ICU mortality In-hospital mortality\nOrgan Failure Non-survivors (n=28) Survivors (n=29) p value Non-survivors (n=30) Survivors (n=27) p value\nRespiratory failure\nRenal failure\nCardiovascular failureLiver failure\nCoagulation failure\nCentral Nervous System failure22 (78.6%)\n19 (67.9%)\n27 (96.4%)\n5 (17.9%)\n9 (32.1%)\n12 (42.9%)7 (24.1%)\n10 (34,5%)\n22 (75.9%)\n2 (6.9%)\n4 (13.8%)\n1 (3.4%)<0.001\n0.012\n0.025\n0.2080.099\n<0.00121 (70%)\n18 (60%)\n28 (93.3%)\n6 (20%)\n10 (33.3%)\n13 (43.3%)8 (29.6%)\n11 (40,7%)\n21 (77.8%)\n(3.7%)\n3 (11.1%)\n00.002\n0.146\n0.091\n0.061\n0.046\n<0.001Table 4   Association between failure of the different organs and ICU and Hospital \nmortalities.\nICU: Intensive care unit\npatients, we were unable to determine that IVIG has a bene -\nficial effect. Due to the significant morbidity and mortality of \ninvasive GAS infections, further studies are warranted to de -\nfine the role new therapeutic strategies to improve the somber prognosis of bacteremic invasive GAS.\nFUNDING\nNone to declare.\nCONFLICT OF INTEREST\nThe authors declare no conflicts of interest\nREFERENCES\n1.  Im\u00f6hl M, van der Linden M. Antimicrobial Susceptibility of Invasive \nStreptococcus pyogenes Isolates in Germany during 2003-2013. \nPloS One 2015; 10:e0137313. doi:10.1371/journal.pone.0137313\n2.  Lamagni TL, Darenberg J, Luca-Harari B, et al. Epidemiology of se -\nvere Streptococcus pyogenes disease in Europe. J Clin Microbiol. \n2008; 46:2359\u20132367. doi:10.1128/JCM.00422-08\n3.  Schmitz M, Roux X, Huttner B, Pugin J. Streptococcal toxic shock \nsyndrome in the intensive care unit. Ann Intensive Care. 2018; 8:88. \ndoi:10.1186/s13613-018-0438-y\n4.  Mulla ZD. Invasive group A streptococcal disease and intensive \ncare unit admissions. Intensive Care Med. 2002; 28:1822\u20131824. \ndoi:10.1007/s00134-002-1538-5\n5.  Carapetis JR, Jacoby P, Carville K, et al. Effectiveness of clindamycin \nand intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014; \n59:358\u2013365. doi:10.1093/cid/ciu304\n6.  Linn\u00e9r A, Darenberg J, Sj\u00f6lin J, et al. Clinical efficacy of polyspecific \nintravenous immunoglobulin therapy in patients with streptococ -\ncal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014; 59:851\u2013857. doi:10.1093/cid/ciu449\n7.  Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; \n13:818\u2013829\n8.  Vincent JL, Moreno R, Takala J, et al.The SOFA (Sepsis-related Organ \nFailure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. \n1996; 22:707\u2013710\n9.  Moreno R, Vincent JL, Matos R, et al. The use of maximum SOFA \nscore to quantify organ dysfunction/failure in intensive care. Re -\nsults of a prospective, multicentre study. Working Group on Sepsis \nrelated Problems of the ESICM. Intensive Care Med. 1999; 25:686\u2013\n696. doi:10.1007/s001340050931\n10.  von Elm E, Altman DG, Egger M, et al.The Strengthening the Re -\nporting of Observational Studies in Epidemiology (STROBE) state -\nment: guidelines for reporting observational studies. PLoS Med. \n2007; 4:e296. doi:10.1371/journal.pmed.0040296\n11.  Bj\u00f6rck V, P\u00e5hlman LI, Bodelsson M, et al. Morbidity and mortality \nin critically ill patients with invasive group A streptococcus infec-\ntion: an observational study. Crit Care. 2020; 24:302. doi:10.1186/s13054-020-03008-z\n12.  Garnacho-Montero J, Guti\u00e9rrez-Pizarraya A, Escoresca-Ortega A, \net al. De-escalation of empirical therapy is associated with lower \nmortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014; 40:32\u201340. doi: 10.1007/s00134-013-3077-7\n13.  Babiker A, Li X, Lai YL, et al. Effectiveness of adjunctive clindamycin \nin \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic \nstreptococcal infections in US hospitals: a retrospective multicen -\ntre cohort study. Lancet Infect Dis. 2021; 21:697\u2013710. doi: 10.1016/\nS1473-3099(20)30523-5\n14.  Mehta S, McGeer A, Low DE, et al. Morbidity and mortality of \npatients with invasive group A streptococcal infections ad -\nmitted to the ICU. Chest, 2006; 130:1679\u20131686. doi: 10.1378/\nchest.130.6.1679\n15.  Bryant AE, Bayer CR, Aldape MJ, et al. Emerging erythromycin and \nclindamycin resistance in group A streptococci: Efficacy of linezolid \nand tedizolid in experimental necrotizing infection. J Glob Antimi -\ncrob Resist. 2020; 22:601\u2013607. doi:10.1016/j.jgar.2020.04.032Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically \nill patients with bacteremic Group A Streptococcal infectionsA. Fern\u00e1ndez-Galilea, et al.\nRev Esp Quimioter 2022;35(5): 475-48148116.  Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: \nInternational Guidelines for Management of Sepsis and Septic \nShock: 2016. Intensive Care Med. 2017; 43:304\u2013377. doi:10.1007/s00134-017-4683-6\n17.  Kadri SS, Swihart BJ, Bonne SL, et al. Impact of Intravenous Im -\nmunoglobulin on Survival in Necrotizing Fasciitis With Vasopres -\nsor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis. 2017; 64:877\u2013885. doi: 10.1093/cid/ciw871\n18.  Darenberg J, Ihendyane N, Sj\u00f6lin J, et al. Intravenous immunoglob -\nulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333\u2013340. doi:10.1086/376630\n19.  Lepoutre A, Doloy A, Bidet P, et al. Epidemiology of invasive Strep -\ntococcus pyogenes infections in France in 2007. J Clin Microbiol. 2011; 49:4094\u20134100. doi:10.1128/JCM.00070-11\n20.  Songsangjinda T, Khwannimit B. Comparison of severity score \nmodels based on different sepsis definitions to predict in-hospital mortality among sepsis patients in the Intensive Care Unit. Med Intensiva 2020; 44:226\u2013232. doi:10.1016/j.medin.2018.12.004\n21.  Darenberg J, S\u00f6derquist B, Normark BH, Norrby-Teglund A. Differ -\nences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implica -\ntions for therapy of toxic shock syndrome. Clin Infect Dis 2004; 38:836\u2013842. doi:10.1086/381979\n22.  Lamagni TL, Neal S, Keshishian C, et al. Predictors of death af -\nter severe Streptococcus pyogenes infection. Emerg Infect Dis. 2009;15:1304\u20131307. doi:10.3201/eid1508.090264\n23.  Nelson GE, Pondo T, Toews K-A, et al. Epidemiology of Invasive \nGroup A Streptococcal Infections in the United States, 2005-2012. \nClin Infect Dis. 2016; 63:478\u2013486. doi:10.1093/cid/ciw248ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/037.2022\nRev Esp Quimioter 2022;35(5): 482-491482Congenital cytomegalovirus infection, is more \nprevalent in our country in newborns exposed \nto HIV?\nABSTRACT \nObjectives. Congenital cytomegalovirus infection \n(cCMV) has been considered more prevalent among HIV-\nexposed children during pregnancy. Spanish national guidelines recommend the cCMV screening in these newborns. \nNowadays, pregnant women have a better control of HIV \ninfection compared to previous decades. We aim to analyze the prevalence and associated risk factors to cCMV in these children. \nPatients and methods.  A retrospective cross-\nsectorial study was performed. All newborns exposed to HIV were assisted in a third-level hospital (2014-2020). \nEpidemiological and clinical data of the mother and \nnewborn were recorded. Shell vial urine culture and/or CRP were performed along the two first weeks of life for the neonatal screening of cCMV.\nResults. Overall 69 newborns were enrolled. A high \nproportion (82.4%) of the mothers had been diagnosed with HIV before getting pregnant. All women received ART during \nthe pregnancy. Median T-CD4 lymphocytes before delivery was \n641/mm\n3 (IQR: 480-865) and the viral load was undetectable \nin 83.6%. Serological test for CMV along the first trimester \nof pregnancy was performed in 73.5% (positive IgG in 96%). \nThere were no congenital cases of HIV neither cCMV (CI 95%: \n0-5.3%).\nConclusions. The cCMV prevalence in newborns exposed \nto HIV was 0%, lower than reported before, probably related to a better and earlier ART during pregnancy, leading to a better \nimmunological status.\nKeyword: congenital cytomegalovirus infection, newborn HIV exposed.La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes \nm\u00e1s prevalente en nuestro medio en neonatos \nexpuestos al VIH?\n1Instituto de investigaci\u00f3n IdiPaz, Madrid.\n2Servicio de Pediatr\u00eda y Enfermedades infecciosas. Hospital Doctor Jos\u00e9 Molina Orosa, Arrecife, Las Palmas.\n3Servicio de Pediatr\u00eda y Enfermedades infecciosas y tropicales. Hospital Infantil Universitario La Paz, Madrid.\n4Servicio de Microbiolog\u00eda y Parasitolog\u00eda. Hospital Infantil Universitario La Paz, Madrid.\n5Servicio de Neonatolog\u00eda. Hospital Infantil Universitario La Paz, Madrid.\n6Servicio de Obstetricia y Ginecolog\u00eda. Hospital Materno-infantil Universitario La Paz, Madrid.\n7Centro de Investigaci\u00f3n Biom\u00e9dica En Red (CIBER), Enfermedades Infecciosas. Instituto de Salud Carlos III. Madrid.Jorge Bustamante-Amador1,2\nIsabel Mellado-Sola3\nMar\u00eda Pilar Romero-G\u00f3mez4\nMarta Cabrera-Lafuente5\nMar\u00eda de la Calle-Fern\u00e1ndez-\nMiranda6,7\nTal\u00eda Sainz-Costa1,3,7\nMar\u00eda Jos\u00e9 Mellado-Pe\u00f1a1,3,7\nLuis Escosa-Garc\u00eda1,3,7\nEn representaci\u00f3n del Grupo de Trabajo sobre Infecci\u00f3n \nPerinatal-Neonatolog\u00eda-\nGinecolog\u00eda (GINPER)Original\nArticle history\nReceived: 4 April 2022; Revision Requested: 2 June 2022; Revision Received: 10 June 2022; Accepted: 29 June 2022; \nPublished: 18 July 2022\nRESUMEN\nObjetivos. La infecci\u00f3n cong\u00e9nita por citomegalovirus \n(CMVc) se ha considerado m\u00e1s prevalente en hijos de madre \ninfectadas por VIH (RNEVIH). Por ello, las gu\u00edas nacionales aconsejan el cribado del CMVc en el RNEVIH. Actualmente estas \ngestantes en Espa\u00f1a presentan mejor control de la infecci\u00f3n \nque en d\u00e9cadas precedentes, pudiendo afectar a dicha prevalencia. El objetivo del estudio es analizar la prevalencia y \nposibles factores de riesgo asociados a la CMVc en RNEVIH en \nla era del tratamiento antirretroviral combinado (TAR).\nPacientes y m\u00e9todos. Estudio transversal retrospectivo, \nincluyendo todos los hijos de madre con VIH nacidos en un hospital de tercer nivel (2014-2020). Se recogieron datos epidemiol\u00f3gicos y cl\u00ednicos de la madre y del neonato. Se realiz\u00f3 cribado neonatal de CMV con cultivo de orina shell vial \ny/o PCR en las 2 primeras semanas de vida.\nResultados. Se incluyeron 69 neonatos. El 82,4% de \nlas madres hab\u00edan sido diagnosticadas de VIH previamente al embarazo. Todas recibieron TAR durante la gestaci\u00f3n. La \nmediana de linfocitos T-CD4 previos al parto fue 641/mm\n3 (RIC: \n480-865) y la CV fue indetectable en el 83,6%. La serolog\u00eda \npara CMV en el primer trimestre se realiz\u00f3 en el 73,5% (IgG positiva en el 96%). No hubo casos de transmisi\u00f3n vertical de \nVIH ni CMVc (IC 95%: 0-5,3%). \nConclusiones. La prevalencia de CMVc en neonatos \nexpuestos al VIH en nuestra cohorte fue del 0%, inferior a la \ndocumentada en estudios previos, posiblemente en relaci\u00f3n con el acceso precoz al TAR en las gestantes y su buena situaci\u00f3n inmunol\u00f3gica. \nPalabras clave: infecci\u00f3n cong\u00e9nita por citomegalovirus, hijo de madre \ninfectada por VIH.\nCorrespondencia:\nLuis Escosa-Garc\u00eda. \nServicio de Pediatr\u00eda y enfermedades infecciosas y tropicales. Hospital Infantil Universitario La \nPaz, P.\u00ba de la Castellana, 261, 28046 Madrid.\nE-mail: luisescosa1983@gmail.comLa infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491483Todas las madres y los neonatos fueron atendidos con un \nprotocolo unificado seg\u00fan las gu\u00edas nacionales de consenso, \nincluyendo TAR durante la gestaci\u00f3n, profilaxis intraparto, exclusi\u00f3n de la lactancia materna, profilaxis del reci\u00e9n nacido, \ncribado auditivo del neonato y realizaci\u00f3n de cribado universal de CMVc [11,12].\nDefiniciones. Se defini\u00f3 como madre con infecci\u00f3n por \nel VIH a todas aquellas gestantes con al menos una prueba microbiol\u00f3gica de cribado y una confirmatoria positivas, en \nmuestras diferentes [13], previas o durante la gestaci\u00f3n. Se \nlas clasific\u00f3 seg\u00fan el estadio de los CDC [14]. Se defini\u00f3 como \nbuen cumplimiento terap\u00e9utico cuando la madre refer\u00eda tomar \nadecuadamente el tratamiento antirretroviral a\u00f1adido a un adecuado control de la CV y linfocitos CD4.\nSe consider\u00f3 CMVc a los neonatos con demostraci\u00f3n \nmicrobiol\u00f3gica de la presencia del virus en muestra urinaria.\nLos neonatos nacidos con m\u00e1s de 37 semanas de edad \ngestacional se consideraron a t\u00e9rmino. Los nacidos entre las 24-28 semanas se definieron como \u201cpret\u00e9rminos extremos\u201d, \nentre las 28-32 semanas \u201cmuy prematuros\u201d y entre las 32-\n37 semanas \u201cmoderados o tard\u00edos\u201d [15]. Para valorar la \nantropometr\u00eda de los reci\u00e9n nacidos, el peso, talla y per\u00edmetro \ncef\u00e1lico fueron comparados con los est\u00e1ndares de los Estudios \nEspa\u00f1oles del Crecimiento (2010), para edad gestacional y sexo, definiendo bajo peso, talla o per\u00edmetro cef\u00e1lico para edad \ngestacional cuando el percentil del paciente era <10, normal si \n10-90 y elevado si >90 [16].\nCon respecto a los valores anal\u00edticos, se consider\u00f3 anemia \ncuando la hemoglobina (Hb) era menor a 15 g/dl en la anal\u00edtica \nrealizada en la primera semana de vida [17], hipertransamina -\nsemia cuando los valores de aspartato-aminotransferasa (AST) \n>50U/L y/o alanina-aminotransferasa (ALT) >45U/L [18]. Nive -\nles >150 U/L de gamma-glutamiltransferasa fueron considera -\ndos elevados [19]. \nSe defini\u00f3 hipoacusia cuando no se obtuvo onda V en los \npotenciales evocados de tronco encef\u00e1lico a 40dB [20].\nSe establecieron como posibles s\u00edntomas de CMVc la hiper -\ntransaminasemia, ictericia, petequias, hepatoesplenomegalia, microcefalia, hipoacusia, alteraciones en pruebas de imagen ce -\nrebral compatibles perinatales, siempre y cuando se demostrase la presencia de CMV en orina [1].\nDiagn\u00f3stico. Para el diagn\u00f3stico de CMVc, se recogi\u00f3 \nmuestra de orina mediante bolsa colectora en las dos primeras \nsemanas de vida. Esta muestra fue estudiada por el servicio de \nMicrobiolog\u00eda, realizando cultivo mediante shell vial (Vircell\u00ae, \nGranada, Espa\u00f1a) para CMV en muestras recogidas hasta \nfebrero de 2018. A partir de septiembre de 2017 se realiz\u00f3 \nPCR para CMV en orina en todos los reci\u00e9n nacidos a trav\u00e9s de Microlab STARlet\u00ae de Hamilton (Nevada, EUA).\nPara valorar la transmisi\u00f3n vertical de VIH, se realiz\u00f3 \nPCR cuantitativa de ARN viral con el sistema Cobas 6800\u00ae de \nRoche Molecular Diagnostics (Pleasanton, EUA), estableciendo el l\u00edmite de indetectabilidad cuando se documentaron INTRODUCCI\u00d3N\nEl citomegalovirus (CMV) es la principal causa de infecci\u00f3n \ncong\u00e9nita en la actualidad en todo el mundo, afectando \naproximadamente al 0.2-2.2% de los reci\u00e9n nacidos vivos \n[1,2]. Se trata de la primera causa de hipoacusia de origen no gen\u00e9tico en la edad pedi\u00e1trica, produciendo asimismo secuelas \ndesde el punto de vista del neurodesarrollo [2]. Los escasos estudios que han analizado la prevalencia de la infecci\u00f3n cong\u00e9nita por citomegalovirus (CMVc) en neonatos hijos \nde madre con infecci\u00f3n por el virus de la inmunodeficiencia \nhumana (RNEVIH) sostienen que dicha prevalencia es mayor que en la poblaci\u00f3n general con tasas que oscilan entre \nel 2,3 y el 6,5% en cohortes recientes, sin embargo algunas series han documentado hasta un 21-23,2% de prevalencia \ncuando se asocia la transmisi\u00f3n del VIH al reci\u00e9n nacido \n[3,4], con diferencias seg\u00fan el desarrollo del pa\u00eds y el nivel \nsocioecon\u00f3mico [5,6]. Asimismo, es posible que estos pacientes muestren s\u00edntomas con m\u00e1s frecuencia y una progresi\u00f3n m\u00e1s r\u00e1pida de la infecci\u00f3n por VIH [3,7\u20139].\nEn el estudio m\u00e1s relevante realizado en nuestro medio \n(1987-2003) [10] se document\u00f3 una prevalencia de CMVc \ndel 4,6% en estos neonatos. Sin embargo, en este mismo \nestudio, conforme las gestantes accedieron al tratamiento \nantirretroviral combinado (TAR) y mejoraron el control de la \ninfecci\u00f3n por el virus de la inmunodeficiencia humana (VIH) \nla prevalencia de CMVc mostr\u00f3 un descenso significativo (1,3% en los \u00faltimos a\u00f1os del estudio) aproxim\u00e1ndose a la \nprevalencia del CMVc en la poblaci\u00f3n general.\nActualmente el documento de consenso nacional de \nvarias sociedades cient\u00edficas para el manejo del reci\u00e9n nacido \nexpuesto al VIH aconseja la realizaci\u00f3n de cribado de CMVc \nen hijos de madre con VIH en las dos primeras semanas de vida [11]. Sin embargo, en los \u00faltimos a\u00f1os, no todas las recomendaciones de las sociedades cient\u00edficas relevantes son \ncoincidentes [12]. \nEl objetivo principal del estudio es determinar la \nprevalencia en nuestro medio de CMVc entre los reci\u00e9n nacidos \nhijos de madre con infecci\u00f3n por VIH en la era del TAR.\nPACIENTES Y M\u00c9TODOS\nDise\u00f1o del estudio y participantes. Se realiz\u00f3 un estudio \ntransversal retrospectivo en un hospital de tercer nivel en \nMadrid. Se incluyeron todos los reci\u00e9n nacidos expuestos a VIH \nintra\u00fatero y nacidos en nuestro centro entre enero de 2014 y \ndiciembre de 2020. Se excluy\u00f3 un paciente nacido en otro \ncentro sanitario. Se recogieron todos los datos epidemiol\u00f3gicos \ny cl\u00ednicos de las madres infectadas por VIH y sus respectivos \nneonatos; todos los datos fueron manejados en una base de datos anonimizada. El proyecto fue revisado y aprobado por el \nComit\u00e9 de \u00c9tica y de Investigaci\u00f3n del hospital. Dado que se trat\u00f3 de un estudio retrospectivo con datos anonimizados obtenidos \na partir de un protocolo asistencial del centro, no se consider\u00f3 necesaria la elaboraci\u00f3n de un consentimiento informado.La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491484No se document\u00f3 ninguna primoinfecci\u00f3n por CMV \ndurante la gestaci\u00f3n. La serolog\u00eda para CMV se hab\u00eda realizado \nen 35/68 (51,5%) de las mujeres previamente a la gestaci\u00f3n \nactual, resultando en 34/35 (97,1%) con IgG positiva. Durante \nla gestaci\u00f3n, se realiz\u00f3 serolog\u00eda en el primer trimestre en \n50/68 (73,5%) siendo en 47/50 (96%) IgG positiva con IgM \nnegativa y en un caso IgM positiva con IgG positiva de alta \navidez; las otras dos pacientes restantes fueron seronegativas \npara CMV. \nAtendiendo a los neonatos, el 55,1% fueron mujeres. La \nmayor\u00eda fueron nacidos a t\u00e9rmino (85,5%). El peso mediano al \nnacimiento fue de 2980g (RIC: 2750-3300); la talla mediana fue de 48 cm (RIC: 46.5-49); respecto al per\u00edmetro cef\u00e1lico, la mediana fue de 34 cm (RIC: 33-35). Los datos anal\u00edticos y cl\u00ednicos de los neonatos se reflejan en la Tabla 4.\nNing\u00fan neonato present\u00f3 al nacimiento s\u00edntomas o Total pacientes N = 68 (%) N (%)\nEdad (a\u00f1os) 35 (28-38)*\nOrigen \nEuropea\nLatinoamericana\nAfricana                     29 (42,6%)\n21 (30,9%)\n18 (26,5%)\nPa\u00eds de nacimiento\nEspa\u00f1a                      \nRep\u00fablica Dominicana                       \nGuinea Ecuatorial                               Nigeria                                                  Ecuador                                                \nRuman\u00eda                                              \nCuba                                                    \nPer\u00fa                                                     \nVenezuela                                            Colombia                                              Costa de Marfil                                     \nGuatemala                                           Honduras                                             \nKenia                                                    \nMarruecos                                            \nParaguay                                              \nPortugal                                                \nSenegal                                                \nSierra Leona                                        26 (38,2%)\n7 (10,3%)\n7 (10,3%)\n5 (7,4%)4 (5,9%)\n3 (4,4%)\n2 (2,9%)\n2 (2,9%)\n2 (2,9%)1 (1,5%)1 (1,5%)\n1 (1,5%)1 (1,5%)\n1 (1,5%)\n1 (1,5%)\n1 (1,5%)\n1 (1,5%)\n1 (1,5%)\n1 (1,5%)Tabla 1   Datos epidemiol\u00f3gicos de las madres \ncon infecci\u00f3n por VIH.\n*Mediana (p25-75); IC 95%: intervalo de confianza al 95%.<20 copias/mL. Las PCR se realizaron al nacimiento, a la \ntercera o cuarta semana de vida, a las 4-6 semanas y entre \nlos 3-4 meses. Se descart\u00f3 la transmisi\u00f3n vertical cuando se obtuvieron al menos 2 pruebas PCR negativas a partir de las 6-8 semanas de vida, siendo alguna entre los 3-4 meses [11]. \nAsimismo se realizaron controles serol\u00f3gicos en el lactante \ndurante el segundo a\u00f1o de vida para confirmar la ausencia \nde anticuerpos maternos a trav\u00e9s de quimioluminiscencia \ncon Atellica IM Analyzer\u00ae de Siemens Healthcare Diagnostics \n(Erlangen, Germany).\nAn\u00e1lisis estad\u00edstico. Los resultados de frecuencia \nson expresados en t\u00e9rminos absolutos, como porcentajes \ne intervalos de confianza. Las variables continuas ser\u00e1n expresadas como media y desviaci\u00f3n est\u00e1ndar (DS) o bien \nmediana (rango intercuart\u00edlico), seg\u00fan distribuci\u00f3n. Los datos \nfueron analizados usando el software de an\u00e1lisis estad\u00edstico \nSPSS 23.0.\nRESULTADOS\nA lo largo del periodo de estudio, se documentaron 39457 \nnacimientos en nuestro centro, con un total de 69 neonatos \n(0,17%) hijos de 68 madres seropositivas para VIH. La mayor\u00eda de las gestantes nacieron en Espa\u00f1a (38,2%), seguidas por las de \norigen latinoamericano (30,9%). Asimismo, la gran mayor\u00eda de \nlas madres hab\u00eda sido diagnosticada de VIH antes de la gestaci\u00f3n \n(82,4%); s\u00f3lo dos de ellas a partir de la semana 20 de gestaci\u00f3n (semana 20 y 22 respectivamente). Todas ellas recibieron TAR \ndesde el inicio del embarazo, la mayor\u00eda con buen cumplimiento \n(91,2%). M\u00e1s de la mitad de las gestantes presentaban estadios A1 y A2 de la clasificaci\u00f3n de los CDC (26,5 y 27,9% respectiva -\nmente). Los datos epidemiol\u00f3gicos y cl\u00ednicos de las madres se muestran en la Tabla 1 y 2 respectivamente. La pauta de trata -\nmiento antirretroviral m\u00e1s frecuente a lo largo de la gestaci\u00f3n \nfue 2 inhibidores de la transcriptasa inversa an\u00e1logos de nucle\u00f3 -\nsidos (ITIAN) + inhibidor de la integrasa (II) (35,3%), seguida por 2 ITIAN + inhibidores de la transcriptasa inversa no an\u00e1logos de \nnucle\u00f3sidos (ITINAN) (29,4%). Ocho mujeres (11,8%) recibieron \nraltegravir en las \u00faltimas semanas de la gestaci\u00f3n para disminuir \nla carga viral dado que \u00e9sta era detectable en el \u00faltimo trimes -\ntre. Los esquemas de tratamiento antirretroviral maternos du -\nrante la gestaci\u00f3n se muestran en la Figura 1. \nEn cuanto a los datos perinatales, m\u00e1s del 75% hab\u00edan \ntenido uno o ning\u00fan hijo previamente. En un caso se detect\u00f3 \nventriculomegalia en la ecograf\u00eda del segundo trimestre, \nsin encontrar otros hallazgos ecogr\u00e1ficos. El 98,5% de las \ngestaciones fueron \u00fanicas, s\u00f3lo hubo una gestaci\u00f3n gemelar. El 80% de las madres present\u00f3 una carga viral indetectable \nen el tercer trimestre de la gestaci\u00f3n, mientras que aquellas \nen las que fue detectable presentaban baja replicaci\u00f3n, con \nuna mediana de 445 copias/mm\n3 (RIC: 37-865). Asimismo, la \nmediana de linfocitos T CD4 fue de 641/mm3 (RIC 480-865). \nHasta el 65% de los neonatos nacieron por ces\u00e1rea; en todos \nlos casos se administr\u00f3 profilaxis antirretroviral intraparto. Los \ndatos perinatales se reflejan en la Tabla 3.La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491485signos compatibles con CMVc. Asimismo, la mayor parte de \nlos neonatos superaron las otoemisiones ac\u00fasticas (97,1%), \ndetect\u00e1ndose \u00fanicamente una hipoacusia grave de etiolog\u00eda \nno infecciosa.\nEn cuanto al estudio diagn\u00f3stico de CMV en orina, se recogi\u00f3 \nla muestra en todos los neonatos, siendo negativo en el 100% \nde los casos. La orina fue recogida con una mediana de 2 d\u00edas de \nvida (RIC 1-3). Por otro lado, no se diagnostic\u00f3 ning\u00fan caso de \ntransmisi\u00f3n vertical de VIH siendo seguidos hasta presentar 3 PCR \nnegativas y ELISA negativo (entre los 12 y 24 meses).\nTodos los neonatos recibieron tratamiento profil\u00e1ctico \npara la transmisi\u00f3n vertical de VIH al nacimiento. Los diferentes \nesquemas de profilaxis en el neonato se muestran en la Figura \n2. La pauta m\u00e1s com\u00fan fue zidovudina en monoterapia \n(81,2%) durante 28 d\u00edas. La exclusi\u00f3n de la lactancia materna \nfue universal. Todos los neonatos fueron controlados en la \nconsulta de Enfermedades Infecciosas de Pediatr\u00eda del Hospital \nLa Paz durante el seguimiento.\nSeg\u00fan los hallazgos obtenidos, se estim\u00f3 una prevalencia \nde CMVc en nuestra cohorte del 0%, con un intervalo de \nconfianza al 95% de 0-5,3%.\nDISCUSI\u00d3N\nLos resultados obtenidos en este trabajo demuestran una \nprevalencia de CMVc en neonatos con exposici\u00f3n al VIH del 0% \nen nuestra cohorte, inferior a la descrita previamente, incluso \nen situaciones sociodemogr\u00e1ficas comparables. \nLos principales estudios recientes han establecido \nprevalencias de CMVc entre neonatos expuestos a la infecci\u00f3n \npor el VIH del 2,3 al 6,5%, sin embargo, se trata de cohortes de \nseguimiento realizadas a lo largo de muchos a\u00f1os [3,8,10,21]. \nLos pacientes con infecci\u00f3n por el VIH de transmisi\u00f3n vertical \nconfirmada presentan prevalencias superiores (10-26%) a los \npacientes expuestos sin infecci\u00f3n [3,8,10]. La situaci\u00f3n de la \nsalud global en las gestantes con infecci\u00f3n por VIH ha variado \nde forma muy significativa respecto a los primeros a\u00f1os de la \nepidemia en Espa\u00f1a, en paralelo a la mejor\u00eda de las tasas de \nmorbimortalidad de los pacientes con infecci\u00f3n por VIH y de la \nreducci\u00f3n en las tasas de transmisi\u00f3n vertical materno-infantil. \nUn estudio realizado en Madrid en 2005 obtuvo una \nprevalencia de CMVc del 4,6% en estos neonatos a lo largo de \nm\u00e1s de 15 a\u00f1os y del 1,3% en la \u00e9poca del TAR en particular \n[10]. Un trabajo posterior, llevado a cabo en la cohorte francesa [8] documenta una prevalencia del 1,5% en la era \ndel TAR, con conclusiones similares al estudio previo. \u00c9ste \ncuenta con un tama\u00f1o muestral a\u00fan mayor que el estudio \nespa\u00f1ol, no obstante, las gestantes comienzan el tratamiento \nantirretroviral (ARV) en el segundo trimestre, con CD4 <200/mm\n3. Esta reducci\u00f3n de la prevalencia de CMVc con el uso de \nTAR no se ha confirmado, sin embargo, en otros estudios. T. \nFrederick et al. publican en el 2012 su investigaci\u00f3n llevada \na cabo en Los \u00c1ngeles (EEUU) y hallan una prevalencia del \n3,6% sin encontrar diferencias significativas entre la \u00e9poca \npre-TAR y la era TAR; en este trabajo tambi\u00e9n se incluye un Total pacientes N = 68 (%) N (%)\nTipo de transmisi\u00f3n del VIH                         \nSexual                                              \nVertical                                               UDVP                                                             Desconocido                                    32 (47,1%)\n9 (13,2%)\n2 (2,9%)\n25 (36,8%)\nEstadio CDC\nA1A2\nA3\nB1                                                                   \nB2                                                                   B3                                                        C2                                                                     C3                                                     Desconocido                                18 (26,5%)19 (27,9%)\n2 (2,9%)\n5 (7,4%)\n5 (7,4%)2 (2,9%)1 (1,5%)\n8 (11,8%)8 (11,8%)\nCumplimiento TAR durante la gestaci\u00f3n                    \nAdecuado                               Mala cumplidora                                   62 (91,2%) \n6 (8,8%)                              \nOtros antecedentes                      \nCondilomas / verrugas genitales         Candidiasis recurrente                         Herpes z\u00f3ster recurrente                     Toxoplasmosis                                     Condilomas / verrugas anales             Tuberculosis                                         Herpes genital                                      Hepatitis B                                            Esofagitis herp\u00e9tica                              Colitis por citomegalovirus                   Neumon\u00eda bacteriana                           Hepatitis C                                           Neumon\u00eda por Pneumocystis jiroveci   Citomegalovirus ocular                        Meningitis linfocitaria                            Absceso corneal por P. aeruginosa     Usuaria de drogas no parenteral 24 (35,3%)\n8 (11,8%)\n6 (8,8%)4 (5,9%)3 (4,4%)3 (4,4%)3 (4,4%)2 (2,9%)2 (2,9%)2 (2,9%)2 (2,9%)1 (1,5%)1 (1,5%)1 (1,5%)1 (1,5%)1 (1,5%)1 (1,5%)\n7 (10,3%)\nMutaciones y resistencias a ARV             \nMutaciones sin resistencias:                    \nTranscriptasa inversa                            Proteasa                                           \nResistencias:                                           EFV, NVP, 3TC/FTCNFV + intermedias: NVP, IDV/RTV, SQV/RTV, EFV3TC/FTC, SQV/RTV, IDV, NFV, APV10 (14,7%)\n7 (10,3%)\n5 (7,4%)4 (5,9%)  3 (4,4%)Tabla 2   Datos cl\u00ednicos de las madres \ninfectadas por VIH.\nIC 95%: intervalo de confianza al 95%;  3TC/FTC: Lamivudina/ Emtricitabina; APV: \nAmprenavir; ARV: antirretrovirales; EFV: Efavirenz; IDV/RTV: Indinavir/ Ritonavir; NFV: Nelfinavir; NVP: Nevirapina; \nP. aeruginosa : Pseudomonas aeruginosa ; SQV/\nRTV: Saquinavir/ Ritonavir; TAR: terapia antirretroviral combinada;  UDVP: usuaria de drogas v\u00eda parenteralLa infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491486unos CD4 superiores a los estudios comentados. S\u00f3lo 11 mu -\njeres presentaron carga viral detectable en el \u00faltimo trimestre \n(la mayor de 2310 copias/ml), por lo que recibieron raltegravir \npara reducir \u00e9sta y s\u00f3lo una paciente presentaba unos linfoci -\ntos CD4 <200/mm3 en el \u00faltimo control (177 CD4//mm3). \nDel an\u00e1lisis de estos estudios y en consonancia con los \nresultados de nuestra cohorte, se concluye que la prevalencia \ndel CMVc en este colectivo parece tener relaci\u00f3n con el grado \nde inmunosupresi\u00f3n materno [6\u20138,23], ya sea por no recibir tratamiento o por presentar unos CD4 <200mm\n3 e impresiona \nque en la era TAR, la prevalencia de CMVc se ha reducido \nsiempre y cuando la madre cumpla adecuadamente con el tratamiento desde el inicio de la gestaci\u00f3n [9]. \n Sin embargo, incluso en las cohortes con resultados m\u00e1s \nfavorables de prevalencia de CMVc (1,3-1,5%), \u00e9sta parece \nsuperior a la prevalencia de CMVc en la poblaci\u00f3n general en \npa\u00edses desarrollados (0,4-0,7%) [24,25]. Tambi\u00e9n en la literatura \npodemos encontrar estudios que hallan una prevalencia de CMVc en hijos de madre con VIH similar a los de la poblaci\u00f3n general en pa\u00edses en v\u00edas de desarrollo (2,7 vs 2,9%), lo cual \nrelacionan con la baja tasa de estadio SIDA de las madres \ninfectadas por el VIH (8,7%) [26]. Recientemente Purswani et alto porcentaje de gestantes que comienzan ARV en tercer trimestre lo que podr\u00eda matizar las conclusiones [21]. Por otro lado, un trabajo llevado a cabo por un grupo brasile\u00f1o [3], \ndemostr\u00f3 incluso una prevalencia de CMVc del 6,5%, mayor \nque en los estudios previos. Este estudio incluye gestantes con alta carga viral de VIH y que no recib\u00edan ARV.\nLa disponibilidad del TAR desde el primer trimestre del \nembarazo se ha sugerido como un factor protector clave \nfrente al CMVc en estos neonatos [8] as\u00ed como su ausencia o la \ntransmisi\u00f3n vertical del VIH al neonato suponen importantes factores de riesgo [3]. No obstante, un estudio reciente \nrealizado en Sud\u00e1frica no encontr\u00f3 relaci\u00f3n con la duraci\u00f3n del TAR materno ni con el estado de inmunosupresi\u00f3n materno. \nAunque s\u00ed encontraron relaci\u00f3n en la cotransmisi\u00f3n de ambos \nvirus y mayor prevalencia de CMVc en neonatos expuestos intra\u00fatero a VIH. Como establecen estos autores, la ausencia \nde diferencia puede ser explicada por el reducido tama\u00f1o de pacientes con CMVc (N: 46) [22].\nEn nuestro estudio, el 92% de las gestantes conoc\u00edan el \ndiagn\u00f3stico de VIH previo a la gestaci\u00f3n, por lo que pudieron \nrecibir ARV desde el primer trimestre. Asimismo, nuestra co -\nhorte presenta un adecuado cumplimiento terap\u00e9utico con \nFigura 1   Tratamiento materno durante la gestaci\u00f3n.\nICYP: inhibidor del citocromo p450 3A; II: inhibidor de la integrasa; IP: inhibidor de la proteasa; ITIAN: Inhibidor de la transcrip -\ntasa inversa an\u00e1logo de nucle\u00f3sido; ITINAN: Inhibidor de la transcriptasa inversa no an\u00e1logo de nucle\u00f3sido.La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491487Total madres N= 68 (%)\nParidad previa\n0\n1\n2\n3Desconocido27 (39,7%)25 (36,8%)\n9 (13,2%)\n5 (7,3%)2 (2,9%)     \nGestaci\u00f3n\n\u00danicaGemelar67 (98,5%)\n1 (1,5%)\nTipo de parto \nCes\u00e1reaPor infecci\u00f3n por VIH\nCausa obst\u00e9trica\nVaginal\nInstrumental44 (64,7%)\n16 (36,4%)\n28 (63,6%)\n24 (35,3%)\n7 (10,3%)\nLinfocitos T CD4 preparto\nDisponibles en641/mm3 (480-865)*\n61 (89,7%)\nCarga viral VIH preparto\nDisponible enIndetectable\nDetectables: \ncopias/mL67 (98,5%)\n56 (83,6%)\n11 (16,2%)\n445 (37-865)*\nProfilaxis intraparto\nZidovudinaZidovudina + nevirapina 66 (97,1%)\n2 (2,9%)Tabla 3   Datos cl\u00ednicos perinatales en los \nneonatos expuestos al VIH.\nTodos los datos se muestran como valores absolutos (porcentaje relativo) salvo \n*Mediana (p25-75)\nal. encuentran una prevalencia de CMVc de 0.9% en pacientes \nbien controladas [5], con tratamiento antirretroviral y la \ninmensa mayor\u00eda con linfocitos CD4 >200/mm3.\nAlgunos estudios han tratado de dilucidar la posible \nasociaci\u00f3n de f\u00e1rmacos antirretrovirales con la no transmisi\u00f3n de CMV al feto [5,23]. El grupo franc\u00e9s no encontr\u00f3 diferencias en los diferentes reg\u00edmenes utilizados [8]. En nuestra cohorte, \nal no documentar pacientes con CMVc, no pudimos valorar si hubo diferencias entre los reg\u00edmenes empleados. \nEs bien conocido que la seroprevalencia de CMV en la \npoblaci\u00f3n var\u00eda en funci\u00f3n de la edad, geograf\u00eda y raza, siendo \nmayor en \u00e1reas m\u00e1s desfavorecidas [3]. Un metaanalisis \npublicado en 2007 report\u00f3 que el CMVc podr\u00eda ser m\u00e1s \nfrecuente en los casos de primoinfecci\u00f3n materna en lugar de \nreactivaci\u00f3n [25]. Posteriormente, se han publicado art\u00edculos \nque documentan que el CMVc parece ser m\u00e1s frecuente por reactivaciones en la madre durante el embarazo [27]. El \nembarazo constituye un estadio de inmunosupresi\u00f3n materna, en el cual podr\u00eda ocurrir dicha reactivaci\u00f3n [28], si a esto se le a\u00f1ade la infecci\u00f3n por VIH con mal control, \u00e9sto podr\u00eda explicar \nque la CMVc en hijos de madre con VIH fuese m\u00e1s frecuente. En \nnuestro estudio, se realiz\u00f3 serolog\u00eda al 73,5% de las gestantes en el primer trimestre, encontrando una seroprevalencia IgG \npara CMV del 96%. Sin embargo, no encontramos ning\u00fan caso \nde CMVc, lo cual podr\u00eda ser explicado por un adecuado control \nmaterno (mediana de linfocitos CD4 previos al parto: 641/mm\n3 y 83.6% con carga viral indetectable). Algunos estudios \nestablecen que las madres m\u00e1s j\u00f3venes VIH-seropositivas son \nun factor de riesgo para el CMVc [8], por la mayor probabilidad \nde tener hijos de corta edad, con mayor riesgo de contagio.\nSe ha postulado en varios estudios, que pueda existir \nuna sinergia entre el VIH y el CMV para producir coinfecci\u00f3n \nen el feto [2,3,8\u201310,23]. De hecho, en los casos en los que se \nproduce transmisi\u00f3n vertical del VIH, la prevalencia de CMVc aumenta hasta el 26% [4,10]. Ambos virus pueden estimular la expresi\u00f3n de genes y la replicaci\u00f3n viral de forma rec\u00edproca \n[9]. Por otra parte, Adachi et al. calculan un riesgo 5 veces \nmayor de transmisi\u00f3n de VIH si la madre presenta viruria de \nCMV [7]. Se conoce que el VIH tipo 2 presenta menores tasas de transmisi\u00f3n vertical que el VIH tipo 1, sin embargo no se ha \nestudiado qu\u00e9 serotipo de VIH se asocia con m\u00e1s frecuencia \na la coinfecci\u00f3n por CMV. Payne et al. anunciaron que la \nviremia de CMV en etapas precoces de la vida podr\u00eda ser un \npredictor del reservorio viral de VIH tras la supresi\u00f3n virol\u00f3gica \ncon antirretrovirales posiblemente por la coinfecci\u00f3n de los mismos linfocitos de memoria [29].\nOtras v\u00edas de transmisi\u00f3n perinatal o postnatal de \nCMV son a trav\u00e9s de la lactancia materna o el contacto con \nsecreciones vaginales en el momento del parto [30]. Estas \nv\u00edas implican un riesgo menor de morbilidad neurol\u00f3gica comparado con el CMVc aunque podr\u00eda estar aumentado en \nni\u00f1os con coinfecci\u00f3n por VIH o en neonatos pret\u00e9rminos, no \nobstante parece que el TAR parece disminuir dicho riesgo [21]. En pa\u00edses desarrollados la lactancia materna en hijos de madre \nVIH se encuentra desaconsejada, aunque es una v\u00eda a tener en \ncuenta en pa\u00edses en v\u00edas de desarrollo.\nLa principal limitaci\u00f3n de este estudio es el reducido \ntama\u00f1o muestral. A pesar de ser un estudio retrospectivo, al \nobtener los datos de un protocolo asistencial de nuestro centro \nen el que se criba de rutina el CMV en muestra urinaria en todos los nacidos hijos de madre con VIH, contamos con todos los datos sin haber p\u00e9rdida de \u00e9stos. \nEl adecuado control del VIH durante la gestaci\u00f3n asociado \na un buen estadio inmunol\u00f3gico, podr\u00eda reducir la tasa de CMVc en hijos de madre con VIH, la cual hab\u00eda sido reportada en la era \npre-TAR como muy superior a la de la poblaci\u00f3n general.\nEn nuestra cohorte la prevalencia de CMVc en hijos de madre \ncon infecci\u00f3n por VIH podr\u00eda estar pr\u00f3xima a la prevalencia de CMVc en la poblaci\u00f3n general. No obstante, estudios con mayor \ntama\u00f1o muestral, multic\u00e9ntricos y prospectivos deber\u00edan ser desarrollados para comprobar dicha prevalencia. De confirmarse La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491488Total reci\u00e9n nacidos N = 69 (%) N (%) IC 95%\nEdad gestacional\nMediana\nA t\u00e9rminoPret\u00e9rminoExtremo (< 28 SEG)\nMuy prematuro (28-32 SEG)\nModerados-tard\u00edos (32-37 SEG)38,4 (37,5-39,1)*\n59 (85.5%)\n10 (14.5%)\n1/10 (10%)\n0 (0%)\n9/10 (90%)75,3-91,9%\n8,1-24,7%\n1,8-4,0%\n0,0-2,8%\n59,6-98,2%\nSexo\nMujeres\nVarones38 (55.1%)\n31 (44.9%)43,4-66,2%33,8-56,6%\nAntropometr\u00eda\nMediana percentil peso\nPeso < p10\nPeso > p90\nMediana percentil longitud\nLongitud < p10\nLongitud > p90\nMediana percentil PC\nPC < p10PC > p9039 (23-65)*\n5 (7.2%)\n4 (5.8%)\n29 (12-55)*\n12 (17.4%)\n1 (1.4%)\n43 (24-67)*\n5 (7.2%)\n6 (8.7%)3,1-15,9%\n2,3-13,9%\n10,2-27,9%\n0,3-7,8%\n3,1-15,9%\n4,1-17,7%\nS\u00edntomas compatibles con CMVc  \nExantemaVisceromegaliaPetequias\nNeurol\u00f3gicos0 (0%)\n0 (0%)0 (0%)\n0 (0%)0,0-5,3%\n0,0-5,3%0,0-5,3%\n0,0-5,3%\nPeriodo neonatal\nIngreso por prematuridad\nSepsis neonatal precoz10 (14.5%)\n2 (2.9%)8,1-24,7%\n0,8-9,9%\nAnal\u00edtica de sangre\nLeucocitos /mm\n3\nPlaquetas /mm3\nPlaquetas <100000/mm3\nHb g/dlHb <15 g/dlAST Elevada\nAST U/L\nAST Elevada\nALT U/L\nGGT Elevada\nGGT U/L\nBilirrubina total mg/dlBilirrubina directa mg/dl14.925 (11.700-18.900)*\n307.000 (261.000-353.000)*\n0 (0%)\n15.9 (14.5-17)*\n22/66 (33.3%)\n38/50 (76%)\n75 (58-98)*\n2/54 (3.7%)\n93 (54-132)*\n24/65 (36.9%)\n241 (192-275)*\n5.2 (4.3-6.4)*\n0.39 (0.2-0.56)*0,0-5,3%\n23,2-45,3%62,6-85,7%\n1,0-12,5%\n26,2-49,1%\nCribado auditivo\nPasa bilateral OEAsNo pasa unilateral OEAs\nPEAT\nNo pasa bilateral OEAs\nPEAT67 (97.1%)\n1 (1.4%)\nNormales\n1 (1.4%)\npasa a 80 dB90,0-99,2%\n0,3-7,8%\n0,3-7,8%\nTransmisi\u00f3n vertical VIH\nCitomegalovirus cong\u00e9nito0 (0%)0 (0%)0,0-5,3%0,0-5,3%Tabla 4   Datos cl\u00ednicos de los neonatos expuestos al VIH.\n*Mediana (p25-75); CMVc: citomegalovirus cong\u00e9nito; PC: per\u00edmetro cef\u00e1lico; < p10: menor de percentil \n10 para edad gestacional y sexo (Estudio Espa\u00f1ol del crecimiento 2010); > p90: mayor de percentil 90 para edad gestacional y sexo (Estudio Espa\u00f1ol del crecimiento 2010); SEG: semanas de edad gestacional; PEAT: \nPotenciales evocados auditivos de tronco encef\u00e1lico; OEAs: Otoemisiones ac\u00fasticas.La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491489estos hallazgos, las gestantes con infecci\u00f3n por el VIH con buen \ncontrol cl\u00ednico, virol\u00f3gico e inmunol\u00f3gico y con TAR precoz en la gestaci\u00f3n podr\u00edan reducir su grado de incertidumbre de cara al potencial riesgo de CMVc en su descendencia. \nAGRADECIMIENTOS\nEn representaci\u00f3n del Grupo de Trabajo sobre Infecci\u00f3n \nPerinatal-Neonatolog\u00eda-Ginecolog\u00eda (GINPER), Hospital Universitario La Paz, Madrid: Fernando Baquero-Artigao, Milagros Garc\u00eda L\u00f3pez Hortelano, Mar\u00eda Jos\u00e9 Mellado Pe\u00f1a, \nLuis Escosa-Garc\u00eda, Marta Cabrera Lafuente, Mar\u00eda Dolores \nElorza Fern\u00e1ndez, Mar\u00eda de la Calle Fern\u00e1ndez-Miranda, Eugenia Antol\u00edn Alvarado, Dolores Montero Vega, Elena Trigo Esteban, Fernando de la Calle Prieto, Silvia Garc\u00eda Bujalance.\nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n \npara la realizaci\u00f3n de este estudio. Tal\u00eda Sainz-Costa ha recibido financiaci\u00f3n por el Instituto de Salud Carlos III - Fondos Feder (BAE21/00022).\nCONFLICTOS DE INTER\u00c9S\nLos autores declaran no presentar conflictos de inter\u00e9s BIBLIOGRAF\u00cdA\n1 Baquero-Artigao F; Grupo de estudio de la infecci\u00f3n cong\u00e9nita \npor citomegalovirus de la Sociedad Espa\u00f1ola de Infectolog\u00eda \nPedi\u00e1trica. Documento de consenso de la Sociedad Espa\u00f1ola de \nInfectolog\u00eda Pedi\u00e1trica sobre el diagn\u00f3stico y el tratamiento de la infecci\u00f3n cong\u00e9nita por citomegalovirus [Consensus document \nfrom the Spanish Society of Paediatric Infectious Diseases (SEIP) \non the diagnosis and treatment of congenital cytomegalovirus infection]. An Pediatr (Barc). 2009 Dec;71(6):535-47. doi: 10.1016/j.\nanpedi.2009.07.029.\n2 Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. \nThe \u201cSilent\u201d global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013;26:86\u2013102. doi: 10.1128/CMR.00062-12 \n3 Adachi K, Xu J, Ank B, Watts DH, Camarca M, Mofenson \nLM, et al. Congenital Cytomegalovirus and HIV Perinatal \nTransmission. Pediatr Infect Dis J 2018;37:1016\u201321. doi: 10.1097/\nINF.0000000000001975 \n4 Doyle M, Atkins JT, Rivera-Matos IR. Congenital cytomegalovirus \ninfection in infants infected with human immunodeficiency virus \ntype. Pediatr Infect Dis J 1996;15:1102\u20136. doi: 10.1097/00006454-\n199612000-00010 \n5 Purswani MU, Russell JS, Dietrich M, Malee K, Spector SA, Williams \nPL, et al. Birth Prevalence of Congenital Cytomegalovirus Infection in HIV-Exposed Uninfected Children in the Era of Combination \nAntiretroviral Therapy. J Pediatr 2020;216:82-87.e2. doi: 10.1016/j.\nFigura 2  Profilaxis o tratamiento muy precoz del reci\u00e9n nacido expuesto al VIH\n3TC: Lamivudina; AZT: Ziduvudina; ddI: didanosina; FTC: emtricitabina; NVP: nevirapina.La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491490jpeds.2019.09.025 \n6 Manicklal S, Van Niekerk AM, Kroon SM, Hutto C, Novak Z, Pati \nSK, et al. Birth prevalence of congenital cytomegalovirus among \ninfants of HIV-infected women on prenatal antiretroviral \nprophylaxis in South Africa. Clin Infect Dis 2014;58:1467\u201372. doi: \n10.1093/cid/ciu096 \n7 Adachi K, Xu J, Ank B, Watts DH, Mofenson LM, Pilotto JH, et al. \nCytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection. Clin. Infect. Dis., vol. 65, Oxford University Press; 2017, p. 405\u201313. doi: 10.1093/\ncid/cix222 \n8 Guibert G, Warszawski J, Chenadec J Le, Blanche S, Benmebarek Y, \nMandelbrot L, et al. Decreased risk of congenital cytomegalovirus \ninfection in children born to HIV-1-infected mothers in the era of \nhighly active antiretroviral therapy. Clin Infect Dis 2009;48:1516\u2013\n25. doi: 10.1086/598934 \n9 Ellington SR, Clarke KEN, Kourtis AP. Cytomegalovirus Infection in \nHuman Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Infants: A Systematic Review. J Infect Dis 2016;213:891\u2013900. doi: 10.1093/infdis/jiv549 \n10 Mar\u00edn Gabriel MA, Fern\u00e1ndez Ibieta M, Gonz\u00e1lez Tom\u00e9 MI, Saavedra \nLozano J, Barajas S\u00e1nchez V, Rojo Conejo P, et al. Infecci\u00f3n cong\u00e9nita por citomegalovirus en hijos de madres infectadas por \nel VIH. An Pediatr 2005;62:38\u201342. doi: 10.1157/13070179\n11 Panel de Expertos de la Secretar\u00eda del Plan Nacional sobre el Sida \n(SPNS), Grupo de Estudio de Sida (GeSIDA), Sociedad Espa\u00f1ola de \nGinecolog\u00eda y Obstetricia (SEGO), Sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica (SEIP). Documento de consenso para el seguimiento de \nla infecci\u00f3n por el VIH en relaci\u00f3n con la reproducci\u00f3n, embarazo, parto y profilaxis de la transmisi\u00f3n vertical del ni\u00f1o expuesto. \nEnferm Infecc Microbiol Clin.2014;32(5):310.e1\u2013310.e33. doi: 10.1016/j.eimc.2013.12.003\n12 Noguera-Julian A, de Jos\u00e9 MI, Grupo de trabajo sobre infecci\u00f3n por \nVIH en el ni\u00f1o de la sociedad Espa\u00f1ola de Infectolog\u00eda Pedi\u00e1trica (SEIP). Recomendaciones de la Sociedad Espa\u00f1ola de Infectolog\u00eda \nPedi\u00e1trica para el seguimiento del ni\u00f1o expuesto al virus de la \ninmunodeficiencia humana y a f\u00e1rmacos antirretrovirales durante el embarazo y el periodo neonatal. An Pediatr (Barc) 2012; 76(6):360.e1---360.e9. doi: 10.1016/j.anpedi.2012.01.007\n13 WHO Recommendations on the Diagnosis of HIV Infection in \nInfants and Children; 2010 [cited 2022 March 18]. ISBN-13: 978-92-4-159908-5 Available from: https://www.ncbi.nlm.nih.gov/\nbooks/NBK138551/\n14 Centers for disease control and prevention. 1993 Revised \nClassification System for HIV Infection and Expanded Surveillance \nCase Definition for AIDS Among Adolescents and Adults. JAMA J Am Med Assoc. 1993 Feb 10;269(6):729\u201330.\n15 World Health Organization. Nacimientos prematuros. [cited 2022 \nMarch 18]. Available from: https://www.who.int/es/news-room/\nfact-sheets/detail/preterm-birth\n16 Carrascosa A, Fern\u00e1ndez JM, Fern\u00e1ndex A, L\u00f3pez-Siguero JP, L\u00f3pez \nD, et al. Estudios Espa\u00f1oles de Crecimiento 2010. [cited 2022 March 18] Available from: https://www.aeped.es/noticias/estudios-espanoles-crecimiento-2010\n17 Bonastre-Blanco E, Thi\u00f3-Lluch M, Monfort-Carretero L. Anemia \nneonatal. An Pediatr Contin 2010;8:73\u201380. doi: 10.1016/S1696-\n2818(10)70013-5\n18 Friedman LS. Approach to the patient with abnormal liver \nbiochemical and function tests - UpToDate . [cited 2022 March 18] Available from: https://www.uptodate.com/contents/approach-to-\nthe-patient-with-abnormal-liver-biochemical-and-function-tests\n19 Hirfanoglu IM, Unal S, Onal EE, Beken S, Turkyilmaz C, Pasaoglu \nH, et al. Analysis of Serum \u03b3-Glutamyl Transferase Levels in \nNeonatal Intensive Care Unit Patients. J Pediatr Gastroenterol Nutr 2014;58:99\u2013101. doi: 10.1097/MPG.0b013e3182a907f2 \n20 Marco Dra Sagrario Mat\u00e9u CODEPEH MINISTERIO SANIDAD Y \nSONSUMO J DE. LIBRO BLANCO SOBRE HIPOACUSIA Detecci\u00f3n \nprecoz de la Hipoacusia en reci\u00e9n nacidos Coordinadores. [cited 2022 March 18] Available from: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/maternoInfantil/\nHipoacusia.htm\n21 Frederick T, Homans J, Spencer L, Kramer F, Stek A, Operskalski E, \net al. The effect of prenatal highly active antiretroviral therapy on the transmission of congenital and perinatal/early postnatal \ncytomegalovirus among HIV-infected and HIV-exposed infants. \nClin Infect Dis 2012;55:877\u201384. doi: 10.1093/cid/cis535 \n22 Pathirana J, Groome M, Dorfman J, Kwatra G, Boppana S, Cutland \nC, et al. Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of in Utero Human Immunodeficiency Virus (HIV) \nAcquisition in a High-HIV Prevalence Setting, South Africa. Clin \nInfect Dis 2019;69:1789\u201396. doi: 10.1093/cid/ciz019 \n23 Gantt S, Leister E, Jacobsen DL, Boucoiran I, Huang ML, Jerome KR, \net al. Risk of congenital cytomegalovirus infection among HIV-\nexposed uninfected infants is not decreased by maternal nelfinavir \nuse during pregnancy. J Med Virol 2016;88:1051\u20138. doi: 10.1002/\njmv.24420 \n24 Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of \nneurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17:355\u201363. doi: 10.1002/rmv.544 \n25 Kenneson A, Cannon MJ. Review and meta-analysis of the \nepidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007;17:253\u201376. doi: 10.1002/rmv.535 \n26 Mussi-Pinhata MM, Yamamoto AY, Figueiredo LTM, Cervi \nMC, Duarte G. Congenital and perinatal cytomegalovirus \ninfection in infants born to mothers infected with human \nimmunodeficiency virus. J Pediatr 1998;132:285\u201390. doi: 10.1097/\nINF.0000000000001975\n27 Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital \ncytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 2011;52. doi: 10.1093/cid/ciq085 \n28 Chilaka VN, Konje JC. HIV in pregnancy \u2013 An update. Eur J \nObstet Gynecol Reprod Biol 2021;256:484\u201391. doi: 10.1016/j.\nejogrb.2020.11.034\n29 Payne H; Watters S; Hsaio M. Early ART and Sustained Virological \nSuppression Limits HIV Proviral DNA Reservoir: CHER Evidence n.d. La infecci\u00f3n cong\u00e9nita por citomegalovirus, \u00bfes m\u00e1s prevalente en nuestro medio en neonatos expuestos al \nVIH?J. Bustamante-Amador, et al.\nRev Esp Quimioter 2022;35(5): 482-491491https://www.croiconference.org/abstract/early-art-and-sustained-\nvirological-suppression-limits-hiv-proviral-dna-reservoir-cher/ (accessed May 31, 2021).\n30 Chang TS, Wiener J, Dollard SC, Amin MM, Ellington S, Chasela \nC, et al. Effect of cytomegalovirus infection on breastfeeding transmission of HIV and on the health of infants born to HIV-infected mothers. AIDS 2015;29:831\u20136. doi: 10.1097/QAD.0000000000000617ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/021.2022\nRev Esp Quimioter 2022;35(5): 492-497492The postal code as a \u201cbar code\u201d of \nantimicrobial resistance\nABSTRACT\nIntroduction. The need to integrate local resistances in -\nto clinical practice is increasingly urgent, especially in Primary \nCare where empirical treatment is frequent.\nMethods. A retrospective observational study of positive \nmicrobiological isolates of Neisseria gonorrhoeae from any \nlocation (urethral, cervical, pharyngeal, rectal or urine) was \ncarried out in the health area of Alcal\u00e1 de Henares. Sociode -\nmographic characteristics and resistance to cephalosporins, azithromycin, penicillin and quinolones were analyzed. Each \nisolate was related to its postal code of origin.\nResults. We analyzed 256 microbiological samples of N. \ngonorrhoeae, most of them male (92.9%) with a mean age of 33 years. Half of the samples (49.8%) were resistant to cip -\nrofloxacin. Temporal and spatial evolution of antimicrobial re -\nsistance was integrated in heat maps. \nConclusion: Knowing local resistances can help to pre -\nscribe more adequate empirical treatments, especially in Pri -\nmary Care, avoiding inadequate antibiotics and decreasing resistance rates.\nKeywords: Neisseria gonorrhoeae ; Drug Resistance, Bacterial, Social Deter -\nminants of Health\nINTRODUCCI\u00d3N\nLa interacci\u00f3n entre los determinantes sociales, entendidos \ncomo condiciones de vida, y la salud es de sobra conocida, espe -\ncialmente en relaci\u00f3n con la calidad de vida y longevidad [1,2]. De hecho, en un editorial sobre este tema titulado \u201cTu c\u00f3digo postal puede modificar tu c\u00f3digo gen\u00e9tico\u201d[3] se explican las in -\ntersecciones entre salud, condiciones de vida, biolog\u00eda y conduc -\nta y resultados de salud, donde podemos englobar tambi\u00e9n el El c\u00f3digo postal como \u201cc\u00f3digo de barras\u201d de las \nresistencias antimicrobianas\n1Departamento de Microbiolog\u00eda Cl\u00ednica, Hospital Universitario Pr\u00edncipe de Asturias, Madrid, Espa\u00f1a.\n2Unidad T\u00e9cnica 3 del \u00c1rea de Salud P\u00fablica, Madrid, Espa\u00f1a\n3Departamento de Biomedicina y Biotecnolog\u00eda, Facultad de Medicina, Universidad de Alcal\u00e1 de Henares, Espa\u00f1a\n4Departamento de Enfermedades Infecciosas, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Espa\u00f1a.\n5Departamento Medicina Cl\u00ednica, Facultad de Medicina, Universidad Miguel Hern\u00e1ndez de Elche, Alicante, Espa\u00f1aPilar Galicia1,*\nManuel Linares1,*\n\u00c1ngel Miguel-Benito2\nFelipe P\u00e9rez Garc\u00eda1,3\nMiguel G\u00f3rgolas4\nJos\u00e9-Manuel Ramos-Rinc\u00f3n5\nJuan Cuadros1,3Original breve\nArticle history\nReceived: 6 March 2022; Revision Requested: 25 March 2022; Revision Received: 22 April 2022; Accepted: 31 May 2022; \nPublished: 13 July 2022\nRESUMEN\nIntroducci\u00f3n. La necesidad de integrar en la pr\u00e1ctica cl\u00ed -\nnica las resistencias locales es cada vez m\u00e1s urgente, especial -\nmente en Atenci\u00f3n Primaria, donde el tratamiento emp\u00edrico es \nfrecuente.\nMaterial y m \u00e9todos. Se desarroll\u00f3 un estudio retrospec -\ntivo observacional en el \u00e1rea de salud de Alcal\u00e1 de Henares de los aislados microbiol\u00f3gicos positivos de Neisseria gono-\nrrhoeae de cualquier localizaci\u00f3n (uretral, cervical, far\u00edngea, rectal u orina). Se analizaron caracter\u00edsticas sociodemogr\u00e1fi-\ncas y resistencias a cefalosporinas, azitromicina, penicilina y \nquinolonas. Se relacion\u00f3 cada aislado con su c\u00f3digo postal de \nprocedencia.\nResultados. Se analizaron 256 muestras microbiol\u00f3gi -\ncas de N. gonorrhoeae, la mayor\u00eda pertenecientes a hombres \n(92,9%) con edad media de 33 a\u00f1os. La mitad de las muestras \n(49,8%) fueron resistentes a ciprofloxacino. La evoluci\u00f3n tem -\nporo-espacial de las resistencias antimicrobianas se integr\u00f3 en mapas de calor con los c\u00f3digos postales con m\u00e1s resistencias \nConclusi\u00f3n. Conocer las resistencias locales puede ayudar \na pautar tratamientos emp\u00edricos m\u00e1s adecuados, especialmen -\nte en Atenci\u00f3n Primaria, evitando la utilizaci\u00f3n de antibi\u00f3ticos inadecuados y disminuyendo las tasas de resistencias.\nPalabras clave: Neisseria gonorrhoeae ; Resistencia antimicrobiana, Bacte -\nria, Determinantes sociales de la salud\nCorrespondencia: \nPilar Galicia\nHospital Universitario Pr\u00edncipe de Asturias. Servicio de Microbiolog\u00eda Cl\u00ednica. Carretera de \nAlcal\u00e1, s/n, 28805 Meco (Madrid); \nN\u00famero: + 34 91 87 81 00\nE-mail: pilarteresa.galicia@salud.madrid.org\n*Ambos autores han contribuido de igual manera al estudioEl c\u00f3digo postal como \u201cc\u00f3digo de barras\u201d de las resistencias antimicrobianas P. Galicia, et al.\nRev Esp Quimioter 2022;35(5): 492-497493t\u00e9rmino \u201cepigen\u00e9tica\u201d. Si hablamos de enfermedades infecciosas, \nsu relaci\u00f3n con las condiciones de vida y salubridad en muchas \nocasiones es m\u00e1s que evidente, incluyendo tambi\u00e9n la vacuna-\nci\u00f3n en este punto (entre ellas la vacuna del SARS-CoV-2) [4,5]. \nSin embargo, existe a\u00fan poca evidencia sobre c\u00f3mo se relacio-nan los determinantes sociales y las resistencias antimicrobia -\nnas, especialmente a peque\u00f1a escala. Resulta adem\u00e1s intere -\nsante que, con el auge de las resistencias antimicrobianas, que constituyen una amenaza para la salud global, las resistencias a \npeque\u00f1a escala en el \u00e1mbito de trabajo habitual no est\u00e1n con -\ntempladas en la mayor\u00eda de los protocolos o gu\u00edas cl\u00ednicas [6]. \nEsto, sumado a los tiempos de respuesta sobre todo en algunos \u00e1mbitos (especialmente en Atenci\u00f3n Primaria, m\u00e1s largos que en otros niveles asistenciales) y a la a\u00fan escasa disponibilidad de test de resistencias r\u00e1pidos en la pr\u00e1ctica cl\u00ednica diaria facilitan \nla prescripci\u00f3n de antimicrobianos con incertidumbre, y en mu -\nchas ocasiones de forma emp\u00edrica. El objetivo \u201ctest and treat\u201d \nse complica en algunas enfermedades donde las resistencias \nantimicrobianas constituyen un verdadero problema. Un claro \nejemplo es la infecci\u00f3n por Neisseria gonorrhoeae, una de las in-\nfecciones de transmisi\u00f3n sexual (ITS) m\u00e1s prevalentes en nuestra \nzona y en la que est\u00e1 aumentando la resistencia antimicrobiana \na los tratamientos habituales. Teniendo en cuenta todas estas \npremisas se llev\u00f3 a cabo un estudio con el objetivo de realizar un an\u00e1lisis geoespacial de la infecci\u00f3n por N. gonorrhoeae resisten-\nte durante los \u00faltimos cinco a\u00f1os (2016-2021). \nMATERIAL Y M\u00c9TODOS\nDise\u00f1o, poblaci\u00f3n y variables. Se realiz\u00f3 un estudio des-\ncriptivo en nuestra \u00e1rea de salud para estimar la frecuencia de \nlas resistencias a los antimicrobianos y su distribuci\u00f3n tempo-\nral de los aislados de N. gonorrhoeae durante 5 a\u00f1os (desde \n2016 hasta octubre de 2021). Se utiliz\u00f3 como definici\u00f3n de \ncaso el diagn\u00f3stico microbiol\u00f3gico de infecci\u00f3n por N. gonorr-\nhoeae mediante cultivo positivo (recomendaciones del Comit\u00e9 \nEuropeo de Susceptibilidad a los Antimicrobianos (EUCAST) [7]. \nSe incluyeron todas las muestras microbiol\u00f3gicas con culti-\nvo positivo remitidas a nuestro laboratorio de microbiolog\u00eda procedentes de pacientes con sospecha de ITS de diferentes fuentes: citolog\u00eda, exudados uretrales, endocervicales, rectales, far\u00edngeos y orina. \nSe recogieron las siguientes variables: a) datos sociode -\nmogr\u00e1ficos (sexo y edad); b) datos cl\u00ednicos (servicio m\u00e9dico de origen del paciente, localizaci\u00f3n) c) variables de resultado (resistencia a los antimicrobianos m\u00e1s utilizados (azitromicina, cefalosporinas de tercera generaci\u00f3n, ciprofloxacino y amoxi -\ncilina). Se aplicaron medidas de geolocalizaci\u00f3n mediante c\u00f3 -\ndigo postal asociado de todos los aislados de N. gonorrhoeae \ndesde 2016 y se visualizaron las \u00e1reas geogr\u00e1ficas con preva -\nlencia de resistencia a diferentes antimicrobianos a trav\u00e9s de \nmapas de c\u00f3digos postales en una base de datos an\u00f3nima de \nmuestras de N. gonorrhoeae. \nAn\u00e1lisis estad\u00edstico. Se realiz\u00f3 una descripci\u00f3n de los \ncasos diagnosticados de N. gonorrhoeae mediante medidas de tendencia central y dispersi\u00f3n para las variables cuantitativas, \nas\u00ed como distribuciones de frecuencias y porcentajes para las \nvariables cuantitativas y cualitativas, respectivamente.\nLas proporciones de resistencia global por distrito se com-\npararon mediante pruebas de contraste de hip\u00f3tesis Chi cua -\ndrado, con correcci\u00f3n exacta de Fisher para celdas inferiores a \n5, y se represent\u00f3 gr\u00e1ficamente la evoluci\u00f3n temporal de las \nresistencias durante los \u00faltimos 5 a\u00f1os. Se llev\u00f3 a cabo un an\u00e1-\nlisis espacial mediante el empleo de datos agregados de mues -\ntras pertenecientes a los c\u00f3digos postales del \u00e1rea estudiada, \npor a\u00f1o (n\u00famero de casos de infecci\u00f3n por N. gonorrhoeae re-\nsistentes a cefotaxima, azitromicina, amoxicilina y quinolonas). \nSe utiliz\u00f3 el c\u00f3digo postal asociado de cada paciente indivi -\ndual) y los resultados se visualizaron mediante el empleo de mapas de calor, tanto para resistencia global como para cada \nuno de los antibi\u00f3ticos de forma independiente.\nEl estudio se realiz\u00f3 de acuerdo con los principios de la \n\u00faltima revisi\u00f3n de la Declaraci\u00f3n de Helsinki. Asimismo, se si -\nguieron las normas internacionales para la realizaci\u00f3n de estu -\ndios epidemiol\u00f3gicos, recogidas en la Gu\u00eda Internacional para la Revisi\u00f3n \u00c9tica de Estudios Epidemiol\u00f3gicos [8]. El estudio \nfue aprobado por el Comit\u00e9 de \u00c9tica del Hospital Universitario \nPr\u00edncipe de Asturias (n\u00famero de protocolo: IE ETS).\nRESULTADOS\nDurante los casi seis a\u00f1os de estudio, se incluyeron 256 \nmuestras microbiol\u00f3gicas procedentes de distintas localizacio-\nnes y correspondientes a pacientes individuales. En esta pobla -\nci\u00f3n se detectaron un total de 159 muestras con al menos un mecanismo de resistencia a antimicrobianos, lo que represen-ta una prevalencia global del 59,4%. Las caracter\u00edsticas de la \nmuestra se encuentran en la Tabla 1. La mayor\u00eda de los pacien -\ntes eran hombres (92,9%), con una edad media en la fecha de \ndiagn\u00f3stico de 33 a\u00f1os (desviaci\u00f3n est\u00e1ndar: 9,4, rango: 18-\n66). La mayor\u00eda de las muestras microbiol\u00f3gicas se obtuvieron \nen servicios hospitalarios con casi un 30% de las muestras pro -\ncedentes de Atenci\u00f3n Primaria. Estratificando por antibi\u00f3tico, \nlas resistencias m\u00e1s frecuentes fueron a ciprofloxacino (49,8%) \nseguidas de amoxicilina (16,8%) y azitromicina (13,8%). \nEl estudio espacial de la muestra se realiz\u00f3 utilizando da -\ntos agregados de muestras pertenecientes a los c\u00f3digos posta -\nles del \u00e1rea estudiada, por a\u00f1o (n\u00famero de casos de infecci\u00f3n \npor N. gonorrhoeae resistentes a cefotaxima, azitromicina, \namoxicilina y quinolonas). Se utiliz\u00f3 el c\u00f3digo postal asociado \na la muestra cl\u00ednica.\nAl comparar los distritos con mayor n\u00famero de muestras \nse observ\u00f3 un rango muy variable de resistencia, con propor -\nciones que oscilaron desde el 1,6% de las muestras hasta el 24,2%, aunque estas diferencias no alcanzaron valores de sig -\nnificaci\u00f3n estad\u00edstica (Tabla 2). \nPosteriormente se visualiz\u00f3 mediante mapas de calor los \nc\u00f3digos postales donde se encontraban el grueso de muestras \ny se asoci\u00f3 un color en funci\u00f3n del n\u00famero de casos resisten -\ntes (Figura 1). Se realiz\u00f3 un mapa de las resistencias totales (re -El c\u00f3digo postal como \u201cc\u00f3digo de barras\u201d de las resistencias antimicrobianas P. Galicia, et al.\nRev Esp Quimioter 2022;35(5): 492-497494sistencia al menos a un antibi\u00f3tico (Figura 1a)), y de las resis -\ntencias a cada antibi\u00f3tico de forma independiente (Figura 1b \nresistencias a cefotaxima; Figura 1c resistencias a penicilina; Figura 1d resistencias a azitromicina y Figura 1e resistencias a \nciprofloxacino).\nEn la figura 2 se muestra una distribuci\u00f3n de las resisten -\ncias por a\u00f1o, pudiendo observarse una tendencia ascendente \nde las resistencias de forma global.\nDISCUSION\nLos resultados de nuestro estudio muestran una resisten -\ncia global de N. gonorrhoeae en las cepas testadas del 59,4%, \ncon una relaci\u00f3n temporal de aumento de resistencias a ci -\nprofloxacino y penicilina claramente mayor en los dos \u00faltimos \na\u00f1os. \nLas tasas de resistencias a ciprofloxacino de nuestro es -\ntudio son levemente mayores que en otras series realizadas \na nivel nacional, donde describen tasas de resistencia de ci -\nprofloxacino en torno a un 50% [9-11]. Sin embargo, en otros estudios realizados a nivel mundial las tasas de resistencias son bastante m\u00e1s elevadas [12-14]. En cuanto a cefalospori -\nnas, nuestra tasa de resistencia en las muestras analizadas se halla en torno a un 1,1%, lo que puede estar en consonancia \ncon las series mencionadas previamente [15], pero claramente \ninferior a la serie de Fuertes Vega et al [16]. Esto podr\u00eda ha -\ncernos concluir que de momento el uso de ceftriaxona como \ntratamiento de la infecci\u00f3n por N. gonorrhoeae es el adecuado \nen nuestro medio. Cabe resaltar que en el estudio de las ITS la \nbiolog\u00eda molecular y la utilizaci\u00f3n de t\u00e9cnicas de secuenciaci\u00f3n \npara identificar cepas es cada vez m\u00e1s frecuente [12,17], espe -\ncialmente en grandes ciudades y a nivel hospitalario, es decir, \na gran escala. Adem\u00e1s, hay que sumar a esto que el control de \nlas ITS es sumamente complejo por m\u00faltiples factores, entre \nlos que intervienen el estigma, desconocimiento, movilidad a otros centros sanitarios y la dificultad de realizar estudios de \ncontacto \u00f3ptimos. Queda por tanto incertidumbre sobre qu\u00e9 \nmedidas podemos implementar en la pr\u00e1ctica cl\u00ednica diaria pa -\nra poder predecir de una forma m\u00e1s ajustada las resistencias \nantimicrobianas de N. gonorrhoeae. Tras visualizar por c\u00f3digos \npostales los aislamientos resistentes (global y estratificados por tipo de antibi\u00f3ticos) podemos deducir r\u00e1pidamente en qu\u00e9 zo -\nnas se encuentran las cepas resistentes y c\u00f3mo se agrupan en \nel tiempo. A pesar de que a\u00fan no hay evidencia para poder \nestablecer correlaciones entre estos datos, el hecho de conocer las resistencias a nivel local nos puede ayudar a pautar trata -\nmientos emp\u00edricos m\u00e1s adecuados, evitando la sobreexposici\u00f3n a antibi\u00f3ticos resistentes. Es decir, utilizar el c\u00f3digo postal del paciente como herramienta para predecir el \u00e9xito o fracaso de \nun tratamiento antibi\u00f3tico (\u201cdime tu c\u00f3digo postal y te dir\u00e9 tus \nresistencias antimicrobianas\u201d). \nNuestro estudio presenta algunas limitaciones, entre las \nque podemos destacar la posibilidad de discrepancias entre c\u00f3digo postal recogido en la historia cl\u00ednica y el real, y la au -\nsencia de conocimiento sobre el tratamiento emp\u00edrico recibido, dado que no est\u00e1 recogido en la historia cl\u00ednica en muchos pa -\ncientes. \nPor \u00faltimo, tras la pandemia por SARS-CoV-2, que ha evi -Datos sociodemogr\u00e1ficos N\nEdad (media \u00b1 DE) 256 33 \u00b1 9\nSexo hombre; n (%) 256 238 (92,9%)\nServicio peticionario, n (%)\nDermatolog\u00eda\nAtenci\u00f3n PrimariaUrolog\u00eda\nUrgenciasMedicina Interna\nOtros\nGinecolog\u00eda256\n78 (30,5%)\n71 (27,7%)\n50 (19,5%)\n29 (11,3%)\n13(5,1%)\n10 (3,9%)\n5 (1,9%)\nA\u00f1o de la muestra positiva; n (%)\n20162017\n20182019\n2020\n2021256\n29 (11,3%)\n49 (19,1%)\n59 (23,0%)50 (19,5%)\n33 (12,9%)\n36 (14,1%)\nResistencia global al menos 1 antimicrobiano; n (%)\nResistente a ciprofloxacino\nResistente a amoxicilina\nResistente a azitromicina\nResistente a cefotaxima256 152 (59,4%)\n127 (49,8%)\n43 (16,8%)\n35 (13,8%)\n3 (1,2%)Tabla 1   Descripci\u00f3n de la muestra\nC\u00f3digo postal No resistencia\nn (%)Resistencia\nn (%)Valor p\n28800 5 (6,1%) 2 (1,6%)\n0,66428801 2 (2,4%) 2 (1,6%)\n28802 12 (14,6%) 20 (16,3%)\n28803 14 (17,1%) 16 (12,9%)\n28804 10 (12,2%) 18 (14,5%)\n28805 13 (15.8%) 27 (21,8%)\n28806 19 (23,2%) 30 (24,2%)\n28807 7 (8,5%) 9 (7,3%)\nTotal 82 124Tabla 2   Proporci\u00f3n de resistencias por distritoEl c\u00f3digo postal como \u201cc\u00f3digo de barras\u201d de las resistencias antimicrobianas P. Galicia, et al.\nRev Esp Quimioter 2022;35(5): 492-497495\nFigura 1   Evoluci\u00f3n geoespacial de los aislados de N. gonorrhoeae  resistentes por c\u00f3digo postal y por a\u00f1oa) Resistencias globales (al menos a 1 antimicrobiano)\nb) Resistencias a cefotaxima c) Resistencias a penicilinas\nd) Resistencias a azitromicina e) Resistencias a ciprofloxacino \nEn eje de abscisas: evoluci\u00f3n temporal; En eje de ordenadas: c\u00f3digo postal asociado. A la derecha se observa la l\u00ednea de calor con la densidad de casos por c\u00f3digo postal. \n28800\n28801\n28802\n288032880428805\n28806\n28807\n28800\n2880128802\n2880328804\n28805\n28806\n2880728800\n28801\n28802\n2880328804\n28805\n28806\n28807\n28800\n2880128802\n28803\n28804\n28805\n28806\n2880728800\n2880128802\n28803\n28804\n28805\n28806\n288072016 2017 2018 2019 2020 2021C\u00f3digo postalC\u00f3digo postal\nC\u00f3digo postalC\u00f3digo postal C\u00f3digo postal2016 2017 2018 2019 2020 2021\n2016 2017 2018 2019 2020 20212016 2017 2018 2019 2020 2021\n2016 2017 2018 2019 2020 2021El c\u00f3digo postal como \u201cc\u00f3digo de barras\u201d de las resistencias antimicrobianas P. Galicia, et al.\nRev Esp Quimioter 2022;35(5): 492-497496denciado todo un cambio de paradigma en la forma de enten -\nder la medicina, y ante el auge de herramientas de geolocali -\nzaci\u00f3n como medida epidemiol\u00f3gica creemos que conocer las \nresistencias locales actualizadas y a muy peque\u00f1a escala puede \nser una herramienta muy \u00fatil de salud p\u00fablica. \nFINANCIACI\u00d3N\nEste estudio ha sido parcialmente financiado por la Fun -\ndaci\u00f3n para la Investigaci\u00f3n del Hospital Universitario Pr\u00edncipe \nde Asturias\nCONFLICTOS DE INTER\u00c9S\nLos autores no declaran conflictos de inter\u00e9s \nBIBLIOGRAF\u00cdA\n1. Marmott M. The Status Syndrome: How Social Standing Affects \nOur health and Longevity. New York 2005.\n2. Makarova N, Klein-Ellinghaus F, Frisina Doetter L. Applications \nand limitations of the concept of \u2018avoidable mortality\u2019 among im -\nmigrant groups in Europe: a scoping review. Public Health. 2015 \n;129(4):342-50. doi: 10.1016/j.puhe.2015.01.006.\n3. Cofi\u00f1o R. Tu c\u00f3digo postal puede modificar tu c\u00f3digo gen\u00e9tico. Ac -\ntualizaci\u00f3n en Medicina de Familia. 2013:2.\n4. Oehler RL, Vega VR. Conquering COVID: How Global Vaccine In -equality Risks Prolonging the Pandemic. Open Forum Infect Dis. \n2021 Sep 9;8(10):ofab443. doi: 10.1093/ofid/ofab443.\n5. Wang L, Xu C, Hu M, Qiao J, Chen W, Li T, et al. Spatio-temporal va -\nriation in tuberculosis incidence and risk factors for the disease in \na region of unbalanced socio-economic development. BMC Public Health. 2021;21(1):1817. doi: 10.1186/s12889-021-11833-2\n6. Stalteri Mastrangelo R, Santesso N, Bognanni A, Darzi A, Karam \nS, Piggott T, et al. Consideration of antimicrobial resistance and contextual factors in infectious disease guidelines: a systema-tic survey. BMJ Open. 2021;11(7):e046097. doi: 10.1136/bmjo-pen-2020-046097.\n7. The European Committee on Antimicrobial Susceptibility Testing. \nBreakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022. http://www.eucast.org.\n8. CIOMS. International Ethical Guidelines for Healthrelated Research  \nInvolving Humans. 2016 [November 2021]; Available from: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMSEthicalGuidelines.\n9. Alonso R, Rodr\u00edguez-Achaerandio A, Aguirre-Qui\u00f1onero A, Artetxe \nA, Mart\u00ednez-Ballesteros I, Rodr\u00edguez-Gasc\u00f3n A, et al. Molecular Epidemiology, Antimicrobial Surveillance, and PK/PD Analysis to Guide the Treatment of Neisseria gonorrhoeae Infections. Pharma -\nceutics. 2021;13(10):1699. doi: 10.3390/pharmaceutics13101699\n10. Salmer\u00f3n P, Vi\u00f1ado B, El Ouazzani R, Hern\u00e1ndez M, Barbera MJ, \nAlberny M, et al. Antimicrobial susceptibility of Neisseria gono-\nrrhoeae in Barcelona during a five-year period, 2013 to 2017. Euro Surveill. 2020;25(42):1900576. doi: 10.2807/1560-7917.ES.2020.25.42.1900576.. Figura 2   Evoluci\u00f3n de la resistencia antimicrobiana de los aislados de N. gonorrhoeae  (2016-2021)\nEl c\u00f3digo postal como \u201cc\u00f3digo de barras\u201d de las resistencias antimicrobianas P. Galicia, et al.\nRev Esp Quimioter 2022;35(5): 492-49749711. P\u00e9rez-Torralba C, Ruiz-Olivares M, Sanbonmatsu-G\u00e1mez S, Exp\u00f3 -\nsito-Ru\u00edz M, Navarro-Mar\u00ed JM, Guti\u00e9rrez-Fern\u00e1ndez J. Increased \ninfections by herpes simplex virus type 1 and polymicrobials of the genital tract, in the general population of a Spanish midd -\nle city. Rev Esp Quimioter. 2021;34(4):320-329. doi: 10.37201/req/004.2021.\n12. Karymbaeva S, Boiko I, Jacobsson S, Mamaeva G, Ibraeva A, Usu -\npova D, et al. Antimicrobial resistance and molecular epidemiolo-gical typing of Neisseria gonorrhoeae isolates from Kyrgyzstan in \nCentral Asia, 2012 and 2017. BMC Infect Dis. 2021;21(1):559. doi: \n10.1186/s12879-021-06262-w.\n13. Selb R, Buder S, Dudareva S, Tamminga T, Bremer V, Ban -\nhart S, et al. Markedly decreasing azithromycin susceptibi -\nlity of Neisseria gonorrhoeae, Germany, 2014 to 2021. Eu -\nro Surveill. 2021;26(31):2100616. doi: 10.2807/1560-7917.\nES.2021.26.31.2100616\n 14. Zhu B, Hu Y, Zhou X, Liu K, Wen W. Retrospective Analysis of Drug \nSensitivity of Neisseria gonorrhoeae in Teaching Hospitals of \nSouth China. Infect Drug Resist. 2021;14:2087-2090. doi: 10.2147/IDR.S317032. eCollection 2021.\n15. Calatrava-Hern\u00e1ndez E, Foronda-Garc\u00eda-Hidalgo C, Guti\u00e9rrez-\nFern\u00e1ndez J. Resistance, molecular characterization and viability of Neisseria gonorrhoeae recent clinical isolates. Med Clin (Barc). \n2021 Mar 12;156(5):249-250. doi: 10.1016/j.medcli.2020.01.007\n16. Fuertes de Vega I, Baliu-Piqu\u00e9 C, Bosch Mestres J, Vergara G\u00f3 -\nmez A, Vall\u00e9s X, Alsina Gibert M. Risk factors for antimicrobial-resistant Neisseria gonorrhoeae and characteristics of patients \ninfected with gonorrhea. Enferm Infecc Microbiol Clin (Engl Ed). \n2018;36(3):165-168. doi: 10.1016/j.eimc.2016.11.012\n17. Salmer\u00f3n P, Moreno-Mingorance A, Trejo J, Amado R, Vi\u00f1ado B, \nCornejo-Sanchez T, et al. Emergence and dissemination of three \nmild outbreaks of Neisseria gonorrhoeae with high-level resis-tance to azithromycin in Barcelona, 2016-18. J Antimicrob Che-mother. 2021;76(4):930-935. doi: 10.1093/jac/dkaa536.ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/009.2022\nRev Esp Quimioter 2022;35(5): 498-499498dio de sensibilidad se realiz\u00f3 mediante tiras de E-test (bioM\u00e9 -\nrieux). A. odontolyticus y A. canis mostraron CMI a penicilina \nde 0,094; F. russi, present\u00f3 sensibilidad a metronidazol (CMI \n0,032 mg/L) y clindamicina (CMI 0,032 mg/L) y resistencia a \namoxicilina-clavul\u00e1nico (CMI>32 mg/L) seg\u00fan criterios EUCAST \n2021.\nEl tratamiento emp\u00edrico al ingreso fue ceftriaxona iv \n(2000mg/24h) y clindamicina iv (600mg/8h) durante 3 d\u00edas, \nal 4\u00ba d\u00eda se cambi\u00f3 ceftriaxona por amoxicilina-clavul\u00e1nico \niv (2000/200mg/8h) y se continu\u00f3 con clindamicina iv. A los \n10 d\u00edas tras la amputaci\u00f3n se paut\u00f3 amoxicilina-clavul\u00e1nico \niv (2000/200mg/8h) m\u00e1s clindamicina iv (600mg/8h). La evo -\nluci\u00f3n del paciente fue favorable y se le dio el alta pasados 7 d\u00edas desde la amputaci\u00f3n con amoxicilina-clavul\u00e1nico oral \n(875/125mg/8h). Tras los resultados microbiol\u00f3gicos (6 d\u00edas \ndespu\u00e9s del alta) se a\u00f1adi\u00f3 clindamicina oral (300mg/8h) du -\nrante 7 d\u00edas, manteniendo amoxicilina-clavul\u00e1nico 20 d\u00edas m\u00e1s. El tiempo de tratamiento tras la amputaci\u00f3n fue de 33 d\u00edas con resoluci\u00f3n total de la infecci\u00f3n.\nF. russi y A. canis son microorganismos anaerobios, cuya \nrecuperaci\u00f3n en cultivo puede tardar entre 5-14 d\u00edas, que se encuentran espec\u00edficamente en la cavidad oral de gatos y pe -\nrros, raramente encontrados en infecciones humanas [1-3]. El tratamiento indicado en casos de mordedura de animales es un antimicrobiano eficaz contra bacterias aerobias y anaero -\nbias, como amoxicilina-clavul\u00e1nico [4-6].\nHay que tener en cuenta factores de riesgo, como la diabe -\ntes, y comenzar r\u00e1pidamente un tratamiento emp\u00edrico adecua -\ndo, para evitar el progreso de la infecci\u00f3n hacia el hueso [5]. \nEs relevante la capacidad de identificar nuevas especies \nde anaerobios debido a la incorporaci\u00f3n de la espectrometr\u00eda de masas (MALDI-TOF), permitiendo conocer otros agentes que pueden contribuir a una peor evoluci\u00f3n  en base a sus caracte-\nr\u00edsticas pat\u00f3genas y de sensibilidad [7], como se observa en el F. russi aislado en este paciente que era resistente a amoxicili-\nna-clavul\u00e1nico. Osteomielitis polimicrobiana en extremidad de la \nmano tras mordedura de gato\n1Servicio de Microbiolog\u00eda, Complejo Hospitalario Pontevedra, Espa\u00f1a.\n2Servivio de Traumatolog\u00eda, Complejo Hospitalario Pontevedra, Vilagarc\u00eda de Arousa, Pontevedra, Espa\u00f1aPablo Camacho Zamora1 \nMercedes Rom\u00e1n Cabello1 \nPatricia \u00c1lvarez Garc\u00eda1\nEsther V\u00e1zquez Canal2Carta al Director\nArticle history\nReceived: 24 January 2022; Revision Requested: 9 July 2022; Revision Received: 13 July 2022; Accepted: 18 July 2022; \nPublished: 20 July 2022\nEstimado Editor: La osteomielitis secundaria a mordedura \nde gato es una complicaci\u00f3n poco frecuente, pero que puede \ntener consecuencias graves. Presentamos un caso de osteo -\nmielitis polimicrobiana en un dedo de la mano, tras mordedu-\nra de gato, producido por Fusobacterium russii, Actinomyces \nodontolyticus y Actinomyces canis. Presentamos el primer ca -\nso documentado de osteomielitis en el que se encuentra impli -\ncado F. russi.\nVar\u00f3n de 82 a\u00f1os con antecedentes personales de diabe -\ntes mellitus tipo II e hipertensi\u00f3n arterial a tratamiento. Remi -\ntido desde atenci\u00f3n primaria por herida sobreinfectada en el 2\u00ba dedo de la mano izquierda de 1 mes de evoluci\u00f3n, tras mor-dedura de gato. Se trat\u00f3 secuencialmente por mala evoluci\u00f3n \ncon ciprofloxacino 6 d\u00edas, cefuroxima 4 d\u00edas y moxifloxacino \n6 d\u00edas. En la exploraci\u00f3n f\u00edsica se observaron 3 heridas san -\ngrantes con supuraci\u00f3n purulenta, dolor y signos de inflama -\nci\u00f3n sin acompa\u00f1amiento de fiebre (Figura 1a). En el estudio de laboratorio present\u00f3 niveles de prote\u00edna C-reactiva 5,2 g/dl y la radiograf\u00eda de la mano izquierda demostr\u00f3 im\u00e1genes de lesiones l\u00edticas a nivel de la falange distal y media compatibles \ncon osteomielitis (Figura 1d).\nAl ingreso se realiz\u00f3 drenaje de la herida con cultivo mi -\ncrobiol\u00f3gico negativo tanto para bacterias como para hongos. A los 7 d\u00edas se realiz\u00f3 nueva radiograf\u00eda, evidenciando avance \nde osteomielitis (Figura 1e). Tras 10 d\u00edas desde el ingreso se realiz\u00f3 amputaci\u00f3n de la falange distal y media del 2\u00ba dedo de \nla mano izquierda, enviando una muestra \u00f3sea a microbiolog\u00eda. \nLa tinci\u00f3n de gram evidenci\u00f3 una alta presencia de leucocitos \npolimorfonucleares sin observaci\u00f3n de microorganismos. En el \ncultivo bacteriol\u00f3gico se identificaron tres microorganismos (A. odontolyticus, A. canis y F. russii (Figuras 1b y 1c)) mediante \nespectrometr\u00eda de masas (MALDI-TOF MS, bioM\u00e9rieux). El estu -\nCorrespondencia:\nPablo Camacho Zamora \nServicio de Microbiolog\u00eda, Complejo Hospitalario Pontevedra, Loureiro Crespo, 2, 36002 Pon -\ntevedra, Espa\u00f1a.E-mail: pablo_peraleo@hotmail.comOsteomielitis polimicrobiana en extremidad de la mano tras mordedura de gato P. Camacho Zamora, et al.\nRev Esp Quimioter 2022;35(5): 498-499499infection complicated by Fusobacterium russii. Anaerobe. 2016; \n42:162-165. doi:10.1016/j.anaerobe.2016.10.010\n3. Riggio MP, Lennon A, Taylor DJ, Bennett D. Molecular identification \nof bacteria associated with canine periodontal disease. Vet Micro -\nbiol. 2011; 150(3-4):394-400. doi:10.1016/j.vetmic.2011.03.001 \n4. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 \nupdate by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(2):e10-e52. doi:10.1093/cid/ciu444\n5. Kheiran A, Palial V, Rollett R, Wildin CJ, Chatterji U, Singh HP. Cat \nbite: an injury not to underestimate. J Plast Surg Hand Surg. 2019; 53(6):341-346. doi:10.1080/2000656X.2019.1637750 \n6. Philipsen TE, Molderez C, Gys T. Cat and dog bites. What to do? Guidelines for the treatment of cat and dog bites in humans. Acta Chir Belg. 2006; 106(6):692-695. doi:10.1080/00015458.2006.116\n79983\n7. Barba MJ, Fern\u00e1ndez A, Ovia\u00f1o M, Fern\u00e1ndez B, Velasco D, Bou G. \nEvaluation of MALDI-TOF mass spectrometry for identification of anaerobic bacteria. Anaerobe. 2014; 30:126-128. doi:10.1016/j.anaerobe.2014.09.008Las mordeduras de gato que presentan una evoluci\u00f3n \nt\u00f3rpida o un tratamiento inadecuado, pueden derivar en una \nafectaci\u00f3n \u00f3sea que en ocasiones \u00fanicamente se resuelve con la amputaci\u00f3n. Un manejo emp\u00edrico adecuado y un diagn\u00f3sti -\nco etiol\u00f3gico precoz son determinantes para un correcto abor -\ndaje de estos casos.\nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n pa -\nra la realizaci\u00f3n de este estudio. \nCONFLICTOS DE INTER\u00c9S\nLos autores declaran no presentar conflictos de inter\u00e9s \nBIBLIOGRAF\u00cdA\n1. Prashant N, Azuhairy A. Actinomycosis of distal phalanx twenty \nyears after flap reconstruction of index finger: A Case Report. Ma -\nlays Orthop J. 2018; 12(1):48-50. doi:10.5704/MOJ.1803.011\n2. Ullrich E, Grisold AJ, Feierl G, Lumenta DB, Leitner E. Severe forefoot Figura 1   a) Herida 2\u00ba dedo mano izquierda. b) Colonia A. canis . c) Colonia F. russii . d) \nRadiograf\u00eda mano izquierda al ingreso. e) Radiograf\u00eda mano izquierda tras 7 \nd\u00edas ingreso\nISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/018.2022\nRev Esp Quimioter 2022;35(5): 500-502500as it met six of the eight criteria described by the Spanish Asso -\nciation of Pediatrics (AEPED) [4] for its diagnosis, namely: pro -\nlonged fever, hepatosplenomegaly, cytopenias (anemia, throm-\nbocytopenia, and leukopenia), hyperferritinemia (2,129-3,212 ng/mL), hypofibrinogenemia (83 mg/dL) and elevated soluble CD25 (470 \u03bcL).\nThe first bronchoalveolar lavage\u2019s auramine stain was neg -\native, but at 14 incubation days, MGIT culture and the con-\nfirmatory Ziehl-Neelsen stain were positive for Mycobacterium \ntuberculosis. IGRA was not performed as the patient was a new -\nborn. Neonatal anti-tuberculous treatment was started (accord -\ning to the 2016 SEIP consensus [5]) with isoniazid (15 mg/kg/day), rifampicin (20 mg/kg/day), pyrazinamide (35 mg/kg/day) \nand amikacin (15 mg/kg/day). She developed hepatotoxicity, \nso pyrazinamide was changed to levofloxacin (7.5 mg/kg/day), \nas it is a second-line anti-tuberculous drug and because of its \ngood diffusion to the central nervous system [6]. The patient \nhad complicated hepatosplenomegaly with hepatic and splenic \nmicroabscesses, which evolved into calcified granulomas [evi-\ndenced by abdominal ultrasound (Figure 2)]. On the other hand, \nHPS resolved spontaneously when TB was treated.\nThe patient\u2019s twin sister was born healthy. The mother, a \n37-year-old Moroccan woman, was asymptomatic and appar-ently without any clinical background of interest. IGRA was not performed beforehand as the parents reported that it was done \nin a private clinic, and it was negative. No abnormalities were \nseen in the chest X-ray, and the sputum\u2019s Ziehl-Neelsen stain \nand cultures were negative. The endometrial aspirate culture \nwas positive for M. tuberculosis, so she also started treatment \nwith isoniazid, rifampicin, pyrazinamide, and ethambutol. \nThe patient completed 1-year oral maintenance anti-tu -\nberculous treatment with isoniazid (90 mg/day), rifampicin (90 \nmg/day), and pyridoxine (12.5 mg/day) with good response. A contact study was not performed as the parents were asympto -\nmatic, and it was suspected that the mother had a disseminated TB years before.Congenital tuberculosis in a premature newborn\n1Servicio de Microbiolog\u00eda, Hospital General Universitari de Castell\u00f3, Spain\n2Servicio de Farmacia Hospitalaria, Hospital General Universitari de Castell\u00f3, SpainLaura Solaz Escrig1\nManuel Belda \u00c1lvarez1\nRaquel Soria Martin1\nAaron Romualdo Pupl\u00e0 Bartoll2\nM\u00aa Dolores Tirado Balaguer1Letter to the Editor\nArticle history\nReceived: 2 March 2022; Revision Requested: 5 April 2022; Revision Received: 7 June 2022; Accepted: 9 June 2022; \nPublished: 19 July 2022\nSir,\nAccording to the World Health Organization, tuberculosis \n(TB) is among the ten leading causes of mortality and the first \netiology of infectious diseases globally [1,2]. The congenital form is an infrequent presentation of TB (only 300 cases have been \nreported in the English literature [3]), and it occurs in newborns \nof mothers who develop active disease during pregnancy or have silent genital TB [3].\nThe most frequent TB clinical form in pregnant women is \nextrapulmonary, and it is very difficult to diagnose due to the high variability of symptoms [3]. In newborns, it may present nonspecific clinical manifestations such as irritability, fever, \ncough, respiratory distress, hepatosplenomegaly, lymphadenop -\nathy, and abdominal distension [3].\nWe present a congenital TB case in a female newborn to a \ndichorionic diamniotic twin gestation, who was admitted to the \npediatric ICU due to severe respiratory distress and prematurity. Bronchopneumonia of possible fungal etiology was suspected to be the cause of the distress, as chest X-rays (Figure 1) showed \nbilateral infiltrates. Chest computerized tomography (CT) scans \n(Figure 2) reported areas of pulmonary consolidation and hepat -\nosplenomegaly. \nTreatment started with ceftazidime (33 mg/kg/8h) and van -\ncomycin (15 mg/kg/6h). As there was no clinical improvement, treatment was changed to meropenem (20 mg/kg/8h), azithromy -\ncin (20 mg/kg/day), cotrimoxazole (10/50 mg/8h), and fluconazole (12 mg/day). Persistent polypnea continued, so fluconazole was \nsubstituted for amphotericin B (5 mg/kg/day) and caspofungin (2 \nmg/day). Despite respiratory support and empiric broad-spectrum \nantimicrobial therapy, she did not respond adequately.\nAfter that, hemophagocytic syndrome (HPS) was suspected \nCorrespondence:\nLaura Solaz Escrig\nServicio de Microbiolog\u00eda, Hospital General Universitario de Castell\u00f3n. \nAvenida de Benic\u00e0ssim 128, 12004 Castell\u00f3n de la Plana, Castell\u00f3n\nE-mail: solaz_lauesc@gva.esCongenital tuberculosis in a premature newborn L. Solaz Escrig, et al.\nRev Esp Quimioter 2022;35(5): 500-502501REFERENCES\n1.  Global tuberculosis report 2021. Geneva: World Health Organiza -\ntion; 2021. License: CC BY-NC-SA 3.0 IGO.\n2.  Sugarman J, Colvin C, Moran AC. Tuberculosis in pregnancy: an \nestimate of the global burden of disease. Lancet Global Health \n2014:2:710-16. Doi: 10.1016/S2214-109X(14)70330-4\n3.  Reyes A, Hern\u00e1ndez M, Delpiano L. Tuberculosis: un reto en la at -\nenci\u00f3n del reci\u00e9n nacido y c\u00f3mo enfrentarlo. Documento de Actu -\nalizaci\u00f3n. Rev Chilena Infectol 2020; 37 (1): 51- 63. doi: 10.4067/\nS0716-10182020000100051\n4.  N\u00fa\u00f1ez Cuadros E, Galindo Zavala R, D\u00edaz-Cordov\u00e9s Rego G. S\u00edn -\ndrome de activaci\u00f3n macrof\u00e1gica. Protoc Diagn Ter Pediatr. \n2020;2:89-100.TB continues to be a global public health problem and ap -\nproaching its diagnosis to pregnant women and their newborns \nrepresents a daunting challenge for clinicians. An exhaustive ep -\nidemiological background study is crucial to firstly establish a \nhigh level of suspicion, and secondly integrate this pathology in -\nto the differential diagnoses of multiple clinical conditions that \nare observed in pregnant women and newborns.\nFUNDING\nNone to declare\nCONFLICT OF INTEREST\nAuthors declare no conflict of interest.Figure 1   Chest X-ray at birth (A): Bilateral infiltrates, predominantly in the right \nlung. Chest X-ray at 60 days (B): Pulmonary nodules consistent with \nmiliary tuberculosis.\nFigure 2   Chest CT at birth (A): Diffuse patchy nodular images of consolidation \nin both lung fields that coalesce to form larger areas of consolidation \nwith air bronchogram. In LIL there is a zone in the area of   gr eatest \nconsolidation that could suggest the beginning of pulmonary cavitation; and 60 days later (B): Pulmonary granulomas, cavitations in the left \nlung and hilar and mediastinal adenopathies.\nCongenital tuberculosis in a premature newborn L. Solaz Escrig, et al.\nRev Esp Quimioter 2022;35(5): 500-5025025.  Mellado Pe\u00f1a MJ, Santiago Garc\u00eda B, Baquero-Artigao F. Actu -\nalizaci\u00f3n del tratamiento de la tuberculosis en ni\u00f1os. An Pediatr \n(Barc). 2018;88(1):52.e1-52.e12 doi: 10.1016/j.anpedi.2017.05.013\n6.  Cabrera-Maqueda JM, Fuentes Rum\u00ed L, Valero L\u00f3pez G. Difusi\u00f3n de \nlos antibi\u00f3ticos en el sistema nervioso central. Rev Esp Quimioter 2018;31(1): 01-12. PMID: 29390599ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/046.2022\nRev Esp Quimioter 2022;35(5): 503-505503replacement was initiated. A hormonal study was performed \nshowing increased levels of TSH (31.59), antibodies anti-\nperoxidase (>1000 UI/mL) and decreased levels of thyroxine \n(<0.28 ng/dL). Moreover, the antinuclear antibodies were \npositives. The patient was diagnosed of systemic lupus \nerythematosus and myxedematous coma. Later, a chest \nultrasound revealed a left pleural effusion; drainage was then \nperformed.\nBoth pleural fluids were sent to the microbiology \nlaboratory for culture. The two samples were inoculated onto \nboth aerobic and anaerobic blood agar (Becton Dickinson), \nchocolate agar (Becton Dickinson), and thioglycolate broth (Becton Dickinson), incubating all media at 37\u00ba C for 5 days. Gram staining of both fluids exhibited abundant Gram-\nnegative rods. On the second day of incubation, numerous Two rare cases of pleural infection due to \nPrevotella species\n1Department of Microbiology and Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA, University Hospital Virgen \nde las Nieves. Granada, Spain\n2Department of Microbiology, University Hospital of Ja\u00e9n, SpainFernando Cobo1\nAna Lara-Oya2\nIgnacio Correa1\nEnrique Rodr\u00edguez-Guerrero1\nVirginia P\u00e9rez-Carrasco1\nJos\u00e9 A. Garc\u00eda-Salcedo1\nJos\u00e9 Mar\u00eda Navarro-Mar\u00ed1Letter to the Editor\nArticle history\nReceived: 27 April 2022; Revision Requested: 14 June 2022; Revision Received: 22 June 2022; Accepted: 23 June 2022; \nPublished: 14 July 2022\nSir,\nPrevotella species are anaerobic bacteria that form part \nof the oral microbiota and upper respiratory and genitourinary \ntracts. They are usually associated with oral infections, but it \ncan be also observed in some other infections such as skin and \nsoft tissue, and pleuropulmonary infections. Until now, there are only few reports on pleural infection published in the literature caused by Prevotella species and obtained in pure \nculture [1-7]. We here present two additional and uncommon cases of pleural infection caused by Prevotella species and a \nreview of the cases previously published.\nCase 1.- A 60-year-old man was admitted due to chest \npain, general malaise and vomiting. Blood analysis showed increased levels of glucose (198 mg/dL), urea (200 mg/dL), creatinine (1.53 mg7dL), procalcitonin (65.26 ng/mL), AST \n(437 U/L), and ALT (308 U/L). A physical exam showed cervical \nedema, and a cervico-thoracic CT scan showed great quantity \nof gas affecting cervical region and mediastinum (Figure 1) along with a pleural effusion. A diagnosis of mediastinitis was established and a thoracotomy was performed along with drainage of pleural effusion as well. Treatment with piperacillin-tazobactam and linezolid was started.\nCase 2.- A 47-year-old woman was admitted due to \ndrowsiness and inability to emit language and open the \neyes. Blood analysis showed increased levels of glucose (150 \nmg/dL), sodium (105 mEq/L), C-reactive protein (42.7 mg/L) and decreased levels of potassium (3.10 mEq/L), chlorine (80 \nmEq/L) and white cell count (3.44 x 10\n3/mm3). A brain CT scan \nwas performed showing no abnormalities. The patient was \nadmitted to the ICU and treatment with fluid and electrolyte \nCorrespondence:\nDr. Fernando Cobo\nDepartment of Microbiology, Hospital Virgen de las Nieves\nAvda Fuerzas Armadas, 2 18014 Granada, Spain\nPhone: +34958020364\nFax: +34958241245E-mail: fernando.cobo.sspa@juntadeandalucia.esFigure 1   Cervical CT scan showing a big quantity \nof gas corresponding to a mediastinitis.\nTwo rare cases of pleural infection due to Prevotella species F. Cobo, et al.\nRev Esp Quimioter 2022;35(5): 503-505504Pleural infections caused by anaerobic bacteria are \nusually of polymicrobial nature, presented as mixed infections \ncontaining aerobes and anaerobes. We here reported two cases of pleural infection due to P. oris and P. denticola in pure \nculture. Table 1 shows the main characteristics of patients with pleural infections due to Prevotella spp. \nThe introduction of MALDI-TOF MS for routine analyses \nin clinical laboratories has improved the identification of \nanaerobic bacteria and may help to detect new species. Last \nyears, antimicrobial resistance is increasing among anaerobic \nbacteria worldwide. Prevotella species have been traditionally \nconsidered susceptible to penicillin, but an increasing rate of \nresistance to this drug has been documented over recent years, \nranging from 33% to 60%, especially in P. bivia [10,11]. Thus, \nempirical treatment with penicillin cannot be recommended \nin infections caused by Prevotella species. Regarding to \nmetronidazole, some studies reported resistance of some \nPrevotella strains to this drug [12,13]. The above findings \nindicate that Prevotella species cannot be considered as \nusually susceptible to antibiotics. Antimicrobial resistance of \nPrevotella spp. and other anaerobes is an emerging problem \nthat warrants closer antimicrobial surveillance, increased resistance testing, and the stringent monitoring of treatment failures. \nThis is a report of two additional cases of P. oris  and P. \ndenticola as cause of pleural effusion and indicates that Prevotella species can produce infections in pure culture at \nthis location. These case reports and recent observations of colonies of microorganisms were observed in pure culture on \nanaerobic blood agar alone in both samples. MALDI-TOF MS \n(Bruker Biotyper, Billerica, MA) results identified the strains as P. oris and P. denticola (log scores of 2.20 in case 1 and 2.14 in case 2). Biotyper software version 9 was used (8468 msp) for \nanalyses. The two strains were sent to the Centre of Genomic \nand Oncologic Research (GENYO, Granada, Spain) for 16S rRNA gene sequence analysis using a previously reported method \n[8]. Fragments of 1,363 bp (case 1) and 1,357 bp (case 2) were \nobtained. The strain from case 1 showed 99.42% similarity \nwith the P. oris strain NCTC 13071 GenBank sequence (accession n\u00ba LR134384.1) and the strain from case 2, 99.2% similarity with the P. denticola strain SEQ210 17855 GenBank \nsequence (accession n\u00ba JN867285.1). 16S rRNA gene sequences \nof the isolates were submitted to GenBank (accession number OM909079 for case 1 and ON248549 for case 2). \nThe gradient diffusion strip method (Etest bioM\u00e9rieux) \nwas used for antimicrobial susceptibility testing based on 2022 \nEUCAST criteria [9]. MIC values for the strain isolated in case 1 were benzylpenicillin (0.125 mg/L), piperacillin-tazobactam (<0.016 mg/L), clindamycin (0.047 mg/L), meropenem (0.012 \nmg/L), and metronidazole (0.19 mg/L). Values for the strain \nisolated in case 2 were benzylpenicillin (8 mg/L), piperacillin-tazobactam (0.032 mg/L), clindamycin (>256 mg/L), \nmeropenem (0.047 mg/L), and metronidazole (1 mg/L). In case \n1, the patient rapidly developed to septic shock and dead after \n6 days. In case 2, the patient was prescribed i.v. meropenem (500 mg/8 h) for 20 days and was discharged after 40 days. Case \n(year of publication) \n[reference]Age \n(years)/\nsexPrevotella \nspeciesIdentification method Underlying conditions \nand/or risk factorsPossible \nsource of \ninfectionClinical manifestations CRP \n(mg/L)Treatment Outcome\n1 (2013) [2] 17/M Prevotella spp PCR (16S rRNA) NR NR Fever, cough, chest pain NR Antibiotics + drainage Cure\n2 (2015) [5] 76/M Prevotella spp PCR (16S rRNA) DM NR Fever, chest pain 147.4 Antibiotics + drainage Cure\n3 (2018) [3] 88/M Prevotella \ndentalisMALDI-TOF MS\nPCR (16S rRNA)CRD\nDMLung Chronic pleural effusion 194.1 Antibiotics + drainage Died\n4 (2020) [5] 42/M Prevotella oris NR DM Lung Chest pain, left upper \nlimb weakness, cough399 Antibiotics + drainage Cure\n5 (2021) [6] 12/M Prevotella \npleuritidisNext-generation \nsequencing-based \nclinical metagenomicsDM Lung Fever, cough, chest \npain, dyspneaNR Antibiotics + drainage Cure\n6 (2021) [7] 49/M Prevotella spp PCR (16S rRNA) NR Lung Asthenia, fever, weight \nloss, dyspnea87.5 Antibiotics + \nthoracoscopic surgeryCure\n7 (2022) [PR] 60/M Prevotella oris MALDI-TOF MS\nPCR (16S rRNA)Mediastinitis Lung Chest pain, general \nmalaise, vomitingNormal Antibiotics + drainage Died\n8 (2022) [PR] 47/F Prevotella \ndenticolaMALDI-TOF MS\nPCR (16S rRNA)Autoimmune disease NR Drowsiness, inhability \nto emit language42.7 Antibiotics + drainage CureTable 1   Main characteristics of Prevotella  pleural infections.\nM: male; F: female; NR: not reported; CRP: C-reactive protein; PR: present report; DM: diabetes mellitus; CRD: chronic respiratory disease.Two rare cases of pleural infection due to Prevotella species F. Cobo, et al.\nRev Esp Quimioter 2022;35(5): 503-505505antimicrobial resistance among Prevotella species highlight \nthe need for caution  when treating these infections with \nantibiotics and for the susceptibility testing of Gram-negative \nanaerobes in all cases. \nFUNDING\nNone to declare\nCONFLICT OF INTEREST\nAuthors declare no conflict of interest.\nREFERENCES\n1 Cobo F, Calatrava E, Rodr\u00edguez-Granger J, Sampedro A, Aliaga-\nMart\u00ednez L, Navarro-Mar\u00ed JM. A rare case of pleural effusion due to \nPrevotella dentalis. Anaerobe 2018; 54: 144-145. DOI: 10.1016/j.\nanaerobe.2018.09.004.\n2 Rayment JH, Weinstein M. An unusual cause of empyema in \na teenage boy. CMAJ 2013; 185: 1151-1153. DOI: 10.1503/cmaj.122089.\n3 Zhou H, Shen Y, Shen Q, Zhou J. Thoracic empyema caused by \nPrevotella spp. diagnosed using 16S rDNA sequence analysis. Clin \nRespir J 2015; 9: 121-124. DOI: 10.1111/crj.12106.\n4 Sakamoto M, Ohkusu K, Masaki T, Kako H, Ezaki T, Benno Y. \nPrevotella pleuritidis sp. nov., isolated from pleural fluid. Int J Syst Evol Microbiol 2007; 57: 1725-1728. DOI: 10.1099/ijs.0.64885-0.\n5 Abufaied M, iqbal P, Yassin MA. A rare and challenging presentation \nof empyema necessitans/necessitasis leading to braquial plexopathy. Cureus 2020; 12: e8267. DOI: 10.7759/cureus.8267.\n6 Galliguez T, Tsou PY, Cabrera A, Fergie J. Next-generation \nsequencing-based clinical metagenomics identifies Prevotella \npleuritidis in a diabetic adolescent with large parapneumonic \neffusion and negative growth of pleural fluid culture: \na case report. Br j Biomed Sci 2021; 78: 101-105. DOI: \n10.1080/09674845.2020.1827846. \n7 Diesler R, Kiakouama-Maleka L. A challenging case of thoracic \nempyema caused by Prevotella spp. Respir med Case Rep 2021; 35: \n101567. DOI: 10.1016/j.rmcr.2021.101567.\n8 Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, \net al. Evaluation of general 16S ribosomal RNA gene PCR primers \nfor classical and next-generation sequencing-based diversity \nstudies.  Nucleic Acids Research 2013; 41: e1-e1. DOI: 10.1093/nar/\ngks808.\n9 European Committee on antimicrobial susceptibility testing. \nBreakpoint tables for interpretation of MICs and zone diameters. \nVersion 12.0, 2022. http://eucast.org. Checked data: 04/21/2022.\n10 Bancescu G, Didilescu A, Bancescu A, Bari M. Antibiotic \nsusceptibility of 33 Prevotella strains isolated from Romanian patients with abscesses in head and neck spaces. Anaerobe 2015; \n35: 41-44. DOI: 10.1016/j.anaerobe.2014.10.006.  \n11 Jeverica S, Kolenc U, Mueller-Premru M, Papst L. Evaluation of the routine antimicrobial susceptibility testing results of \nclinically significant anaerobic bacteria in a Slovenian tertiary-care hospital in 2015. Anaerobe 2017; 47: 64-69. DOI: 10.1016/j.anaerobe.2017.04.007.\n12 Mory F, Carlier JP, Alauzet C, Thouvenin M, Schuhmacher H, \nLozniewski A. Bacteremia caused by a metronidazole-resistant Prevotella sp strain. J Clin Microbiol 2005; 43: 5380-5383. DOI: \n10.1128/JCM.43.10.5380-5383.2005.\n13 Alauzet C, Mory F, Teyssiere C, et al. Metronidazole resistance in \nPrevotella spp. and description of a new nim gene in Prevotella \nbaroniae. Antimicrob Agents Chemother 2010; 54: 60-64. DOI: 10.1128/AAC.01003-09.ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/049.2022\nRev Esp Quimioter 2022;35(5): 506-507506las cuales se incuban en atm\u00f3sfera aerobia con enriquecimien -\nto en CO 2, y en agar Schaedler y agar Kanamicina-Vancomicina, \nque se incuban en atm\u00f3sfera anaerobia. En todas las muestras \nse aisl\u00f3, a las 72 horas de incubaci\u00f3n, M. smegmatis, identifica-\ndo mediante MALDI-TOF con un score superior a 2,0. La cepa se envi\u00f3 al Centro de Referencia del Hospital Universitario Reina Sof\u00eda de C\u00f3rdoba para realizaci\u00f3n de antibiograma mediante la t\u00e9cnica de microdiluci\u00f3n en caldo. Seg\u00fan criterios CLSI [5] para micobacterias de crecimiento r\u00e1pido, esta cepa fue resistente a ceftriaxona, cefepima, claritromicina y minociclina y sensible \na aminogluc\u00f3sidos (tobramicina, amikacina) quinolonas (moxi -\nfloxacino, ciprofloxacino), imipenem, linezolid, doxiciclina y \ncotrimoxazol.\nTras los resultados de los cultivos microbiol\u00f3gicos, la an -\ntibioterapia del paciente se sustituy\u00f3 por una combinaci\u00f3n de doxiciclina 100mg/12 horas, ciprofloxacino 750 mg/12 horas y cotrimoxazol 800/160 mg /8 horas.\nEl paciente present\u00f3 una buena evoluci\u00f3n cl\u00ednica (Figura \n1) y toler\u00f3 la deambulaci\u00f3n, por lo que se pudo continuar el tratamiento ambulatorio tras 10 d\u00edas de hospitalizaci\u00f3n. Se \nmantuvo el tratamiento final de doxiciclina; ciprofloxacino y \ncotrimoxazol a las mismas dosis ya pautadas en el ingreso du -\nrante 6 semanas. \nAunque M. smegmatis se ha descrito como causante de \nneumon\u00eda en pacientes con enfermedades de base [6,7] y en bacteriemias relacionada con cat\u00e9ter [8], estos casos son muy \ninfrecuentes y produce, principalmente, infecciones de piel y \ntejidos blandos; por inoculaci\u00f3n accidental por traumatismos, como pinchazos con espinas de plantas, o por cirug\u00edas y pro -\nductos sanitarios contaminados [9-13]. En nuestro paciente, la puerta de entrada fue un pinchazo accidental con un cla -\nvo probablemente contaminado con la micobacteria. Adem\u00e1s, \nel crecimiento de una micobacteria no tuberculosa como este \ncaso suele suponer el cambio del tratamiento inicialmente prescrito, junto con una prolongaci\u00f3n del mismo en el tiempo.\nM. smegmatis produce raramente infecciones en huma -Osteomielitis del cuboides por Mycobacterium \nsmegmatis\nHospital Universitario Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain.Ana Ruiz-Castillo\nAlberto Tenorio-Abreu\nAlicia Hidalgo-Jim\u00e9nez\nJos\u00e9 Mar\u00eda Saavedra-Mart\u00ednCarta al Director\nArticle history\nReceived: 4 May 2022; Revision Requested: 2 June 2022; Revision Received: 7 June 2022; Accepted: 14 June 2022; Published: \n18 July 2022\nEstimado Editor: Mycobacterium smegmatis es una mico-\nbacteria no tuberculosa de crecimiento r\u00e1pido y escotocrom\u00f3 -\ngena, descrita por primera vez en 1884 en un chancro sifil\u00edtico \ny, un a\u00f1o despu\u00e9s, en muestras de secreciones genitales nor -\nmales [1], aunque hasta 1986 no se reconoci\u00f3 como pat\u00f3geno \nhumano [2]. Actualmente el grupo Mycobacterium smegmatis \nse compone de M. smegmatis sensu stricto, M. wolinskyi y M. \ngoodii [3] Las micobacterias ambientales forman biofilms en \nlas redes de agua urbanas, encontr\u00e1ndose tambi\u00e9n en el sue -\nlo, vegetaci\u00f3n y animales [4]. Estas micobacterias tienen como \nmecanismo patog\u00e9nico una inflamaci\u00f3n granulomatosa con destrucci\u00f3n del tejido.\nPresentamos un caso de osteomielitis del cuboides tras un \npinchazo con un clavo. Se trata de un var\u00f3n de 42 a\u00f1os sin antecedentes de inter\u00e9s que acude en varias ocasiones a urgen -\ncias por dolor e inflamaci\u00f3n en el lateral externo del pie izquier-do y fiebre superior a 38\u00baC. Hab\u00eda sido tratado con cefadroxilo (500 mg/12h) y amoxicilina-clavul\u00e1nico (875/125 mg/8h) por v\u00eda oral sin experimentar una respuesta favorable. El paciente refiri\u00f3 un traumatismo con un clavo un mes antes del inicio de los s\u00edntomas.\nTras dos semanas de tratamiento ambulatorio con los an -\ntibi\u00f3ticos mencionados, y debido el empeoramiento del cuadro cl\u00ednico, el paciente acude de nuevo a urgencias donde se realiza \nun TAC, que muestra hallazgos compatibles con una osteomie -\nlitis aguda del cuboides con formaci\u00f3n de absceso intra\u00f3seo y \nafectaci\u00f3n de las partes blandas circundantes. Se decide ingre -\nsar al paciente e incrementar la dosis de amoxicilina-clavul\u00e1ni-co a dosis de 2 g/8h.\nTras 10 d\u00edas de ingreso y falta de respuesta al tratamiento, \nse interviene desbridamiento quir\u00fargico y se toman 5 muestras que se env\u00edan al laboratorio, donde se homogenizan y se siem -\nbran en placas de agar sangre, agar chocolate, agar McConkey; \nCorrespondencia:\nAlberto Tenorio-Abreu\nHospital Universitario Juan Ram\u00f3n Jim\u00e9nez, Huelva. Ronda Norte, s/n, 21005 Huelva.\nE-mail: albeteno@hotmail.comOsteomielitis del cuboides por Mycobacterium smegmatis A. Ruiz-Castillo, et al.\nRev Esp Quimioter 2022;35(5): 506-5075072. Vonmoos S, Leuenberger P, Beer V, de Haller R. Pleuropulmonary \ninfection caused by Mycobacterium smegmatis. Case description \nand literature review. Schweiz. Med. Wochenschr. 1986; 116: 1852\u20131856.\n3. Brown-Elliot BA an Wallace RJ. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002; 15(4):716\u2013746.  doi: \n10.1128/CMR.15.4.716-746.2002.\n4. Franco-Paredes C, Marcos LA, Henao-Mart\u00ednez AF, Rodr\u00edguez-Morales AJ, Vilamil-G\u00f3mez WE, Gotuzzo E, Bonifaz A. Cutaneous mycobacterial infections. Clin Microbiol Rev 2018; 32(1):e00069-18. doi: 10.1128/CMR.00069-18.\n5. Alcaide-Fern\u00e1ndez de Vega F,Esteban-Moreno J, Gonz\u00e1lez-Mart\u00edn J,Palacios-Guti\u00e9rrez JJ. M\u00e9todos de determinaci\u00f3n de sensibilidad a los antimicrobianos en micobacterias. Procedimientos en Micro -\nbiolog\u00eda Cl\u00ednica. Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC).2016.\n6. Ergan B, \u00c7\u00f6pl\u00fc L, Alp A, Artvinli M. Mycobacterium smegmatis \npneumonia. Respirology 2004; 9:283\u2013285.\n7. Driks M, Weinhold F and Cokingtin Q. Pneumonia caused by Myco-\nbacterium smegmatis in a patient with a previous gastrectomy. BMJ Case Rep 2011; 2011:3281. \ndoi: 10.1136/bcr.08.2010.3281.  \n8. Butt S and Tirmizi A. Mycobacterium smegmatis bacteremia in an \nimmunocompetent host. IDCases. 2019; 15 (2019) e00523. doi: 10.1016/j.idcr.2019.e00523.\n9. Shimizu F. Mycobacterium smegmatis soft tissue infection. \nInt J Dermatol 2012; 51:1517\u20131530.  doi: 10.1111/j.1365-\n4632.2010.04835.x.  \n10. Xu Z, Lu D, Zhang X, Li H, Meng S, Pan YS, Boyd AS, Ma L, Tang YW. Mycobacterium smegmatis in skin biopsy specimens from patients  \nwith suppurative granulomatous inflammation. J Clin Microbiol 2013; 51(3):1028-30. \ndoi: 10.1128/JCM.03421-12.  \n11. Newton JA, Weiss PJ, Bowler WA, Oldfield EC. Soft-tissue infection due to Mycobacterium smegmatis : Report of two cases. Clin Infect \nDis 1993; 16(4):531-3. doi: 10.1093/clind/16.4.531.\n12. Belda-\u00c1lvarez M, Chanza-Avi\u00f1o M, Sanfeliu-Giner M, Guna-Serra -\nno MR, Gimeno-Cardona C. Infection of prosthetic material due to Mycobacterium smegmatis. Rev Esp Quimioter 2019; 32(5):475-\n476.\n13. Saffo Z and Ognjan A. Mycobacterium smegmatis infection of a \nprosthetic total knee arthroplasty. IDCases 2016 1;5:80-2. doi: \n10.1016/j.idcr.2016.07.007.  nos, siendo las m\u00e1s importantes las que afectan a piel, tejidos \nblandos y hueso. Adem\u00e1s, suelen requerir intervenci\u00f3n quir\u00far -\ngica y tratamientos combinados y prolongados para su reso -\nluci\u00f3n.\nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n \npara la realizaci\u00f3n de este estudio. \nCONFLICTOS DE INTER\u00c9S\nLos autores declaran no presentar conflictos de inter\u00e9s \nBIBLIOGRAF\u00cdA\n1. Wallace RJ Jr, Nash DR, Tsukamura M, Blacklock ZM, Silcox VA. Hu -\nman disease due to Mycobacterium smegmatis. J Infect Dis. 1988; \n158(1):52-9. doi: 10.1093/infdis/158.1.52.Figura 1   A: Edema en regi\u00f3n lateral externa \ncon inflamaci\u00f3n de partes blandas \ncircundantes. B: Pie tras la intervenci\u00f3n \npara desbridamiento quir\u00fargico. C: \nEstado del pie un a\u00f1o despu\u00e9s del ingreso \nhospitalario.\nThis should read instead:\n\u201cCeftolozane is a potent antimicrobial against Pseu-\ndomonas aeruginosa, including carbapenem-resistant and \nmultidrug-resistant strains, and is also active against Entero -\nbacteriaceae. It\u2019s MIC. (minimal inhibitory concentration) and MPC (mutant prevention concentration) are close together, \nallowing to avoid the mutant selection window specifically in \nthe treatment of Pseudomonas aeruginosa infection. The mole -\ncule is time-dependent and stable when reconstituted at room \ntemperature, facilitating safety and effectiveness. dosage opti-\nmization in frail and critically ill patients. It has been shown to \nbe non-inferior to meropenem in the treatment of nosocomial \ninfection in the ASPECT-NP study but superior in post-hoc \nstudies on the subgroup of patients with ventilated hos -\npital acquired bacterial pneumonia (vHABP) , without the \nemergence of resistance during treatment. It is FDA approved \nat a dose of 3 g every 8 hours in the treatment of nosocomial pneumonia (HABP/VABP) in adults.\nThe authors would like to apologise for any inconvenience \ncaused.Ceftolozane-tazobactam in nosocomial \npneumonia.\nRev Esp Quimioter. 2022 Apr;35 Suppl 1(Suppl 1):35-39.\ndoi: 10.37201/req/s01.08.2022.Erratum\nThe authors regret that in the abstract of the manuscript \nthe following is written:\n\u201cCeftolozane is a potent antimicrobial against Pseu-\ndomonas aerugi nosa, including carbapenem-resistant and \nmultidrug-resistant strains, and is also active against Entero -\nbacteriaceae. It MIC (minimal inhibitory concentration) and \nMPC (mutant preventive concentration) are close together, al -\nlowing to avoid the mutant selection window specifically in the treatment of Pseudomonas aeruginosa infection. The molecule \nis time-dependent and stable when reconstituted at room tem -\nperature, facilitating safe and effective dosage optimization in \nfrail and critically ill patients. It has been shown to be non-in-\nferior to meropenem in the treatment of nosocomial infection \nin the ASPECT-NP study but superior in post-hoc studies \nin the subgroup of patients with ventilator-associated \npneumonia, without the emergence of resistance during treat -\nment. It is FDA approved at a dose of 3 g every 8 hours in the \ntreatment of nosocomial pneumonia (HABP/VABP) in adults.\u201dCandel FJ, Gonz\u00e1lez Del Castillo J, Juli\u00e1n Jim\u00e9nez A, Matesanz M.\nRev Esp Quimioter 2022;35(5): 508 508ISSN: 0214-3429 / \u00a9The Author 2022. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia \ndoi:10.37201/req/erratum01.2022", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}